[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fTKLxQklQJdSbDLyuvtUqK6O6CHg2O2oTs7lBpguM9Ds":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":7,"truncated":8,"activeTrials":9,"phase3Count":10,"totalEnrollment":11,"activePrograms":12,"nonDrugCount":13,"topConditions":14,"upcomingReadouts":38,"phaseBuckets":89,"rows":96},"University of Sao Paulo",[4,6],"University of Sao Paulo General Hospital",1602,false,176,109,372036,47,1216,[15,18,21,24,27,30,33,36],{"name":16,"count":17},"Obesity",40,{"name":19,"count":20},"Heart Failure",33,{"name":22,"count":23},"Dental Caries",27,{"name":25,"count":26},"Coronary Artery Disease",24,{"name":28,"count":29},"Pain",23,{"name":31,"count":32},"Stroke",20,{"name":34,"count":35},"Quality of Life",19,{"name":37,"count":35},"Parkinson Disease",[39,44,49,54,59,64,69,74,79,84],{"nctId":40,"briefTitle":41,"date":42,"intervention":43},"NCT03399175","Early Immunosuppressive Therapy on the Course of Vogt-Koyanagi-Harada Disease","2023-05-18","Early high-dose corticosteroid and immunosuppressive therapy",{"nctId":45,"briefTitle":46,"date":47,"intervention":48},"NCT03092180","Optimizing Treatment on Idiopathic Inflammatory Myopathies","2024-05-06","Intravenous",{"nctId":50,"briefTitle":51,"date":52,"intervention":53},"NCT06584773","Efficacy of a Quadruple Immunosuppressor Regimen With mTOR Inhibitors in Sensitized Kidney Transplant Patients","2024-08","Everolimus",{"nctId":55,"briefTitle":56,"date":57,"intervention":58},"NCT06557811","Effect of Oral Semaglutide on Epicardial and Pericoronary Adipose Tissues in Type 2 Diabetes After Myocardial Infarction","2024-09-01","Semaglutide",{"nctId":60,"briefTitle":61,"date":62,"intervention":63},"NCT05611268","Pentoxifylline as an Adjunct Therapy for Patients With Eisenmenger Syndrome","2024-09-30","Pentoxifylline",{"nctId":65,"briefTitle":66,"date":67,"intervention":68},"NCT07415811","Spironolactone and XPB-1 Integrity in the TFIIH Complex","2024-12-11","Spironolactone",{"nctId":70,"briefTitle":71,"date":72,"intervention":73},"NCT06465056","Use of Botulinum Toxin A in Direct Eyebrow Lift Scar","2025-01-01","Botulinum toxin type A",{"nctId":75,"briefTitle":76,"date":77,"intervention":78},"NCT05846490","Impact of Obstructive Sleep Apnea (OSA) Treatment on Blood Pressure Control in Chronic Kidney Disease","2025-05","Usual care",{"nctId":80,"briefTitle":81,"date":82,"intervention":83},"NCT06527066","Effect of Aromatherapy for Facial Aesthetics in Alleviating Signs of Aging: Pilot Study","2025-06","Geranium (Pelargonium graveolens) essential oil (EO) diluted to 1% in All.me Beauty® Gel Sérum Biocompatível",{"nctId":85,"briefTitle":86,"date":87,"intervention":88},"NCT06934798","Inotropic Effects of Vasopressin Versus Noradrenaline In Patients With Vasoplegic Syndrome After Cardiac Surgery","2025-07-30","Vasopressin intravenous",[90,91,92,93,94,95],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[97,137,178,215,253,279,301,323,341,368,394,425,460,485,503,531,552,588,611,639,657,695,770,808,846,873,897,924,942,969,987,1038,1068,1093,1118,1147,1181,1207,1225,1259,1294,1328,1356,1377,1396,1416,1438,1464,1511,1564,1614,1650,1672,1711,1743,1779,1808,1849,1884,1920,1951,1980,2020,2054,2087,2117,2142,2167,2193,2220,2238,2256,2282,2300,2325,2343,2361,2379,2408,2426,2450,2473,2500,2518,2536,2562,2588,2606,2631,2654,2684,2702,2720,2746,2773,2797,2815,2841,2865,2883,2908,2926,2952,2970,2992,3010,3035,3053,3071,3089,3112,3137,3155,3184,3209,3227,3253,3271,3294,3312,3337,3355,3373,3399,3421,3444,3471,3489,3507,3525,3549,3580,3605,3629,3653,3671,3689,3714,3738,3760,3778,3801,3819,3841,3864,3892,3916,3934,3963,3985,4003,4025,4043,4066,4093,4111,4133,4156,4174,4198,4216,4239,4257,4281,4302,4328,4346,4370,4388,4415,4443,4461,4479,4503,4526,4552,4570,4593,4611,4633,4651,4674,4699,4717,4740,4765,4789,4815,4842,4860,4884,4902,4945,4991,5041,5072,5106,5128,5163,5185,5208,5234,5252,5270,5297,5315,5342,5360,5378,5401,5426,5444,5467,5485,5510,5528,5553,5578,5596,5618,5643,5661,5684,5711,5729,5756,5774,5801,5826,5849,5867,5885,5903,5927,5950,5975,5993,6011,6038,6064,6082,6105,6128,6146,6171,6195,6221,6246,6271,6289,6307,6325,6343,6366,6390,6408,6433,6459,6484,6502,6524,6551,6569,6595,6613,6640,6658,6685,6703,6721,6739,6760,6785,6809,6839,6886,6913,6945,6968,6989,7013,7041,7059,7082,7100,7122,7148,7171,7194,7217,7235,7261,7279,7297,7315,7338,7364,7382,7406,7424,7442,7465,7489,7507,7525,7551,7577,7595,7621,7644,7668,7686,7707,7729,7747,7772,7795,7813,7837,7863,7881,7904,7929,7947,7971,7989,8015,8033,8055,8079,8105,8123,8141,8164,8189,8207,8229,8253,8276,8300,8329,8353,8377,8395,8417,8442,8464,8489,8516,8534,8552,8575,8600,8618,8636,8654,8679,8702,8728,8751,8769,8791,8816,8841,8901,8938,8973,9002,9039,9075,9109,9141,9166,9199,9232,9263,9299,9324,9357,9396,9418,9446,9468,9492,9510,9531,9554,9578,9596,9619,9637,9660,9690,9708,9726,9744,9762,9786,9810,9828,9850,9876,9905,9930,9951,9975,10001,10019,10037,10055,10073,10095,10121,10139,10164,10187,10205,10223,10244,10271,10289,10312,10339,10362,10385,10403,10427,10448,10470,10488,10512,10530,10548,10573,10598,10616,10640,10666,10684,10706,10729,10753,10771,10796,10814,10832,10856,10879,10897,10920,10943,10964,10989,11013,11031,11056,11074,11092,11110,11133,11157,11175,11199,11225,11247,11265,11283,11301,11324,11342,11365,11387,11410,11428,11453,11478,11496,11518,11540,11564,11586,11604,11629,11647,11665,11692,11719],{"intervention":98,"totalTrials":99,"cells":100},"Pneumococcal Vaccine",2,{"EARLY_PHASE1":101,"PHASE1":104,"PHASE2":106,"PHASE3":108,"PHASE4":110,"NA":135},{"trials":102,"activeCount":103},[],0,{"trials":105,"activeCount":103},[],{"trials":107,"activeCount":103},[],{"trials":109,"activeCount":103},[],{"trials":111,"activeCount":99,"soonestReadout":117},[112,124],{"nctId":113,"briefTitle":114,"status":115,"phases":116,"primaryCompletion":117,"completion":118,"start":119,"enrollment":120,"conditions":121,"interventions":123},"NCT07252791","Safety and Immunogenicity of PCV20 in Pediatric Patients With Autoimmune Rheumatic Diseases","RECRUITING",[94],"2026-12-30","2027-12-30","2026-01-16",114,[122],"Autoimmune Rheumatologic Disease",[98],{"nctId":125,"briefTitle":126,"status":127,"phases":128,"primaryCompletion":118,"completion":129,"start":130,"enrollment":131,"conditions":132,"interventions":134},"NCT07242092","Influence of Methotrexate Discontinuation on Immunogenicity After PCV-20 Vaccine in Patients ARDs","NOT_YET_RECRUITING",[94],"2028-12-30","2026-03-25",192,[133],"Autoimmune Rheumatic Diseases",[98],{"trials":136,"activeCount":103},[],{"intervention":138,"totalTrials":99,"cells":139},"Acyclovir",{"EARLY_PHASE1":140,"PHASE1":142,"PHASE2":144,"PHASE3":146,"PHASE4":148,"NA":176},{"trials":141,"activeCount":103},[],{"trials":143,"activeCount":103},[],{"trials":145,"activeCount":103},[],{"trials":147,"activeCount":103},[],{"trials":149,"activeCount":175,"soonestReadout":154},[150,162],{"nctId":151,"briefTitle":152,"status":127,"phases":153,"primaryCompletion":154,"completion":155,"start":156,"enrollment":157,"conditions":158,"interventions":161},"NCT07341386","Prevention of Recurrence of Herpes Simplex in Autoimmune Rheumatic Diseases",[94],"2027-04-01","2028-04-01","2026-04-01",62,[133,159,160],"Recurrent Herpes Simplex","Prevention",[138],{"nctId":163,"briefTitle":164,"status":165,"phases":166,"primaryCompletion":167,"completion":168,"start":169,"enrollment":170,"conditions":171,"interventions":173},"NCT03831165","Melatonin Effects on Genital Herpes in Brazilian Women","COMPLETED",[94],"2021-09","2021-12-28","2015-09-02",90,[172],"Genital Herpes",[174,138],"Melatonin 3 mg",1,{"trials":177,"activeCount":103},[],{"intervention":53,"totalTrials":99,"cells":179},{"EARLY_PHASE1":180,"PHASE1":182,"PHASE2":184,"PHASE3":186,"PHASE4":188,"NA":213},{"trials":181,"activeCount":103},[],{"trials":183,"activeCount":103},[],{"trials":185,"activeCount":103},[],{"trials":187,"activeCount":103},[],{"trials":189,"activeCount":175,"soonestReadout":52},[190,204],{"nctId":191,"briefTitle":192,"status":193,"phases":194,"primaryCompletion":195,"completion":196,"start":197,"enrollment":170,"conditions":198,"interventions":203},"NCT01631058","Renal Transplantation in the Elderly - nEverOld Study","UNKNOWN",[94],"2014-07","2019-06","2012-07",[199,200,201,202],"Chronic Renal Failure (CRF)","Graft Failure","Transplant; Failure, Kidney","Renal Transplant Rejection",[53],{"nctId":50,"briefTitle":51,"status":115,"phases":205,"primaryCompletion":52,"completion":206,"start":207,"enrollment":208,"conditions":209,"interventions":211},[94],"2025-07","2015-06",80,[210],"Disorder Related to Renal Transplantation",[53,212],"standard maintenance immunosuppression",{"trials":214,"activeCount":103},[],{"intervention":216,"totalTrials":99,"cells":217},"Eszopiclone 3 mg",{"EARLY_PHASE1":218,"PHASE1":220,"PHASE2":222,"PHASE3":224,"PHASE4":226,"NA":251},{"trials":219,"activeCount":103},[],{"trials":221,"activeCount":103},[],{"trials":223,"activeCount":103},[],{"trials":225,"activeCount":103},[],{"trials":227,"activeCount":175,"soonestReadout":244},[228,240],{"nctId":229,"briefTitle":230,"status":165,"phases":231,"primaryCompletion":232,"completion":233,"start":234,"enrollment":235,"conditions":236,"interventions":239},"NCT06017921","Effect of Eszopiclone on Adherence to CPAP and Severity of Insomnia in Patients With COMISA",[94],"2025-10-20","2026-03-20","2023-08-24",60,[237,238],"Obstructive Sleep Apnea","Insomnia",[216],{"nctId":241,"briefTitle":242,"status":115,"phases":243,"primaryCompletion":244,"completion":245,"start":246,"enrollment":247,"conditions":248,"interventions":250},"NCT07018557","Impact of Eszopiclone on Blood Pressure in Patients With Insomnia and Hypertension (PRYSMA-HTN)",[94],"2026-06-01","2026-12-31","2025-06-04",150,[238,249],"Hypertension",[216],{"trials":252,"activeCount":103},[],{"intervention":254,"totalTrials":175,"cells":255},"Donepezil group",{"EARLY_PHASE1":256,"PHASE1":258,"PHASE2":260,"PHASE3":262,"PHASE4":264,"NA":277},{"trials":257,"activeCount":103},[],{"trials":259,"activeCount":103},[],{"trials":261,"activeCount":103},[],{"trials":263,"activeCount":103},[],{"trials":265,"activeCount":175,"soonestReadout":271},[266],{"nctId":267,"briefTitle":268,"status":269,"phases":270,"primaryCompletion":271,"completion":271,"start":272,"enrollment":273,"conditions":274,"interventions":276},"NCT07153991","Efficacy of Donepezil in Patients With Chronic Tinnitus","ACTIVE_NOT_RECRUITING",[94],"2025-12-09","2021-11-19",70,[275],"Tinnitus",[254],{"trials":278,"activeCount":103},[],{"intervention":58,"totalTrials":175,"cells":280},{"EARLY_PHASE1":281,"PHASE1":283,"PHASE2":285,"PHASE3":287,"PHASE4":289,"NA":299},{"trials":282,"activeCount":103},[],{"trials":284,"activeCount":103},[],{"trials":286,"activeCount":103},[],{"trials":288,"activeCount":103},[],{"trials":290,"activeCount":175,"soonestReadout":57},[291],{"nctId":55,"briefTitle":56,"status":127,"phases":292,"primaryCompletion":57,"completion":293,"start":57,"enrollment":294,"conditions":295,"interventions":298},[94],"2026-09-01",88,[296,297],"Diabetic Patients","Acute Myocardial Infarction",[58],{"trials":300,"activeCount":103},[],{"intervention":88,"totalTrials":175,"cells":302},{"EARLY_PHASE1":303,"PHASE1":305,"PHASE2":307,"PHASE3":309,"PHASE4":311,"NA":321},{"trials":304,"activeCount":103},[],{"trials":306,"activeCount":103},[],{"trials":308,"activeCount":103},[],{"trials":310,"activeCount":103},[],{"trials":312,"activeCount":175,"soonestReadout":87},[313],{"nctId":85,"briefTitle":86,"status":115,"phases":314,"primaryCompletion":87,"completion":87,"start":315,"enrollment":316,"conditions":317,"interventions":319},[94],"2024-04-01",350,[318],"Vasoplegic Syndrome of Cardiac Surgery",[88,320],"Norepinephrine intravenous",{"trials":322,"activeCount":103},[],{"intervention":320,"totalTrials":175,"cells":324},{"EARLY_PHASE1":325,"PHASE1":327,"PHASE2":329,"PHASE3":331,"PHASE4":333,"NA":339},{"trials":326,"activeCount":103},[],{"trials":328,"activeCount":103},[],{"trials":330,"activeCount":103},[],{"trials":332,"activeCount":103},[],{"trials":334,"activeCount":175,"soonestReadout":87},[335],{"nctId":85,"briefTitle":86,"status":115,"phases":336,"primaryCompletion":87,"completion":87,"start":315,"enrollment":316,"conditions":337,"interventions":338},[94],[318],[88,320],{"trials":340,"activeCount":103},[],{"intervention":342,"totalTrials":175,"cells":343},"Amoxicillin",{"EARLY_PHASE1":344,"PHASE1":346,"PHASE2":348,"PHASE3":350,"PHASE4":352,"NA":366},{"trials":345,"activeCount":103},[],{"trials":347,"activeCount":103},[],{"trials":349,"activeCount":103},[],{"trials":351,"activeCount":103},[],{"trials":353,"activeCount":175,"soonestReadout":358},[354],{"nctId":355,"briefTitle":356,"status":127,"phases":357,"primaryCompletion":358,"completion":359,"start":244,"enrollment":360,"conditions":361,"interventions":365},"NCT07275580","Antibiotic Prophylaxis After Simple Tooth Extraction in Immunosuppressed Patients With Autoimmune Rheumatic Diseases",[94],"2029-06-01","2029-12-30",352,[133,362,363,364],"Tooth Extraction","Infection Prevention","Antibiotic Prophylaxis",[342],{"trials":367,"activeCount":103},[],{"intervention":369,"totalTrials":175,"cells":370},"Vitamin B Complex",{"EARLY_PHASE1":371,"PHASE1":373,"PHASE2":375,"PHASE3":377,"PHASE4":379,"NA":392},{"trials":372,"activeCount":103},[],{"trials":374,"activeCount":103},[],{"trials":376,"activeCount":103},[],{"trials":378,"activeCount":103},[],{"trials":380,"activeCount":175,"soonestReadout":385},[381],{"nctId":382,"briefTitle":383,"status":127,"phases":384,"primaryCompletion":385,"completion":386,"start":387,"enrollment":388,"conditions":389,"interventions":391},"NCT07592897","Vitamin B Complex for Inferior Alveolar Nerve Paresthesia Recovery",[94],"2026-11-10","2028-06-10","2026-06-10",50,[390],"Paresthesia and Hypoesthesia",[369],{"trials":393,"activeCount":103},[],{"intervention":395,"totalTrials":175,"cells":396},"Liraglutide (Saxenda) 6Mg\u002FMl Inj Pen 3Ml",{"EARLY_PHASE1":397,"PHASE1":399,"PHASE2":401,"PHASE3":403,"PHASE4":405,"NA":423},{"trials":398,"activeCount":103},[],{"trials":400,"activeCount":103},[],{"trials":402,"activeCount":103},[],{"trials":404,"activeCount":103},[],{"trials":406,"activeCount":175,"soonestReadout":411},[407],{"nctId":408,"briefTitle":409,"status":269,"phases":410,"primaryCompletion":411,"completion":412,"start":413,"enrollment":414,"conditions":415,"interventions":422},"NCT07590219","Use of Liraglutide in Children Aged 6 to 12 Years With Severe Obesity",[94],"2027-04","2028-04","2024-03-30",30,[416,417,418,419,420,421],"Severe Obesity","Cardiovascular Function","Liraglutide","Childhood Obesity","Echocardiography","Speckle Tracking",[395],{"trials":424,"activeCount":103},[],{"intervention":426,"totalTrials":175,"cells":427},"Dengue 1,2,3,4 (attenuated) vaccine",{"EARLY_PHASE1":428,"PHASE1":430,"PHASE2":432,"PHASE3":434,"PHASE4":436,"NA":458},{"trials":429,"activeCount":103},[],{"trials":431,"activeCount":103},[],{"trials":433,"activeCount":103},[],{"trials":435,"activeCount":103},[],{"trials":437,"activeCount":175,"soonestReadout":118},[438],{"nctId":439,"briefTitle":440,"status":115,"phases":441,"primaryCompletion":118,"completion":129,"start":442,"enrollment":443,"conditions":444,"interventions":457},"NCT07087912","Safety and Immunogenicity of the Live Attenuated Tetravalent Butantan-Dengue Vaccine in Autoimmune Rheumatic Diseases",[94],"2026-03-16",477,[445,446,447,448,449,450,451,452,453,454,455,456],"Rheumatoid Arthritis (RA)","Juvenile Idiopathic Arthritis (JIA)","Systemic Lupus Erythematosus (SLE)","Juvenile Systemic Lupus Erythematosus","Systemic Sclerosis (SSc)","Idiopathic Inflammatory Myopathies (IIMs)","Axial Spondyloarthritis","Psoriatic Arthritis (PsA)","Granulomatosis With Polyangiitis","Microscopic Polyangiitis","Antiphospholipid Syndrome","Takayasu Arteritis",[426],{"trials":459,"activeCount":103},[],{"intervention":461,"totalTrials":175,"cells":462},"Recombinant Zoster Vaccine",{"EARLY_PHASE1":463,"PHASE1":465,"PHASE2":467,"PHASE3":469,"PHASE4":471,"NA":483},{"trials":464,"activeCount":103},[],{"trials":466,"activeCount":103},[],{"trials":468,"activeCount":103},[],{"trials":470,"activeCount":103},[],{"trials":472,"activeCount":175,"soonestReadout":477},[473],{"nctId":474,"briefTitle":475,"status":115,"phases":476,"primaryCompletion":477,"completion":478,"start":479,"enrollment":480,"conditions":481,"interventions":482},"NCT07280741","Recombinant Herpes Zoster Vaccine in Patients With Autoimmune Rheumatic Diseases Under Immunomodulators",[94],"2027-07-30","2028-07-30","2025-12-02",200,[133],[461],{"trials":484,"activeCount":103},[],{"intervention":212,"totalTrials":175,"cells":486},{"EARLY_PHASE1":487,"PHASE1":489,"PHASE2":491,"PHASE3":493,"PHASE4":495,"NA":501},{"trials":488,"activeCount":103},[],{"trials":490,"activeCount":103},[],{"trials":492,"activeCount":103},[],{"trials":494,"activeCount":103},[],{"trials":496,"activeCount":175,"soonestReadout":52},[497],{"nctId":50,"briefTitle":51,"status":115,"phases":498,"primaryCompletion":52,"completion":206,"start":207,"enrollment":208,"conditions":499,"interventions":500},[94],[210],[53,212],{"trials":502,"activeCount":103},[],{"intervention":504,"totalTrials":175,"cells":505},"Intravenous Esketamine",{"EARLY_PHASE1":506,"PHASE1":508,"PHASE2":510,"PHASE3":512,"PHASE4":514,"NA":529},{"trials":507,"activeCount":103},[],{"trials":509,"activeCount":103},[],{"trials":511,"activeCount":103},[],{"trials":513,"activeCount":103},[],{"trials":515,"activeCount":175,"soonestReadout":520},[516],{"nctId":517,"briefTitle":518,"status":127,"phases":519,"primaryCompletion":520,"completion":521,"start":522,"enrollment":523,"conditions":524,"interventions":528},"NCT07120477","Esketamine Versus Crisis Response Planning Versus Optimized Treatment as Usual for Suicide Prevention: A Pragmatic Controlled Trial in Two Brazilian Cities",[94],"2028-12","2029-12","2026-05",468,[525,526,527],"Suicide Prevention","Ketamine","Crisis Response Plan",[504],{"trials":530,"activeCount":103},[],{"intervention":78,"totalTrials":175,"cells":532},{"EARLY_PHASE1":533,"PHASE1":535,"PHASE2":537,"PHASE3":539,"PHASE4":541,"NA":550},{"trials":534,"activeCount":103},[],{"trials":536,"activeCount":103},[],{"trials":538,"activeCount":103},[],{"trials":540,"activeCount":103},[],{"trials":542,"activeCount":175,"soonestReadout":77},[543],{"nctId":75,"briefTitle":76,"status":115,"phases":544,"primaryCompletion":77,"completion":522,"start":545,"enrollment":247,"conditions":546,"interventions":549},[94],"2024-01-08",[547,548],"Sleep Apnea","Chronic Kidney Diseases",[78],{"trials":551,"activeCount":103},[],{"intervention":553,"totalTrials":175,"cells":554},"Recombinant Herpes Zoster Vaccine",{"EARLY_PHASE1":555,"PHASE1":557,"PHASE2":559,"PHASE3":561,"PHASE4":563,"NA":586},{"trials":556,"activeCount":103},[],{"trials":558,"activeCount":103},[],{"trials":560,"activeCount":103},[],{"trials":562,"activeCount":103},[],{"trials":564,"activeCount":175,"soonestReadout":569},[565],{"nctId":566,"briefTitle":567,"status":269,"phases":568,"primaryCompletion":569,"completion":570,"start":571,"enrollment":572,"conditions":573,"interventions":585},"NCT05879419","Recombinant Herpes Zoster Vaccine in Patients With Autoimmune Rheumatic Diseases",[94],"2025-12-01","2032-06-30","2023-05-23",2005,[574,575,576,577,578,579,580,581,582,583,584],"Rheumatoid Arthritis","Spondylitis, Ankylosing","Spondyloarthritis","Systemic Lupus Erythematosus","Sjogren's Syndrome","Systemic Sclerosis","Idiopathic Inflammatory Myopathies","Vasculitis, Systemic","Juvenile Idiopathic Arthritis","Dermatomyositis, Juvenile","Behçet Disease",[553],{"trials":587,"activeCount":103},[],{"intervention":589,"totalTrials":175,"cells":590},"Meningococcal B",{"EARLY_PHASE1":591,"PHASE1":593,"PHASE2":595,"PHASE3":597,"PHASE4":599,"NA":609},{"trials":592,"activeCount":103},[],{"trials":594,"activeCount":103},[],{"trials":596,"activeCount":103},[],{"trials":598,"activeCount":103},[],{"trials":600,"activeCount":175,"soonestReadout":117},[601],{"nctId":602,"briefTitle":603,"status":115,"phases":604,"primaryCompletion":117,"completion":118,"start":605,"enrollment":606,"conditions":607,"interventions":608},"NCT07252804","Immunogenicity and Safety of MenB Vaccine in Pediatric Patients With Autoimmune Rheumatic Diseases",[94],"2026-02-19",263,[122],[589],{"trials":610,"activeCount":103},[],{"intervention":612,"totalTrials":175,"cells":613},"clonidine",{"EARLY_PHASE1":614,"PHASE1":616,"PHASE2":618,"PHASE3":620,"PHASE4":622,"NA":637},{"trials":615,"activeCount":103},[],{"trials":617,"activeCount":103},[],{"trials":619,"activeCount":103},[],{"trials":621,"activeCount":103},[],{"trials":623,"activeCount":175,"soonestReadout":628},[624],{"nctId":625,"briefTitle":626,"status":115,"phases":627,"primaryCompletion":628,"completion":629,"start":630,"enrollment":631,"conditions":632,"interventions":635},"NCT07313371","Efficacy of Clonidine in Reducing Craving in Inpatients With Cocaine and Crack Use Disorder",[94],"2026-07","2027-07","2026-01-28",36,[633,634],"Cocaine Use Disorder","Crack Abuse or Dependence",[612,636],"clonazepam 0,25 mg",{"trials":638,"activeCount":103},[],{"intervention":636,"totalTrials":175,"cells":640},{"EARLY_PHASE1":641,"PHASE1":643,"PHASE2":645,"PHASE3":647,"PHASE4":649,"NA":655},{"trials":642,"activeCount":103},[],{"trials":644,"activeCount":103},[],{"trials":646,"activeCount":103},[],{"trials":648,"activeCount":103},[],{"trials":650,"activeCount":175,"soonestReadout":628},[651],{"nctId":625,"briefTitle":626,"status":115,"phases":652,"primaryCompletion":628,"completion":629,"start":630,"enrollment":631,"conditions":653,"interventions":654},[94],[633,634],[612,636],{"trials":656,"activeCount":103},[],{"intervention":658,"totalTrials":99,"cells":659},"Promestriene Vaginal",{"EARLY_PHASE1":660,"PHASE1":662,"PHASE2":664,"PHASE3":666,"PHASE4":668,"NA":682},{"trials":661,"activeCount":103},[],{"trials":663,"activeCount":103},[],{"trials":665,"activeCount":103},[],{"trials":667,"activeCount":103},[],{"trials":669,"activeCount":175,"soonestReadout":674},[670],{"nctId":671,"briefTitle":672,"status":115,"phases":673,"primaryCompletion":674,"completion":675,"start":676,"enrollment":235,"conditions":677,"interventions":681},"NCT07153276","TREATMENT OF VAGINAL DRYNESS IN SJÖGREN'S DISEASE WITH CO2-LASER VERSUS TOPICAL PROMESTRIENE",[94],"2029-09-27","2030-01-30","2026-02-27",[678,679,680],"Sjogren Syndrome","Sjogren Disease","Primary Sjogren Syndrome",[658],{"trials":683,"activeCount":103},[684],{"nctId":685,"briefTitle":686,"status":165,"phases":687,"primaryCompletion":688,"completion":689,"start":690,"enrollment":691,"conditions":692,"interventions":694},"NCT04717245","Comparative Study: Vaginal Promestriene Use, Fractional CO2 LASER and Radiofrequency in the Vaginal Atrophy Treatment",[95],"2019-03-07","2020-02-18","2018-10-25",75,[693],"Vaginal Atrophy",[658],{"intervention":696,"totalTrials":697,"cells":698},"Clopidogrel",5,{"EARLY_PHASE1":699,"PHASE1":701,"PHASE2":703,"PHASE3":718,"PHASE4":744,"NA":758},{"trials":700,"activeCount":103},[],{"trials":702,"activeCount":103},[],{"trials":704,"activeCount":103},[705],{"nctId":706,"briefTitle":707,"status":165,"phases":708,"primaryCompletion":709,"completion":709,"start":710,"enrollment":170,"conditions":711,"interventions":716},"NCT03039205","Platelet Aggregation in Patients With Coronary Artery Disease and Kidney Dysfunction Taking Clopidogrel or Ticagrelor",[92],"2019-12-19","2017-11-07",[712,713,25,714,715],"Platelet Aggregation","Adenosine","Kidney Dysfunction","Antiplatelet Therapy",[696,717],"Ticagrelor",{"trials":719,"activeCount":175,"soonestReadout":737},[720,733],{"nctId":721,"briefTitle":722,"status":165,"phases":723,"primaryCompletion":724,"completion":724,"start":725,"enrollment":726,"conditions":727,"interventions":730},"NCT05122455","Effects of Edoxaban on Platelet Aggregation",[92,93],"2024-06-24","2021-09-14",61,[728,729],"SCAD","AMI",[731,696,732],"ASA","Edoxaban",{"nctId":734,"briefTitle":735,"status":269,"phases":736,"primaryCompletion":737,"completion":738,"start":739,"enrollment":740,"conditions":741,"interventions":743},"NCT06872541","Evaluation of Platelet Aggregability in Patients with Non-small Cell Lung Carcinomas",[92,93],"2026-10-20","2027-10-20","2025-01-20",100,[742],"Assessment of Platelet Aggregability in Patients Patients with Non-small Cell Lung Carcinoma",[696],{"trials":745,"activeCount":103},[746],{"nctId":747,"briefTitle":748,"status":165,"phases":749,"primaryCompletion":750,"completion":750,"start":751,"enrollment":752,"conditions":753,"interventions":755},"NCT01896557","Ranitidin Versus Omeprazole in Patients Taking Clopidogrel",[94],"2013-06","2011-10",92,[25,754],"Drug Interaction Potentiation",[756,757,696],"omeprazole","Ranitidine",{"trials":759,"activeCount":175,"soonestReadout":764},[760],{"nctId":761,"briefTitle":762,"status":269,"phases":763,"primaryCompletion":764,"completion":765,"start":766,"enrollment":740,"conditions":767,"interventions":769},"NCT06454045","Evaluation of Platelet Aggregability in Patients With Previous Acute Myocardial Infarction or Concomitant Lower Extremity Peripheral Artery Disease",[],"2026-05-13","2028-05-13","2024-05-13",[25,768],"Peripheral Arterial Disease",[696],{"intervention":771,"totalTrials":99,"cells":772},"Dapagliflozin",{"EARLY_PHASE1":773,"PHASE1":775,"PHASE2":777,"PHASE3":779,"PHASE4":792,"NA":806},{"trials":774,"activeCount":103},[],{"trials":776,"activeCount":103},[],{"trials":778,"activeCount":103},[],{"trials":780,"activeCount":175,"soonestReadout":87},[781],{"nctId":782,"briefTitle":783,"status":115,"phases":784,"primaryCompletion":87,"completion":87,"start":785,"enrollment":208,"conditions":786,"interventions":791},"NCT06286878","Pleiotropic Effects of Dapagliflozin in Patients With Acute Coronary Syndromes",[92,93],"2021-12-08",[787,788,789,790],"Myocardial Infarction","Acute Coronary Syndrome","Diabetes","Ventricular Dysfunction",[771],{"trials":793,"activeCount":103},[794],{"nctId":795,"briefTitle":796,"status":165,"phases":797,"primaryCompletion":798,"completion":798,"start":799,"enrollment":800,"conditions":801,"interventions":805},"NCT04743453","EFFECT OF ADDING DAPAGLIFLOZIN TO ALLOGRAFT DYSFUNCTION OF RENAL TRANSPLANTED PATIENTS.",[94],"2024-09-02","2021-08-17",211,[802,803,804],"Kidney Transplantation","Diabetes Mellitus, Type 2","Diabetes Complications",[771],{"trials":807,"activeCount":103},[],{"intervention":809,"totalTrials":99,"cells":810},"Cabergoline",{"EARLY_PHASE1":811,"PHASE1":813,"PHASE2":815,"PHASE3":817,"PHASE4":842,"NA":844},{"trials":812,"activeCount":103},[],{"trials":814,"activeCount":103},[],{"trials":816,"activeCount":103},[],{"trials":818,"activeCount":175,"soonestReadout":823},[819,830],{"nctId":820,"briefTitle":821,"status":115,"phases":822,"primaryCompletion":823,"completion":824,"start":825,"enrollment":273,"conditions":826,"interventions":829},"NCT07463235","Safety and Potency of a High Cabergoline Dosage in Microprolactinomas",[93],"2027-08-20","2029-12-20","2026-03-04",[827,828],"Prolactinoma","Prolactin Excess",[809,809],{"nctId":831,"briefTitle":832,"status":165,"phases":833,"primaryCompletion":834,"completion":835,"start":836,"enrollment":837,"conditions":838,"interventions":841},"NCT03271918","Cabergoline in Nonfunctioning Pituitary Adenomas",[93],"2017-02-01","2017-08-01","2015-02-01",140,[839,840],"Pituitary Adenoma","Nonfunctioning Pituitary Adenoma",[809],{"trials":843,"activeCount":103},[],{"trials":845,"activeCount":103},[],{"intervention":847,"totalTrials":175,"cells":848},"testosterone pellet",{"EARLY_PHASE1":849,"PHASE1":851,"PHASE2":853,"PHASE3":855,"PHASE4":869,"NA":871},{"trials":850,"activeCount":103},[],{"trials":852,"activeCount":103},[],{"trials":854,"activeCount":103},[],{"trials":856,"activeCount":175,"soonestReadout":861},[857],{"nctId":858,"briefTitle":859,"status":115,"phases":860,"primaryCompletion":861,"completion":862,"start":863,"enrollment":837,"conditions":864,"interventions":868},"NCT06343870","Estradiol and Testosterone Subdermal Implants for Menopause Treatment (ESTIME)",[93],"2026-08-18","2027-04-30","2025-12-18",[865,866,867],"Menopause","Testosterone Deficiency","Estrogen Deficiency",[847],{"trials":870,"activeCount":103},[],{"trials":872,"activeCount":103},[],{"intervention":874,"totalTrials":175,"cells":875},"Lacosamide",{"EARLY_PHASE1":876,"PHASE1":878,"PHASE2":880,"PHASE3":882,"PHASE4":893,"NA":895},{"trials":877,"activeCount":103},[],{"trials":879,"activeCount":103},[],{"trials":881,"activeCount":103},[],{"trials":883,"activeCount":175,"soonestReadout":888},[884],{"nctId":885,"briefTitle":886,"status":115,"phases":887,"primaryCompletion":888,"completion":888,"start":889,"enrollment":17,"conditions":890,"interventions":892},"NCT07412132","Evaluation of the Efficacy, Safety, and Tolerability of Lacosamide in Major Depressive Episodes of Bipolar Disorder Types I and II.",[93],"2027-01","2026-01-09",[891],"Bipolar Affective Disorder",[874],{"trials":894,"activeCount":103},[],{"trials":896,"activeCount":103},[],{"intervention":898,"totalTrials":175,"cells":899},"Control Arm",{"EARLY_PHASE1":900,"PHASE1":902,"PHASE2":904,"PHASE3":906,"PHASE4":920,"NA":922},{"trials":901,"activeCount":103},[],{"trials":903,"activeCount":103},[],{"trials":905,"activeCount":103},[],{"trials":907,"activeCount":175,"soonestReadout":912},[908],{"nctId":909,"briefTitle":910,"status":115,"phases":911,"primaryCompletion":912,"completion":913,"start":914,"enrollment":915,"conditions":916,"interventions":918},"NCT07381972","Photodynamic Therapy Associated With Sonodynamic Therapy for the Treatment of Nodular Basal Cell Carcinoma",[93],"2026-08","2026-12","2025-11-24",142,[917],"Nodular Basal Cell Carcinoma of Skin",[898,919],"Experimental arm",{"trials":921,"activeCount":103},[],{"trials":923,"activeCount":103},[],{"intervention":919,"totalTrials":175,"cells":925},{"EARLY_PHASE1":926,"PHASE1":928,"PHASE2":930,"PHASE3":932,"PHASE4":938,"NA":940},{"trials":927,"activeCount":103},[],{"trials":929,"activeCount":103},[],{"trials":931,"activeCount":103},[],{"trials":933,"activeCount":175,"soonestReadout":912},[934],{"nctId":909,"briefTitle":910,"status":115,"phases":935,"primaryCompletion":912,"completion":913,"start":914,"enrollment":915,"conditions":936,"interventions":937},[93],[917],[898,919],{"trials":939,"activeCount":103},[],{"trials":941,"activeCount":103},[],{"intervention":943,"totalTrials":175,"cells":944},"Dendritic Cell Vaccine",{"EARLY_PHASE1":945,"PHASE1":947,"PHASE2":949,"PHASE3":951,"PHASE4":965,"NA":967},{"trials":946,"activeCount":103},[],{"trials":948,"activeCount":103},[],{"trials":950,"activeCount":103},[],{"trials":952,"activeCount":175,"soonestReadout":957},[953],{"nctId":954,"briefTitle":955,"status":127,"phases":956,"primaryCompletion":957,"completion":958,"start":959,"enrollment":960,"conditions":961,"interventions":963},"NCT06749925","Clinical Trial Assessing the Efficacy and Safety of Dendritic Cell-Based Immunotherapy for Glioblastoma",[93],"2028-01","2029-01","2026-01",186,[962],"Glioblastoma",[943,964],"Pembrolizumab",{"trials":966,"activeCount":103},[],{"trials":968,"activeCount":103},[],{"intervention":964,"totalTrials":175,"cells":970},{"EARLY_PHASE1":971,"PHASE1":973,"PHASE2":975,"PHASE3":977,"PHASE4":983,"NA":985},{"trials":972,"activeCount":103},[],{"trials":974,"activeCount":103},[],{"trials":976,"activeCount":103},[],{"trials":978,"activeCount":175,"soonestReadout":957},[979],{"nctId":954,"briefTitle":955,"status":127,"phases":980,"primaryCompletion":957,"completion":958,"start":959,"enrollment":960,"conditions":981,"interventions":982},[93],[962],[943,964],{"trials":984,"activeCount":103},[],{"trials":986,"activeCount":103},[],{"intervention":988,"totalTrials":989,"cells":990},"Ayahuasca",4,{"EARLY_PHASE1":991,"PHASE1":993,"PHASE2":995,"PHASE3":1019,"PHASE4":1021,"NA":1023},{"trials":992,"activeCount":103},[],{"trials":994,"activeCount":103},[],{"trials":996,"activeCount":175,"soonestReadout":1001},[997,1008],{"nctId":998,"briefTitle":999,"status":115,"phases":1000,"primaryCompletion":1001,"completion":628,"start":1002,"enrollment":1003,"conditions":1004,"interventions":1006},"NCT07317206","Ayahuasca, Esketamine and PTSD",[92],"2026-06","2025-12-20",10,[1005],"Posttraumatic Stress Disorder (PTSD)",[988,1007],"Esketamine",{"nctId":1009,"briefTitle":1010,"status":165,"phases":1011,"primaryCompletion":1012,"completion":1013,"start":1014,"enrollment":1015,"conditions":1016,"interventions":1018},"NCT07212946","Ayahuasca and Esketamine for Major Depression",[92],"2024-10-30","2025-10-01","2022-10-30",22,[1017],"Major Depression Severe",[988,1007],{"trials":1020,"activeCount":103},[],{"trials":1022,"activeCount":103},[],{"trials":1024,"activeCount":99,"soonestReadout":1001},[1025,1032],{"nctId":1026,"briefTitle":1027,"status":115,"phases":1028,"primaryCompletion":1001,"completion":628,"start":1002,"enrollment":32,"conditions":1029,"interventions":1031},"NCT07317219","Ayahuasca, Esketamine and Body Image Perception",[95],[1030],"Healthy Women Volunteers",[988,1007],{"nctId":1033,"briefTitle":1034,"status":115,"phases":1035,"primaryCompletion":1001,"completion":628,"start":1002,"enrollment":32,"conditions":1036,"interventions":1037},"NCT07317232","Ayahuasca, Esketamine and Premenstrual Symptoms",[95],[1030],[988,1007],{"intervention":1007,"totalTrials":989,"cells":1039},{"EARLY_PHASE1":1040,"PHASE1":1042,"PHASE2":1044,"PHASE3":1054,"PHASE4":1056,"NA":1058},{"trials":1041,"activeCount":103},[],{"trials":1043,"activeCount":103},[],{"trials":1045,"activeCount":175,"soonestReadout":1001},[1046,1050],{"nctId":998,"briefTitle":999,"status":115,"phases":1047,"primaryCompletion":1001,"completion":628,"start":1002,"enrollment":1003,"conditions":1048,"interventions":1049},[92],[1005],[988,1007],{"nctId":1009,"briefTitle":1010,"status":165,"phases":1051,"primaryCompletion":1012,"completion":1013,"start":1014,"enrollment":1015,"conditions":1052,"interventions":1053},[92],[1017],[988,1007],{"trials":1055,"activeCount":103},[],{"trials":1057,"activeCount":103},[],{"trials":1059,"activeCount":99,"soonestReadout":1001},[1060,1064],{"nctId":1026,"briefTitle":1027,"status":115,"phases":1061,"primaryCompletion":1001,"completion":628,"start":1002,"enrollment":32,"conditions":1062,"interventions":1063},[95],[1030],[988,1007],{"nctId":1033,"briefTitle":1034,"status":115,"phases":1065,"primaryCompletion":1001,"completion":628,"start":1002,"enrollment":32,"conditions":1066,"interventions":1067},[95],[1030],[988,1007],{"intervention":1069,"totalTrials":175,"cells":1070},"CART-19",{"EARLY_PHASE1":1071,"PHASE1":1073,"PHASE2":1075,"PHASE3":1087,"PHASE4":1089,"NA":1091},{"trials":1072,"activeCount":103},[],{"trials":1074,"activeCount":103},[],{"trials":1076,"activeCount":175,"soonestReadout":520},[1077],{"nctId":1078,"briefTitle":1079,"status":115,"phases":1080,"primaryCompletion":520,"completion":520,"start":1081,"enrollment":1082,"conditions":1083,"interventions":1086},"NCT06101381","CD19-directed CAR-T Cell Therapy for R\u002FR Acute Leukemia and Lymphoma",[91,92],"2024-03-21",81,[1084,1085],"Leukemia, Acute Lymphoblastic","Lymphoma, Non-Hodgkin",[1069],{"trials":1088,"activeCount":103},[],{"trials":1090,"activeCount":103},[],{"trials":1092,"activeCount":103},[],{"intervention":1094,"totalTrials":175,"cells":1095},"Subcutaneous Testosterone Implants",{"EARLY_PHASE1":1096,"PHASE1":1098,"PHASE2":1100,"PHASE3":1112,"PHASE4":1114,"NA":1116},{"trials":1097,"activeCount":103},[],{"trials":1099,"activeCount":103},[],{"trials":1101,"activeCount":175,"soonestReadout":1001},[1102],{"nctId":1103,"briefTitle":1104,"status":127,"phases":1105,"primaryCompletion":1001,"completion":411,"start":1106,"enrollment":414,"conditions":1107,"interventions":1111},"NCT07500766","Clinical Evaluation of Subcutaneous Testosterone Implants in Men With Symptomatic Hypogonadism",[92],"2026-03",[1108,866,1109,1110],"Male Hypogonadism","Testosterone Replacement Therapy","Testosterone",[1094],{"trials":1113,"activeCount":103},[],{"trials":1115,"activeCount":103},[],{"trials":1117,"activeCount":103},[],{"intervention":1119,"totalTrials":175,"cells":1120},"StrepIncor",{"EARLY_PHASE1":1121,"PHASE1":1123,"PHASE2":1125,"PHASE3":1141,"PHASE4":1143,"NA":1145},{"trials":1122,"activeCount":103},[],{"trials":1124,"activeCount":103},[],{"trials":1126,"activeCount":175,"soonestReadout":1131},[1127],{"nctId":1128,"briefTitle":1129,"status":127,"phases":1130,"primaryCompletion":1131,"completion":1132,"start":1013,"enrollment":235,"conditions":1133,"interventions":1140},"NCT07078357","Clinical Trial Phase I\u002FIIa to Evaluate the Safety and Immunogenicity of StreptInCor",[91,92],"2027-10-01","2028-12-01",[1134,1135,1136,1137,1138,1139],"Rheumatic Heart Disease","Rheumatic Heart Disease in Children","Vaccine Adverse Reaction","Rheumatic Diseases","Vaccine Acceptance","Vaccine",[1119],{"trials":1142,"activeCount":103},[],{"trials":1144,"activeCount":103},[],{"trials":1146,"activeCount":103},[],{"intervention":73,"totalTrials":99,"cells":1148},{"EARLY_PHASE1":1149,"PHASE1":1151,"PHASE2":1153,"PHASE3":1163,"PHASE4":1165,"NA":1167},{"trials":1150,"activeCount":103},[],{"trials":1152,"activeCount":103},[],{"trials":1154,"activeCount":175,"soonestReadout":72},[1155],{"nctId":70,"briefTitle":71,"status":115,"phases":1156,"primaryCompletion":72,"completion":1157,"start":1158,"enrollment":17,"conditions":1159,"interventions":1162},[92],"2026-01-01","2024-01-01",[1160,1161],"Skin Scarring","Eyebrow Ptosis",[73],{"trials":1164,"activeCount":103},[],{"trials":1166,"activeCount":103},[],{"trials":1168,"activeCount":103},[1169],{"nctId":1170,"briefTitle":1171,"status":165,"phases":1172,"primaryCompletion":1173,"completion":1174,"start":1175,"enrollment":1176,"conditions":1177,"interventions":1179},"NCT00989209","Myofunctional Therapy in Facial Palsy",[95],"2005-12","2006-12","2005-01",25,[1178],"Facial Paralysis",[1180],"Botulinum Toxin Type A",{"intervention":1182,"totalTrials":175,"cells":1183},"Intervention1: Cannabidiol",{"EARLY_PHASE1":1184,"PHASE1":1197,"PHASE2":1199,"PHASE3":1201,"PHASE4":1203,"NA":1205},{"trials":1185,"activeCount":175,"soonestReadout":1190},[1186],{"nctId":1187,"briefTitle":1188,"status":127,"phases":1189,"primaryCompletion":1190,"completion":245,"start":1191,"enrollment":1192,"conditions":1193,"interventions":1195},"NCT06617247","Effects of Cannabidiol on Burnout Syndrome and Empathy of Caregivers of Older Adults",[90],"2026-12-01","2024-12-01",26,[1194],"Burnout Syndrome",[1182,1196],"Intervention 2: Placebo",{"trials":1198,"activeCount":103},[],{"trials":1200,"activeCount":103},[],{"trials":1202,"activeCount":103},[],{"trials":1204,"activeCount":103},[],{"trials":1206,"activeCount":103},[],{"intervention":1196,"totalTrials":175,"cells":1208},{"EARLY_PHASE1":1209,"PHASE1":1215,"PHASE2":1217,"PHASE3":1219,"PHASE4":1221,"NA":1223},{"trials":1210,"activeCount":175,"soonestReadout":1190},[1211],{"nctId":1187,"briefTitle":1188,"status":127,"phases":1212,"primaryCompletion":1190,"completion":245,"start":1191,"enrollment":1192,"conditions":1213,"interventions":1214},[90],[1194],[1182,1196],{"trials":1216,"activeCount":103},[],{"trials":1218,"activeCount":103},[],{"trials":1220,"activeCount":103},[],{"trials":1222,"activeCount":103},[],{"trials":1224,"activeCount":103},[],{"intervention":1226,"totalTrials":175,"cells":1227},"CTZ Paste",{"EARLY_PHASE1":1228,"PHASE1":1249,"PHASE2":1251,"PHASE3":1253,"PHASE4":1255,"NA":1257},{"trials":1229,"activeCount":175,"soonestReadout":1234},[1230],{"nctId":1231,"briefTitle":1232,"status":127,"phases":1233,"primaryCompletion":1234,"completion":1235,"start":1236,"enrollment":1237,"conditions":1238,"interventions":1248},"NCT07542639","Chloramphenicol, Tetracycline, Zinc Oxide and Eugenol Paste (CTZ Paste) for Emergency Dental Treatment in Public Health Settings: A Randomized Trial",[90],"2027-12-20","2028-02-28","2026-06-08",110,[1239,1240,1241,1242,1243,1244,1245,1246,34,1247],"Pulp Disease, Dental","Pulp Necrosis","Pulp Therapy in Primary Molars","Primary Teeth","Pulpectomy","Endodontics","Dental Care for Children","Treatment Outcome","Health Services Accessibility",[1226],{"trials":1250,"activeCount":103},[],{"trials":1252,"activeCount":103},[],{"trials":1254,"activeCount":103},[],{"trials":1256,"activeCount":103},[],{"trials":1258,"activeCount":103},[],{"intervention":1260,"totalTrials":99,"cells":1261},"Selexipag",{"EARLY_PHASE1":1262,"PHASE1":1264,"PHASE2":1266,"PHASE3":1279,"PHASE4":1281,"NA":1283},{"trials":1263,"activeCount":103},[],{"trials":1265,"activeCount":103},[],{"trials":1267,"activeCount":103},[1268],{"nctId":1269,"briefTitle":1270,"status":193,"phases":1271,"primaryCompletion":1272,"completion":1273,"start":1274,"enrollment":32,"conditions":1275,"interventions":1278},"NCT04589390","Selexipag for the Treatment of Schistosomiasis-Associated Pulmonary Arterial Hypertension",[92],"2021-11-30","2022-03-31","2020-10-15",[1276,1277],"Pulmonary Hypertension","Schistosomiasis",[1260],{"trials":1280,"activeCount":103},[],{"trials":1282,"activeCount":103},[],{"trials":1284,"activeCount":175,"soonestReadout":245},[1285],{"nctId":1286,"briefTitle":1287,"status":127,"phases":1288,"primaryCompletion":245,"completion":245,"start":1289,"enrollment":1290,"conditions":1291,"interventions":1293},"NCT07356375","Patient-Reported Outcomes and Adherence After Transition From Inhaled Iloprost to Oral Selexipag in Pulmonary Arterial Hypertension",[],"2026-03-01",32,[1292],"Pulmonary Arterial Hypertension (PAH)",[1260],{"intervention":68,"totalTrials":99,"cells":1295},{"EARLY_PHASE1":1296,"PHASE1":1298,"PHASE2":1300,"PHASE3":1302,"PHASE4":1304,"NA":1317},{"trials":1297,"activeCount":103},[],{"trials":1299,"activeCount":103},[],{"trials":1301,"activeCount":103},[],{"trials":1303,"activeCount":103},[],{"trials":1305,"activeCount":103},[1306],{"nctId":1307,"briefTitle":1308,"status":193,"phases":1309,"primaryCompletion":1013,"completion":569,"start":1310,"enrollment":1311,"conditions":1312,"interventions":1316},"NCT06005259","Effect of Spironolactone in the Prevention of Anthracycline-induced Cardiotoxicity (SPIROTOX)",[94],"2023-10-01",264,[1313,1314,1315,19],"Cardiotoxicity","Neoplasms","Chemotherapy Effect",[68],{"trials":1318,"activeCount":175,"soonestReadout":67},[1319],{"nctId":65,"briefTitle":66,"status":1320,"phases":1321,"primaryCompletion":67,"completion":1322,"start":1323,"enrollment":1324,"conditions":1325,"interventions":1327},"ENROLLING_BY_INVITATION",[95],"2027-07-01","2024-07-24",12,[1326],"HIV",[68],{"intervention":1329,"totalTrials":175,"cells":1330},"Iloprost is a synthetic molecule with pharmacological action",{"EARLY_PHASE1":1331,"PHASE1":1333,"PHASE2":1335,"PHASE3":1337,"PHASE4":1339,"NA":1341},{"trials":1332,"activeCount":103},[],{"trials":1334,"activeCount":103},[],{"trials":1336,"activeCount":103},[],{"trials":1338,"activeCount":103},[],{"trials":1340,"activeCount":103},[],{"trials":1342,"activeCount":175,"soonestReadout":1347},[1343],{"nctId":1344,"briefTitle":1345,"status":127,"phases":1346,"primaryCompletion":1347,"completion":1348,"start":1349,"enrollment":1350,"conditions":1351,"interventions":1355},"NCT07263958","Hemodynamic Effects of Inhaled Iloprost in PH-COPD (HOLLYWOOD)",[95],"2026-06-30","2026-12-20","2025-12-10",15,[1352,1353,1354],"Pulmnary Hypertension","COPD","Pulmonary Hypertension Secondary to Lung Disease and\u002For Hypoxia",[1329],{"intervention":83,"totalTrials":175,"cells":1357},{"EARLY_PHASE1":1358,"PHASE1":1360,"PHASE2":1362,"PHASE3":1364,"PHASE4":1366,"NA":1368},{"trials":1359,"activeCount":103},[],{"trials":1361,"activeCount":103},[],{"trials":1363,"activeCount":103},[],{"trials":1365,"activeCount":103},[],{"trials":1367,"activeCount":103},[],{"trials":1369,"activeCount":175,"soonestReadout":82},[1370],{"nctId":80,"briefTitle":81,"status":115,"phases":1371,"primaryCompletion":82,"completion":206,"start":1372,"enrollment":1373,"conditions":1374,"interventions":1376},[95],"2024-09-16",38,[1375],"Aging Well",[83],{"intervention":48,"totalTrials":175,"cells":1378},{"EARLY_PHASE1":1379,"PHASE1":1381,"PHASE2":1383,"PHASE3":1385,"PHASE4":1387,"NA":1389},{"trials":1380,"activeCount":103},[],{"trials":1382,"activeCount":103},[],{"trials":1384,"activeCount":103},[],{"trials":1386,"activeCount":103},[],{"trials":1388,"activeCount":103},[],{"trials":1390,"activeCount":175,"soonestReadout":47},[1391],{"nctId":45,"briefTitle":46,"status":115,"phases":1392,"primaryCompletion":47,"completion":1393,"start":1175,"enrollment":235,"conditions":1394,"interventions":1395},[],"2024-12-04",[580],[48],{"intervention":43,"totalTrials":175,"cells":1397},{"EARLY_PHASE1":1398,"PHASE1":1400,"PHASE2":1402,"PHASE3":1404,"PHASE4":1406,"NA":1408},{"trials":1399,"activeCount":103},[],{"trials":1401,"activeCount":103},[],{"trials":1403,"activeCount":103},[],{"trials":1405,"activeCount":103},[],{"trials":1407,"activeCount":103},[],{"trials":1409,"activeCount":175,"soonestReadout":42},[1410],{"nctId":40,"briefTitle":41,"status":115,"phases":1411,"primaryCompletion":42,"completion":520,"start":1412,"enrollment":17,"conditions":1413,"interventions":1415},[95],"2015-03-23",[1414],"Vogt Koyanagi Harada Disease",[43],{"intervention":63,"totalTrials":175,"cells":1417},{"EARLY_PHASE1":1418,"PHASE1":1420,"PHASE2":1422,"PHASE3":1424,"PHASE4":1426,"NA":1428},{"trials":1419,"activeCount":103},[],{"trials":1421,"activeCount":103},[],{"trials":1423,"activeCount":103},[],{"trials":1425,"activeCount":103},[],{"trials":1427,"activeCount":103},[],{"trials":1429,"activeCount":175,"soonestReadout":62},[1430],{"nctId":60,"briefTitle":61,"status":115,"phases":1431,"primaryCompletion":62,"completion":1432,"start":1433,"enrollment":1434,"conditions":1435,"interventions":1437},[95],"2026-09-30","2022-06-03",48,[1436],"Eisenmenger Syndrome",[63],{"intervention":1439,"totalTrials":175,"cells":1440},"Empagliflozin",{"EARLY_PHASE1":1441,"PHASE1":1443,"PHASE2":1445,"PHASE3":1447,"PHASE4":1449,"NA":1451},{"trials":1442,"activeCount":103},[],{"trials":1444,"activeCount":103},[],{"trials":1446,"activeCount":103},[],{"trials":1448,"activeCount":103},[],{"trials":1450,"activeCount":103},[],{"trials":1452,"activeCount":175,"soonestReadout":1457},[1453],{"nctId":1454,"briefTitle":1455,"status":127,"phases":1456,"primaryCompletion":1457,"completion":913,"start":1458,"enrollment":32,"conditions":1459,"interventions":1463},"NCT07472920","Empagliflozin Adjunctive Therapy in Bipolar Depression",[95],"2026-09","2026-03-09",[1460,1461,1462],"Bipolar Disorder","Bipolar Depression","Insulin Resistance",[1439],{"intervention":1465,"totalTrials":1466,"cells":1467},"Empagliflozin 25 MG",3,{"EARLY_PHASE1":1468,"PHASE1":1470,"PHASE2":1472,"PHASE3":1474,"PHASE4":1476,"NA":1509},{"trials":1469,"activeCount":103},[],{"trials":1471,"activeCount":103},[],{"trials":1473,"activeCount":103},[],{"trials":1475,"activeCount":103},[],{"trials":1477,"activeCount":103},[1478,1489,1499],{"nctId":1479,"briefTitle":1480,"status":165,"phases":1481,"primaryCompletion":1482,"completion":1482,"start":1483,"enrollment":1484,"conditions":1485,"interventions":1488},"NCT04523064","POST-CABGDM: Empagliflozin in Perioperative CABG",[94],"2024-01-30","2020-09-22",155,[803,25,1486,1487],"Coronary Artery Bypass Surgery","Acute Kidney Injury",[1465],{"nctId":1490,"briefTitle":1491,"status":193,"phases":1492,"primaryCompletion":1493,"completion":1494,"start":1495,"enrollment":17,"conditions":1496,"interventions":1497},"NCT05037695","SGLT-2 Inhibitors in Prevention of Post-procedural Renal and Cardiovascular Complications aFter PCI Among Patients With Diabetes Mellitus and Coronary Artery Disease: a Prospective, Randomized, Pilot Study (SAFE-PCI)",[94],"2022-07","2022-12","2021-07-21",[803,25,1487],[1498],"empagliflozin 25 MG",{"nctId":1500,"briefTitle":1501,"status":165,"phases":1502,"primaryCompletion":1503,"completion":1503,"start":1504,"enrollment":170,"conditions":1505,"interventions":1508},"NCT04117763","Effect of Empagliflozin on Ventricular Repolarization.",[94],"2024-03-31","2019-10-04",[803,1506,1507],"Coronary Heart Disease","Arrythmia, Cardiac",[1465],{"trials":1510,"activeCount":103},[],{"intervention":1512,"totalTrials":1466,"cells":1513},"Placebos",{"EARLY_PHASE1":1514,"PHASE1":1516,"PHASE2":1518,"PHASE3":1533,"PHASE4":1535,"NA":1562},{"trials":1515,"activeCount":103},[],{"trials":1517,"activeCount":103},[],{"trials":1519,"activeCount":103},[1520],{"nctId":1521,"briefTitle":1522,"status":193,"phases":1523,"primaryCompletion":1524,"completion":1525,"start":1526,"enrollment":1527,"conditions":1528,"interventions":1531},"NCT03658850","Safety and Efficacy of Hydrochlorothiazide in the Treatment of Hypernatremia in Critically Ill Patients",[92],"2019-12-10","2020-03-10","2018-10-01",184,[1529,1530],"Hypernatremia","Critical Illness",[1532,1512],"Hydrochlorothiazide 50Mg",{"trials":1534,"activeCount":103},[],{"trials":1536,"activeCount":103},[1537,1552],{"nctId":1538,"briefTitle":1539,"status":193,"phases":1540,"primaryCompletion":1541,"completion":1542,"start":1543,"enrollment":1544,"conditions":1545,"interventions":1550},"NCT03440268","Prevention of Acute Kidney Injury by N-Acetylcystein in Patients Undergone Cardiac Valve Replacement",[94],"2019-03-15","2020-03-15","2018-03-15",154,[1546,1547,1487,1548,1549],"Surgery--Complications","Cardiac Valve Disease","Oxygen Radical Damage","Post-Op Complication",[1551,1512],"N Acetyl Cysteine",{"nctId":1553,"briefTitle":1554,"status":193,"phases":1555,"primaryCompletion":196,"completion":196,"start":1556,"enrollment":131,"conditions":1557,"interventions":1560},"NCT02966236","Impact of Tranexamic Acid Use in Percutaneous Nephrolithotomy",[94],"2016-06",[1558,1559],"Nephrolithiasis","Staghorn Calculus",[1561,1512],"Tranexamic Acid",{"trials":1563,"activeCount":103},[],{"intervention":1565,"totalTrials":1466,"cells":1566},"Enalapril",{"EARLY_PHASE1":1567,"PHASE1":1569,"PHASE2":1571,"PHASE3":1573,"PHASE4":1584,"NA":1612},{"trials":1568,"activeCount":103},[],{"trials":1570,"activeCount":103},[],{"trials":1572,"activeCount":103},[],{"trials":1574,"activeCount":103},[1575],{"nctId":1576,"briefTitle":1577,"status":193,"phases":1578,"primaryCompletion":1191,"completion":1191,"start":1579,"enrollment":480,"conditions":1580,"interventions":1582},"NCT04853758","Angiotensin Receptor-Neprilysin Inhibition in Chagas Cardiomyopathy With Reduced Ejection Fraction: ANSWER-HF.",[93],"2021-05-06",[1581],"Chagas Cardiomyopathy",[1583,1565],"Sacubitril \u002F Valsartan Oral Tablet [Entresto]",{"trials":1585,"activeCount":103},[1586,1597],{"nctId":1587,"briefTitle":1588,"status":165,"phases":1589,"primaryCompletion":1590,"completion":1590,"start":1591,"enrollment":208,"conditions":1592,"interventions":1594},"NCT00419835","Effect of Enalapril and Losartan Association Therapy on Proteinuria and Inflammatory Biomarkers in Diabetic Nephropathy: a Clinical Trial on Type 2 Diabetes Mellitus",[94],"2007-09","2005-05",[1593],"Macroalbuminuric Diabetic Nephropathy",[1595,1596],"enalapril","losartan",{"nctId":1598,"briefTitle":1599,"status":165,"phases":1600,"primaryCompletion":1601,"completion":1602,"start":1603,"enrollment":1604,"conditions":1605,"interventions":1610},"NCT03190304","The Effect of Neprilysin (LCZ696) on Exercise Tolerance in Patients With Heart Failure",[94],"2020-09-14","2020-09-23","2017-06-14",52,[19,1606,1607,1608,1609],"Exercise Tolerance","Vasodilation","Body Composition","Muscle Strength",[1611,1565],"Neprilysin",{"trials":1613,"activeCount":103},[],{"intervention":1615,"totalTrials":99,"cells":1616},"Quetiapine",{"EARLY_PHASE1":1617,"PHASE1":1619,"PHASE2":1621,"PHASE3":1623,"PHASE4":1625,"NA":1648},{"trials":1618,"activeCount":103},[],{"trials":1620,"activeCount":103},[],{"trials":1622,"activeCount":103},[],{"trials":1624,"activeCount":103},[],{"trials":1626,"activeCount":103},[1627,1638],{"nctId":1628,"briefTitle":1629,"status":165,"phases":1630,"primaryCompletion":1631,"completion":1631,"start":1632,"enrollment":1633,"conditions":1634,"interventions":1636},"NCT00564564","Quetiapine Augmentation Versus Clomipramine Augmentation of SSRI for Obsessive-compulsive Disorder Patients",[94],"2007-12","2006-01",21,[1635],"Obsessive Compulsive Disorder",[1615,1637],"Clomipramine",{"nctId":1639,"briefTitle":1640,"status":165,"phases":1641,"primaryCompletion":1642,"completion":1643,"start":1644,"enrollment":1645,"conditions":1646,"interventions":1647},"NCT00466609","Using Drug Augmentation to Treat Obsessive Compulsive Disorder Patients Who Did Not Respond to Previous Treatment",[94],"2010-03","2010-04","2007-05",54,[1635],[1637,1615],{"trials":1649,"activeCount":103},[],{"intervention":1637,"totalTrials":99,"cells":1651},{"EARLY_PHASE1":1652,"PHASE1":1654,"PHASE2":1656,"PHASE3":1658,"PHASE4":1660,"NA":1670},{"trials":1653,"activeCount":103},[],{"trials":1655,"activeCount":103},[],{"trials":1657,"activeCount":103},[],{"trials":1659,"activeCount":103},[],{"trials":1661,"activeCount":103},[1662,1666],{"nctId":1628,"briefTitle":1629,"status":165,"phases":1663,"primaryCompletion":1631,"completion":1631,"start":1632,"enrollment":1633,"conditions":1664,"interventions":1665},[94],[1635],[1615,1637],{"nctId":1639,"briefTitle":1640,"status":165,"phases":1667,"primaryCompletion":1642,"completion":1643,"start":1644,"enrollment":1645,"conditions":1668,"interventions":1669},[94],[1635],[1637,1615],{"trials":1671,"activeCount":103},[],{"intervention":1673,"totalTrials":99,"cells":1674},"Magnesium Sulfate",{"EARLY_PHASE1":1675,"PHASE1":1677,"PHASE2":1679,"PHASE3":1681,"PHASE4":1694,"NA":1709},{"trials":1676,"activeCount":103},[],{"trials":1678,"activeCount":103},[],{"trials":1680,"activeCount":103},[],{"trials":1682,"activeCount":103},[1683],{"nctId":1684,"briefTitle":1685,"status":165,"phases":1686,"primaryCompletion":1687,"completion":1687,"start":1688,"enrollment":170,"conditions":1689,"interventions":1691},"NCT04300985","Magnesium Sulfate Versus Dexmedetomidine on Anesthesia Awakening.",[93],"2022-12-20","2021-10-01",[1690],"Cholecystectomy",[1692,1693,1673],"Dexmedetomidine","Sham treatment",{"trials":1695,"activeCount":103},[1696],{"nctId":1697,"briefTitle":1698,"status":165,"phases":1699,"primaryCompletion":1700,"completion":1701,"start":1702,"enrollment":1434,"conditions":1703,"interventions":1705},"NCT02483611","Effects of Intravenous Lidocaine Associated With Magnesium Sulfate on the Cisatracurium-Induced Neuromuscular Block",[94],"2015-08","2015-09","2015-07",[1704],"Neuromuscular Block",[1673,1706,1707,1708],"Lidocaine","Isotonic Solution","Cisatracurium",{"trials":1710,"activeCount":103},[],{"intervention":1712,"totalTrials":99,"cells":1713},"Lithium",{"EARLY_PHASE1":1714,"PHASE1":1716,"PHASE2":1718,"PHASE3":1720,"PHASE4":1722,"NA":1741},{"trials":1715,"activeCount":103},[],{"trials":1717,"activeCount":103},[],{"trials":1719,"activeCount":103},[],{"trials":1721,"activeCount":103},[],{"trials":1723,"activeCount":103},[1724,1732],{"nctId":1725,"briefTitle":1726,"status":165,"phases":1727,"primaryCompletion":1728,"completion":1728,"start":1729,"enrollment":414,"conditions":1730,"interventions":1731},"NCT01919892","Longitudinal Study on the Neuroprotective and Neurotrophic Effects of Lithium",[94],"2012-11","2010-09",[1460,1461],[1712],{"nctId":1733,"briefTitle":1734,"status":193,"phases":1735,"primaryCompletion":750,"completion":207,"start":1736,"enrollment":388,"conditions":1737,"interventions":1739},"NCT01710163","Potentiation of Quetiapine Treatment With Lithium or Aripiprazole in Bipolar 1 Nonresponders Patients",[94],"2012-06",[1738],"Bipolar I Disorder",[1712,1740],"Aripiprazole",{"trials":1742,"activeCount":103},[],{"intervention":1744,"totalTrials":99,"cells":1745},"Dabigatran",{"EARLY_PHASE1":1746,"PHASE1":1748,"PHASE2":1750,"PHASE3":1752,"PHASE4":1754,"NA":1777},{"trials":1747,"activeCount":103},[],{"trials":1749,"activeCount":103},[],{"trials":1751,"activeCount":103},[],{"trials":1753,"activeCount":103},[],{"trials":1755,"activeCount":103},[1756,1767],{"nctId":1757,"briefTitle":1758,"status":165,"phases":1759,"primaryCompletion":1760,"completion":1760,"start":1761,"enrollment":1762,"conditions":1763,"interventions":1765},"NCT02389582","Effects of Low Molecular Weight Heparin Versus Dabigatran on Platelet Aggregation in Patients With Stable Coronary Artery Disease",[94],"2015-11","2014-05",29,[1764],"Coronary Disease",[1744,1766],"Enoxaparin",{"nctId":1768,"briefTitle":1769,"status":165,"phases":1770,"primaryCompletion":1771,"completion":1771,"start":1772,"enrollment":480,"conditions":1773,"interventions":1775},"NCT01994265","Cognitive Impairment Related to Atrial Fibrillation Prevention Trial",[94],"2021-03-09","2014-11-07",[1774],"Atrial Fibrillation",[1776,1744],"Warfarin",{"trials":1778,"activeCount":103},[],{"intervention":717,"totalTrials":99,"cells":1780},{"EARLY_PHASE1":1781,"PHASE1":1783,"PHASE2":1785,"PHASE3":1791,"PHASE4":1793,"NA":1806},{"trials":1782,"activeCount":103},[],{"trials":1784,"activeCount":103},[],{"trials":1786,"activeCount":103},[1787],{"nctId":706,"briefTitle":707,"status":165,"phases":1788,"primaryCompletion":709,"completion":709,"start":710,"enrollment":170,"conditions":1789,"interventions":1790},[92],[712,713,25,714,715],[696,717],{"trials":1792,"activeCount":103},[],{"trials":1794,"activeCount":103},[1795],{"nctId":1796,"briefTitle":1797,"status":165,"phases":1798,"primaryCompletion":1799,"completion":1800,"start":1801,"enrollment":1802,"conditions":1803,"interventions":1804},"NCT05247385","Platelet Aggregation and Adenosine Levels Among Patients Taking Ticagrelor or Prasugrel",[94],"2021-02-26","2021-12-20","2017-03-20",87,[25],[1805,717],"Prasugrel",{"trials":1807,"activeCount":103},[],{"intervention":1809,"totalTrials":99,"cells":1810},"Fibrinogen concentrate",{"EARLY_PHASE1":1811,"PHASE1":1813,"PHASE2":1815,"PHASE3":1831,"PHASE4":1833,"NA":1847},{"trials":1812,"activeCount":103},[],{"trials":1814,"activeCount":103},[],{"trials":1816,"activeCount":103},[1817],{"nctId":1818,"briefTitle":1819,"status":165,"phases":1820,"primaryCompletion":1821,"completion":1822,"start":1823,"enrollment":1824,"conditions":1825,"interventions":1830},"NCT01187225","Fibrinogen Concentrate In Children After Cardiac Surgery",[92],"2011-01","2011-11","2010-08",63,[1826,1827,1828,1829],"Cardiac Surgical Procedures","Blood Coagulation Disorders","Fibrinogen","Cryoprecipitate",[1809,1829],{"trials":1832,"activeCount":103},[],{"trials":1834,"activeCount":103},[1835],{"nctId":1836,"briefTitle":1837,"status":165,"phases":1838,"primaryCompletion":1839,"completion":1840,"start":1841,"enrollment":1290,"conditions":1842,"interventions":1846},"NCT02864875","Early Administration of Fibrinogen in Polytraumatized Patients With Hypofibrinogenemia: a Randomized Feasibility Trial",[94],"2017-01","2018-07","2015-12",[1843,1844,1845],"Trauma","Bleeding Disorder","Fibrinogen; Deficiency, Acquired",[1809],{"trials":1848,"activeCount":103},[],{"intervention":1850,"totalTrials":99,"cells":1851},"atenolol",{"EARLY_PHASE1":1852,"PHASE1":1854,"PHASE2":1856,"PHASE3":1858,"PHASE4":1860,"NA":1882},{"trials":1853,"activeCount":103},[],{"trials":1855,"activeCount":103},[],{"trials":1857,"activeCount":103},[],{"trials":1859,"activeCount":103},[],{"trials":1861,"activeCount":103},[1862,1871],{"nctId":1863,"briefTitle":1864,"status":165,"phases":1865,"primaryCompletion":1866,"completion":1866,"start":1644,"enrollment":1003,"conditions":1867,"interventions":1870},"NCT01030016","Study of Atenolol Influence on Blood Pressure During Resistance Exercise",[94],"2009-05",[1868,1869],"Blood Pressure","Exercise",[1850],{"nctId":1872,"briefTitle":1873,"status":193,"phases":1874,"primaryCompletion":1875,"completion":1876,"start":1877,"enrollment":1878,"conditions":1879,"interventions":1880},"NCT00813722","Effect of Active Telephone Calls in the Compliance of Hypertensive Patients With Treatment",[94],"2009-01","2009-06","1999-03",400,[1868],[1881,1850],"amlodipine",{"trials":1883,"activeCount":103},[],{"intervention":1885,"totalTrials":99,"cells":1886},"NPH insulin",{"EARLY_PHASE1":1887,"PHASE1":1889,"PHASE2":1891,"PHASE3":1893,"PHASE4":1895,"NA":1918},{"trials":1888,"activeCount":103},[],{"trials":1890,"activeCount":103},[],{"trials":1892,"activeCount":103},[],{"trials":1894,"activeCount":103},[],{"trials":1896,"activeCount":103},[1897,1909],{"nctId":1898,"briefTitle":1899,"status":165,"phases":1900,"primaryCompletion":1901,"completion":1901,"start":1902,"enrollment":1903,"conditions":1904,"interventions":1907},"NCT02451917","Glargine Versus NPH in Patients With Chronic Kidney Disease",[94],"2016-08","2013-12",34,[1905,1906],"Type 2 Diabetes Mellitus","Chronic Kidney Disease",[1908,1885],"Glargine insulin",{"nctId":1910,"briefTitle":1911,"status":165,"phases":1912,"primaryCompletion":1913,"completion":195,"start":1914,"enrollment":17,"conditions":1915,"interventions":1916},"NCT02607410","Sitagliptin (DPP-4 Inhibitor) and NPH Insulin in Patients With T2D",[94],"2012-01","2010-01",[1905],[1917,1885],"sitagliptin",{"trials":1919,"activeCount":103},[],{"intervention":1921,"totalTrials":99,"cells":1922},"Zoledronic acid",{"EARLY_PHASE1":1923,"PHASE1":1925,"PHASE2":1927,"PHASE3":1937,"PHASE4":1939,"NA":1949},{"trials":1924,"activeCount":103},[],{"trials":1926,"activeCount":103},[],{"trials":1928,"activeCount":103},[1929],{"nctId":1930,"briefTitle":1931,"status":193,"phases":1932,"primaryCompletion":1841,"completion":1933,"start":1902,"enrollment":17,"conditions":1934,"interventions":1936},"NCT01788176","The Use of Zoledronic Acid to Complex Regional Pain Syndrome",[92],"2016-12",[1935],"Complex Regional Pain Syndromes",[1921],{"trials":1938,"activeCount":103},[],{"trials":1940,"activeCount":103},[1941],{"nctId":1942,"briefTitle":1943,"status":165,"phases":1944,"primaryCompletion":1945,"completion":1761,"start":197,"enrollment":1903,"conditions":1946,"interventions":1948},"NCT01675089","Zoledronic Acid to Prevent Bone Loss After Kidney Transplantation",[94],"2013-07",[1947],"Renal Osteodystrophy",[1921],{"trials":1950,"activeCount":103},[],{"intervention":1952,"totalTrials":99,"cells":1953},"N acetyl cysteine",{"EARLY_PHASE1":1954,"PHASE1":1956,"PHASE2":1958,"PHASE3":1960,"PHASE4":1962,"NA":1978},{"trials":1955,"activeCount":103},[],{"trials":1957,"activeCount":103},[],{"trials":1959,"activeCount":103},[],{"trials":1961,"activeCount":103},[],{"trials":1963,"activeCount":103},[1964,1974],{"nctId":1965,"briefTitle":1966,"status":165,"phases":1967,"primaryCompletion":1913,"completion":1968,"start":1969,"enrollment":29,"conditions":1970,"interventions":1973},"NCT01614431","N Acetyl Cysteine for Cystinosis Patients",[94],"2012-05","2011-03",[1971,1972],"Renal Disease","Cystinosis",[1952,1952],{"nctId":1538,"briefTitle":1539,"status":193,"phases":1975,"primaryCompletion":1541,"completion":1542,"start":1543,"enrollment":1544,"conditions":1976,"interventions":1977},[94],[1546,1547,1487,1548,1549],[1551,1512],{"trials":1979,"activeCount":103},[],{"intervention":1981,"totalTrials":99,"cells":1982},"Ropivacaine",{"EARLY_PHASE1":1983,"PHASE1":1985,"PHASE2":1987,"PHASE3":1989,"PHASE4":2003,"NA":2018},{"trials":1984,"activeCount":103},[],{"trials":1986,"activeCount":103},[],{"trials":1988,"activeCount":103},[],{"trials":1990,"activeCount":103},[1991],{"nctId":1992,"briefTitle":1993,"status":193,"phases":1994,"primaryCompletion":1995,"completion":1996,"start":1997,"enrollment":1998,"conditions":1999,"interventions":2001},"NCT02841488","Ischemic Pain Control With Analgesic Methods Clinical Trial",[93],"2018-09","2018-10","2016-09",56,[2000],"Arterial Occlusive Diseases",[2002,1981],"Fentanyl",{"trials":2004,"activeCount":103},[2005],{"nctId":2006,"briefTitle":2007,"status":193,"phases":2008,"primaryCompletion":2009,"completion":2010,"start":2011,"enrollment":1434,"conditions":2012,"interventions":2016},"NCT00523289","Cardiovascular Safety Research: Bupivacaine With Vasoconstrictor Versus Ropivacaine in Brachial Plexus Block",[94],"2009-03","2009-07","2007-10",[2013,2014,2015],"Injuries, Hand","Anesthesia Conduction","Anesthetics, Local",[2017,1981],"Bupivacaine",{"trials":2019,"activeCount":103},[],{"intervention":2021,"totalTrials":99,"cells":2022},"COOL-COS",{"EARLY_PHASE1":2023,"PHASE1":2025,"PHASE2":2037,"PHASE3":2039,"PHASE4":2041,"NA":2052},{"trials":2024,"activeCount":103},[],{"trials":2026,"activeCount":103},[2027],{"nctId":2028,"briefTitle":2029,"status":165,"phases":2030,"primaryCompletion":2031,"completion":2032,"start":2033,"enrollment":17,"conditions":2034,"interventions":2036},"NCT02448459","COmbining Oral Letrozole and Clomiphene for Ovarian Stimulation (COOL-COS) Associated With Corifollitropin Alfa: a Pilot Study",[91],"2016-03","2016-05","2015-05",[2035],"Infertility",[2021],{"trials":2038,"activeCount":103},[],{"trials":2040,"activeCount":103},[],{"trials":2042,"activeCount":103},[2043],{"nctId":2044,"briefTitle":2045,"status":165,"phases":2046,"primaryCompletion":2047,"completion":2047,"start":2048,"enrollment":2049,"conditions":2050,"interventions":2051},"NCT02288143","COmbining Oral Letrozole and Clomiphene for Ovarian Stimulation",[94],"2015-03","2015-01",28,[2035],[2021],{"trials":2053,"activeCount":103},[],{"intervention":2055,"totalTrials":99,"cells":2056},"Sertraline",{"EARLY_PHASE1":2057,"PHASE1":2059,"PHASE2":2061,"PHASE3":2063,"PHASE4":2075,"NA":2085},{"trials":2058,"activeCount":103},[],{"trials":2060,"activeCount":103},[],{"trials":2062,"activeCount":103},[],{"trials":2064,"activeCount":103},[2065],{"nctId":2066,"briefTitle":2067,"status":165,"phases":2068,"primaryCompletion":2069,"completion":2069,"start":2070,"enrollment":2071,"conditions":2072,"interventions":2074},"NCT01033084","Efficacy Study of Transcranial Direct Current Stimulation to Treat Major Depressive Disorder",[92,93],"2011-12","2009-12",120,[2073],"Depressive Disorder, Major",[2055],{"trials":2076,"activeCount":103},[2077],{"nctId":2078,"briefTitle":2079,"status":193,"phases":2080,"primaryCompletion":1839,"completion":1839,"start":2081,"enrollment":740,"conditions":2082,"interventions":2084},"NCT02268487","Integral Assessment in Unipolar Depression",[94],"2014-01",[2083],"Major Depressive Disorder",[2055],{"trials":2086,"activeCount":103},[],{"intervention":2088,"totalTrials":99,"cells":2089},"Tranexamic acid",{"EARLY_PHASE1":2090,"PHASE1":2092,"PHASE2":2094,"PHASE3":2096,"PHASE4":2098,"NA":2115},{"trials":2091,"activeCount":103},[],{"trials":2093,"activeCount":103},[],{"trials":2095,"activeCount":103},[],{"trials":2097,"activeCount":103},[],{"trials":2099,"activeCount":103},[2100,2111],{"nctId":2101,"briefTitle":2102,"status":193,"phases":2103,"primaryCompletion":2104,"completion":2033,"start":2105,"enrollment":2106,"conditions":2107,"interventions":2109},"NCT02152917","Comparison of Floseal® and Tranexamic Acid on Bleeding Control After Total Knee Arthroplasty",[94],"2015-02","2014-02",45,[2108],"Knee Osteoarthritis",[2088,2110],"Floseal®",{"nctId":1553,"briefTitle":1554,"status":193,"phases":2112,"primaryCompletion":196,"completion":196,"start":1556,"enrollment":131,"conditions":2113,"interventions":2114},[94],[1558,1559],[1561,1512],{"trials":2116,"activeCount":103},[],{"intervention":2118,"totalTrials":175,"cells":2119},"Collagen Matrix",{"EARLY_PHASE1":2120,"PHASE1":2122,"PHASE2":2124,"PHASE3":2126,"PHASE4":2128,"NA":2140},{"trials":2121,"activeCount":103},[],{"trials":2123,"activeCount":103},[],{"trials":2125,"activeCount":103},[],{"trials":2127,"activeCount":103},[],{"trials":2129,"activeCount":103},[2130],{"nctId":2131,"briefTitle":2132,"status":165,"phases":2133,"primaryCompletion":2134,"completion":2135,"start":2136,"enrollment":1350,"conditions":2137,"interventions":2139},"NCT02818855","Treatment of Multiple Gingival Recessions",[94],"2015-10","2016-04","2014-03",[2138],"Gingival Recession",[2118],{"trials":2141,"activeCount":103},[],{"intervention":2143,"totalTrials":175,"cells":2144},"Cannabis Extract Oil SR",{"EARLY_PHASE1":2145,"PHASE1":2147,"PHASE2":2149,"PHASE3":2151,"PHASE4":2153,"NA":2165},{"trials":2146,"activeCount":103},[],{"trials":2148,"activeCount":103},[],{"trials":2150,"activeCount":103},[],{"trials":2152,"activeCount":103},[],{"trials":2154,"activeCount":103},[2155],{"nctId":2156,"briefTitle":2157,"status":193,"phases":2158,"primaryCompletion":2159,"completion":2160,"start":2161,"enrollment":235,"conditions":2162,"interventions":2164},"NCT06159387","Randomized, Double-blind, Placebo-controlled Cannabis Extract x Placebo for Cocaine Addicts",[94],"2024-10-23","2025-10-23","2023-10-23",[2163],"Cocaine Dependence",[2143],{"trials":2166,"activeCount":103},[],{"intervention":2168,"totalTrials":175,"cells":2169},"Varenicline Tartrate or bupropion",{"EARLY_PHASE1":2170,"PHASE1":2172,"PHASE2":2174,"PHASE3":2176,"PHASE4":2178,"NA":2191},{"trials":2171,"activeCount":103},[],{"trials":2173,"activeCount":103},[],{"trials":2175,"activeCount":103},[],{"trials":2177,"activeCount":103},[],{"trials":2179,"activeCount":103},[2180],{"nctId":2181,"briefTitle":2182,"status":165,"phases":2183,"primaryCompletion":2184,"completion":2184,"start":2185,"enrollment":2186,"conditions":2187,"interventions":2190},"NCT03362099","Efficacy of the Use of Genetic Markers in the Choice of the Pharmacological Treatment of Smoking (GENTSMOKING)",[94],"2022-04-15","2016-11-01",361,[2188,2189],"Smoking Cessation","Genetic Predisposition",[2168],{"trials":2192,"activeCount":103},[],{"intervention":2194,"totalTrials":175,"cells":2195},"0,9% Saline",{"EARLY_PHASE1":2196,"PHASE1":2198,"PHASE2":2200,"PHASE3":2202,"PHASE4":2204,"NA":2218},{"trials":2197,"activeCount":103},[],{"trials":2199,"activeCount":103},[],{"trials":2201,"activeCount":103},[],{"trials":2203,"activeCount":103},[],{"trials":2205,"activeCount":103},[2206],{"nctId":2207,"briefTitle":2208,"status":193,"phases":2209,"primaryCompletion":2210,"completion":2211,"start":2212,"enrollment":2213,"conditions":2214,"interventions":2217},"NCT05079672","Efficacy and Safety of Dexmedetomidine in the Analgesic Prophylaxis , in Patients Undergoing Cardiovascular Surgery",[94],"2022-10-10","2023-10-10","2021-10-07",102,[2215,25,2216,28],"Cardiopathy","Valve Heart Disease",[1692,2194],{"trials":2219,"activeCount":103},[],{"intervention":756,"totalTrials":175,"cells":2221},{"EARLY_PHASE1":2222,"PHASE1":2224,"PHASE2":2226,"PHASE3":2228,"PHASE4":2230,"NA":2236},{"trials":2223,"activeCount":103},[],{"trials":2225,"activeCount":103},[],{"trials":2227,"activeCount":103},[],{"trials":2229,"activeCount":103},[],{"trials":2231,"activeCount":103},[2232],{"nctId":747,"briefTitle":748,"status":165,"phases":2233,"primaryCompletion":750,"completion":750,"start":751,"enrollment":752,"conditions":2234,"interventions":2235},[94],[25,754],[756,757,696],{"trials":2237,"activeCount":103},[],{"intervention":757,"totalTrials":175,"cells":2239},{"EARLY_PHASE1":2240,"PHASE1":2242,"PHASE2":2244,"PHASE3":2246,"PHASE4":2248,"NA":2254},{"trials":2241,"activeCount":103},[],{"trials":2243,"activeCount":103},[],{"trials":2245,"activeCount":103},[],{"trials":2247,"activeCount":103},[],{"trials":2249,"activeCount":103},[2250],{"nctId":747,"briefTitle":748,"status":165,"phases":2251,"primaryCompletion":750,"completion":750,"start":751,"enrollment":752,"conditions":2252,"interventions":2253},[94],[25,754],[756,757,696],{"trials":2255,"activeCount":103},[],{"intervention":2257,"totalTrials":175,"cells":2258},"Intravitreal Ranibizumabe",{"EARLY_PHASE1":2259,"PHASE1":2261,"PHASE2":2263,"PHASE3":2265,"PHASE4":2267,"NA":2280},{"trials":2260,"activeCount":103},[],{"trials":2262,"activeCount":103},[],{"trials":2264,"activeCount":103},[],{"trials":2266,"activeCount":103},[],{"trials":2268,"activeCount":103},[2269],{"nctId":2270,"briefTitle":2271,"status":193,"phases":2272,"primaryCompletion":2273,"start":2274,"enrollment":2275,"conditions":2276,"interventions":2278},"NCT02005432","PASCAL Laser Versus ETDRS Laser Associated With Intravitreal Ranibizumab (IVR) Versus Only IVR for Proliferative Diabetic Retinopathy",[94],"2014-11","2012-02",31,[2277],"Proliferative Diabetic Retinopathy",[2257,2279,2279],"panfotocoagulation",{"trials":2281,"activeCount":103},[],{"intervention":2279,"totalTrials":175,"cells":2283},{"EARLY_PHASE1":2284,"PHASE1":2286,"PHASE2":2288,"PHASE3":2290,"PHASE4":2292,"NA":2298},{"trials":2285,"activeCount":103},[],{"trials":2287,"activeCount":103},[],{"trials":2289,"activeCount":103},[],{"trials":2291,"activeCount":103},[],{"trials":2293,"activeCount":103},[2294],{"nctId":2270,"briefTitle":2271,"status":193,"phases":2295,"primaryCompletion":2273,"start":2274,"enrollment":2275,"conditions":2296,"interventions":2297},[94],[2277],[2257,2279,2279],{"trials":2299,"activeCount":103},[],{"intervention":2301,"totalTrials":175,"cells":2302},"Simvastatin 20mg plus ezetimibe 10mg",{"EARLY_PHASE1":2303,"PHASE1":2305,"PHASE2":2307,"PHASE3":2309,"PHASE4":2311,"NA":2323},{"trials":2304,"activeCount":103},[],{"trials":2306,"activeCount":103},[],{"trials":2308,"activeCount":103},[],{"trials":2310,"activeCount":103},[],{"trials":2312,"activeCount":103},[2313],{"nctId":2314,"briefTitle":2315,"status":165,"phases":2316,"primaryCompletion":1914,"completion":1914,"start":2317,"enrollment":1176,"conditions":2318,"interventions":2319},"NCT00481351","Effects of Statin and Ezetimibe Association on Kinetics of Artificial Chilomicrons",[94],"2007-06",[1506],[2301,2320,2321,2322],"ezetimibe","simvastatin 20mg","Simvastatin 80mg",{"trials":2324,"activeCount":103},[],{"intervention":2320,"totalTrials":175,"cells":2326},{"EARLY_PHASE1":2327,"PHASE1":2329,"PHASE2":2331,"PHASE3":2333,"PHASE4":2335,"NA":2341},{"trials":2328,"activeCount":103},[],{"trials":2330,"activeCount":103},[],{"trials":2332,"activeCount":103},[],{"trials":2334,"activeCount":103},[],{"trials":2336,"activeCount":103},[2337],{"nctId":2314,"briefTitle":2315,"status":165,"phases":2338,"primaryCompletion":1914,"completion":1914,"start":2317,"enrollment":1176,"conditions":2339,"interventions":2340},[94],[1506],[2301,2320,2321,2322],{"trials":2342,"activeCount":103},[],{"intervention":2321,"totalTrials":175,"cells":2344},{"EARLY_PHASE1":2345,"PHASE1":2347,"PHASE2":2349,"PHASE3":2351,"PHASE4":2353,"NA":2359},{"trials":2346,"activeCount":103},[],{"trials":2348,"activeCount":103},[],{"trials":2350,"activeCount":103},[],{"trials":2352,"activeCount":103},[],{"trials":2354,"activeCount":103},[2355],{"nctId":2314,"briefTitle":2315,"status":165,"phases":2356,"primaryCompletion":1914,"completion":1914,"start":2317,"enrollment":1176,"conditions":2357,"interventions":2358},[94],[1506],[2301,2320,2321,2322],{"trials":2360,"activeCount":103},[],{"intervention":2322,"totalTrials":175,"cells":2362},{"EARLY_PHASE1":2363,"PHASE1":2365,"PHASE2":2367,"PHASE3":2369,"PHASE4":2371,"NA":2377},{"trials":2364,"activeCount":103},[],{"trials":2366,"activeCount":103},[],{"trials":2368,"activeCount":103},[],{"trials":2370,"activeCount":103},[],{"trials":2372,"activeCount":103},[2373],{"nctId":2314,"briefTitle":2315,"status":165,"phases":2374,"primaryCompletion":1914,"completion":1914,"start":2317,"enrollment":1176,"conditions":2375,"interventions":2376},[94],[1506],[2301,2320,2321,2322],{"trials":2378,"activeCount":103},[],{"intervention":2380,"totalTrials":175,"cells":2381},"Vancomycin Continuous",{"EARLY_PHASE1":2382,"PHASE1":2384,"PHASE2":2386,"PHASE3":2388,"PHASE4":2390,"NA":2406},{"trials":2383,"activeCount":103},[],{"trials":2385,"activeCount":103},[],{"trials":2387,"activeCount":103},[],{"trials":2389,"activeCount":103},[],{"trials":2391,"activeCount":103},[2392],{"nctId":2393,"briefTitle":2394,"status":193,"phases":2395,"primaryCompletion":2396,"completion":2397,"start":2398,"enrollment":2399,"conditions":2400,"interventions":2404},"NCT03438214","Effect of Intermittent Infusion Versus Continuous Infusion of Vancomycin on Kidney Failure in Critically Ill Patients",[94],"2020-02-28","2022-12-01","2018-04-28",222,[2401,2402,2403],"Gram-Positive Bacterial Infections","Nephrotoxicity","Sepsis",[2380,2405],"Vancomycin Intermittent",{"trials":2407,"activeCount":103},[],{"intervention":2405,"totalTrials":175,"cells":2409},{"EARLY_PHASE1":2410,"PHASE1":2412,"PHASE2":2414,"PHASE3":2416,"PHASE4":2418,"NA":2424},{"trials":2411,"activeCount":103},[],{"trials":2413,"activeCount":103},[],{"trials":2415,"activeCount":103},[],{"trials":2417,"activeCount":103},[],{"trials":2419,"activeCount":103},[2420],{"nctId":2393,"briefTitle":2394,"status":193,"phases":2421,"primaryCompletion":2396,"completion":2397,"start":2398,"enrollment":2399,"conditions":2422,"interventions":2423},[94],[2401,2402,2403],[2380,2405],{"trials":2425,"activeCount":103},[],{"intervention":2427,"totalTrials":175,"cells":2428},"Pilocarpine",{"EARLY_PHASE1":2429,"PHASE1":2431,"PHASE2":2433,"PHASE3":2435,"PHASE4":2437,"NA":2448},{"trials":2430,"activeCount":103},[],{"trials":2432,"activeCount":103},[],{"trials":2434,"activeCount":103},[],{"trials":2436,"activeCount":103},[],{"trials":2438,"activeCount":103},[2439],{"nctId":2440,"briefTitle":2441,"status":193,"phases":2442,"primaryCompletion":2443,"completion":2444,"start":2135,"enrollment":208,"conditions":2445,"interventions":2447},"NCT02982577","Effect of Pilocarpine in Patients With Xerostomia",[94],"2017-06","2017-07",[2446],"Xerostomia",[2427],{"trials":2449,"activeCount":103},[],{"intervention":2451,"totalTrials":175,"cells":2452},"Glimepiride",{"EARLY_PHASE1":2453,"PHASE1":2455,"PHASE2":2457,"PHASE3":2459,"PHASE4":2461,"NA":2471},{"trials":2454,"activeCount":103},[],{"trials":2456,"activeCount":103},[],{"trials":2458,"activeCount":103},[],{"trials":2460,"activeCount":103},[],{"trials":2462,"activeCount":103},[2463],{"nctId":2464,"briefTitle":2465,"status":165,"phases":2466,"primaryCompletion":1913,"completion":1913,"start":1821,"enrollment":32,"conditions":2467,"interventions":2469},"NCT01509001","Study of Metabolic and Haemodynamic Effects of Metformin and Glimepiride in Patients With Type 2 Diabetes Mellitus",[94],[2468],"Type 2 Diabetes",[2470,2451],"Metformin",{"trials":2472,"activeCount":103},[],{"intervention":2474,"totalTrials":175,"cells":2475},"Dienogest",{"EARLY_PHASE1":2476,"PHASE1":2478,"PHASE2":2480,"PHASE3":2482,"PHASE4":2484,"NA":2498},{"trials":2477,"activeCount":103},[],{"trials":2479,"activeCount":103},[],{"trials":2481,"activeCount":103},[],{"trials":2483,"activeCount":103},[],{"trials":2485,"activeCount":103},[2486],{"nctId":2487,"briefTitle":2488,"status":2489,"phases":2490,"primaryCompletion":1933,"completion":2491,"start":1913,"enrollment":2492,"conditions":2493,"interventions":2495},"NCT01738724","Study of the Efficacy of Dienogest in the Treatment of Uterine Leiomyomas When Compared to Desogestrel and Goserelin","TERMINATED",[94],"2017-12",14,[2494],"Uterine Leiomyoma",[2474,2496,2497],"Goserelin","Desogestrel",{"trials":2499,"activeCount":103},[],{"intervention":2496,"totalTrials":175,"cells":2501},{"EARLY_PHASE1":2502,"PHASE1":2504,"PHASE2":2506,"PHASE3":2508,"PHASE4":2510,"NA":2516},{"trials":2503,"activeCount":103},[],{"trials":2505,"activeCount":103},[],{"trials":2507,"activeCount":103},[],{"trials":2509,"activeCount":103},[],{"trials":2511,"activeCount":103},[2512],{"nctId":2487,"briefTitle":2488,"status":2489,"phases":2513,"primaryCompletion":1933,"completion":2491,"start":1913,"enrollment":2492,"conditions":2514,"interventions":2515},[94],[2494],[2474,2496,2497],{"trials":2517,"activeCount":103},[],{"intervention":2497,"totalTrials":175,"cells":2519},{"EARLY_PHASE1":2520,"PHASE1":2522,"PHASE2":2524,"PHASE3":2526,"PHASE4":2528,"NA":2534},{"trials":2521,"activeCount":103},[],{"trials":2523,"activeCount":103},[],{"trials":2525,"activeCount":103},[],{"trials":2527,"activeCount":103},[],{"trials":2529,"activeCount":103},[2530],{"nctId":2487,"briefTitle":2488,"status":2489,"phases":2531,"primaryCompletion":1933,"completion":2491,"start":1913,"enrollment":2492,"conditions":2532,"interventions":2533},[94],[2494],[2474,2496,2497],{"trials":2535,"activeCount":103},[],{"intervention":2537,"totalTrials":175,"cells":2538},"Methylphenidate",{"EARLY_PHASE1":2539,"PHASE1":2541,"PHASE2":2543,"PHASE3":2545,"PHASE4":2547,"NA":2560},{"trials":2540,"activeCount":103},[],{"trials":2542,"activeCount":103},[],{"trials":2544,"activeCount":103},[],{"trials":2546,"activeCount":103},[],{"trials":2548,"activeCount":103},[2549],{"nctId":2550,"briefTitle":2551,"status":165,"phases":2552,"primaryCompletion":2553,"completion":2554,"start":1556,"enrollment":2555,"conditions":2556,"interventions":2559},"NCT02807870","Early Interventions in Children With Attention Deficit\u002FHyperactivity Disorder",[94],"2019-12","2020-06-30",153,[2557,2558],"Attention Deficit Disorder With Hyperactivity","Preschool Child",[2537],{"trials":2561,"activeCount":103},[],{"intervention":2563,"totalTrials":175,"cells":2564},"Piroxicam",{"EARLY_PHASE1":2565,"PHASE1":2567,"PHASE2":2569,"PHASE3":2571,"PHASE4":2573,"NA":2586},{"trials":2566,"activeCount":103},[],{"trials":2568,"activeCount":103},[],{"trials":2570,"activeCount":103},[],{"trials":2572,"activeCount":103},[],{"trials":2574,"activeCount":103},[2575],{"nctId":2576,"briefTitle":2577,"status":165,"phases":2578,"primaryCompletion":2134,"completion":1841,"start":2579,"enrollment":2580,"conditions":2581,"interventions":2585},"NCT02450487","Influence of Genotype of CYP2C9 on Clinical Efficacy and Pharmacokinetics of Piroxicam After Lower Third Molar Surgery",[94],"2012-10",105,[28,2582,2583,2584],"Other Surgical Procedures","Impacted Third Molar Tooth","Cytochrome P450 CYP2C9 Enzyme Deficiency",[2563],{"trials":2587,"activeCount":103},[],{"intervention":1805,"totalTrials":175,"cells":2589},{"EARLY_PHASE1":2590,"PHASE1":2592,"PHASE2":2594,"PHASE3":2596,"PHASE4":2598,"NA":2604},{"trials":2591,"activeCount":103},[],{"trials":2593,"activeCount":103},[],{"trials":2595,"activeCount":103},[],{"trials":2597,"activeCount":103},[],{"trials":2599,"activeCount":103},[2600],{"nctId":1796,"briefTitle":1797,"status":165,"phases":2601,"primaryCompletion":1799,"completion":1800,"start":1801,"enrollment":1802,"conditions":2602,"interventions":2603},[94],[25],[1805,717],{"trials":2605,"activeCount":103},[],{"intervention":2607,"totalTrials":175,"cells":2608},"Glibenclamide",{"EARLY_PHASE1":2609,"PHASE1":2611,"PHASE2":2613,"PHASE3":2615,"PHASE4":2617,"NA":2629},{"trials":2610,"activeCount":103},[],{"trials":2612,"activeCount":103},[],{"trials":2614,"activeCount":103},[],{"trials":2616,"activeCount":103},[],{"trials":2618,"activeCount":103},[2619],{"nctId":2620,"briefTitle":2621,"status":193,"phases":2622,"primaryCompletion":2623,"completion":2624,"start":2625,"enrollment":388,"conditions":2626,"interventions":2628},"NCT03569540","Glibenclamide in Aneurysmatic Subarachnoid Hemorrhage",[94],"2019-07-01","2019-12-01","2018-07-03",[2627],"Subarachnoid Hemorrhage, Aneurysmal",[2607],{"trials":2630,"activeCount":103},[],{"intervention":2632,"totalTrials":175,"cells":2633},"Intervention: inferior alveolar nerve block",{"EARLY_PHASE1":2634,"PHASE1":2636,"PHASE2":2638,"PHASE3":2640,"PHASE4":2642,"NA":2652},{"trials":2635,"activeCount":103},[],{"trials":2637,"activeCount":103},[],{"trials":2639,"activeCount":103},[],{"trials":2641,"activeCount":103},[],{"trials":2643,"activeCount":103},[2644],{"nctId":2645,"briefTitle":2646,"status":165,"phases":2647,"primaryCompletion":1728,"completion":1945,"start":1823,"enrollment":2648,"conditions":2649,"interventions":2651},"NCT02054767","Anesthetic Efficacy in Irreversible Pulpitis",[94],66,[2650],"Anesthesia",[2632],{"trials":2653,"activeCount":103},[],{"intervention":2655,"totalTrials":175,"cells":2656},"Carbamazepine-Implant",{"EARLY_PHASE1":2657,"PHASE1":2659,"PHASE2":2661,"PHASE3":2663,"PHASE4":2665,"NA":2682},{"trials":2658,"activeCount":103},[],{"trials":2660,"activeCount":103},[],{"trials":2662,"activeCount":103},[],{"trials":2664,"activeCount":103},[],{"trials":2666,"activeCount":103},[2667],{"nctId":2668,"briefTitle":2669,"status":2670,"phases":2671,"primaryCompletion":2672,"completion":2673,"start":2674,"enrollment":2675,"conditions":2676,"interventions":2679},"NCT03307863","Effect of Anti-epileptic Drugs on Etonogestrel-releasing Implant Pharmacokinetics in Women With Epilepsy","SUSPENDED",[94],"2027-11-30","2028-11-30","2017-11-01",69,[2677,2678],"Contraception","Drug Interactions",[2655,2680,2681],"Topiramate-Implant","Implant",{"trials":2683,"activeCount":103},[],{"intervention":2680,"totalTrials":175,"cells":2685},{"EARLY_PHASE1":2686,"PHASE1":2688,"PHASE2":2690,"PHASE3":2692,"PHASE4":2694,"NA":2700},{"trials":2687,"activeCount":103},[],{"trials":2689,"activeCount":103},[],{"trials":2691,"activeCount":103},[],{"trials":2693,"activeCount":103},[],{"trials":2695,"activeCount":103},[2696],{"nctId":2668,"briefTitle":2669,"status":2670,"phases":2697,"primaryCompletion":2672,"completion":2673,"start":2674,"enrollment":2675,"conditions":2698,"interventions":2699},[94],[2677,2678],[2655,2680,2681],{"trials":2701,"activeCount":103},[],{"intervention":2681,"totalTrials":175,"cells":2703},{"EARLY_PHASE1":2704,"PHASE1":2706,"PHASE2":2708,"PHASE3":2710,"PHASE4":2712,"NA":2718},{"trials":2705,"activeCount":103},[],{"trials":2707,"activeCount":103},[],{"trials":2709,"activeCount":103},[],{"trials":2711,"activeCount":103},[],{"trials":2713,"activeCount":103},[2714],{"nctId":2668,"briefTitle":2669,"status":2670,"phases":2715,"primaryCompletion":2672,"completion":2673,"start":2674,"enrollment":2675,"conditions":2716,"interventions":2717},[94],[2677,2678],[2655,2680,2681],{"trials":2719,"activeCount":103},[],{"intervention":2721,"totalTrials":175,"cells":2722},"Antipsychotics",{"EARLY_PHASE1":2723,"PHASE1":2725,"PHASE2":2727,"PHASE3":2729,"PHASE4":2731,"NA":2744},{"trials":2724,"activeCount":103},[],{"trials":2726,"activeCount":103},[],{"trials":2728,"activeCount":103},[],{"trials":2730,"activeCount":103},[],{"trials":2732,"activeCount":103},[2733],{"nctId":2734,"briefTitle":2735,"status":193,"phases":2736,"primaryCompletion":2737,"completion":2738,"start":2739,"enrollment":2740,"conditions":2741,"interventions":2743},"NCT01016145","Identifying Predictors of Response to Antipsychotics Using a Treatment Algorithm",[94],"2010-06","2010-07","2009-04",126,[2742],"Schizophrenia or Schizoaffective Disorder",[2721,2721],{"trials":2745,"activeCount":103},[],{"intervention":2747,"totalTrials":175,"cells":2748},"natural progesterone",{"EARLY_PHASE1":2749,"PHASE1":2751,"PHASE2":2753,"PHASE3":2755,"PHASE4":2757,"NA":2771},{"trials":2750,"activeCount":103},[],{"trials":2752,"activeCount":103},[],{"trials":2754,"activeCount":103},[],{"trials":2756,"activeCount":103},[],{"trials":2758,"activeCount":103},[2759],{"nctId":2760,"briefTitle":2761,"status":165,"phases":2762,"primaryCompletion":2763,"completion":2764,"start":2765,"enrollment":2766,"conditions":2767,"interventions":2770},"NCT02511574","Comparison Between Natural Progesterone and Vaginal Pessary for the Prevention of Spontaneous Preterm Birth",[94],"2022-12-10","2023-08-30","2015-08-03",203,[2768,2769],"Preterm Labor","Premature Birth",[2747],{"trials":2772,"activeCount":103},[],{"intervention":2774,"totalTrials":175,"cells":2775},"Use of Intraoperative Intravenous Methadone",{"EARLY_PHASE1":2776,"PHASE1":2778,"PHASE2":2780,"PHASE3":2782,"PHASE4":2784,"NA":2795},{"trials":2777,"activeCount":103},[],{"trials":2779,"activeCount":103},[],{"trials":2781,"activeCount":103},[],{"trials":2783,"activeCount":103},[],{"trials":2785,"activeCount":103},[2786],{"nctId":2787,"briefTitle":2788,"status":165,"phases":2789,"primaryCompletion":1839,"completion":1839,"start":1556,"enrollment":1290,"conditions":2790,"interventions":2793},"NCT02775474","Does Intraoperative Methadone Prevent Postoperative Pain in Bariatric Surgery?",[94],[2791,2792],"Pain, Postoperative","Chronic Pain",[2774,2794],"Use of Intraoperative Intravenous Fentanyl",{"trials":2796,"activeCount":103},[],{"intervention":2794,"totalTrials":175,"cells":2798},{"EARLY_PHASE1":2799,"PHASE1":2801,"PHASE2":2803,"PHASE3":2805,"PHASE4":2807,"NA":2813},{"trials":2800,"activeCount":103},[],{"trials":2802,"activeCount":103},[],{"trials":2804,"activeCount":103},[],{"trials":2806,"activeCount":103},[],{"trials":2808,"activeCount":103},[2809],{"nctId":2787,"briefTitle":2788,"status":165,"phases":2810,"primaryCompletion":1839,"completion":1839,"start":1556,"enrollment":1290,"conditions":2811,"interventions":2812},[94],[2791,2792],[2774,2794],{"trials":2814,"activeCount":103},[],{"intervention":2816,"totalTrials":175,"cells":2817},"Donepezil",{"EARLY_PHASE1":2818,"PHASE1":2820,"PHASE2":2822,"PHASE3":2824,"PHASE4":2826,"NA":2839},{"trials":2819,"activeCount":103},[],{"trials":2821,"activeCount":103},[],{"trials":2823,"activeCount":103},[],{"trials":2825,"activeCount":103},[],{"trials":2827,"activeCount":103},[2828],{"nctId":2829,"briefTitle":2830,"status":2489,"phases":2831,"primaryCompletion":1841,"completion":2832,"start":2833,"enrollment":35,"conditions":2834,"interventions":2838},"NCT01633593","Treatment of Delirium in the Elderly With Donepezil: a Double-blind, Randomized, Placebo-controlled Clinical Trial",[94],"2016-07","2012-08",[2835,2836,2837],"Elderly","Delirium of Unknown (Axis III) Etiology","Intensive Care (ICU) Myopathy",[2816],{"trials":2840,"activeCount":103},[],{"intervention":2842,"totalTrials":175,"cells":2843},"Hylan GF-20 alone",{"EARLY_PHASE1":2844,"PHASE1":2846,"PHASE2":2848,"PHASE3":2850,"PHASE4":2852,"NA":2863},{"trials":2845,"activeCount":103},[],{"trials":2847,"activeCount":103},[],{"trials":2849,"activeCount":103},[],{"trials":2851,"activeCount":103},[],{"trials":2853,"activeCount":103},[2854],{"nctId":2855,"briefTitle":2856,"status":165,"phases":2857,"primaryCompletion":1822,"completion":197,"start":1969,"enrollment":2858,"conditions":2859,"interventions":2861},"NCT01335321","Evaluation of the Effect of Adding Corticosteroid to Viscosupplementation",[94],108,[2860],"Osteoarthritis",[2842,2862],"Triamcinolone",{"trials":2864,"activeCount":103},[],{"intervention":2862,"totalTrials":175,"cells":2866},{"EARLY_PHASE1":2867,"PHASE1":2869,"PHASE2":2871,"PHASE3":2873,"PHASE4":2875,"NA":2881},{"trials":2868,"activeCount":103},[],{"trials":2870,"activeCount":103},[],{"trials":2872,"activeCount":103},[],{"trials":2874,"activeCount":103},[],{"trials":2876,"activeCount":103},[2877],{"nctId":2855,"briefTitle":2856,"status":165,"phases":2878,"primaryCompletion":1822,"completion":197,"start":1969,"enrollment":2858,"conditions":2879,"interventions":2880},[94],[2860],[2842,2862],{"trials":2882,"activeCount":103},[],{"intervention":2884,"totalTrials":175,"cells":2885},"early insertion",{"EARLY_PHASE1":2886,"PHASE1":2888,"PHASE2":2890,"PHASE3":2892,"PHASE4":2894,"NA":2906},{"trials":2887,"activeCount":103},[],{"trials":2889,"activeCount":103},[],{"trials":2891,"activeCount":103},[],{"trials":2893,"activeCount":103},[],{"trials":2895,"activeCount":103},[2896],{"nctId":2897,"briefTitle":2898,"status":165,"phases":2899,"primaryCompletion":1901,"completion":1997,"start":207,"enrollment":740,"conditions":2900,"interventions":2904},"NCT02469454","Effect of t of the Etonogestrel Releasing Implant on Infant Growth and Development",[94],[2677,2901,2902,2903],"Newborn","Child Development","Growth",[2884,2905],"conventional insertion",{"trials":2907,"activeCount":103},[],{"intervention":2905,"totalTrials":175,"cells":2909},{"EARLY_PHASE1":2910,"PHASE1":2912,"PHASE2":2914,"PHASE3":2916,"PHASE4":2918,"NA":2924},{"trials":2911,"activeCount":103},[],{"trials":2913,"activeCount":103},[],{"trials":2915,"activeCount":103},[],{"trials":2917,"activeCount":103},[],{"trials":2919,"activeCount":103},[2920],{"nctId":2897,"briefTitle":2898,"status":165,"phases":2921,"primaryCompletion":1901,"completion":1997,"start":207,"enrollment":740,"conditions":2922,"interventions":2923},[94],[2677,2901,2902,2903],[2884,2905],{"trials":2925,"activeCount":103},[],{"intervention":2927,"totalTrials":175,"cells":2928},"LNG-IUS: levonorgestrel intrauterine system",{"EARLY_PHASE1":2929,"PHASE1":2931,"PHASE2":2933,"PHASE3":2935,"PHASE4":2937,"NA":2950},{"trials":2930,"activeCount":103},[],{"trials":2932,"activeCount":103},[],{"trials":2934,"activeCount":103},[],{"trials":2936,"activeCount":103},[],{"trials":2938,"activeCount":103},[2939],{"nctId":2940,"briefTitle":2941,"status":165,"phases":2942,"primaryCompletion":2943,"completion":2943,"start":2944,"enrollment":2945,"conditions":2946,"interventions":2948},"NCT02158845","Levonorgestrel-releasing Intrauterine System in Patients With Endometriosis",[94],"2012-09","2010-02",44,[2947],"Endometriosis",[2927,2949],"GnRHa: leuprolide",{"trials":2951,"activeCount":103},[],{"intervention":2949,"totalTrials":175,"cells":2953},{"EARLY_PHASE1":2954,"PHASE1":2956,"PHASE2":2958,"PHASE3":2960,"PHASE4":2962,"NA":2968},{"trials":2955,"activeCount":103},[],{"trials":2957,"activeCount":103},[],{"trials":2959,"activeCount":103},[],{"trials":2961,"activeCount":103},[],{"trials":2963,"activeCount":103},[2964],{"nctId":2940,"briefTitle":2941,"status":165,"phases":2965,"primaryCompletion":2943,"completion":2943,"start":2944,"enrollment":2945,"conditions":2966,"interventions":2967},[94],[2947],[2927,2949],{"trials":2969,"activeCount":103},[],{"intervention":2971,"totalTrials":175,"cells":2972},"Cholecalciferol",{"EARLY_PHASE1":2973,"PHASE1":2975,"PHASE2":2977,"PHASE3":2979,"PHASE4":2981,"NA":2990},{"trials":2974,"activeCount":103},[],{"trials":2976,"activeCount":103},[],{"trials":2978,"activeCount":103},[],{"trials":2980,"activeCount":103},[],{"trials":2982,"activeCount":103},[2983],{"nctId":2984,"briefTitle":2985,"status":193,"phases":2986,"primaryCompletion":2443,"completion":2443,"start":1736,"enrollment":170,"conditions":2987,"interventions":2989},"NCT01632514","Vitamin D Deficiency and Postoperative Hypocalcemia",[94],[2988],"Hypocalcemia",[2971],{"trials":2991,"activeCount":103},[],{"intervention":1908,"totalTrials":175,"cells":2993},{"EARLY_PHASE1":2994,"PHASE1":2996,"PHASE2":2998,"PHASE3":3000,"PHASE4":3002,"NA":3008},{"trials":2995,"activeCount":103},[],{"trials":2997,"activeCount":103},[],{"trials":2999,"activeCount":103},[],{"trials":3001,"activeCount":103},[],{"trials":3003,"activeCount":103},[3004],{"nctId":1898,"briefTitle":1899,"status":165,"phases":3005,"primaryCompletion":1901,"completion":1901,"start":1902,"enrollment":1903,"conditions":3006,"interventions":3007},[94],[1905,1906],[1908,1885],{"trials":3009,"activeCount":103},[],{"intervention":3011,"totalTrials":175,"cells":3012},"Tenoxicam",{"EARLY_PHASE1":3013,"PHASE1":3015,"PHASE2":3017,"PHASE3":3019,"PHASE4":3021,"NA":3033},{"trials":3014,"activeCount":103},[],{"trials":3016,"activeCount":103},[],{"trials":3018,"activeCount":103},[],{"trials":3020,"activeCount":103},[],{"trials":3022,"activeCount":103},[3023],{"nctId":3024,"briefTitle":3025,"status":165,"phases":3026,"primaryCompletion":2623,"completion":3027,"start":3028,"enrollment":3029,"conditions":3030,"interventions":3032},"NCT04182191","Influence of CYP2C9 Genotype on Clinical Efficacy of Tenoxicam",[94],"2019-11-01","2018-03-01",89,[3031,28],"Molar, Third",[3011],{"trials":3034,"activeCount":103},[],{"intervention":1707,"totalTrials":175,"cells":3036},{"EARLY_PHASE1":3037,"PHASE1":3039,"PHASE2":3041,"PHASE3":3043,"PHASE4":3045,"NA":3051},{"trials":3038,"activeCount":103},[],{"trials":3040,"activeCount":103},[],{"trials":3042,"activeCount":103},[],{"trials":3044,"activeCount":103},[],{"trials":3046,"activeCount":103},[3047],{"nctId":1697,"briefTitle":1698,"status":165,"phases":3048,"primaryCompletion":1700,"completion":1701,"start":1702,"enrollment":1434,"conditions":3049,"interventions":3050},[94],[1704],[1673,1706,1707,1708],{"trials":3052,"activeCount":103},[],{"intervention":1708,"totalTrials":175,"cells":3054},{"EARLY_PHASE1":3055,"PHASE1":3057,"PHASE2":3059,"PHASE3":3061,"PHASE4":3063,"NA":3069},{"trials":3056,"activeCount":103},[],{"trials":3058,"activeCount":103},[],{"trials":3060,"activeCount":103},[],{"trials":3062,"activeCount":103},[],{"trials":3064,"activeCount":103},[3065],{"nctId":1697,"briefTitle":1698,"status":165,"phases":3066,"primaryCompletion":1700,"completion":1701,"start":1702,"enrollment":1434,"conditions":3067,"interventions":3068},[94],[1704],[1673,1706,1707,1708],{"trials":3070,"activeCount":103},[],{"intervention":2017,"totalTrials":175,"cells":3072},{"EARLY_PHASE1":3073,"PHASE1":3075,"PHASE2":3077,"PHASE3":3079,"PHASE4":3081,"NA":3087},{"trials":3074,"activeCount":103},[],{"trials":3076,"activeCount":103},[],{"trials":3078,"activeCount":103},[],{"trials":3080,"activeCount":103},[],{"trials":3082,"activeCount":103},[3083],{"nctId":2006,"briefTitle":2007,"status":193,"phases":3084,"primaryCompletion":2009,"completion":2010,"start":2011,"enrollment":1434,"conditions":3085,"interventions":3086},[94],[2013,2014,2015],[2017,1981],{"trials":3088,"activeCount":103},[],{"intervention":3090,"totalTrials":175,"cells":3091},"Probiotic Formula",{"EARLY_PHASE1":3092,"PHASE1":3094,"PHASE2":3096,"PHASE3":3098,"PHASE4":3100,"NA":3110},{"trials":3093,"activeCount":103},[],{"trials":3095,"activeCount":103},[],{"trials":3097,"activeCount":103},[],{"trials":3099,"activeCount":103},[],{"trials":3101,"activeCount":103},[3102],{"nctId":3103,"briefTitle":3104,"status":193,"phases":3105,"primaryCompletion":2491,"completion":3106,"start":1839,"enrollment":480,"conditions":3107,"interventions":3109},"NCT03021161","The Effect of Probiotics on Asthma Risk in Animal Laboratory Workers",[94],"2020-01",[3108],"Asthma Occupational",[3090],{"trials":3111,"activeCount":103},[],{"intervention":3113,"totalTrials":175,"cells":3114},"viscosupplementation 1+1+1",{"EARLY_PHASE1":3115,"PHASE1":3117,"PHASE2":3119,"PHASE3":3121,"PHASE4":3123,"NA":3135},{"trials":3116,"activeCount":103},[],{"trials":3118,"activeCount":103},[],{"trials":3120,"activeCount":103},[],{"trials":3122,"activeCount":103},[],{"trials":3124,"activeCount":103},[3125],{"nctId":3126,"briefTitle":3127,"status":165,"phases":3128,"primaryCompletion":2136,"completion":3129,"start":3130,"enrollment":3131,"conditions":3132,"interventions":3133},"NCT01824485","Comparison of Two Application Regimens for Viscosupplementation",[94],"2014-04","2013-03",104,[2860],[3113,3134],"viscosupplementation 3 at once",{"trials":3136,"activeCount":103},[],{"intervention":3134,"totalTrials":175,"cells":3138},{"EARLY_PHASE1":3139,"PHASE1":3141,"PHASE2":3143,"PHASE3":3145,"PHASE4":3147,"NA":3153},{"trials":3140,"activeCount":103},[],{"trials":3142,"activeCount":103},[],{"trials":3144,"activeCount":103},[],{"trials":3146,"activeCount":103},[],{"trials":3148,"activeCount":103},[3149],{"nctId":3126,"briefTitle":3127,"status":165,"phases":3150,"primaryCompletion":2136,"completion":3129,"start":3130,"enrollment":3131,"conditions":3151,"interventions":3152},[94],[2860],[3113,3134],{"trials":3154,"activeCount":103},[],{"intervention":3156,"totalTrials":175,"cells":3157},"Anti-pandemic H1N1 influenza vaccine",{"EARLY_PHASE1":3158,"PHASE1":3160,"PHASE2":3162,"PHASE3":3164,"PHASE4":3166,"NA":3182},{"trials":3159,"activeCount":103},[],{"trials":3161,"activeCount":103},[],{"trials":3163,"activeCount":103},[],{"trials":3165,"activeCount":103},[],{"trials":3167,"activeCount":103},[3168],{"nctId":3169,"briefTitle":3170,"status":193,"phases":3171,"primaryCompletion":2738,"completion":3172,"start":1643,"enrollment":3173,"conditions":3174,"interventions":3181},"NCT01151644","Safety and Efficacy of Anti-Pandemic H1N1 Vaccination in Rheumatic Diseases",[94],"2010-12",5000,[574,576,447,3175,3176,3177,449,3178,455,582,3179,3180],"Dermatomyositis (DM)","DMixed Connective Tissue Disease","Systemic Vasculitis","Sjögren's Syndrome","Juvenile SLE","Juvenile DM",[3156],{"trials":3183,"activeCount":103},[],{"intervention":3185,"totalTrials":175,"cells":3186},"Surgery with 2%Articaine first, then Surgery with 4% Articaine",{"EARLY_PHASE1":3187,"PHASE1":3189,"PHASE2":3191,"PHASE3":3193,"PHASE4":3195,"NA":3207},{"trials":3188,"activeCount":103},[],{"trials":3190,"activeCount":103},[],{"trials":3192,"activeCount":103},[],{"trials":3194,"activeCount":103},[],{"trials":3196,"activeCount":103},[3197],{"nctId":3198,"briefTitle":3199,"status":165,"phases":3200,"primaryCompletion":3201,"completion":3201,"start":3202,"enrollment":388,"conditions":3203,"interventions":3205},"NCT02457325","Lower Third Molar Removal With 2% and 4% Articaine",[94],"2012-12","2011-06",[2583,3204],"Adverse Reaction to Other Local Anesthetics",[3185,3206],"Surgery with 4%Articaine first, then Surgery with 2% Articaine",{"trials":3208,"activeCount":103},[],{"intervention":3206,"totalTrials":175,"cells":3210},{"EARLY_PHASE1":3211,"PHASE1":3213,"PHASE2":3215,"PHASE3":3217,"PHASE4":3219,"NA":3225},{"trials":3212,"activeCount":103},[],{"trials":3214,"activeCount":103},[],{"trials":3216,"activeCount":103},[],{"trials":3218,"activeCount":103},[],{"trials":3220,"activeCount":103},[3221],{"nctId":3198,"briefTitle":3199,"status":165,"phases":3222,"primaryCompletion":3201,"completion":3201,"start":3202,"enrollment":388,"conditions":3223,"interventions":3224},[94],[2583,3204],[3185,3206],{"trials":3226,"activeCount":103},[],{"intervention":3228,"totalTrials":175,"cells":3229},"Pharmacogenetic anticoagulation",{"EARLY_PHASE1":3230,"PHASE1":3232,"PHASE2":3234,"PHASE3":3236,"PHASE4":3238,"NA":3251},{"trials":3231,"activeCount":103},[],{"trials":3233,"activeCount":103},[],{"trials":3235,"activeCount":103},[],{"trials":3237,"activeCount":103},[],{"trials":3239,"activeCount":103},[3240],{"nctId":3241,"briefTitle":3242,"status":193,"phases":3243,"primaryCompletion":3244,"completion":3245,"start":3246,"enrollment":3247,"conditions":3248,"interventions":3249},"NCT02592980","Evaluation of a Pharmacogenetic-based Warfarin Dosing Algorithm in Patients",[94],"2019-11","2020-12","2016-01",300,[1774],[3228,3250],"Traditional anticoagulation",{"trials":3252,"activeCount":103},[],{"intervention":3250,"totalTrials":175,"cells":3254},{"EARLY_PHASE1":3255,"PHASE1":3257,"PHASE2":3259,"PHASE3":3261,"PHASE4":3263,"NA":3269},{"trials":3256,"activeCount":103},[],{"trials":3258,"activeCount":103},[],{"trials":3260,"activeCount":103},[],{"trials":3262,"activeCount":103},[],{"trials":3264,"activeCount":103},[3265],{"nctId":3241,"briefTitle":3242,"status":193,"phases":3266,"primaryCompletion":3244,"completion":3245,"start":3246,"enrollment":3247,"conditions":3267,"interventions":3268},[94],[1774],[3228,3250],{"trials":3270,"activeCount":103},[],{"intervention":3272,"totalTrials":175,"cells":3273},"BioMend and ReproBone",{"EARLY_PHASE1":3274,"PHASE1":3276,"PHASE2":3278,"PHASE3":3280,"PHASE4":3282,"NA":3292},{"trials":3275,"activeCount":103},[],{"trials":3277,"activeCount":103},[],{"trials":3279,"activeCount":103},[],{"trials":3281,"activeCount":103},[],{"trials":3283,"activeCount":103},[3284],{"nctId":3285,"briefTitle":3286,"status":165,"phases":3287,"primaryCompletion":2136,"completion":2048,"start":1945,"enrollment":1350,"conditions":3288,"interventions":3290},"NCT02894528","Evaluation of a Synthetic Bone Substitute for Ridge Preservation",[94],[3289],"Alveolar Process",[3272,3291],"BioMend without ReproBone",{"trials":3293,"activeCount":103},[],{"intervention":3291,"totalTrials":175,"cells":3295},{"EARLY_PHASE1":3296,"PHASE1":3298,"PHASE2":3300,"PHASE3":3302,"PHASE4":3304,"NA":3310},{"trials":3297,"activeCount":103},[],{"trials":3299,"activeCount":103},[],{"trials":3301,"activeCount":103},[],{"trials":3303,"activeCount":103},[],{"trials":3305,"activeCount":103},[3306],{"nctId":3285,"briefTitle":3286,"status":165,"phases":3307,"primaryCompletion":2136,"completion":2048,"start":1945,"enrollment":1350,"conditions":3308,"interventions":3309},[94],[3289],[3272,3291],{"trials":3311,"activeCount":103},[],{"intervention":3313,"totalTrials":175,"cells":3314},"1 ampoule of Hylan GF-20",{"EARLY_PHASE1":3315,"PHASE1":3317,"PHASE2":3319,"PHASE3":3321,"PHASE4":3323,"NA":3335},{"trials":3316,"activeCount":103},[],{"trials":3318,"activeCount":103},[],{"trials":3320,"activeCount":103},[],{"trials":3322,"activeCount":103},[],{"trials":3324,"activeCount":103},[3325],{"nctId":3326,"briefTitle":3327,"status":193,"phases":3328,"primaryCompletion":3329,"completion":2273,"start":3330,"enrollment":208,"conditions":3331,"interventions":3332},"NCT01810809","Hip Viscosupplementation: What is the Best Dosage?",[94],"2014-06","2013-04",[2860],[3313,3333,3334],"2 ampoules of Hylan GF-20","3 ampoules of Hylan GF-20",{"trials":3336,"activeCount":103},[],{"intervention":3333,"totalTrials":175,"cells":3338},{"EARLY_PHASE1":3339,"PHASE1":3341,"PHASE2":3343,"PHASE3":3345,"PHASE4":3347,"NA":3353},{"trials":3340,"activeCount":103},[],{"trials":3342,"activeCount":103},[],{"trials":3344,"activeCount":103},[],{"trials":3346,"activeCount":103},[],{"trials":3348,"activeCount":103},[3349],{"nctId":3326,"briefTitle":3327,"status":193,"phases":3350,"primaryCompletion":3329,"completion":2273,"start":3330,"enrollment":208,"conditions":3351,"interventions":3352},[94],[2860],[3313,3333,3334],{"trials":3354,"activeCount":103},[],{"intervention":3334,"totalTrials":175,"cells":3356},{"EARLY_PHASE1":3357,"PHASE1":3359,"PHASE2":3361,"PHASE3":3363,"PHASE4":3365,"NA":3371},{"trials":3358,"activeCount":103},[],{"trials":3360,"activeCount":103},[],{"trials":3362,"activeCount":103},[],{"trials":3364,"activeCount":103},[],{"trials":3366,"activeCount":103},[3367],{"nctId":3326,"briefTitle":3327,"status":193,"phases":3368,"primaryCompletion":3329,"completion":2273,"start":3330,"enrollment":208,"conditions":3369,"interventions":3370},[94],[2860],[3313,3333,3334],{"trials":3372,"activeCount":103},[],{"intervention":3374,"totalTrials":175,"cells":3375},"Mepolizumab 100 MG [Nucala]",{"EARLY_PHASE1":3376,"PHASE1":3378,"PHASE2":3380,"PHASE3":3382,"PHASE4":3384,"NA":3397},{"trials":3377,"activeCount":103},[],{"trials":3379,"activeCount":103},[],{"trials":3381,"activeCount":103},[],{"trials":3383,"activeCount":103},[],{"trials":3385,"activeCount":103},[3386],{"nctId":3387,"briefTitle":3388,"status":193,"phases":3389,"primaryCompletion":3390,"completion":3391,"start":3392,"enrollment":3393,"conditions":3394,"interventions":3396},"NCT04228588","A Pragmatic Study to Investigate the Efficacy and Safety of Mepolizumab in Severe Uncontrolled Asthma in Brazil",[94],"2021-01-09","2021-12","2020-01-09",18,[3395],"Eosinophilic Asthma",[3374],{"trials":3398,"activeCount":103},[],{"intervention":3400,"totalTrials":175,"cells":3401},"Testosterone replacement",{"EARLY_PHASE1":3402,"PHASE1":3404,"PHASE2":3406,"PHASE3":3408,"PHASE4":3410,"NA":3419},{"trials":3403,"activeCount":103},[],{"trials":3405,"activeCount":103},[],{"trials":3407,"activeCount":103},[],{"trials":3409,"activeCount":103},[],{"trials":3411,"activeCount":103},[3412],{"nctId":3413,"briefTitle":3414,"status":165,"phases":3415,"primaryCompletion":1702,"completion":1702,"start":2010,"enrollment":3416,"conditions":3417,"interventions":3418},"NCT01852994","Exercise Training and Testosterone Replacement in Heart Failure Patients",[94],39,[19],[3400],{"trials":3420,"activeCount":103},[],{"intervention":3422,"totalTrials":175,"cells":3423},"SSRI",{"EARLY_PHASE1":3424,"PHASE1":3426,"PHASE2":3428,"PHASE3":3430,"PHASE4":3432,"NA":3442},{"trials":3425,"activeCount":103},[],{"trials":3427,"activeCount":103},[],{"trials":3429,"activeCount":103},[],{"trials":3431,"activeCount":103},[],{"trials":3433,"activeCount":103},[3434],{"nctId":3435,"briefTitle":3436,"status":165,"phases":3437,"primaryCompletion":3438,"completion":3438,"start":1632,"enrollment":3439,"conditions":3440,"interventions":3441},"NCT00680602","Group Cognitive Behavioral Therapy Versus Fluoxetine for Obsessive-Compulsive Disorder: a Practical Trial",[94],"2008-09",158,[1635],[3422],{"trials":3443,"activeCount":103},[],{"intervention":3445,"totalTrials":175,"cells":3446},"Sensodyne Repair and Protect",{"EARLY_PHASE1":3447,"PHASE1":3449,"PHASE2":3451,"PHASE3":3453,"PHASE4":3455,"NA":3469},{"trials":3448,"activeCount":103},[],{"trials":3450,"activeCount":103},[],{"trials":3452,"activeCount":103},[],{"trials":3454,"activeCount":103},[],{"trials":3456,"activeCount":103},[3457],{"nctId":3458,"briefTitle":3459,"status":165,"phases":3460,"primaryCompletion":3461,"completion":3461,"start":3462,"enrollment":20,"conditions":3463,"interventions":3466},"NCT04422184","Comparative Clinical Evaluation of Three Different Agents in Reducing Dental Hypersensitivity in Periodontal Patients",[94],"2023-05-03","2019-07-29",[3464,3465],"Dentin Hypersensitivity","Periodontal Diseases",[3445,3467,3468],"Dentalclean Daily Regenerator","Dentalclean Daily Regenerator with potassium citrate",{"trials":3470,"activeCount":103},[],{"intervention":3467,"totalTrials":175,"cells":3472},{"EARLY_PHASE1":3473,"PHASE1":3475,"PHASE2":3477,"PHASE3":3479,"PHASE4":3481,"NA":3487},{"trials":3474,"activeCount":103},[],{"trials":3476,"activeCount":103},[],{"trials":3478,"activeCount":103},[],{"trials":3480,"activeCount":103},[],{"trials":3482,"activeCount":103},[3483],{"nctId":3458,"briefTitle":3459,"status":165,"phases":3484,"primaryCompletion":3461,"completion":3461,"start":3462,"enrollment":20,"conditions":3485,"interventions":3486},[94],[3464,3465],[3445,3467,3468],{"trials":3488,"activeCount":103},[],{"intervention":3468,"totalTrials":175,"cells":3490},{"EARLY_PHASE1":3491,"PHASE1":3493,"PHASE2":3495,"PHASE3":3497,"PHASE4":3499,"NA":3505},{"trials":3492,"activeCount":103},[],{"trials":3494,"activeCount":103},[],{"trials":3496,"activeCount":103},[],{"trials":3498,"activeCount":103},[],{"trials":3500,"activeCount":103},[3501],{"nctId":3458,"briefTitle":3459,"status":165,"phases":3502,"primaryCompletion":3461,"completion":3461,"start":3462,"enrollment":20,"conditions":3503,"interventions":3504},[94],[3464,3465],[3445,3467,3468],{"trials":3506,"activeCount":103},[],{"intervention":1596,"totalTrials":175,"cells":3508},{"EARLY_PHASE1":3509,"PHASE1":3511,"PHASE2":3513,"PHASE3":3515,"PHASE4":3517,"NA":3523},{"trials":3510,"activeCount":103},[],{"trials":3512,"activeCount":103},[],{"trials":3514,"activeCount":103},[],{"trials":3516,"activeCount":103},[],{"trials":3518,"activeCount":103},[3519],{"nctId":1587,"briefTitle":1588,"status":165,"phases":3520,"primaryCompletion":1590,"completion":1590,"start":1591,"enrollment":208,"conditions":3521,"interventions":3522},[94],[1593],[1595,1596],{"trials":3524,"activeCount":103},[],{"intervention":526,"totalTrials":175,"cells":3526},{"EARLY_PHASE1":3527,"PHASE1":3529,"PHASE2":3531,"PHASE3":3533,"PHASE4":3535,"NA":3547},{"trials":3528,"activeCount":103},[],{"trials":3530,"activeCount":103},[],{"trials":3532,"activeCount":103},[],{"trials":3534,"activeCount":103},[],{"trials":3536,"activeCount":103},[3537],{"nctId":3538,"briefTitle":3539,"status":193,"phases":3540,"primaryCompletion":3541,"completion":3542,"start":3543,"enrollment":294,"conditions":3544,"interventions":3546},"NCT04234776","Intramuscular Ketamine Versus Aripiprazole and Escitalopram in the Treatment of Resistant Depression",[94],"2020-06-03","2021-04-03","2018-04-03",[3545],"Depressive Disorder",[526],{"trials":3548,"activeCount":103},[],{"intervention":3550,"totalTrials":175,"cells":3551},"CoronaVac",{"EARLY_PHASE1":3552,"PHASE1":3554,"PHASE2":3556,"PHASE3":3558,"PHASE4":3560,"NA":3578},{"trials":3553,"activeCount":103},[],{"trials":3555,"activeCount":103},[],{"trials":3557,"activeCount":103},[],{"trials":3559,"activeCount":103},[],{"trials":3561,"activeCount":103},[3562],{"nctId":3563,"briefTitle":3564,"status":165,"phases":3565,"primaryCompletion":3566,"completion":3567,"start":3568,"enrollment":3569,"conditions":3570,"interventions":3577},"NCT04754698","COVID-19 CoronaVac in Patients With Autoimmune Rheumatic Diseases and HIV\u002FAIDS",[94],"2023-11-27","2024-03-22","2021-02-09",2196,[3571,3572,3573,3574,3575,3576],"Rheumatic Disease","HIV Infections","AIDS","Safety Issues","Immunogenicity","COVID-19",[3550],{"trials":3579,"activeCount":103},[],{"intervention":3581,"totalTrials":175,"cells":3582},"Sertraline Hydrochloride",{"EARLY_PHASE1":3583,"PHASE1":3585,"PHASE2":3587,"PHASE3":3589,"PHASE4":3591,"NA":3603},{"trials":3584,"activeCount":103},[],{"trials":3586,"activeCount":103},[],{"trials":3588,"activeCount":103},[],{"trials":3590,"activeCount":103},[],{"trials":3592,"activeCount":103},[3593],{"nctId":3594,"briefTitle":3595,"status":165,"phases":3596,"primaryCompletion":3597,"completion":3598,"start":3599,"enrollment":2675,"conditions":3600,"interventions":3602},"NCT03068429","Fear Conditioned Response in Healthy Subjects and in OCD Patients Pre and Post Treatment With Sertraline.",[94],"2019-12-20","2020-07-31","2016-12-01",[3601],"Obsessive-Compulsive Disorder",[3581],{"trials":3604,"activeCount":103},[],{"intervention":3606,"totalTrials":175,"cells":3607},"Chloroquine diphosphate 250mg",{"EARLY_PHASE1":3608,"PHASE1":3610,"PHASE2":3612,"PHASE3":3614,"PHASE4":3616,"NA":3627},{"trials":3609,"activeCount":103},[],{"trials":3611,"activeCount":103},[],{"trials":3613,"activeCount":103},[],{"trials":3615,"activeCount":103},[],{"trials":3617,"activeCount":103},[3618],{"nctId":3619,"briefTitle":3620,"status":165,"phases":3621,"primaryCompletion":3622,"completion":207,"start":3623,"enrollment":726,"conditions":3624,"interventions":3626},"NCT01980745","CHLOROQUINE FOR MAINTENANCE REMISSION OF AUTOIMMUNE HEPATITIS",[94],"2013-11","2002-02",[3625],"Hepatitis, Autoimmune",[3606],{"trials":3628,"activeCount":103},[],{"intervention":3630,"totalTrials":175,"cells":3631},"Heparin Lock Solution",{"EARLY_PHASE1":3632,"PHASE1":3634,"PHASE2":3636,"PHASE3":3638,"PHASE4":3640,"NA":3651},{"trials":3633,"activeCount":103},[],{"trials":3635,"activeCount":103},[],{"trials":3637,"activeCount":103},[],{"trials":3639,"activeCount":103},[],{"trials":3641,"activeCount":103},[3642],{"nctId":3643,"briefTitle":3644,"status":165,"phases":3645,"primaryCompletion":3646,"completion":2031,"start":1945,"enrollment":691,"conditions":3647,"interventions":3648},"NCT02618317","Comparison of Effectiveness and Safety of Three Lock Solutions for Long-Term Central Venous Catheter for Hemodialysis",[94],"2016-02",[1906],[3630,3649,3650],"Trissodium Citrate 30%","Minocycline-EDTA 30 mg\u002Fml - 3 mg\u002Fml",{"trials":3652,"activeCount":103},[],{"intervention":3649,"totalTrials":175,"cells":3654},{"EARLY_PHASE1":3655,"PHASE1":3657,"PHASE2":3659,"PHASE3":3661,"PHASE4":3663,"NA":3669},{"trials":3656,"activeCount":103},[],{"trials":3658,"activeCount":103},[],{"trials":3660,"activeCount":103},[],{"trials":3662,"activeCount":103},[],{"trials":3664,"activeCount":103},[3665],{"nctId":3643,"briefTitle":3644,"status":165,"phases":3666,"primaryCompletion":3646,"completion":2031,"start":1945,"enrollment":691,"conditions":3667,"interventions":3668},[94],[1906],[3630,3649,3650],{"trials":3670,"activeCount":103},[],{"intervention":3650,"totalTrials":175,"cells":3672},{"EARLY_PHASE1":3673,"PHASE1":3675,"PHASE2":3677,"PHASE3":3679,"PHASE4":3681,"NA":3687},{"trials":3674,"activeCount":103},[],{"trials":3676,"activeCount":103},[],{"trials":3678,"activeCount":103},[],{"trials":3680,"activeCount":103},[],{"trials":3682,"activeCount":103},[3683],{"nctId":3643,"briefTitle":3644,"status":165,"phases":3684,"primaryCompletion":3646,"completion":2031,"start":1945,"enrollment":691,"conditions":3685,"interventions":3686},[94],[1906],[3630,3649,3650],{"trials":3688,"activeCount":103},[],{"intervention":3690,"totalTrials":175,"cells":3691},"Inactivated and fragmented influenza vaccine",{"EARLY_PHASE1":3692,"PHASE1":3694,"PHASE2":3696,"PHASE3":3698,"PHASE4":3700,"NA":3712},{"trials":3693,"activeCount":103},[],{"trials":3695,"activeCount":103},[],{"trials":3697,"activeCount":103},[],{"trials":3699,"activeCount":103},[],{"trials":3701,"activeCount":103},[3702],{"nctId":3703,"briefTitle":3704,"status":165,"phases":3705,"primaryCompletion":3706,"completion":3707,"start":3708,"enrollment":3247,"conditions":3709,"interventions":3711},"NCT03540823","Evaluation of Influenza A\u002FH3N2 Vaccine in Patients With Rheumatologic Diseases",[94],"2018-06-23","2018-08-23","2018-04-23",[3710,578],"Systemic Lupus",[3690],{"trials":3713,"activeCount":103},[],{"intervention":3715,"totalTrials":175,"cells":3716},"latanoprost",{"EARLY_PHASE1":3717,"PHASE1":3719,"PHASE2":3721,"PHASE3":3723,"PHASE4":3725,"NA":3736},{"trials":3718,"activeCount":103},[],{"trials":3720,"activeCount":103},[],{"trials":3722,"activeCount":103},[],{"trials":3724,"activeCount":103},[],{"trials":3726,"activeCount":103},[3727],{"nctId":3728,"briefTitle":3729,"status":165,"phases":3730,"primaryCompletion":3731,"completion":3732,"start":1590,"enrollment":1998,"conditions":3733,"interventions":3735},"NCT00906594","Additive Intra-ocular Pressure Reduction Effect of Fixed Combination of Maleate Timolol 0.5%\u002FDorzolamide 2% on Monotherapy With Latanoprost in Patients With Elevated Intra-ocular Pressure",[94],"2008-01","2008-07",[3734],"Glaucoma",[3715],{"trials":3737,"activeCount":103},[],{"intervention":3739,"totalTrials":175,"cells":3740},"etonogestrel-releasing implant contraceptive",{"EARLY_PHASE1":3741,"PHASE1":3743,"PHASE2":3745,"PHASE3":3747,"PHASE4":3749,"NA":3758},{"trials":3742,"activeCount":103},[],{"trials":3744,"activeCount":103},[],{"trials":3746,"activeCount":103},[],{"trials":3748,"activeCount":103},[],{"trials":3750,"activeCount":103},[3751],{"nctId":3752,"briefTitle":3753,"status":165,"phases":3754,"primaryCompletion":1996,"completion":196,"start":2048,"enrollment":1762,"conditions":3755,"interventions":3757},"NCT02594462","Contraception in Women With Sickle Cell Disease",[94],[3756],"Sickle Cell Disease",[3739],{"trials":3759,"activeCount":103},[],{"intervention":174,"totalTrials":175,"cells":3761},{"EARLY_PHASE1":3762,"PHASE1":3764,"PHASE2":3766,"PHASE3":3768,"PHASE4":3770,"NA":3776},{"trials":3763,"activeCount":103},[],{"trials":3765,"activeCount":103},[],{"trials":3767,"activeCount":103},[],{"trials":3769,"activeCount":103},[],{"trials":3771,"activeCount":103},[3772],{"nctId":163,"briefTitle":164,"status":165,"phases":3773,"primaryCompletion":167,"completion":168,"start":169,"enrollment":170,"conditions":3774,"interventions":3775},[94],[172],[174,138],{"trials":3777,"activeCount":103},[],{"intervention":3779,"totalTrials":175,"cells":3780},"Codeine + Diclofenac",{"EARLY_PHASE1":3781,"PHASE1":3783,"PHASE2":3785,"PHASE3":3787,"PHASE4":3789,"NA":3799},{"trials":3782,"activeCount":103},[],{"trials":3784,"activeCount":103},[],{"trials":3786,"activeCount":103},[],{"trials":3788,"activeCount":103},[],{"trials":3790,"activeCount":103},[3791],{"nctId":3792,"briefTitle":3793,"status":165,"phases":3794,"primaryCompletion":207,"completion":1701,"start":3795,"enrollment":388,"conditions":3796,"interventions":3797},"NCT02547896","Effectiveness of Diclofenac and Its Association to Codeine After Lower Third Molar Extraction.",[94],"2014-09",[2583],[3779,3798],"Diclofenac",{"trials":3800,"activeCount":103},[],{"intervention":3798,"totalTrials":175,"cells":3802},{"EARLY_PHASE1":3803,"PHASE1":3805,"PHASE2":3807,"PHASE3":3809,"PHASE4":3811,"NA":3817},{"trials":3804,"activeCount":103},[],{"trials":3806,"activeCount":103},[],{"trials":3808,"activeCount":103},[],{"trials":3810,"activeCount":103},[],{"trials":3812,"activeCount":103},[3813],{"nctId":3792,"briefTitle":3793,"status":165,"phases":3814,"primaryCompletion":207,"completion":1701,"start":3795,"enrollment":388,"conditions":3815,"interventions":3816},[94],[2583],[3779,3798],{"trials":3818,"activeCount":103},[],{"intervention":3820,"totalTrials":175,"cells":3821},"dynamized estrogen",{"EARLY_PHASE1":3822,"PHASE1":3824,"PHASE2":3826,"PHASE3":3828,"PHASE4":3830,"NA":3839},{"trials":3823,"activeCount":103},[],{"trials":3825,"activeCount":103},[],{"trials":3827,"activeCount":103},[],{"trials":3829,"activeCount":103},[],{"trials":3831,"activeCount":103},[3832],{"nctId":3833,"briefTitle":3834,"status":165,"phases":3835,"primaryCompletion":3646,"completion":1933,"start":1761,"enrollment":388,"conditions":3836,"interventions":3838},"NCT02427386","Homeopathic Treatment of Chronic Pelvic Pain in Women With Endometriosis",[94],[2947,3837],"Pelvic Pain",[3820],{"trials":3840,"activeCount":103},[],{"intervention":3842,"totalTrials":175,"cells":3843},"progesterone",{"EARLY_PHASE1":3844,"PHASE1":3846,"PHASE2":3848,"PHASE3":3850,"PHASE4":3852,"NA":3862},{"trials":3845,"activeCount":103},[],{"trials":3847,"activeCount":103},[],{"trials":3849,"activeCount":103},[],{"trials":3851,"activeCount":103},[],{"trials":3853,"activeCount":103},[3854],{"nctId":3855,"briefTitle":3856,"status":165,"phases":3857,"primaryCompletion":1761,"completion":3329,"start":2317,"enrollment":3858,"conditions":3859,"interventions":3861},"NCT01031017","Prophylactic Administration of Natural Progesterone in the Prevention of Preterm Delivery in Twin Pregnancies",[94],390,[3860],"Preterm Delivery",[3842],{"trials":3863,"activeCount":103},[],{"intervention":3865,"totalTrials":175,"cells":3866},"Sotalol Oral",{"EARLY_PHASE1":3867,"PHASE1":3869,"PHASE2":3871,"PHASE3":3873,"PHASE4":3875,"NA":3890},{"trials":3868,"activeCount":103},[],{"trials":3870,"activeCount":103},[],{"trials":3872,"activeCount":103},[],{"trials":3874,"activeCount":103},[],{"trials":3876,"activeCount":103},[3877],{"nctId":3878,"briefTitle":3879,"status":193,"phases":3880,"primaryCompletion":3881,"completion":3882,"start":3883,"enrollment":1237,"conditions":3884,"interventions":3889},"NCT05418036","Safety Assessment for Sotalol Protocol in Outpatient Unit",[94],"2023-02","2023-06","2020-10-26",[3885,3886,3887,3888],"Supraventricular Arrhythmia","Ventricular Arrythmia","Proarrhythmia","Antiarrhythmic Drug Adverse Reaction",[3865],{"trials":3891,"activeCount":103},[],{"intervention":3893,"totalTrials":175,"cells":3894},"Nystatin 100.000 units",{"EARLY_PHASE1":3895,"PHASE1":3897,"PHASE2":3899,"PHASE3":3901,"PHASE4":3903,"NA":3914},{"trials":3896,"activeCount":103},[],{"trials":3898,"activeCount":103},[],{"trials":3900,"activeCount":103},[],{"trials":3902,"activeCount":103},[],{"trials":3904,"activeCount":103},[3905],{"nctId":3906,"briefTitle":3907,"status":165,"phases":3908,"primaryCompletion":3909,"completion":3910,"start":2010,"enrollment":1015,"conditions":3911,"interventions":3913},"NCT02642900","Photodynamic Therapy Against Candida Spp. in Complete Denture Wearers",[94],"2011-02","2011-07",[3912],"Photochemotherapy Reaction",[3893],{"trials":3915,"activeCount":103},[],{"intervention":1740,"totalTrials":175,"cells":3917},{"EARLY_PHASE1":3918,"PHASE1":3920,"PHASE2":3922,"PHASE3":3924,"PHASE4":3926,"NA":3932},{"trials":3919,"activeCount":103},[],{"trials":3921,"activeCount":103},[],{"trials":3923,"activeCount":103},[],{"trials":3925,"activeCount":103},[],{"trials":3927,"activeCount":103},[3928],{"nctId":1733,"briefTitle":1734,"status":193,"phases":3929,"primaryCompletion":750,"completion":207,"start":1736,"enrollment":388,"conditions":3930,"interventions":3931},[94],[1738],[1712,1740],{"trials":3933,"activeCount":103},[],{"intervention":3935,"totalTrials":175,"cells":3936},"Vitamin D",{"EARLY_PHASE1":3937,"PHASE1":3939,"PHASE2":3941,"PHASE3":3943,"PHASE4":3945,"NA":3961},{"trials":3938,"activeCount":103},[],{"trials":3940,"activeCount":103},[],{"trials":3942,"activeCount":103},[],{"trials":3944,"activeCount":103},[],{"trials":3946,"activeCount":103},[3947],{"nctId":3948,"briefTitle":3949,"status":3950,"phases":3951,"primaryCompletion":1273,"completion":3952,"start":1273,"enrollment":103,"conditions":3953,"interventions":3960},"NCT03063190","Cholecalciferol Supplementation in Restless Leg Syndrome in Patients With Chronic Kidney Disease","WITHDRAWN",[94],"2023-03",[3954,3955,3956,3957,3958,3959],"Restless Leg Disorder","Renal Disease Bone","Renal Disease, End Stage","Hyperparathyroidism, Secondary","Adynamic Bone Disease","Vitamin D Deficiency",[3935],{"trials":3962,"activeCount":103},[],{"intervention":3964,"totalTrials":175,"cells":3965},"Sirolimus",{"EARLY_PHASE1":3966,"PHASE1":3968,"PHASE2":3970,"PHASE3":3972,"PHASE4":3974,"NA":3983},{"trials":3967,"activeCount":103},[],{"trials":3969,"activeCount":103},[],{"trials":3971,"activeCount":103},[],{"trials":3973,"activeCount":103},[],{"trials":3975,"activeCount":103},[3976],{"nctId":3977,"briefTitle":3978,"status":193,"phases":3979,"primaryCompletion":2832,"completion":2444,"start":195,"enrollment":2106,"conditions":3980,"interventions":3981},"NCT02208791","Effects of the Quadruple Immunosuppression on Peripheral Blood Lymphocytes and Development of Anti-HLA Antibodies in Kidney Transplant",[94],[802],[3964,3982],"No intervention",{"trials":3984,"activeCount":103},[],{"intervention":3982,"totalTrials":175,"cells":3986},{"EARLY_PHASE1":3987,"PHASE1":3989,"PHASE2":3991,"PHASE3":3993,"PHASE4":3995,"NA":4001},{"trials":3988,"activeCount":103},[],{"trials":3990,"activeCount":103},[],{"trials":3992,"activeCount":103},[],{"trials":3994,"activeCount":103},[],{"trials":3996,"activeCount":103},[3997],{"nctId":3977,"briefTitle":3978,"status":193,"phases":3998,"primaryCompletion":2832,"completion":2444,"start":195,"enrollment":2106,"conditions":3999,"interventions":4000},[94],[802],[3964,3982],{"trials":4002,"activeCount":103},[],{"intervention":4004,"totalTrials":175,"cells":4005},"30EE+DRSP",{"EARLY_PHASE1":4006,"PHASE1":4008,"PHASE2":4010,"PHASE3":4012,"PHASE4":4014,"NA":4023},{"trials":4007,"activeCount":103},[],{"trials":4009,"activeCount":103},[],{"trials":4011,"activeCount":103},[],{"trials":4013,"activeCount":103},[],{"trials":4015,"activeCount":103},[4016],{"nctId":4017,"briefTitle":4018,"status":165,"phases":4019,"primaryCompletion":1945,"completion":3795,"start":1821,"enrollment":2945,"conditions":4020,"interventions":4021},"NCT02342093","Contraceptives Containing Drospirenone and Blood Pressure",[94],[1868,2677],[4004,4022],"20EE+DRSP",{"trials":4024,"activeCount":103},[],{"intervention":4022,"totalTrials":175,"cells":4026},{"EARLY_PHASE1":4027,"PHASE1":4029,"PHASE2":4031,"PHASE3":4033,"PHASE4":4035,"NA":4041},{"trials":4028,"activeCount":103},[],{"trials":4030,"activeCount":103},[],{"trials":4032,"activeCount":103},[],{"trials":4034,"activeCount":103},[],{"trials":4036,"activeCount":103},[4037],{"nctId":4017,"briefTitle":4018,"status":165,"phases":4038,"primaryCompletion":1945,"completion":3795,"start":1821,"enrollment":2945,"conditions":4039,"interventions":4040},[94],[1868,2677],[4004,4022],{"trials":4042,"activeCount":103},[],{"intervention":4044,"totalTrials":175,"cells":4045},"Galantamine",{"EARLY_PHASE1":4046,"PHASE1":4048,"PHASE2":4050,"PHASE3":4052,"PHASE4":4054,"NA":4064},{"trials":4047,"activeCount":103},[],{"trials":4049,"activeCount":103},[],{"trials":4051,"activeCount":103},[],{"trials":4053,"activeCount":103},[],{"trials":4055,"activeCount":103},[4056],{"nctId":4057,"briefTitle":4058,"status":165,"phases":4059,"primaryCompletion":2047,"completion":4060,"start":2136,"enrollment":235,"conditions":4061,"interventions":4063},"NCT02283242","Galantamine Effects in Patients With Metabolic Syndrome",[94],"2017-02",[4062],"Abdominal Obesity Metabolic Syndrome",[4044],{"trials":4065,"activeCount":103},[],{"intervention":4067,"totalTrials":175,"cells":4068},"Naproxen",{"EARLY_PHASE1":4069,"PHASE1":4071,"PHASE2":4073,"PHASE3":4075,"PHASE4":4077,"NA":4091},{"trials":4070,"activeCount":103},[],{"trials":4072,"activeCount":103},[],{"trials":4074,"activeCount":103},[],{"trials":4076,"activeCount":103},[],{"trials":4078,"activeCount":103},[4079],{"nctId":4080,"briefTitle":4081,"status":165,"phases":4082,"primaryCompletion":4083,"completion":4083,"start":4084,"enrollment":4085,"conditions":4086,"interventions":4089},"NCT03092193","Pharmacogenetic and Pharmacokinetics of Naproxen and Associated Naproxen-esomeprazole",[94],"2017-10-01","2017-03-01",8,[4087,4088],"Poor Metabolizer Due to Cytochrome P450 CYP2C9 Variant","Poor Metabolizer Due to Cytochrome p450 CYP2C19 Variant",[4067,4090],"Naproxen-esomeprazole",{"trials":4092,"activeCount":103},[],{"intervention":4090,"totalTrials":175,"cells":4094},{"EARLY_PHASE1":4095,"PHASE1":4097,"PHASE2":4099,"PHASE3":4101,"PHASE4":4103,"NA":4109},{"trials":4096,"activeCount":103},[],{"trials":4098,"activeCount":103},[],{"trials":4100,"activeCount":103},[],{"trials":4102,"activeCount":103},[],{"trials":4104,"activeCount":103},[4105],{"nctId":4080,"briefTitle":4081,"status":165,"phases":4106,"primaryCompletion":4083,"completion":4083,"start":4084,"enrollment":4085,"conditions":4107,"interventions":4108},[94],[4087,4088],[4067,4090],{"trials":4110,"activeCount":103},[],{"intervention":4112,"totalTrials":175,"cells":4113},"Oxybutynin",{"EARLY_PHASE1":4114,"PHASE1":4116,"PHASE2":4118,"PHASE3":4120,"PHASE4":4122,"NA":4131},{"trials":4115,"activeCount":103},[],{"trials":4117,"activeCount":103},[],{"trials":4119,"activeCount":103},[],{"trials":4121,"activeCount":103},[],{"trials":4123,"activeCount":103},[4124],{"nctId":4125,"briefTitle":4126,"status":165,"phases":4127,"primaryCompletion":3909,"completion":1969,"start":3172,"enrollment":388,"conditions":4128,"interventions":4130},"NCT01310712","Use of Oxybutynin for Treating Hyperhidrosis: A Placebo-control Study",[94],[4129],"Hyperhidrosis",[4112],{"trials":4132,"activeCount":103},[],{"intervention":4134,"totalTrials":175,"cells":4135},"HPV vaccine",{"EARLY_PHASE1":4136,"PHASE1":4138,"PHASE2":4140,"PHASE3":4142,"PHASE4":4144,"NA":4154},{"trials":4137,"activeCount":103},[],{"trials":4139,"activeCount":103},[],{"trials":4141,"activeCount":103},[],{"trials":4143,"activeCount":103},[],{"trials":4145,"activeCount":103},[4146],{"nctId":4147,"briefTitle":4148,"status":165,"phases":4149,"primaryCompletion":4150,"completion":2081,"start":1913,"enrollment":414,"conditions":4151,"interventions":4153},"NCT02236234","Immune Response to HPV Vaccine Among HIV-1-infected Subjects in Brazil",[94],"2013-01",[4152],"Infection",[4134],{"trials":4155,"activeCount":103},[],{"intervention":1917,"totalTrials":175,"cells":4157},{"EARLY_PHASE1":4158,"PHASE1":4160,"PHASE2":4162,"PHASE3":4164,"PHASE4":4166,"NA":4172},{"trials":4159,"activeCount":103},[],{"trials":4161,"activeCount":103},[],{"trials":4163,"activeCount":103},[],{"trials":4165,"activeCount":103},[],{"trials":4167,"activeCount":103},[4168],{"nctId":1910,"briefTitle":1911,"status":165,"phases":4169,"primaryCompletion":1913,"completion":195,"start":1914,"enrollment":17,"conditions":4170,"interventions":4171},[94],[1905],[1917,1885],{"trials":4173,"activeCount":103},[],{"intervention":4175,"totalTrials":175,"cells":4176},"selective serotonin reuptake inhibitor",{"EARLY_PHASE1":4177,"PHASE1":4179,"PHASE2":4181,"PHASE3":4183,"PHASE4":4185,"NA":4196},{"trials":4178,"activeCount":103},[],{"trials":4180,"activeCount":103},[],{"trials":4182,"activeCount":103},[],{"trials":4184,"activeCount":103},[],{"trials":4186,"activeCount":103},[4187],{"nctId":4188,"briefTitle":4189,"status":165,"phases":4190,"primaryCompletion":4191,"completion":4191,"start":4192,"enrollment":4193,"conditions":4194,"interventions":4195},"NCT03993535","Predicting Treatment Response in Patients With OCD",[94],"2023-04-30","2018-10-10",250,[3601],[4175],{"trials":4197,"activeCount":103},[],{"intervention":2110,"totalTrials":175,"cells":4199},{"EARLY_PHASE1":4200,"PHASE1":4202,"PHASE2":4204,"PHASE3":4206,"PHASE4":4208,"NA":4214},{"trials":4201,"activeCount":103},[],{"trials":4203,"activeCount":103},[],{"trials":4205,"activeCount":103},[],{"trials":4207,"activeCount":103},[],{"trials":4209,"activeCount":103},[4210],{"nctId":2101,"briefTitle":2102,"status":193,"phases":4211,"primaryCompletion":2104,"completion":2033,"start":2105,"enrollment":2106,"conditions":4212,"interventions":4213},[94],[2108],[2088,2110],{"trials":4215,"activeCount":103},[],{"intervention":4217,"totalTrials":175,"cells":4218},"TNF blockers",{"EARLY_PHASE1":4219,"PHASE1":4221,"PHASE2":4223,"PHASE3":4225,"PHASE4":4227,"NA":4237},{"trials":4220,"activeCount":103},[],{"trials":4222,"activeCount":103},[],{"trials":4224,"activeCount":103},[],{"trials":4226,"activeCount":103},[],{"trials":4228,"activeCount":103},[4229],{"nctId":4230,"briefTitle":4231,"status":193,"phases":4232,"primaryCompletion":3909,"start":4233,"enrollment":740,"conditions":4234,"interventions":4236},"NCT01072058","Heart Function in Rheumatoid Arthritis and Ankylosing Spondylitis Pre and Post-TNF Blocker",[94],"2008-02",[4235,575],"Arthritis, Rheumatoid",[4217],{"trials":4238,"activeCount":103},[],{"intervention":1611,"totalTrials":175,"cells":4240},{"EARLY_PHASE1":4241,"PHASE1":4243,"PHASE2":4245,"PHASE3":4247,"PHASE4":4249,"NA":4255},{"trials":4242,"activeCount":103},[],{"trials":4244,"activeCount":103},[],{"trials":4246,"activeCount":103},[],{"trials":4248,"activeCount":103},[],{"trials":4250,"activeCount":103},[4251],{"nctId":1598,"briefTitle":1599,"status":165,"phases":4252,"primaryCompletion":1601,"completion":1602,"start":1603,"enrollment":1604,"conditions":4253,"interventions":4254},[94],[19,1606,1607,1608,1609],[1611,1565],{"trials":4256,"activeCount":103},[],{"intervention":4258,"totalTrials":175,"cells":4259},"homeopathic medicine",{"EARLY_PHASE1":4260,"PHASE1":4262,"PHASE2":4264,"PHASE3":4266,"PHASE4":4268,"NA":4279},{"trials":4261,"activeCount":103},[],{"trials":4263,"activeCount":103},[],{"trials":4265,"activeCount":103},[],{"trials":4267,"activeCount":103},[],{"trials":4269,"activeCount":103},[4270],{"nctId":4271,"briefTitle":4272,"status":165,"phases":4273,"completion":1174,"start":4274,"enrollment":4275,"conditions":4276,"interventions":4278},"NCT00822406","Effectiveness of Individualized Homeopathic Treatment in Perennial Allergic Rhinitis",[94],"2002-07",41,[4277],"Rhinitis",[4258],{"trials":4280,"activeCount":103},[],{"intervention":4282,"totalTrials":175,"cells":4283},"anti-TNF",{"EARLY_PHASE1":4284,"PHASE1":4286,"PHASE2":4288,"PHASE3":4290,"PHASE4":4292,"NA":4300},{"trials":4285,"activeCount":103},[],{"trials":4287,"activeCount":103},[],{"trials":4289,"activeCount":103},[],{"trials":4291,"activeCount":103},[],{"trials":4293,"activeCount":103},[4294],{"nctId":4295,"briefTitle":4296,"status":165,"phases":4297,"primaryCompletion":3202,"completion":1736,"start":3731,"enrollment":23,"conditions":4298,"interventions":4299},"NCT02196480","23-valent Polysaccharide Pneumococcal Vaccine in Juvenile Idiopathic Arthritis Patients Under Anti-TNF Therapy",[94],[582],[4282],{"trials":4301,"activeCount":103},[],{"intervention":4303,"totalTrials":175,"cells":4304},"Chloroquine diphosphate",{"EARLY_PHASE1":4305,"PHASE1":4307,"PHASE2":4309,"PHASE3":4311,"PHASE4":4313,"NA":4326},{"trials":4306,"activeCount":103},[],{"trials":4308,"activeCount":103},[],{"trials":4310,"activeCount":103},[],{"trials":4312,"activeCount":103},[],{"trials":4314,"activeCount":103},[4315],{"nctId":4316,"briefTitle":4317,"status":165,"phases":4318,"primaryCompletion":207,"completion":2832,"start":4319,"enrollment":4320,"conditions":4321,"interventions":4323},"NCT02463331","Possible Role of Chloroquine to Induce a Complete Remission in the Treatment of Autoimmune Hepatitis: a Randomized Trial",[94],"2003-05",57,[4322],"Autoimmune Hepatitis",[4303,4324,4325],"prednisone","azathioprine",{"trials":4327,"activeCount":103},[],{"intervention":4325,"totalTrials":175,"cells":4329},{"EARLY_PHASE1":4330,"PHASE1":4332,"PHASE2":4334,"PHASE3":4336,"PHASE4":4338,"NA":4344},{"trials":4331,"activeCount":103},[],{"trials":4333,"activeCount":103},[],{"trials":4335,"activeCount":103},[],{"trials":4337,"activeCount":103},[],{"trials":4339,"activeCount":103},[4340],{"nctId":4316,"briefTitle":4317,"status":165,"phases":4341,"primaryCompletion":207,"completion":2832,"start":4319,"enrollment":4320,"conditions":4342,"interventions":4343},[94],[4322],[4303,4324,4325],{"trials":4345,"activeCount":103},[],{"intervention":4347,"totalTrials":175,"cells":4348},"Hemospray",{"EARLY_PHASE1":4349,"PHASE1":4351,"PHASE2":4353,"PHASE3":4355,"PHASE4":4357,"NA":4368},{"trials":4350,"activeCount":103},[],{"trials":4352,"activeCount":103},[],{"trials":4354,"activeCount":103},[],{"trials":4356,"activeCount":103},[],{"trials":4358,"activeCount":103},[4359],{"nctId":4360,"briefTitle":4361,"status":193,"phases":4362,"primaryCompletion":2444,"completion":4363,"start":1701,"enrollment":17,"conditions":4364,"interventions":4366},"NCT02537353","Trial of Hemospray Plus Epinephrine Injection Versus Endoscopic Hemoclip",[94],"2017-08",[4365],"Upper Gastrointestinal Bleeding",[4347,4367],"Adrenaline",{"trials":4369,"activeCount":103},[],{"intervention":4367,"totalTrials":175,"cells":4371},{"EARLY_PHASE1":4372,"PHASE1":4374,"PHASE2":4376,"PHASE3":4378,"PHASE4":4380,"NA":4386},{"trials":4373,"activeCount":103},[],{"trials":4375,"activeCount":103},[],{"trials":4377,"activeCount":103},[],{"trials":4379,"activeCount":103},[],{"trials":4381,"activeCount":103},[4382],{"nctId":4360,"briefTitle":4361,"status":193,"phases":4383,"primaryCompletion":2444,"completion":4363,"start":1701,"enrollment":17,"conditions":4384,"interventions":4385},[94],[4365],[4347,4367],{"trials":4387,"activeCount":103},[],{"intervention":4389,"totalTrials":175,"cells":4390},"Aspirin",{"EARLY_PHASE1":4391,"PHASE1":4393,"PHASE2":4395,"PHASE3":4397,"PHASE4":4399,"NA":4413},{"trials":4392,"activeCount":103},[],{"trials":4394,"activeCount":103},[],{"trials":4396,"activeCount":103},[],{"trials":4398,"activeCount":103},[],{"trials":4400,"activeCount":103},[4401],{"nctId":4402,"briefTitle":4403,"status":165,"phases":4404,"primaryCompletion":750,"completion":750,"start":2010,"enrollment":2766,"conditions":4405,"interventions":4412},"NCT00766896","Platelet Hyperreactivity to Aspirin and Stroke",[94],[31,4406,4407,4408,4409,4410,4411,788],"Cerebral Infarction","Cardiovascular Diseases","Vascular Diseases","Atherosclerosis","Ischemia","Thrombosis",[4389],{"trials":4414,"activeCount":103},[],{"intervention":4416,"totalTrials":175,"cells":4417},"Thalidomide",{"EARLY_PHASE1":4418,"PHASE1":4420,"PHASE2":4422,"PHASE3":4424,"PHASE4":4426,"NA":4441},{"trials":4419,"activeCount":103},[],{"trials":4421,"activeCount":103},[],{"trials":4423,"activeCount":103},[],{"trials":4425,"activeCount":103},[],{"trials":4427,"activeCount":103},[4428],{"nctId":4429,"briefTitle":4430,"status":165,"phases":4431,"primaryCompletion":4432,"completion":4433,"start":4434,"enrollment":4435,"conditions":4436,"interventions":4438},"NCT03122431","Relevance of Monitoring Blood and Salivar Levels of Drugs Used in Rheumatic Autoimmune Diseases",[94],"2020-12-30","2021-03-30","2017-06-05",93,[447,3179,4437],"Cutaneous Lupus",[4416,4439,4440],"Hydroxychloroquine reduced","standard dose of HCQ",{"trials":4442,"activeCount":103},[],{"intervention":4439,"totalTrials":175,"cells":4444},{"EARLY_PHASE1":4445,"PHASE1":4447,"PHASE2":4449,"PHASE3":4451,"PHASE4":4453,"NA":4459},{"trials":4446,"activeCount":103},[],{"trials":4448,"activeCount":103},[],{"trials":4450,"activeCount":103},[],{"trials":4452,"activeCount":103},[],{"trials":4454,"activeCount":103},[4455],{"nctId":4429,"briefTitle":4430,"status":165,"phases":4456,"primaryCompletion":4432,"completion":4433,"start":4434,"enrollment":4435,"conditions":4457,"interventions":4458},[94],[447,3179,4437],[4416,4439,4440],{"trials":4460,"activeCount":103},[],{"intervention":4440,"totalTrials":175,"cells":4462},{"EARLY_PHASE1":4463,"PHASE1":4465,"PHASE2":4467,"PHASE3":4469,"PHASE4":4471,"NA":4477},{"trials":4464,"activeCount":103},[],{"trials":4466,"activeCount":103},[],{"trials":4468,"activeCount":103},[],{"trials":4470,"activeCount":103},[],{"trials":4472,"activeCount":103},[4473],{"nctId":4429,"briefTitle":4430,"status":165,"phases":4474,"primaryCompletion":4432,"completion":4433,"start":4434,"enrollment":4435,"conditions":4475,"interventions":4476},[94],[447,3179,4437],[4416,4439,4440],{"trials":4478,"activeCount":103},[],{"intervention":4480,"totalTrials":175,"cells":4481},"Imiquimod 5% cream",{"EARLY_PHASE1":4482,"PHASE1":4484,"PHASE2":4486,"PHASE3":4488,"PHASE4":4490,"NA":4501},{"trials":4483,"activeCount":103},[],{"trials":4485,"activeCount":103},[],{"trials":4487,"activeCount":103},[],{"trials":4489,"activeCount":103},[],{"trials":4491,"activeCount":103},[4492],{"nctId":4493,"briefTitle":4494,"status":193,"phases":4495,"primaryCompletion":2943,"completion":4496,"start":4497,"enrollment":32,"conditions":4498,"interventions":4500},"NCT00803907","Imiquimod 5% Cream for the Treatment of Periocular Basal Cell Carcinoma",[94],"2013-02","2008-12",[4499],"Carcinoma, Basal Cell",[4480],{"trials":4502,"activeCount":103},[],{"intervention":4504,"totalTrials":175,"cells":4505},"Rosuvastatin",{"EARLY_PHASE1":4506,"PHASE1":4508,"PHASE2":4510,"PHASE3":4512,"PHASE4":4514,"NA":4524},{"trials":4507,"activeCount":103},[],{"trials":4509,"activeCount":103},[],{"trials":4511,"activeCount":103},[],{"trials":4513,"activeCount":103},[],{"trials":4515,"activeCount":103},[4516],{"nctId":4517,"briefTitle":4518,"status":165,"phases":4519,"primaryCompletion":1902,"completion":1902,"start":1969,"enrollment":4520,"conditions":4521,"interventions":4523},"NCT02737319","A Randomized Trial of Rosuvastatin in Elective Angioplasty to Prevent Contrast-induced Nephropathy (CLEAR-CIN).",[94],493,[4522],"Nephropathy",[4504],{"trials":4525,"activeCount":103},[],{"intervention":4527,"totalTrials":175,"cells":4528},"Antiarrythmic Drugs",{"EARLY_PHASE1":4529,"PHASE1":4531,"PHASE2":4533,"PHASE3":4535,"PHASE4":4537,"NA":4550},{"trials":4530,"activeCount":103},[],{"trials":4532,"activeCount":103},[],{"trials":4534,"activeCount":103},[],{"trials":4536,"activeCount":103},[],{"trials":4538,"activeCount":103},[4539],{"nctId":4540,"briefTitle":4541,"status":193,"phases":4542,"primaryCompletion":4543,"completion":4544,"start":4545,"enrollment":208,"conditions":4546,"interventions":4548},"NCT03299517","PROSPECTIVE ANALYSIS BETWEEN AMIODARONE Versus LIDOCAINE IN SVT",[94],"2019-08-02","2022-08-02","2017-08-02",[4547],"Arrhythmias Ventricular",[4527,4549],"Antiarrhythmic drugs",{"trials":4551,"activeCount":103},[],{"intervention":4549,"totalTrials":175,"cells":4553},{"EARLY_PHASE1":4554,"PHASE1":4556,"PHASE2":4558,"PHASE3":4560,"PHASE4":4562,"NA":4568},{"trials":4555,"activeCount":103},[],{"trials":4557,"activeCount":103},[],{"trials":4559,"activeCount":103},[],{"trials":4561,"activeCount":103},[],{"trials":4563,"activeCount":103},[4564],{"nctId":4540,"briefTitle":4541,"status":193,"phases":4565,"primaryCompletion":4543,"completion":4544,"start":4545,"enrollment":208,"conditions":4566,"interventions":4567},[94],[4547],[4527,4549],{"trials":4569,"activeCount":103},[],{"intervention":4571,"totalTrials":175,"cells":4572},"Tacrolimus",{"EARLY_PHASE1":4573,"PHASE1":4575,"PHASE2":4577,"PHASE3":4579,"PHASE4":4581,"NA":4591},{"trials":4574,"activeCount":103},[],{"trials":4576,"activeCount":103},[],{"trials":4578,"activeCount":103},[],{"trials":4580,"activeCount":103},[],{"trials":4582,"activeCount":103},[4583],{"nctId":4584,"briefTitle":4585,"status":165,"phases":4586,"primaryCompletion":1822,"completion":1822,"start":2944,"enrollment":26,"conditions":4587,"interventions":4589},"NCT01850979","Treatment of Dry Eye Using 0.03% Tacrolimus Eye Drops",[94],[678,4588],"Dry Eye Syndrome",[4571,4590],"Olive Oil",{"trials":4592,"activeCount":103},[],{"intervention":4590,"totalTrials":175,"cells":4594},{"EARLY_PHASE1":4595,"PHASE1":4597,"PHASE2":4599,"PHASE3":4601,"PHASE4":4603,"NA":4609},{"trials":4596,"activeCount":103},[],{"trials":4598,"activeCount":103},[],{"trials":4600,"activeCount":103},[],{"trials":4602,"activeCount":103},[],{"trials":4604,"activeCount":103},[4605],{"nctId":4584,"briefTitle":4585,"status":165,"phases":4606,"primaryCompletion":1822,"completion":1822,"start":2944,"enrollment":26,"conditions":4607,"interventions":4608},[94],[678,4588],[4571,4590],{"trials":4610,"activeCount":103},[],{"intervention":4612,"totalTrials":175,"cells":4613},"lithium plus carbamazepine",{"EARLY_PHASE1":4614,"PHASE1":4616,"PHASE2":4618,"PHASE3":4620,"PHASE4":4622,"NA":4631},{"trials":4615,"activeCount":103},[],{"trials":4617,"activeCount":103},[],{"trials":4619,"activeCount":103},[],{"trials":4621,"activeCount":103},[],{"trials":4623,"activeCount":103},[4624],{"nctId":4625,"briefTitle":4626,"status":165,"phases":4627,"primaryCompletion":1736,"completion":1736,"start":1875,"enrollment":17,"conditions":4628,"interventions":4629},"NCT00976794","Efficacy of Combined Treatment for Young Bipolar I Disorder",[94],[1738],[4612,4630],"lithium plus valproate",{"trials":4632,"activeCount":103},[],{"intervention":4630,"totalTrials":175,"cells":4634},{"EARLY_PHASE1":4635,"PHASE1":4637,"PHASE2":4639,"PHASE3":4641,"PHASE4":4643,"NA":4649},{"trials":4636,"activeCount":103},[],{"trials":4638,"activeCount":103},[],{"trials":4640,"activeCount":103},[],{"trials":4642,"activeCount":103},[],{"trials":4644,"activeCount":103},[4645],{"nctId":4625,"briefTitle":4626,"status":165,"phases":4646,"primaryCompletion":1736,"completion":1736,"start":1875,"enrollment":17,"conditions":4647,"interventions":4648},[94],[1738],[4612,4630],{"trials":4650,"activeCount":103},[],{"intervention":4652,"totalTrials":175,"cells":4653},"Hyaluronic Acid and hydroxypropylmethylcellulose",{"EARLY_PHASE1":4654,"PHASE1":4656,"PHASE2":4658,"PHASE3":4660,"PHASE4":4662,"NA":4672},{"trials":4655,"activeCount":103},[],{"trials":4657,"activeCount":103},[],{"trials":4659,"activeCount":103},[],{"trials":4661,"activeCount":103},[],{"trials":4663,"activeCount":103},[4664],{"nctId":4665,"briefTitle":4666,"status":165,"phases":4667,"primaryCompletion":2944,"completion":3172,"start":1876,"enrollment":3416,"conditions":4668,"interventions":4671},"NCT01387620","Comparison of DisCoVisc and Hydroxypropylmethylcellulose 2%",[94],[4669,4670],"Corneal Edema","Intraocular Pressure",[4652],{"trials":4673,"activeCount":103},[],{"intervention":4675,"totalTrials":175,"cells":4676},"Hydroxyethyl Starch",{"EARLY_PHASE1":4677,"PHASE1":4679,"PHASE2":4681,"PHASE3":4683,"PHASE4":4685,"NA":4697},{"trials":4678,"activeCount":103},[],{"trials":4680,"activeCount":103},[],{"trials":4682,"activeCount":103},[],{"trials":4684,"activeCount":103},[],{"trials":4686,"activeCount":103},[4687],{"nctId":4688,"briefTitle":4689,"status":165,"phases":4690,"completion":4691,"start":4692,"enrollment":1434,"conditions":4693,"interventions":4695},"NCT00542516","Comparison Between Two Techniques of Volemic Expansion in Hip Replacement Arthroplasty",[94],"2008-11","2006-09",[4694],"Hip Replacement Arthroplasty",[4675,4696],"Ringer's lactate",{"trials":4698,"activeCount":103},[],{"intervention":4696,"totalTrials":175,"cells":4700},{"EARLY_PHASE1":4701,"PHASE1":4703,"PHASE2":4705,"PHASE3":4707,"PHASE4":4709,"NA":4715},{"trials":4702,"activeCount":103},[],{"trials":4704,"activeCount":103},[],{"trials":4706,"activeCount":103},[],{"trials":4708,"activeCount":103},[],{"trials":4710,"activeCount":103},[4711],{"nctId":4688,"briefTitle":4689,"status":165,"phases":4712,"completion":4691,"start":4692,"enrollment":1434,"conditions":4713,"interventions":4714},[94],[4694],[4675,4696],{"trials":4716,"activeCount":103},[],{"intervention":4718,"totalTrials":175,"cells":4719},"Sufentanil",{"EARLY_PHASE1":4720,"PHASE1":4722,"PHASE2":4724,"PHASE3":4726,"PHASE4":4728,"NA":4738},{"trials":4721,"activeCount":103},[],{"trials":4723,"activeCount":103},[],{"trials":4725,"activeCount":103},[],{"trials":4727,"activeCount":103},[],{"trials":4729,"activeCount":103},[4730],{"nctId":4731,"briefTitle":4732,"status":165,"phases":4733,"primaryCompletion":4734,"completion":2048,"start":197,"enrollment":17,"conditions":4735,"interventions":4737},"NCT01777100","Sufentanil for Anesthesia Induction in Continuous Remifentanil Anesthesia",[94],"2014-10",[4736],"Postoperative Pain",[4718],{"trials":4739,"activeCount":103},[],{"intervention":4741,"totalTrials":175,"cells":4742},"Rivaroxaban 20 MG Oral",{"EARLY_PHASE1":4743,"PHASE1":4745,"PHASE2":4747,"PHASE3":4749,"PHASE4":4751,"NA":4763},{"trials":4744,"activeCount":103},[],{"trials":4746,"activeCount":103},[],{"trials":4748,"activeCount":103},[],{"trials":4750,"activeCount":103},[],{"trials":4752,"activeCount":103},[4753],{"nctId":4754,"briefTitle":4755,"status":193,"phases":4756,"primaryCompletion":4757,"completion":4758,"start":4759,"enrollment":388,"conditions":4760,"interventions":4762},"NCT05300555","Cost-effectiveness Analysis Between Two Anticoagulation Strategies for Atrial Fibrillation in the Postoperative Period of Coronary Artery Bypass Graft Surgery",[94],"2022-01-01","2022-11-01","2021-01-05",[4761],"Atrial Fibrillation New Onset",[4741,1776],{"trials":4764,"activeCount":103},[],{"intervention":4766,"totalTrials":175,"cells":4767},"Ramelteon",{"EARLY_PHASE1":4768,"PHASE1":4770,"PHASE2":4772,"PHASE3":4774,"PHASE4":4776,"NA":4787},{"trials":4769,"activeCount":103},[],{"trials":4771,"activeCount":103},[],{"trials":4773,"activeCount":103},[],{"trials":4775,"activeCount":103},[],{"trials":4777,"activeCount":103},[4778],{"nctId":4779,"briefTitle":4780,"status":2489,"phases":4781,"primaryCompletion":4782,"completion":4783,"start":4784,"enrollment":697,"conditions":4785,"interventions":4786},"NCT05414864","Insomnia Prevalence and Treatment Impact on Systemic Hypertension",[94],"2022-07-31","2022-09-30","2022-05-01",[238,249],[4766],{"trials":4788,"activeCount":103},[],{"intervention":2650,"totalTrials":175,"cells":4790},{"EARLY_PHASE1":4791,"PHASE1":4793,"PHASE2":4795,"PHASE3":4797,"PHASE4":4799,"NA":4813},{"trials":4792,"activeCount":103},[],{"trials":4794,"activeCount":103},[],{"trials":4796,"activeCount":103},[],{"trials":4798,"activeCount":103},[],{"trials":4800,"activeCount":103},[4801],{"nctId":4802,"briefTitle":4803,"status":165,"phases":4804,"primaryCompletion":4805,"completion":4806,"start":4807,"enrollment":3247,"conditions":4808,"interventions":4812},"NCT03111342","Intracervical Anesthesia and Pain Associated With Intrauterine Contraceptive Insertion",[94],"2018-08-30","2018-08-31","2017-06-01",[4809,4810,4811],"Pain, Acute","Anesthesia, Local","IUD Insertion Complication",[2650],{"trials":4814,"activeCount":103},[],{"intervention":4816,"totalTrials":175,"cells":4817},"Fluoride Varnishes",{"EARLY_PHASE1":4818,"PHASE1":4820,"PHASE2":4822,"PHASE3":4824,"PHASE4":4826,"NA":4840},{"trials":4819,"activeCount":103},[],{"trials":4821,"activeCount":103},[],{"trials":4823,"activeCount":103},[],{"trials":4825,"activeCount":103},[],{"trials":4827,"activeCount":103},[4828],{"nctId":4829,"briefTitle":4830,"status":165,"phases":4831,"primaryCompletion":4832,"completion":4833,"start":4834,"enrollment":4835,"conditions":4836,"interventions":4838},"NCT06426108","Interventions to Control Hypersensitivity Pain in Teeth With Insisive Molar Hypomineralization",[94],"2025-01-03","2025-01-07","2024-07-01",72,[4837],"Molar Incisor Hypomineralization",[4816,4839],"Varnishes placebo",{"trials":4841,"activeCount":103},[],{"intervention":4839,"totalTrials":175,"cells":4843},{"EARLY_PHASE1":4844,"PHASE1":4846,"PHASE2":4848,"PHASE3":4850,"PHASE4":4852,"NA":4858},{"trials":4845,"activeCount":103},[],{"trials":4847,"activeCount":103},[],{"trials":4849,"activeCount":103},[],{"trials":4851,"activeCount":103},[],{"trials":4853,"activeCount":103},[4854],{"nctId":4829,"briefTitle":4830,"status":165,"phases":4855,"primaryCompletion":4832,"completion":4833,"start":4834,"enrollment":4835,"conditions":4856,"interventions":4857},[94],[4837],[4816,4839],{"trials":4859,"activeCount":103},[],{"intervention":4861,"totalTrials":175,"cells":4862},"Norethisterone 10mg\u002Fday",{"EARLY_PHASE1":4863,"PHASE1":4865,"PHASE2":4867,"PHASE3":4869,"PHASE4":4871,"NA":4882},{"trials":4864,"activeCount":103},[],{"trials":4866,"activeCount":103},[],{"trials":4868,"activeCount":103},[],{"trials":4870,"activeCount":103},[],{"trials":4872,"activeCount":103},[4873],{"nctId":4874,"briefTitle":4875,"status":165,"phases":4876,"primaryCompletion":4877,"completion":4877,"start":4878,"enrollment":120,"conditions":4879,"interventions":4881},"NCT04047875","Treatment of Prolonged Uterine Bleeding of Etonogestrel (ENG)-Releasing Implant",[94],"2023-05-05","2020-09-15",[4880],"Breakthrough Bleeding",[4861],{"trials":4883,"activeCount":103},[],{"intervention":1881,"totalTrials":175,"cells":4885},{"EARLY_PHASE1":4886,"PHASE1":4888,"PHASE2":4890,"PHASE3":4892,"PHASE4":4894,"NA":4900},{"trials":4887,"activeCount":103},[],{"trials":4889,"activeCount":103},[],{"trials":4891,"activeCount":103},[],{"trials":4893,"activeCount":103},[],{"trials":4895,"activeCount":103},[4896],{"nctId":1872,"briefTitle":1873,"status":193,"phases":4897,"primaryCompletion":1875,"completion":1876,"start":1877,"enrollment":1878,"conditions":4898,"interventions":4899},[94],[1868],[1881,1850],{"trials":4901,"activeCount":103},[],{"intervention":4903,"totalTrials":1466,"cells":4904},"Methadone",{"EARLY_PHASE1":4905,"PHASE1":4907,"PHASE2":4909,"PHASE3":4911,"PHASE4":4941,"NA":4943},{"trials":4906,"activeCount":103},[],{"trials":4908,"activeCount":103},[],{"trials":4910,"activeCount":103},[],{"trials":4912,"activeCount":103},[4913,4923,4933],{"nctId":4914,"briefTitle":4915,"status":165,"phases":4916,"primaryCompletion":4917,"completion":4917,"start":4918,"enrollment":208,"conditions":4919,"interventions":4921},"NCT05235191","Effectiveness and Safety of Methadone Versus Placebo for the Control of Neuropathic Pain in Different Etiologies",[93],"2023-01-20","2019-09-06",[4920],"Neuropathic Pain",[4922],"methadone",{"nctId":4924,"briefTitle":4925,"status":193,"phases":4926,"primaryCompletion":4927,"completion":4927,"start":4928,"enrollment":1290,"conditions":4929,"interventions":4932},"NCT04908345","Methadone Anesthesia For Kidney Transplant Receptors",[93],"2022-01","2021-05-17",[4930,4931],"Renal Failure Chronic","Surgery",[4903,2002],{"nctId":4934,"briefTitle":4935,"status":165,"phases":4936,"primaryCompletion":4496,"completion":3130,"start":4937,"enrollment":1003,"conditions":4938,"interventions":4940},"NCT01752699","Methadone in Post-Herpetic Neuralgia Pain",[93],"1998-01",[4939],"Post-herpetic Neuralgia",[4903],{"trials":4942,"activeCount":103},[],{"trials":4944,"activeCount":103},[],{"intervention":4946,"totalTrials":1466,"cells":4947},"Acetazolamide",{"EARLY_PHASE1":4948,"PHASE1":4950,"PHASE2":4952,"PHASE3":4976,"PHASE4":4987,"NA":4989},{"trials":4949,"activeCount":103},[],{"trials":4951,"activeCount":103},[],{"trials":4953,"activeCount":103},[4954,4966],{"nctId":4955,"briefTitle":4956,"status":165,"phases":4957,"conditions":4958,"interventions":4962},"NCT00804921","Effectiveness of Oral Acetazolamide, Brimonidine Tartarate, and Anterior Chamber Paracentesis in Intraocular Pressure (IOP) After Bevacizumab",[92],[4959,4960,4961],"Macular Edema","Diabetic Retinopathy","Macular Degeneration",[4963,4964,4965],"bevacizumab","acetazolamide","brimonidine",{"nctId":4967,"briefTitle":4968,"status":165,"phases":4969,"primaryCompletion":4970,"completion":2009,"start":4971,"enrollment":1998,"conditions":4972,"interventions":4974},"NCT00864838","Oral Acetazolamide, Brimonidine Tartarate, and Anterior Chamber Paracentesis for Ocular Hypertension Control After Intravitreal Bevacizumab",[92],"2009-02","2008-06",[4973,4960],"Age Related Macular Degeneration",[4946,4975],"Brimonidine tartarate",{"trials":4977,"activeCount":103},[4978],{"nctId":4979,"briefTitle":4980,"status":193,"phases":4981,"primaryCompletion":4982,"completion":4983,"start":1526,"enrollment":170,"conditions":4984,"interventions":4986},"NCT03720288","Acetazolamide in Patients With Acute Heart Failure",[93],"2019-10-01","2020-10-01",[19,4985],"Acute Heart Failure",[4946],{"trials":4988,"activeCount":103},[],{"trials":4990,"activeCount":103},[],{"intervention":4992,"totalTrials":1466,"cells":4993},"Colchicine",{"EARLY_PHASE1":4994,"PHASE1":4996,"PHASE2":5008,"PHASE3":5023,"PHASE4":5037,"NA":5039},{"trials":4995,"activeCount":103},[],{"trials":4997,"activeCount":103},[4998],{"nctId":4999,"briefTitle":5000,"status":193,"phases":5001,"primaryCompletion":5002,"completion":5003,"start":5004,"enrollment":17,"conditions":5005,"interventions":5007},"NCT05347316","Colchicine Effect on Perivascular Inflammation Index on Coronary CTA",[91],"2023-03-07","2025-03-07","2022-03-07",[4409,5006,1764],"Inflammatory Response",[4992],{"trials":5009,"activeCount":103},[5010],{"nctId":5011,"briefTitle":5012,"status":165,"phases":5013,"primaryCompletion":5014,"completion":5014,"start":5015,"enrollment":740,"conditions":5016,"interventions":5022},"NCT05726019","Colchicine in Patients Undergoing Coronary Artery Bypass Grafting After Acute Coronary Syndrome",[92],"2025-12-21","2022-02-05",[25,788,5017,5018,5019,5020,5021],"Coronary Artery Bypass","Myocardial Reperfusion","Postpericardiotomy Syndrome","Postoperative Atrial Fibrilation","Perioperative Myocardial Infarction",[4992],{"trials":5024,"activeCount":103},[5025],{"nctId":5026,"briefTitle":5027,"status":165,"phases":5028,"primaryCompletion":5029,"completion":5030,"start":4759,"enrollment":235,"conditions":5031,"interventions":5033},"NCT04724629","Survival TRial Using CytoKines in COVID-19 (STRUCK Trial)",[93],"2021-03-31","2021-07-30",[5032],"Covid19",[5034,5035,4992,5036],"Ixekizumab","Aldesleukin","Standard of care",{"trials":5038,"activeCount":103},[],{"trials":5040,"activeCount":103},[],{"intervention":5042,"totalTrials":99,"cells":5043},"Intravitreal bevacizumab",{"EARLY_PHASE1":5044,"PHASE1":5046,"PHASE2":5048,"PHASE3":5050,"PHASE4":5068,"NA":5070},{"trials":5045,"activeCount":103},[],{"trials":5047,"activeCount":103},[],{"trials":5049,"activeCount":103},[],{"trials":5051,"activeCount":103},[5052,5061],{"nctId":5053,"briefTitle":5054,"status":165,"phases":5055,"primaryCompletion":1822,"completion":1822,"start":5056,"enrollment":1324,"conditions":5057,"interventions":5059},"NCT00997191","Intravitreal Bevacizumab and Triamcinolone Associated to Laser Photocoagulation for Diabetic Macular Edema(IBeTA)",[93],"2009-10",[5058],"Diabetic Macular Edema",[5060,5042],"Intravitreal triamcinolone",{"nctId":5062,"briefTitle":5063,"status":165,"phases":5064,"primaryCompletion":2069,"completion":4496,"start":4970,"enrollment":4275,"conditions":5065,"interventions":5066},"NCT02308644","Intravitreous Bevacizumab and Standard Metabolic Control for Diabetic Macular Edema - A Contrast Sensitivity Study",[93],[5058],[5067],"intravitreal bevacizumab",{"trials":5069,"activeCount":103},[],{"trials":5071,"activeCount":103},[],{"intervention":5073,"totalTrials":99,"cells":5074},"Vasopressin",{"EARLY_PHASE1":5075,"PHASE1":5077,"PHASE2":5079,"PHASE3":5081,"PHASE4":5102,"NA":5104},{"trials":5076,"activeCount":103},[],{"trials":5078,"activeCount":103},[],{"trials":5080,"activeCount":103},[],{"trials":5082,"activeCount":103},[5083,5094],{"nctId":5084,"briefTitle":5085,"status":3950,"phases":5086,"primaryCompletion":5087,"completion":5087,"start":5088,"enrollment":103,"conditions":5089,"interventions":5092},"NCT03483753","Vasopressin or Norepinephrine in Vasoplegic Shock After Non-cardiac Surgery",[92,93],"2023-10-02","2019-01",[5090,5091],"Circulatory Shock","Non-cardiac Surgery",[5073,5093],"Norepinephrine",{"nctId":5095,"briefTitle":5096,"status":193,"phases":5097,"primaryCompletion":4496,"completion":5098,"start":1913,"enrollment":3247,"conditions":5099,"interventions":5101},"NCT01505231","Vasopressin Versus Norepinephrine for the Management of Shock After Cardiac Surgery",[93],"2013-05",[5100],"Shock",[5073,5093],{"trials":5103,"activeCount":103},[],{"trials":5105,"activeCount":103},[],{"intervention":5093,"totalTrials":99,"cells":5107},{"EARLY_PHASE1":5108,"PHASE1":5110,"PHASE2":5112,"PHASE3":5114,"PHASE4":5124,"NA":5126},{"trials":5109,"activeCount":103},[],{"trials":5111,"activeCount":103},[],{"trials":5113,"activeCount":103},[],{"trials":5115,"activeCount":103},[5116,5120],{"nctId":5084,"briefTitle":5085,"status":3950,"phases":5117,"primaryCompletion":5087,"completion":5087,"start":5088,"enrollment":103,"conditions":5118,"interventions":5119},[92,93],[5090,5091],[5073,5093],{"nctId":5095,"briefTitle":5096,"status":193,"phases":5121,"primaryCompletion":4496,"completion":5098,"start":1913,"enrollment":3247,"conditions":5122,"interventions":5123},[93],[5100],[5073,5093],{"trials":5125,"activeCount":103},[],{"trials":5127,"activeCount":103},[],{"intervention":5129,"totalTrials":99,"cells":5130},"Cannabidiol",{"EARLY_PHASE1":5131,"PHASE1":5133,"PHASE2":5135,"PHASE3":5137,"PHASE4":5159,"NA":5161},{"trials":5132,"activeCount":103},[],{"trials":5134,"activeCount":103},[],{"trials":5136,"activeCount":103},[],{"trials":5138,"activeCount":103},[5139,5150],{"nctId":5140,"briefTitle":5141,"status":165,"phases":5142,"primaryCompletion":5143,"completion":5144,"start":5145,"enrollment":2071,"conditions":5146,"interventions":5149},"NCT04504877","Burnout and Distress preventiOn With caNnabidiol in Front-line Health Care workerS deAling wIth COVID-19",[92,93],"2020-11-16","2020-12-16","2020-06-16",[5032,5147,5148],"Burn Out","Post Traumatic Stress Disorder",[5129],{"nctId":5151,"briefTitle":5152,"status":193,"phases":5153,"primaryCompletion":5154,"completion":5154,"start":5155,"enrollment":740,"conditions":5156,"interventions":5158},"NCT04467918","CANnabiDiol for CoviD-19 pATiEnts With Mild to Moderate Symptoms",[92,93],"2021-11-16","2020-07-06",[5157],"SARS-CoV2",[5129],{"trials":5160,"activeCount":103},[],{"trials":5162,"activeCount":103},[],{"intervention":2002,"totalTrials":99,"cells":5164},{"EARLY_PHASE1":5165,"PHASE1":5167,"PHASE2":5169,"PHASE3":5171,"PHASE4":5181,"NA":5183},{"trials":5166,"activeCount":103},[],{"trials":5168,"activeCount":103},[],{"trials":5170,"activeCount":103},[],{"trials":5172,"activeCount":103},[5173,5177],{"nctId":1992,"briefTitle":1993,"status":193,"phases":5174,"primaryCompletion":1995,"completion":1996,"start":1997,"enrollment":1998,"conditions":5175,"interventions":5176},[93],[2000],[2002,1981],{"nctId":4924,"briefTitle":4925,"status":193,"phases":5178,"primaryCompletion":4927,"completion":4927,"start":4928,"enrollment":1290,"conditions":5179,"interventions":5180},[93],[4930,4931],[4903,2002],{"trials":5182,"activeCount":103},[],{"trials":5184,"activeCount":103},[],{"intervention":5186,"totalTrials":175,"cells":5187},"Miconazole",{"EARLY_PHASE1":5188,"PHASE1":5190,"PHASE2":5192,"PHASE3":5194,"PHASE4":5204,"NA":5206},{"trials":5189,"activeCount":103},[],{"trials":5191,"activeCount":103},[],{"trials":5193,"activeCount":103},[],{"trials":5195,"activeCount":103},[5196],{"nctId":5197,"briefTitle":5198,"status":165,"phases":5199,"primaryCompletion":1556,"completion":1556,"start":3246,"enrollment":17,"conditions":5200,"interventions":5203},"NCT02818803","Efficacy of Standardized-propolis Extract (EPP-AF®) Gel Formulation as Buccal Antiseptic",[93],[5201,5202],"Candidiasis, Oral","Stomatitis, Denture",[5186],{"trials":5205,"activeCount":103},[],{"trials":5207,"activeCount":103},[],{"intervention":5209,"totalTrials":175,"cells":5210},"Magnesium sulfate dose through real weight group",{"EARLY_PHASE1":5211,"PHASE1":5213,"PHASE2":5215,"PHASE3":5217,"PHASE4":5230,"NA":5232},{"trials":5212,"activeCount":103},[],{"trials":5214,"activeCount":103},[],{"trials":5216,"activeCount":103},[],{"trials":5218,"activeCount":103},[5219],{"nctId":5220,"briefTitle":5221,"status":193,"phases":5222,"primaryCompletion":5223,"completion":569,"start":5224,"enrollment":691,"conditions":5225,"interventions":5228},"NCT04645719","Dose of Magnesium Sulfate Infusion in Obese",[93],"2025-06-01","2022-04-01",[5226,5227],"Obese","Analgesia",[5209,5229],"Magnesium sulfate dose through corrected ideal weight group",{"trials":5231,"activeCount":103},[],{"trials":5233,"activeCount":103},[],{"intervention":5229,"totalTrials":175,"cells":5235},{"EARLY_PHASE1":5236,"PHASE1":5238,"PHASE2":5240,"PHASE3":5242,"PHASE4":5248,"NA":5250},{"trials":5237,"activeCount":103},[],{"trials":5239,"activeCount":103},[],{"trials":5241,"activeCount":103},[],{"trials":5243,"activeCount":103},[5244],{"nctId":5220,"briefTitle":5221,"status":193,"phases":5245,"primaryCompletion":5223,"completion":569,"start":5224,"enrollment":691,"conditions":5246,"interventions":5247},[93],[5226,5227],[5209,5229],{"trials":5249,"activeCount":103},[],{"trials":5251,"activeCount":103},[],{"intervention":5060,"totalTrials":175,"cells":5253},{"EARLY_PHASE1":5254,"PHASE1":5256,"PHASE2":5258,"PHASE3":5260,"PHASE4":5266,"NA":5268},{"trials":5255,"activeCount":103},[],{"trials":5257,"activeCount":103},[],{"trials":5259,"activeCount":103},[],{"trials":5261,"activeCount":103},[5262],{"nctId":5053,"briefTitle":5054,"status":165,"phases":5263,"primaryCompletion":1822,"completion":1822,"start":5056,"enrollment":1324,"conditions":5264,"interventions":5265},[93],[5058],[5060,5042],{"trials":5267,"activeCount":103},[],{"trials":5269,"activeCount":103},[],{"intervention":5271,"totalTrials":175,"cells":5272},"Lactated Ringer",{"EARLY_PHASE1":5273,"PHASE1":5275,"PHASE2":5277,"PHASE3":5279,"PHASE4":5293,"NA":5295},{"trials":5274,"activeCount":103},[],{"trials":5276,"activeCount":103},[],{"trials":5278,"activeCount":103},[],{"trials":5280,"activeCount":103},[5281],{"nctId":5282,"briefTitle":5283,"status":165,"phases":5284,"primaryCompletion":5285,"completion":2491,"start":5286,"enrollment":5287,"conditions":5288,"interventions":5291},"NCT01337934","Lactated Ringer Versus Albumin in Early Sepsis Therapy",[93],"2016-10","2013-10",360,[5289,5290],"Septic Shock","Severe Sepsis",[5271,5292],"Albumin",{"trials":5294,"activeCount":103},[],{"trials":5296,"activeCount":103},[],{"intervention":5292,"totalTrials":175,"cells":5298},{"EARLY_PHASE1":5299,"PHASE1":5301,"PHASE2":5303,"PHASE3":5305,"PHASE4":5311,"NA":5313},{"trials":5300,"activeCount":103},[],{"trials":5302,"activeCount":103},[],{"trials":5304,"activeCount":103},[],{"trials":5306,"activeCount":103},[5307],{"nctId":5282,"briefTitle":5283,"status":165,"phases":5308,"primaryCompletion":5285,"completion":2491,"start":5286,"enrollment":5287,"conditions":5309,"interventions":5310},[93],[5289,5290],[5271,5292],{"trials":5312,"activeCount":103},[],{"trials":5314,"activeCount":103},[],{"intervention":5316,"totalTrials":175,"cells":5317},"Tocilizumab",{"EARLY_PHASE1":5318,"PHASE1":5320,"PHASE2":5322,"PHASE3":5324,"PHASE4":5338,"NA":5340},{"trials":5319,"activeCount":103},[],{"trials":5321,"activeCount":103},[],{"trials":5323,"activeCount":103},[],{"trials":5325,"activeCount":103},[5326],{"nctId":5327,"briefTitle":5328,"status":165,"phases":5329,"primaryCompletion":5330,"completion":5331,"start":5332,"enrollment":5333,"conditions":5334,"interventions":5335},"NCT04600141","Clinical Efficacy of Heparin and Tocilizumab in Patients With Severe COVID-19 Infection",[93],"2021-10-20","2021-12-31","2020-11-10",308,[5032],[5316,5336,5337],"Heparin - Therapeutic dosage","Heparin - Prophylactic dosage",{"trials":5339,"activeCount":103},[],{"trials":5341,"activeCount":103},[],{"intervention":5336,"totalTrials":175,"cells":5343},{"EARLY_PHASE1":5344,"PHASE1":5346,"PHASE2":5348,"PHASE3":5350,"PHASE4":5356,"NA":5358},{"trials":5345,"activeCount":103},[],{"trials":5347,"activeCount":103},[],{"trials":5349,"activeCount":103},[],{"trials":5351,"activeCount":103},[5352],{"nctId":5327,"briefTitle":5328,"status":165,"phases":5353,"primaryCompletion":5330,"completion":5331,"start":5332,"enrollment":5333,"conditions":5354,"interventions":5355},[93],[5032],[5316,5336,5337],{"trials":5357,"activeCount":103},[],{"trials":5359,"activeCount":103},[],{"intervention":5337,"totalTrials":175,"cells":5361},{"EARLY_PHASE1":5362,"PHASE1":5364,"PHASE2":5366,"PHASE3":5368,"PHASE4":5374,"NA":5376},{"trials":5363,"activeCount":103},[],{"trials":5365,"activeCount":103},[],{"trials":5367,"activeCount":103},[],{"trials":5369,"activeCount":103},[5370],{"nctId":5327,"briefTitle":5328,"status":165,"phases":5371,"primaryCompletion":5330,"completion":5331,"start":5332,"enrollment":5333,"conditions":5372,"interventions":5373},[93],[5032],[5316,5336,5337],{"trials":5375,"activeCount":103},[],{"trials":5377,"activeCount":103},[],{"intervention":5379,"totalTrials":175,"cells":5380},"Intravitreal Injection of Bevacizumab",{"EARLY_PHASE1":5381,"PHASE1":5383,"PHASE2":5385,"PHASE3":5387,"PHASE4":5397,"NA":5399},{"trials":5382,"activeCount":103},[],{"trials":5384,"activeCount":103},[],{"trials":5386,"activeCount":103},[],{"trials":5388,"activeCount":103},[5389],{"nctId":5390,"briefTitle":5391,"status":165,"phases":5392,"primaryCompletion":1174,"completion":1631,"start":1632,"enrollment":2275,"conditions":5393,"interventions":5396},"NCT00451763","Intravitreal Bevacizumab for Idiopathic Macular Telangiectasia",[93],[5394,5395],"Retina","Telangiectasis",[5379],{"trials":5398,"activeCount":103},[],{"trials":5400,"activeCount":103},[],{"intervention":5402,"totalTrials":175,"cells":5403},"Citrate Anticoagulation Solution",{"EARLY_PHASE1":5404,"PHASE1":5406,"PHASE2":5408,"PHASE3":5410,"PHASE4":5422,"NA":5424},{"trials":5405,"activeCount":103},[],{"trials":5407,"activeCount":103},[],{"trials":5409,"activeCount":103},[],{"trials":5411,"activeCount":103},[5412],{"nctId":5413,"briefTitle":5414,"status":2670,"phases":5415,"primaryCompletion":4782,"completion":4782,"start":5416,"enrollment":480,"conditions":5417,"interventions":5420},"NCT04297839","Evaluation of Regional Anticoagulation With Citrate in Extended Hemodialysis",[93],"2019-02-12",[5418,1487,5419],"Hemodialysis Complication","Anticoagulant Toxicity",[5402,5421],"Control Group",{"trials":5423,"activeCount":103},[],{"trials":5425,"activeCount":103},[],{"intervention":5421,"totalTrials":175,"cells":5427},{"EARLY_PHASE1":5428,"PHASE1":5430,"PHASE2":5432,"PHASE3":5434,"PHASE4":5440,"NA":5442},{"trials":5429,"activeCount":103},[],{"trials":5431,"activeCount":103},[],{"trials":5433,"activeCount":103},[],{"trials":5435,"activeCount":103},[5436],{"nctId":5413,"briefTitle":5414,"status":2670,"phases":5437,"primaryCompletion":4782,"completion":4782,"start":5416,"enrollment":480,"conditions":5438,"interventions":5439},[93],[5418,1487,5419],[5402,5421],{"trials":5441,"activeCount":103},[],{"trials":5443,"activeCount":103},[],{"intervention":5445,"totalTrials":175,"cells":5446},"Triamcinolone Acetonide 4 mg intravitreal",{"EARLY_PHASE1":5447,"PHASE1":5449,"PHASE2":5451,"PHASE3":5453,"PHASE4":5463,"NA":5465},{"trials":5448,"activeCount":103},[],{"trials":5450,"activeCount":103},[],{"trials":5452,"activeCount":103},[],{"trials":5454,"activeCount":103},[5455],{"nctId":5456,"briefTitle":5457,"status":165,"phases":5458,"completion":5459,"start":5460,"enrollment":414,"conditions":5461,"interventions":5462},"NCT00443521","Triamcinolone as Adjunctive Treatment to Laser Panretinal Photocoagulation for Proliferative Diabetic Retinopathy",[92,93],"2006-07","2005-03",[4960],[5445],{"trials":5464,"activeCount":103},[],{"trials":5466,"activeCount":103},[],{"intervention":1693,"totalTrials":175,"cells":5468},{"EARLY_PHASE1":5469,"PHASE1":5471,"PHASE2":5473,"PHASE3":5475,"PHASE4":5481,"NA":5483},{"trials":5470,"activeCount":103},[],{"trials":5472,"activeCount":103},[],{"trials":5474,"activeCount":103},[],{"trials":5476,"activeCount":103},[5477],{"nctId":1684,"briefTitle":1685,"status":165,"phases":5478,"primaryCompletion":1687,"completion":1687,"start":1688,"enrollment":170,"conditions":5479,"interventions":5480},[93],[1690],[1692,1693,1673],{"trials":5482,"activeCount":103},[],{"trials":5484,"activeCount":103},[],{"intervention":5486,"totalTrials":175,"cells":5487},"Bevacizumab Injection [Avastin]",{"EARLY_PHASE1":5488,"PHASE1":5490,"PHASE2":5492,"PHASE3":5494,"PHASE4":5506,"NA":5508},{"trials":5489,"activeCount":103},[],{"trials":5491,"activeCount":103},[],{"trials":5493,"activeCount":103},[],{"trials":5495,"activeCount":103},[5496],{"nctId":5497,"briefTitle":5498,"status":165,"phases":5499,"primaryCompletion":5500,"completion":5501,"start":5502,"enrollment":740,"conditions":5503,"interventions":5504},"NCT02985619","Bevacizumabe or Triamcinolone for Persistent Diabetic Macular Edema",[92,93],"2017-04-14","2017-12-21","2016-07-21",[5058],[5486,5505,5486],"Triamcinolone Acetonide 10mg\u002FmL",{"trials":5507,"activeCount":103},[],{"trials":5509,"activeCount":103},[],{"intervention":5505,"totalTrials":175,"cells":5511},{"EARLY_PHASE1":5512,"PHASE1":5514,"PHASE2":5516,"PHASE3":5518,"PHASE4":5524,"NA":5526},{"trials":5513,"activeCount":103},[],{"trials":5515,"activeCount":103},[],{"trials":5517,"activeCount":103},[],{"trials":5519,"activeCount":103},[5520],{"nctId":5497,"briefTitle":5498,"status":165,"phases":5521,"primaryCompletion":5500,"completion":5501,"start":5502,"enrollment":740,"conditions":5522,"interventions":5523},[92,93],[5058],[5486,5505,5486],{"trials":5525,"activeCount":103},[],{"trials":5527,"activeCount":103},[],{"intervention":5529,"totalTrials":175,"cells":5530},"Methotrexate-LDE",{"EARLY_PHASE1":5531,"PHASE1":5533,"PHASE2":5535,"PHASE3":5537,"PHASE4":5549,"NA":5551},{"trials":5532,"activeCount":103},[],{"trials":5534,"activeCount":103},[],{"trials":5536,"activeCount":103},[],{"trials":5538,"activeCount":103},[5539],{"nctId":5540,"briefTitle":5541,"status":193,"phases":5542,"primaryCompletion":5543,"completion":5544,"start":5545,"enrollment":17,"conditions":5546,"interventions":5548},"NCT04616872","Treatment of Patients With Atherosclerotic Disease With Methotrexate-associated to LDL Like Nanoparticles",[92,93],"2022-10-12","2023-10-12","2020-10-10",[4409,25,5547],"Inflammation",[5529],{"trials":5550,"activeCount":103},[],{"trials":5552,"activeCount":103},[],{"intervention":5554,"totalTrials":175,"cells":5555},"Liberal dobutamine protocol",{"EARLY_PHASE1":5556,"PHASE1":5558,"PHASE2":5560,"PHASE3":5562,"PHASE4":5574,"NA":5576},{"trials":5557,"activeCount":103},[],{"trials":5559,"activeCount":103},[],{"trials":5561,"activeCount":103},[],{"trials":5563,"activeCount":103},[5564],{"nctId":5565,"briefTitle":5566,"status":165,"phases":5567,"primaryCompletion":3646,"completion":5568,"start":2104,"enrollment":5569,"conditions":5570,"interventions":5572},"NCT02361801","Liberal Versus Restrictive Use of Dobutamine in Cardiac Surgery",[93],"2018-06",160,[5571,1764],"Cardiac Output, Low",[5554,5573],"Restrictive dobutamine protocol",{"trials":5575,"activeCount":103},[],{"trials":5577,"activeCount":103},[],{"intervention":5573,"totalTrials":175,"cells":5579},{"EARLY_PHASE1":5580,"PHASE1":5582,"PHASE2":5584,"PHASE3":5586,"PHASE4":5592,"NA":5594},{"trials":5581,"activeCount":103},[],{"trials":5583,"activeCount":103},[],{"trials":5585,"activeCount":103},[],{"trials":5587,"activeCount":103},[5588],{"nctId":5565,"briefTitle":5566,"status":165,"phases":5589,"primaryCompletion":3646,"completion":5568,"start":2104,"enrollment":5569,"conditions":5590,"interventions":5591},[93],[5571,1764],[5554,5573],{"trials":5593,"activeCount":103},[],{"trials":5595,"activeCount":103},[],{"intervention":5597,"totalTrials":175,"cells":5598},"2012 trivalent influenza vaccine",{"EARLY_PHASE1":5599,"PHASE1":5601,"PHASE2":5603,"PHASE3":5605,"PHASE4":5614,"NA":5616},{"trials":5600,"activeCount":103},[],{"trials":5602,"activeCount":103},[],{"trials":5604,"activeCount":103},[],{"trials":5606,"activeCount":103},[5607],{"nctId":5608,"briefTitle":5609,"status":193,"phases":5610,"primaryCompletion":2833,"completion":2943,"start":197,"enrollment":3247,"conditions":5611,"interventions":5613},"NCT01582633","Assessment of Needle-free Disposable-syringe Jet Injector (DSJI) ID Dose-sparing of Pandemic A H1N1 Influenza Vaccine",[92,93],[5612],"Influenza",[5597],{"trials":5615,"activeCount":103},[],{"trials":5617,"activeCount":103},[],{"intervention":5619,"totalTrials":175,"cells":5620},"Cannabis Derivatives",{"EARLY_PHASE1":5621,"PHASE1":5623,"PHASE2":5625,"PHASE3":5627,"PHASE4":5639,"NA":5641},{"trials":5622,"activeCount":103},[],{"trials":5624,"activeCount":103},[],{"trials":5626,"activeCount":103},[],{"trials":5628,"activeCount":103},[5629],{"nctId":5630,"briefTitle":5631,"status":2489,"phases":5632,"primaryCompletion":5633,"completion":5634,"start":5635,"enrollment":388,"conditions":5636,"interventions":5637},"NCT05670353","Cannabidiol for the Treatment of Pelvic Pain in Endometriosis (DREAMLAND)",[92,93],"2024-09-12","2024-11-20","2023-01-03",[2947,3837],[5619,5638],"Hormonal Contraceptive Agents",{"trials":5640,"activeCount":103},[],{"trials":5642,"activeCount":103},[],{"intervention":5638,"totalTrials":175,"cells":5644},{"EARLY_PHASE1":5645,"PHASE1":5647,"PHASE2":5649,"PHASE3":5651,"PHASE4":5657,"NA":5659},{"trials":5646,"activeCount":103},[],{"trials":5648,"activeCount":103},[],{"trials":5650,"activeCount":103},[],{"trials":5652,"activeCount":103},[5653],{"nctId":5630,"briefTitle":5631,"status":2489,"phases":5654,"primaryCompletion":5633,"completion":5634,"start":5635,"enrollment":388,"conditions":5655,"interventions":5656},[92,93],[2947,3837],[5619,5638],{"trials":5658,"activeCount":103},[],{"trials":5660,"activeCount":103},[],{"intervention":5662,"totalTrials":175,"cells":5663},"non-surgical periodontal therapy + systemic doxycycline",{"EARLY_PHASE1":5664,"PHASE1":5666,"PHASE2":5668,"PHASE3":5670,"PHASE4":5680,"NA":5682},{"trials":5665,"activeCount":103},[],{"trials":5667,"activeCount":103},[],{"trials":5669,"activeCount":103},[],{"trials":5671,"activeCount":103},[5672],{"nctId":5673,"briefTitle":5674,"status":165,"phases":5675,"primaryCompletion":5676,"completion":1736,"start":2009,"enrollment":1998,"conditions":5677,"interventions":5679},"NCT02220751","Diagnostic Biomarkers Related to Periodontal Disease Activity in Diabetic",[93],"2011-09",[5678,1905],"Periodontitis",[5662],{"trials":5681,"activeCount":103},[],{"trials":5683,"activeCount":103},[],{"intervention":5685,"totalTrials":175,"cells":5686},"Amitriptyline",{"EARLY_PHASE1":5687,"PHASE1":5689,"PHASE2":5691,"PHASE3":5693,"PHASE4":5707,"NA":5709},{"trials":5688,"activeCount":103},[],{"trials":5690,"activeCount":103},[],{"trials":5692,"activeCount":103},[],{"trials":5694,"activeCount":103},[5695],{"nctId":5696,"briefTitle":5697,"status":193,"phases":5698,"primaryCompletion":5699,"completion":5700,"start":4084,"enrollment":2213,"conditions":5701,"interventions":5705},"NCT03324035","Treatment of Neuropathic Pain in Leprosy",[93],"2021-05-03","2022-08-01",[5702,5703,5704,5685],"Pain, Neuropathic","Leprosy","Leprosy Neuropathy",[5685,5706],"Tramadol",{"trials":5708,"activeCount":103},[],{"trials":5710,"activeCount":103},[],{"intervention":5706,"totalTrials":175,"cells":5712},{"EARLY_PHASE1":5713,"PHASE1":5715,"PHASE2":5717,"PHASE3":5719,"PHASE4":5725,"NA":5727},{"trials":5714,"activeCount":103},[],{"trials":5716,"activeCount":103},[],{"trials":5718,"activeCount":103},[],{"trials":5720,"activeCount":103},[5721],{"nctId":5696,"briefTitle":5697,"status":193,"phases":5722,"primaryCompletion":5699,"completion":5700,"start":4084,"enrollment":2213,"conditions":5723,"interventions":5724},[93],[5702,5703,5704,5685],[5685,5706],{"trials":5726,"activeCount":103},[],{"trials":5728,"activeCount":103},[],{"intervention":5730,"totalTrials":175,"cells":5731},"Rivaroxaban",{"EARLY_PHASE1":5732,"PHASE1":5734,"PHASE2":5736,"PHASE3":5738,"PHASE4":5752,"NA":5754},{"trials":5733,"activeCount":103},[],{"trials":5735,"activeCount":103},[],{"trials":5737,"activeCount":103},[],{"trials":5739,"activeCount":103},[5740],{"nctId":5741,"briefTitle":5742,"status":165,"phases":5743,"primaryCompletion":5744,"completion":5745,"start":5746,"enrollment":235,"conditions":5747,"interventions":5750},"NCT03181386","Tooth Extraction in Patients With Atrial Fibrillation in Use of New Oral Anticoagulants",[93],"2020-11-30","2022-02-01","2017-05-03",[1774,5748,5749],"Periodontal Disease","Hemorrhage",[5730,5751,1776],"Dabigatran and Apixaban",{"trials":5753,"activeCount":103},[],{"trials":5755,"activeCount":103},[],{"intervention":5751,"totalTrials":175,"cells":5757},{"EARLY_PHASE1":5758,"PHASE1":5760,"PHASE2":5762,"PHASE3":5764,"PHASE4":5770,"NA":5772},{"trials":5759,"activeCount":103},[],{"trials":5761,"activeCount":103},[],{"trials":5763,"activeCount":103},[],{"trials":5765,"activeCount":103},[5766],{"nctId":5741,"briefTitle":5742,"status":165,"phases":5767,"primaryCompletion":5744,"completion":5745,"start":5746,"enrollment":235,"conditions":5768,"interventions":5769},[93],[1774,5748,5749],[5730,5751,1776],{"trials":5771,"activeCount":103},[],{"trials":5773,"activeCount":103},[],{"intervention":5775,"totalTrials":175,"cells":5776},"Folic Acid",{"EARLY_PHASE1":5777,"PHASE1":5779,"PHASE2":5781,"PHASE3":5783,"PHASE4":5797,"NA":5799},{"trials":5778,"activeCount":103},[],{"trials":5780,"activeCount":103},[],{"trials":5782,"activeCount":103},[],{"trials":5784,"activeCount":103},[5785],{"nctId":5786,"briefTitle":5787,"status":2489,"phases":5788,"primaryCompletion":5789,"completion":5789,"start":5790,"enrollment":5791,"conditions":5792,"interventions":5795},"NCT03516903","Effect of Methotrexate Carried by a Lipid Nanoemulsion on Left Ventricular Remodeling After STEMI",[92,93],"2020-12-17","2018-04-17",35,[5793,5794],"Myocardial Infarction, Anterior Wall","Myocardial Remodeling, Ventricular",[5796,5775],"Methotrexate",{"trials":5798,"activeCount":103},[],{"trials":5800,"activeCount":103},[],{"intervention":5802,"totalTrials":175,"cells":5803},"Bifidobacterium animalis subsp. lactis",{"EARLY_PHASE1":5804,"PHASE1":5806,"PHASE2":5808,"PHASE3":5810,"PHASE4":5822,"NA":5824},{"trials":5805,"activeCount":103},[],{"trials":5807,"activeCount":103},[],{"trials":5809,"activeCount":103},[],{"trials":5811,"activeCount":103},[5812],{"nctId":5813,"briefTitle":5814,"status":165,"phases":5815,"primaryCompletion":5816,"completion":5817,"start":5818,"enrollment":1373,"conditions":5819,"interventions":5821},"NCT04187222","Effect of Probiotic Use Bifidobacterium Animalis Subsp. Lactis in Peri-implant Mucositis",[93],"2019-08-31","2019-11-15","2018-07-01",[5820],"Mucositis Oral",[5802],{"trials":5823,"activeCount":103},[],{"trials":5825,"activeCount":103},[],{"intervention":5827,"totalTrials":175,"cells":5828},"Codeine",{"EARLY_PHASE1":5829,"PHASE1":5831,"PHASE2":5833,"PHASE3":5835,"PHASE4":5845,"NA":5847},{"trials":5830,"activeCount":103},[],{"trials":5832,"activeCount":103},[],{"trials":5834,"activeCount":103},[],{"trials":5836,"activeCount":103},[5837],{"nctId":5838,"briefTitle":5839,"status":165,"phases":5840,"primaryCompletion":207,"completion":2134,"start":2273,"enrollment":17,"conditions":5841,"interventions":5843},"NCT02625753","Codeine Plus Paracetamol Versus Placebo for PRK Post-operative Pain",[93],[5842],"Myopia",[5827,5844],"paracetamol",{"trials":5846,"activeCount":103},[],{"trials":5848,"activeCount":103},[],{"intervention":5844,"totalTrials":175,"cells":5850},{"EARLY_PHASE1":5851,"PHASE1":5853,"PHASE2":5855,"PHASE3":5857,"PHASE4":5863,"NA":5865},{"trials":5852,"activeCount":103},[],{"trials":5854,"activeCount":103},[],{"trials":5856,"activeCount":103},[],{"trials":5858,"activeCount":103},[5859],{"nctId":5838,"briefTitle":5839,"status":165,"phases":5860,"primaryCompletion":207,"completion":2134,"start":2273,"enrollment":17,"conditions":5861,"interventions":5862},[93],[5842],[5827,5844],{"trials":5864,"activeCount":103},[],{"trials":5866,"activeCount":103},[],{"intervention":731,"totalTrials":175,"cells":5868},{"EARLY_PHASE1":5869,"PHASE1":5871,"PHASE2":5873,"PHASE3":5875,"PHASE4":5881,"NA":5883},{"trials":5870,"activeCount":103},[],{"trials":5872,"activeCount":103},[],{"trials":5874,"activeCount":103},[],{"trials":5876,"activeCount":103},[5877],{"nctId":721,"briefTitle":722,"status":165,"phases":5878,"primaryCompletion":724,"completion":724,"start":725,"enrollment":726,"conditions":5879,"interventions":5880},[92,93],[728,729],[731,696,732],{"trials":5882,"activeCount":103},[],{"trials":5884,"activeCount":103},[],{"intervention":732,"totalTrials":175,"cells":5886},{"EARLY_PHASE1":5887,"PHASE1":5889,"PHASE2":5891,"PHASE3":5893,"PHASE4":5899,"NA":5901},{"trials":5888,"activeCount":103},[],{"trials":5890,"activeCount":103},[],{"trials":5892,"activeCount":103},[],{"trials":5894,"activeCount":103},[5895],{"nctId":721,"briefTitle":722,"status":165,"phases":5896,"primaryCompletion":724,"completion":724,"start":725,"enrollment":726,"conditions":5897,"interventions":5898},[92,93],[728,729],[731,696,732],{"trials":5900,"activeCount":103},[],{"trials":5902,"activeCount":103},[],{"intervention":5904,"totalTrials":175,"cells":5905},"sitagliptin OR saxagliptin",{"EARLY_PHASE1":5906,"PHASE1":5908,"PHASE2":5910,"PHASE3":5912,"PHASE4":5923,"NA":5925},{"trials":5907,"activeCount":103},[],{"trials":5909,"activeCount":103},[],{"trials":5911,"activeCount":103},[],{"trials":5913,"activeCount":103},[5914],{"nctId":5915,"briefTitle":5916,"status":165,"phases":5917,"primaryCompletion":2396,"completion":2396,"start":5918,"enrollment":5919,"conditions":5920,"interventions":5922},"NCT02377388","DPP-4 Inhibitors and Acute Myocardial Infarction:Effects on Platelet Function",[93],"2017-02-07",74,[5921],"Platelet Aggregation During Acute Myocardial Infarction",[5904],{"trials":5924,"activeCount":103},[],{"trials":5926,"activeCount":103},[],{"intervention":5928,"totalTrials":175,"cells":5929},"OCYTOCINA - SPRAY NASAL",{"EARLY_PHASE1":5930,"PHASE1":5932,"PHASE2":5934,"PHASE3":5936,"PHASE4":5946,"NA":5948},{"trials":5931,"activeCount":103},[],{"trials":5933,"activeCount":103},[],{"trials":5935,"activeCount":103},[],{"trials":5937,"activeCount":103},[5938],{"nctId":5939,"briefTitle":5940,"status":2489,"phases":5941,"primaryCompletion":1700,"completion":5942,"start":207,"enrollment":414,"conditions":5943,"interventions":5945},"NCT02007447","Oxytocin in Adolescents With Autism Spectrum Disorders",[92,93],"2018-05-04",[5944],"Autism Spectrum Disorder",[5928],{"trials":5947,"activeCount":103},[],{"trials":5949,"activeCount":103},[],{"intervention":5951,"totalTrials":175,"cells":5952},"Valproic acid",{"EARLY_PHASE1":5953,"PHASE1":5955,"PHASE2":5957,"PHASE3":5959,"PHASE4":5971,"NA":5973},{"trials":5954,"activeCount":103},[],{"trials":5956,"activeCount":103},[],{"trials":5958,"activeCount":103},[],{"trials":5960,"activeCount":103},[5961],{"nctId":5962,"briefTitle":5963,"status":165,"phases":5964,"primaryCompletion":5965,"completion":1841,"start":4233,"enrollment":235,"conditions":5966,"interventions":5968},"NCT00681980","Use Of Valproid Acid To Treat Tropical Spastic Paraparesis\u002FHTLV-1-Associated Myelopathy (TSP\u002FHAM)",[93],"2009-09",[5967],"Paraparesis Spastic Tropical",[5951,5969,5970],"costicosteroids","valproid acid plus corticosteroids",{"trials":5972,"activeCount":103},[],{"trials":5974,"activeCount":103},[],{"intervention":5969,"totalTrials":175,"cells":5976},{"EARLY_PHASE1":5977,"PHASE1":5979,"PHASE2":5981,"PHASE3":5983,"PHASE4":5989,"NA":5991},{"trials":5978,"activeCount":103},[],{"trials":5980,"activeCount":103},[],{"trials":5982,"activeCount":103},[],{"trials":5984,"activeCount":103},[5985],{"nctId":5962,"briefTitle":5963,"status":165,"phases":5986,"primaryCompletion":5965,"completion":1841,"start":4233,"enrollment":235,"conditions":5987,"interventions":5988},[93],[5967],[5951,5969,5970],{"trials":5990,"activeCount":103},[],{"trials":5992,"activeCount":103},[],{"intervention":5970,"totalTrials":175,"cells":5994},{"EARLY_PHASE1":5995,"PHASE1":5997,"PHASE2":5999,"PHASE3":6001,"PHASE4":6007,"NA":6009},{"trials":5996,"activeCount":103},[],{"trials":5998,"activeCount":103},[],{"trials":6000,"activeCount":103},[],{"trials":6002,"activeCount":103},[6003],{"nctId":5962,"briefTitle":5963,"status":165,"phases":6004,"primaryCompletion":5965,"completion":1841,"start":4233,"enrollment":235,"conditions":6005,"interventions":6006},[93],[5967],[5951,5969,5970],{"trials":6008,"activeCount":103},[],{"trials":6010,"activeCount":103},[],{"intervention":6012,"totalTrials":175,"cells":6013},"Butantan",{"EARLY_PHASE1":6014,"PHASE1":6016,"PHASE2":6018,"PHASE3":6020,"PHASE4":6034,"NA":6036},{"trials":6015,"activeCount":103},[],{"trials":6017,"activeCount":103},[],{"trials":6019,"activeCount":103},[],{"trials":6021,"activeCount":103},[6022],{"nctId":6023,"briefTitle":6024,"status":165,"phases":6025,"primaryCompletion":6026,"completion":6027,"start":6028,"enrollment":6029,"conditions":6030,"interventions":6032},"NCT02305160","A Multicenter, Randomized, Open Label Trial of a New Animal Extracted Surfactant to Treat RDS in Preterm Infants",[92,93],"2006-05","2007-07","2005-04",327,[6031],"Respiratory Distress Syndrome",[6012,6033],"Control",{"trials":6035,"activeCount":103},[],{"trials":6037,"activeCount":103},[],{"intervention":6039,"totalTrials":175,"cells":6040},"Endodontic treatment using Guedes-Pinto Paste",{"EARLY_PHASE1":6041,"PHASE1":6043,"PHASE2":6045,"PHASE3":6047,"PHASE4":6060,"NA":6062},{"trials":6042,"activeCount":103},[],{"trials":6044,"activeCount":103},[],{"trials":6046,"activeCount":103},[],{"trials":6048,"activeCount":103},[6049],{"nctId":6050,"briefTitle":6051,"status":165,"phases":6052,"primaryCompletion":6053,"completion":6054,"start":6055,"enrollment":740,"conditions":6056,"interventions":6058},"NCT03839485","Endodontic Treatment of Primary Teeth With Guedes-Pinto Paste Without Antibiotic",[93],"2019-06-30","2021-04-10","2018-06-08",[6057],"Pulp Disorder",[6039,6059],"Endodontic using Guedes-Pinto Paste without antibiotic",{"trials":6061,"activeCount":103},[],{"trials":6063,"activeCount":103},[],{"intervention":6059,"totalTrials":175,"cells":6065},{"EARLY_PHASE1":6066,"PHASE1":6068,"PHASE2":6070,"PHASE3":6072,"PHASE4":6078,"NA":6080},{"trials":6067,"activeCount":103},[],{"trials":6069,"activeCount":103},[],{"trials":6071,"activeCount":103},[],{"trials":6073,"activeCount":103},[6074],{"nctId":6050,"briefTitle":6051,"status":165,"phases":6075,"primaryCompletion":6053,"completion":6054,"start":6055,"enrollment":740,"conditions":6076,"interventions":6077},[93],[6057],[6039,6059],{"trials":6079,"activeCount":103},[],{"trials":6081,"activeCount":103},[],{"intervention":6083,"totalTrials":175,"cells":6084},"trimetazidine",{"EARLY_PHASE1":6085,"PHASE1":6087,"PHASE2":6089,"PHASE3":6091,"PHASE4":6101,"NA":6103},{"trials":6086,"activeCount":103},[],{"trials":6088,"activeCount":103},[],{"trials":6090,"activeCount":103},[],{"trials":6092,"activeCount":103},[6093],{"nctId":6094,"briefTitle":6095,"status":193,"phases":6096,"primaryCompletion":4983,"completion":1688,"start":1526,"enrollment":2071,"conditions":6097,"interventions":6100},"NCT03715582","Trimetazidine in Myocardial Injury After Percutaneous Coronary Intervention in Patients With Angina and Diabetes",[93],[6098,6099],"Diabetes Mellitus","Angina, Unstable",[6083],{"trials":6102,"activeCount":103},[],{"trials":6104,"activeCount":103},[],{"intervention":6106,"totalTrials":175,"cells":6107},"Systemic Doxycycline and Sham aPDT",{"EARLY_PHASE1":6108,"PHASE1":6110,"PHASE2":6112,"PHASE3":6114,"PHASE4":6124,"NA":6126},{"trials":6109,"activeCount":103},[],{"trials":6111,"activeCount":103},[],{"trials":6113,"activeCount":103},[],{"trials":6115,"activeCount":103},[6116],{"nctId":6117,"briefTitle":6118,"status":165,"phases":6119,"primaryCompletion":6120,"completion":2579,"start":1642,"enrollment":414,"conditions":6121,"interventions":6122},"NCT01595594","Comparison Between aPDT and Systemic Doxycycline on Non-surgical Periodontal Therapy in Type 2 Diabetics",[93],"2012-04",[5748,2468],[6106,6123],"aPDT + Doxycycline Placebo",{"trials":6125,"activeCount":103},[],{"trials":6127,"activeCount":103},[],{"intervention":6123,"totalTrials":175,"cells":6129},{"EARLY_PHASE1":6130,"PHASE1":6132,"PHASE2":6134,"PHASE3":6136,"PHASE4":6142,"NA":6144},{"trials":6131,"activeCount":103},[],{"trials":6133,"activeCount":103},[],{"trials":6135,"activeCount":103},[],{"trials":6137,"activeCount":103},[6138],{"nctId":6117,"briefTitle":6118,"status":165,"phases":6139,"primaryCompletion":6120,"completion":2579,"start":1642,"enrollment":414,"conditions":6140,"interventions":6141},[93],[5748,2468],[6106,6123],{"trials":6143,"activeCount":103},[],{"trials":6145,"activeCount":103},[],{"intervention":6147,"totalTrials":175,"cells":6148},"Escitalopram oxalate",{"EARLY_PHASE1":6149,"PHASE1":6151,"PHASE2":6153,"PHASE3":6155,"PHASE4":6167,"NA":6169},{"trials":6150,"activeCount":103},[],{"trials":6152,"activeCount":103},[],{"trials":6154,"activeCount":103},[],{"trials":6156,"activeCount":103},[6157],{"nctId":6158,"briefTitle":6159,"status":165,"phases":6160,"primaryCompletion":2832,"completion":6161,"start":5286,"enrollment":6162,"conditions":6163,"interventions":6166},"NCT01894815","Escitalopram, Placebo and tDCS in Depression: a Non-inferiority Trial",[93],"2016-11",245,[2083,6164,6165],"Major Depressive Disorder, Recurrent, Unspecified","Major Depressive Disorder, Single Episode, Unspecified",[6147],{"trials":6168,"activeCount":103},[],{"trials":6170,"activeCount":103},[],{"intervention":6172,"totalTrials":175,"cells":6173},"Tamsulosin",{"EARLY_PHASE1":6174,"PHASE1":6176,"PHASE2":6178,"PHASE3":6180,"PHASE4":6191,"NA":6193},{"trials":6175,"activeCount":103},[],{"trials":6177,"activeCount":103},[],{"trials":6179,"activeCount":103},[],{"trials":6181,"activeCount":103},[6182],{"nctId":6183,"briefTitle":6184,"status":193,"phases":6185,"primaryCompletion":2737,"completion":3172,"start":6186,"enrollment":6187,"conditions":6188,"interventions":6190},"NCT01215708","Effects of the Use of Adjuvant Drugs After Extracorporeal Shockwave Lithotripsy (ESWL) in Renal Calculus",[93],"2006-08",136,[6189],"Renal Calculi",[6172],{"trials":6192,"activeCount":103},[],{"trials":6194,"activeCount":103},[],{"intervention":6196,"totalTrials":175,"cells":6197},"Insulin",{"EARLY_PHASE1":6198,"PHASE1":6200,"PHASE2":6202,"PHASE3":6204,"PHASE4":6217,"NA":6219},{"trials":6199,"activeCount":103},[],{"trials":6201,"activeCount":103},[],{"trials":6203,"activeCount":103},[],{"trials":6205,"activeCount":103},[6206],{"nctId":6207,"briefTitle":6208,"status":2489,"phases":6209,"primaryCompletion":6210,"completion":6211,"start":6212,"enrollment":6213,"conditions":6214,"interventions":6216},"NCT02574156","Control of Hyperglycemia After Cardiac Surgery: CHyCS Trial",[93],"2018-08-01","2019-04-01","2017-01-01",500,[6215],"Hyperglycemia",[6196],{"trials":6218,"activeCount":103},[],{"trials":6220,"activeCount":103},[],{"intervention":6222,"totalTrials":175,"cells":6223},"TDM-621",{"EARLY_PHASE1":6224,"PHASE1":6226,"PHASE2":6228,"PHASE3":6230,"PHASE4":6242,"NA":6244},{"trials":6225,"activeCount":103},[],{"trials":6227,"activeCount":103},[],{"trials":6229,"activeCount":103},[],{"trials":6231,"activeCount":103},[6232],{"nctId":6233,"briefTitle":6234,"status":193,"phases":6235,"primaryCompletion":3245,"completion":3245,"start":6236,"enrollment":480,"conditions":6237,"interventions":6241},"NCT03917862","Strategy for Aortic Surgery Hemostasis",[92,93],"2018-12-04",[6238,6239,6240],"Ascending Aorta Abnormality","Ascending Aortic Dissection","Ascending Aorta Aneurysm",[6222],{"trials":6243,"activeCount":103},[],{"trials":6245,"activeCount":103},[],{"intervention":6247,"totalTrials":175,"cells":6248},"Polihexanide 2%",{"EARLY_PHASE1":6249,"PHASE1":6251,"PHASE2":6253,"PHASE3":6255,"PHASE4":6267,"NA":6269},{"trials":6250,"activeCount":103},[],{"trials":6252,"activeCount":103},[],{"trials":6254,"activeCount":103},[],{"trials":6256,"activeCount":103},[6257],{"nctId":6258,"briefTitle":6259,"status":165,"phases":6260,"primaryCompletion":195,"completion":1701,"start":6261,"enrollment":26,"conditions":6262,"interventions":6265},"NCT02394821","Odor Management in Fungating Wounds Comparing Metronidazole and Polihexanide",[93],"2013-09",[6263,6264],"Neoplasm","Wounds and Injuries",[6247,6266],"Metronidazole 0.8%",{"trials":6268,"activeCount":103},[],{"trials":6270,"activeCount":103},[],{"intervention":6266,"totalTrials":175,"cells":6272},{"EARLY_PHASE1":6273,"PHASE1":6275,"PHASE2":6277,"PHASE3":6279,"PHASE4":6285,"NA":6287},{"trials":6274,"activeCount":103},[],{"trials":6276,"activeCount":103},[],{"trials":6278,"activeCount":103},[],{"trials":6280,"activeCount":103},[6281],{"nctId":6258,"briefTitle":6259,"status":165,"phases":6282,"primaryCompletion":195,"completion":1701,"start":6261,"enrollment":26,"conditions":6283,"interventions":6284},[93],[6263,6264],[6247,6266],{"trials":6286,"activeCount":103},[],{"trials":6288,"activeCount":103},[],{"intervention":5034,"totalTrials":175,"cells":6290},{"EARLY_PHASE1":6291,"PHASE1":6293,"PHASE2":6295,"PHASE3":6297,"PHASE4":6303,"NA":6305},{"trials":6292,"activeCount":103},[],{"trials":6294,"activeCount":103},[],{"trials":6296,"activeCount":103},[],{"trials":6298,"activeCount":103},[6299],{"nctId":5026,"briefTitle":5027,"status":165,"phases":6300,"primaryCompletion":5029,"completion":5030,"start":4759,"enrollment":235,"conditions":6301,"interventions":6302},[93],[5032],[5034,5035,4992,5036],{"trials":6304,"activeCount":103},[],{"trials":6306,"activeCount":103},[],{"intervention":5035,"totalTrials":175,"cells":6308},{"EARLY_PHASE1":6309,"PHASE1":6311,"PHASE2":6313,"PHASE3":6315,"PHASE4":6321,"NA":6323},{"trials":6310,"activeCount":103},[],{"trials":6312,"activeCount":103},[],{"trials":6314,"activeCount":103},[],{"trials":6316,"activeCount":103},[6317],{"nctId":5026,"briefTitle":5027,"status":165,"phases":6318,"primaryCompletion":5029,"completion":5030,"start":4759,"enrollment":235,"conditions":6319,"interventions":6320},[93],[5032],[5034,5035,4992,5036],{"trials":6322,"activeCount":103},[],{"trials":6324,"activeCount":103},[],{"intervention":5036,"totalTrials":175,"cells":6326},{"EARLY_PHASE1":6327,"PHASE1":6329,"PHASE2":6331,"PHASE3":6333,"PHASE4":6339,"NA":6341},{"trials":6328,"activeCount":103},[],{"trials":6330,"activeCount":103},[],{"trials":6332,"activeCount":103},[],{"trials":6334,"activeCount":103},[6335],{"nctId":5026,"briefTitle":5027,"status":165,"phases":6336,"primaryCompletion":5029,"completion":5030,"start":4759,"enrollment":235,"conditions":6337,"interventions":6338},[93],[5032],[5034,5035,4992,5036],{"trials":6340,"activeCount":103},[],{"trials":6342,"activeCount":103},[],{"intervention":6344,"totalTrials":175,"cells":6345},"Hydralazine\u002Famlodipine",{"EARLY_PHASE1":6346,"PHASE1":6348,"PHASE2":6350,"PHASE3":6352,"PHASE4":6362,"NA":6364},{"trials":6347,"activeCount":103},[],{"trials":6349,"activeCount":103},[],{"trials":6351,"activeCount":103},[],{"trials":6353,"activeCount":103},[6354],{"nctId":6355,"briefTitle":6356,"status":165,"phases":6357,"primaryCompletion":2579,"completion":4150,"start":1821,"enrollment":1633,"conditions":6358,"interventions":6361},"NCT01255475","Blood Pressure Reduction in Heart Failure",[92,93],[19,6359,6360],"Cardiac Failure","Congestive Heart Failure",[6344],{"trials":6363,"activeCount":103},[],{"trials":6365,"activeCount":103},[],{"intervention":6367,"totalTrials":175,"cells":6368},"Renin-angiotensin system inhibitors",{"EARLY_PHASE1":6369,"PHASE1":6371,"PHASE2":6373,"PHASE3":6375,"PHASE4":6386,"NA":6388},{"trials":6370,"activeCount":103},[],{"trials":6372,"activeCount":103},[],{"trials":6374,"activeCount":103},[],{"trials":6376,"activeCount":103},[6377],{"nctId":6378,"briefTitle":6379,"status":2489,"phases":6380,"primaryCompletion":6381,"completion":6381,"start":6382,"enrollment":3393,"conditions":6383,"interventions":6385},"NCT04493359","Switch of Renin-Angiotensin System Inhibitors in Patients With Covid-19",[92,93],"2021-09-28","2020-07-25",[5032,6384],"Angiotensin II Receptor Antagonist Adverse Reaction",[6367],{"trials":6387,"activeCount":103},[],{"trials":6389,"activeCount":103},[],{"intervention":1583,"totalTrials":175,"cells":6391},{"EARLY_PHASE1":6392,"PHASE1":6394,"PHASE2":6396,"PHASE3":6398,"PHASE4":6404,"NA":6406},{"trials":6393,"activeCount":103},[],{"trials":6395,"activeCount":103},[],{"trials":6397,"activeCount":103},[],{"trials":6399,"activeCount":103},[6400],{"nctId":1576,"briefTitle":1577,"status":193,"phases":6401,"primaryCompletion":1191,"completion":1191,"start":1579,"enrollment":480,"conditions":6402,"interventions":6403},[93],[1581],[1583,1565],{"trials":6405,"activeCount":103},[],{"trials":6407,"activeCount":103},[],{"intervention":6409,"totalTrials":175,"cells":6410},"Metoprolol succinate",{"EARLY_PHASE1":6411,"PHASE1":6413,"PHASE2":6415,"PHASE3":6417,"PHASE4":6429,"NA":6431},{"trials":6412,"activeCount":103},[],{"trials":6414,"activeCount":103},[],{"trials":6416,"activeCount":103},[],{"trials":6418,"activeCount":103},[6419],{"nctId":6420,"briefTitle":6421,"status":165,"phases":6422,"primaryCompletion":6261,"completion":2136,"start":1913,"enrollment":6423,"conditions":6424,"interventions":6428},"NCT01676285","Metoprolol Succinate in Cardiac Remodeling Related to Cirrhosis",[93],125,[6425,6426,6427],"Cirrhosis","Cirrhotic Cardiomyopathy","Cardiac Remodeling",[6409],{"trials":6430,"activeCount":103},[],{"trials":6432,"activeCount":103},[],{"intervention":6434,"totalTrials":175,"cells":6435},"1% lidocaine injection in trigger points",{"EARLY_PHASE1":6436,"PHASE1":6438,"PHASE2":6440,"PHASE3":6442,"PHASE4":6455,"NA":6457},{"trials":6437,"activeCount":103},[],{"trials":6439,"activeCount":103},[],{"trials":6441,"activeCount":103},[],{"trials":6443,"activeCount":103},[6444],{"nctId":6445,"briefTitle":6446,"status":165,"phases":6447,"primaryCompletion":6448,"completion":6449,"start":6450,"enrollment":414,"conditions":6451,"interventions":6454},"NCT04703803","Efficacy of Myofascial Pain Syndrome Treatment in Patients With Cancer in Palliative Care",[93],"2021-03-19","2022-05-17","2020-08-17",[6452,6453],"Myofascial Pain Syndromes","Cancer",[6434],{"trials":6456,"activeCount":103},[],{"trials":6458,"activeCount":103},[],{"intervention":6460,"totalTrials":175,"cells":6461},"LDE-Paclitaxel",{"EARLY_PHASE1":6462,"PHASE1":6464,"PHASE2":6466,"PHASE3":6468,"PHASE4":6480,"NA":6482},{"trials":6463,"activeCount":103},[],{"trials":6465,"activeCount":103},[],{"trials":6467,"activeCount":103},[],{"trials":6469,"activeCount":103},[6470],{"nctId":6471,"briefTitle":6472,"status":193,"phases":6473,"primaryCompletion":6474,"completion":6475,"start":6476,"enrollment":17,"conditions":6477,"interventions":6478},"NCT04148833","Treatment of Patients With Atherosclerotic Disease With Paclitaxel-associated to LDL Like Nanoparticles",[92,93],"2020-08-12","2021-08-23","2019-06-23",[25,4409,5547],[6460,6479],"LDE-Placebo",{"trials":6481,"activeCount":103},[],{"trials":6483,"activeCount":103},[],{"intervention":6479,"totalTrials":175,"cells":6485},{"EARLY_PHASE1":6486,"PHASE1":6488,"PHASE2":6490,"PHASE3":6492,"PHASE4":6498,"NA":6500},{"trials":6487,"activeCount":103},[],{"trials":6489,"activeCount":103},[],{"trials":6491,"activeCount":103},[],{"trials":6493,"activeCount":103},[6494],{"nctId":6471,"briefTitle":6472,"status":193,"phases":6495,"primaryCompletion":6474,"completion":6475,"start":6476,"enrollment":17,"conditions":6496,"interventions":6497},[92,93],[25,4409,5547],[6460,6479],{"trials":6499,"activeCount":103},[],{"trials":6501,"activeCount":103},[],{"intervention":6503,"totalTrials":175,"cells":6504},"Carvedilol",{"EARLY_PHASE1":6505,"PHASE1":6507,"PHASE2":6509,"PHASE3":6511,"PHASE4":6520,"NA":6522},{"trials":6506,"activeCount":103},[],{"trials":6508,"activeCount":103},[],{"trials":6510,"activeCount":103},[],{"trials":6512,"activeCount":103},[6513],{"nctId":6514,"briefTitle":6515,"status":165,"phases":6516,"primaryCompletion":2443,"completion":2443,"start":3330,"enrollment":480,"conditions":6517,"interventions":6519},"NCT01724450","Carvedilol Effect in Preventing Chemotherapy - Induced Cardiotoxicity",[93],[6518,19,1313],"Breast Cancer",[6503],{"trials":6521,"activeCount":103},[],{"trials":6523,"activeCount":103},[],{"intervention":6525,"totalTrials":175,"cells":6526},"Amiodarone",{"EARLY_PHASE1":6527,"PHASE1":6529,"PHASE2":6531,"PHASE3":6533,"PHASE4":6547,"NA":6549},{"trials":6528,"activeCount":103},[],{"trials":6530,"activeCount":103},[],{"trials":6532,"activeCount":103},[],{"trials":6534,"activeCount":103},[6535],{"nctId":6536,"briefTitle":6537,"status":193,"phases":6538,"primaryCompletion":6539,"completion":6540,"start":6541,"enrollment":2740,"conditions":6542,"interventions":6545},"NCT03715556","Control Versus Liberal Cardiac Frequency in Patients in Sepse With Atrial Fibrillation of High Ventricular Response",[93],"2020-12-01","2021-12-01","2018-12-01",[2403,5289,1774,6543,6544],"Ventricular Fibrillation","Atrial Fibrillation Rapid",[6525,6546],"0.9% physiological solution",{"trials":6548,"activeCount":103},[],{"trials":6550,"activeCount":103},[],{"intervention":6546,"totalTrials":175,"cells":6552},{"EARLY_PHASE1":6553,"PHASE1":6555,"PHASE2":6557,"PHASE3":6559,"PHASE4":6565,"NA":6567},{"trials":6554,"activeCount":103},[],{"trials":6556,"activeCount":103},[],{"trials":6558,"activeCount":103},[],{"trials":6560,"activeCount":103},[6561],{"nctId":6536,"briefTitle":6537,"status":193,"phases":6562,"primaryCompletion":6539,"completion":6540,"start":6541,"enrollment":2740,"conditions":6563,"interventions":6564},[93],[2403,5289,1774,6543,6544],[6525,6546],{"trials":6566,"activeCount":103},[],{"trials":6568,"activeCount":103},[],{"intervention":6570,"totalTrials":175,"cells":6571},"Fluoride Varnish",{"EARLY_PHASE1":6572,"PHASE1":6574,"PHASE2":6576,"PHASE3":6578,"PHASE4":6591,"NA":6593},{"trials":6573,"activeCount":103},[],{"trials":6575,"activeCount":103},[],{"trials":6577,"activeCount":103},[],{"trials":6579,"activeCount":103},[6580],{"nctId":6581,"briefTitle":6582,"status":165,"phases":6583,"primaryCompletion":6584,"completion":6585,"start":1839,"enrollment":6586,"conditions":6587,"interventions":6589},"NCT04591444","Fluoride Varnish X Glass Ionomer Sealant on Cervical Dentin Hypersensitivity",[93],"2019-10","2020-03",121,[3464,6588],"Dentin Sensitivity",[6570,6590],"Glass Ionomer Sealant",{"trials":6592,"activeCount":103},[],{"trials":6594,"activeCount":103},[],{"intervention":6590,"totalTrials":175,"cells":6596},{"EARLY_PHASE1":6597,"PHASE1":6599,"PHASE2":6601,"PHASE3":6603,"PHASE4":6609,"NA":6611},{"trials":6598,"activeCount":103},[],{"trials":6600,"activeCount":103},[],{"trials":6602,"activeCount":103},[],{"trials":6604,"activeCount":103},[6605],{"nctId":6581,"briefTitle":6582,"status":165,"phases":6606,"primaryCompletion":6584,"completion":6585,"start":1839,"enrollment":6586,"conditions":6607,"interventions":6608},[93],[3464,6588],[6570,6590],{"trials":6610,"activeCount":103},[],{"trials":6612,"activeCount":103},[],{"intervention":6614,"totalTrials":175,"cells":6615},"Varicella Vaccine",{"EARLY_PHASE1":6616,"PHASE1":6618,"PHASE2":6620,"PHASE3":6622,"PHASE4":6636,"NA":6638},{"trials":6617,"activeCount":103},[],{"trials":6619,"activeCount":103},[],{"trials":6621,"activeCount":103},[],{"trials":6623,"activeCount":103},[6624],{"nctId":6625,"briefTitle":6626,"status":193,"phases":6627,"primaryCompletion":6628,"completion":6629,"start":1876,"enrollment":6630,"conditions":6631,"interventions":6634},"NCT00926419","Serological Evaluation of Varicella and Hepatitis A Vaccines Using Injector Delivery",[92,93],"2009-11","2010-05",600,[6632,6633],"Varicella","Hepatitis A",[6614,6635],"Hepatitis A Vaccine",{"trials":6637,"activeCount":103},[],{"trials":6639,"activeCount":103},[],{"intervention":6635,"totalTrials":175,"cells":6641},{"EARLY_PHASE1":6642,"PHASE1":6644,"PHASE2":6646,"PHASE3":6648,"PHASE4":6654,"NA":6656},{"trials":6643,"activeCount":103},[],{"trials":6645,"activeCount":103},[],{"trials":6647,"activeCount":103},[],{"trials":6649,"activeCount":103},[6650],{"nctId":6625,"briefTitle":6626,"status":193,"phases":6651,"primaryCompletion":6628,"completion":6629,"start":1876,"enrollment":6630,"conditions":6652,"interventions":6653},[92,93],[6632,6633],[6614,6635],{"trials":6655,"activeCount":103},[],{"trials":6657,"activeCount":103},[],{"intervention":6659,"totalTrials":175,"cells":6660},"intranasal dexmedetomidine",{"EARLY_PHASE1":6661,"PHASE1":6663,"PHASE2":6665,"PHASE3":6667,"PHASE4":6681,"NA":6683},{"trials":6662,"activeCount":103},[],{"trials":6664,"activeCount":103},[],{"trials":6666,"activeCount":103},[],{"trials":6668,"activeCount":103},[6669],{"nctId":6670,"briefTitle":6671,"status":193,"phases":6672,"primaryCompletion":167,"completion":3391,"start":6673,"enrollment":235,"conditions":6674,"interventions":6677},"NCT04621110","Intranasal Versus Intravenous Drug in Painful Procedure for Outpatient Oncologic Participants",[93],"2021-06-01",[6675,5227,6676],"Pediatric Cancer","Procedural Pain",[6659,6678,6679,6680],"intranasal fentanyl","intravenous ketamine","intravenous midazolam",{"trials":6682,"activeCount":103},[],{"trials":6684,"activeCount":103},[],{"intervention":6678,"totalTrials":175,"cells":6686},{"EARLY_PHASE1":6687,"PHASE1":6689,"PHASE2":6691,"PHASE3":6693,"PHASE4":6699,"NA":6701},{"trials":6688,"activeCount":103},[],{"trials":6690,"activeCount":103},[],{"trials":6692,"activeCount":103},[],{"trials":6694,"activeCount":103},[6695],{"nctId":6670,"briefTitle":6671,"status":193,"phases":6696,"primaryCompletion":167,"completion":3391,"start":6673,"enrollment":235,"conditions":6697,"interventions":6698},[93],[6675,5227,6676],[6659,6678,6679,6680],{"trials":6700,"activeCount":103},[],{"trials":6702,"activeCount":103},[],{"intervention":6679,"totalTrials":175,"cells":6704},{"EARLY_PHASE1":6705,"PHASE1":6707,"PHASE2":6709,"PHASE3":6711,"PHASE4":6717,"NA":6719},{"trials":6706,"activeCount":103},[],{"trials":6708,"activeCount":103},[],{"trials":6710,"activeCount":103},[],{"trials":6712,"activeCount":103},[6713],{"nctId":6670,"briefTitle":6671,"status":193,"phases":6714,"primaryCompletion":167,"completion":3391,"start":6673,"enrollment":235,"conditions":6715,"interventions":6716},[93],[6675,5227,6676],[6659,6678,6679,6680],{"trials":6718,"activeCount":103},[],{"trials":6720,"activeCount":103},[],{"intervention":6680,"totalTrials":175,"cells":6722},{"EARLY_PHASE1":6723,"PHASE1":6725,"PHASE2":6727,"PHASE3":6729,"PHASE4":6735,"NA":6737},{"trials":6724,"activeCount":103},[],{"trials":6726,"activeCount":103},[],{"trials":6728,"activeCount":103},[],{"trials":6730,"activeCount":103},[6731],{"nctId":6670,"briefTitle":6671,"status":193,"phases":6732,"primaryCompletion":167,"completion":3391,"start":6673,"enrollment":235,"conditions":6733,"interventions":6734},[93],[6675,5227,6676],[6659,6678,6679,6680],{"trials":6736,"activeCount":103},[],{"trials":6738,"activeCount":103},[],{"intervention":6740,"totalTrials":175,"cells":6741},"GnRH agonist",{"EARLY_PHASE1":6742,"PHASE1":6744,"PHASE2":6746,"PHASE3":6748,"PHASE4":6756,"NA":6758},{"trials":6743,"activeCount":103},[],{"trials":6745,"activeCount":103},[],{"trials":6747,"activeCount":103},[],{"trials":6749,"activeCount":103},[6750],{"nctId":6751,"briefTitle":6752,"status":193,"phases":6753,"primaryCompletion":2070,"completion":2738,"start":1875,"enrollment":1176,"conditions":6754,"interventions":6755},"NCT00948805","Evaluation of the Luteolytic Effect of a Gonadotropin Releasing Hormone (GnRH) Agonist After the Administration of Human Chorionic Gonadotropin (hCG) in the Initial Follicular Phase a Its Influence on the Prognosis of in Vitro Fertilization Treatment",[93],[2035],[6740,6033],{"trials":6757,"activeCount":103},[],{"trials":6759,"activeCount":103},[],{"intervention":6761,"totalTrials":175,"cells":6762},"Corticosteroid Topical",{"EARLY_PHASE1":6763,"PHASE1":6765,"PHASE2":6767,"PHASE3":6769,"PHASE4":6781,"NA":6783},{"trials":6764,"activeCount":103},[],{"trials":6766,"activeCount":103},[],{"trials":6768,"activeCount":103},[],{"trials":6770,"activeCount":103},[6771],{"nctId":6772,"briefTitle":6773,"status":193,"phases":6774,"primaryCompletion":6775,"completion":6776,"start":6777,"enrollment":631,"conditions":6778,"interventions":6780},"NCT05450471","Effectiveness of Endonasal Polymeric Implant for Chronic Rhinosinusitis",[93],"2022-07-15","2022-12-15","2021-08-20",[6779],"Rhinosinusitis Chronic",[6761],{"trials":6782,"activeCount":103},[],{"trials":6784,"activeCount":103},[],{"intervention":6786,"totalTrials":175,"cells":6787},"Pregabalin, Oxaliplatin",{"EARLY_PHASE1":6788,"PHASE1":6790,"PHASE2":6792,"PHASE3":6794,"PHASE4":6805,"NA":6807},{"trials":6789,"activeCount":103},[],{"trials":6791,"activeCount":103},[],{"trials":6793,"activeCount":103},[],{"trials":6795,"activeCount":103},[6796],{"nctId":6797,"briefTitle":6798,"status":165,"phases":6799,"primaryCompletion":4734,"completion":6800,"start":6801,"enrollment":480,"conditions":6802,"interventions":6804},"NCT01450163","Evaluate The Efficacy and Safety Of Pregabalin In Prevention, Reduction of Oxaliplatin-Induced Painful Neuropathy",[93],"2014-12","2011-08",[28,4920,6803],"Polyneuropathy",[6786],{"trials":6806,"activeCount":103},[],{"trials":6808,"activeCount":103},[],{"intervention":6810,"totalTrials":175,"cells":6811},"Therapeutic anticoagulation",{"EARLY_PHASE1":6812,"PHASE1":6814,"PHASE2":6816,"PHASE3":6818,"PHASE4":6835,"NA":6837},{"trials":6813,"activeCount":103},[],{"trials":6815,"activeCount":103},[],{"trials":6817,"activeCount":103},[],{"trials":6819,"activeCount":103},[6820],{"nctId":6821,"briefTitle":6822,"status":165,"phases":6823,"primaryCompletion":6824,"completion":6825,"start":6826,"enrollment":6827,"conditions":6828,"interventions":6834},"NCT04444700","A Pragmatic Randomized Controlled Trial of Therapeutic Anticoagulation Versus Standard Care as a Rapid Response to (SARS-CoV-2) COVID-19 Pandemic",[93],"2021-05-10","2021-10-14","2020-07-04",465,[6829,6830,6831,6832,6833],"COVID","Coronavirus Infection","Severe Acute Respiratory Syndrome","Thromboembolism, Venous","Anticoagulants and Bleeding Disorders",[6810],{"trials":6836,"activeCount":103},[],{"trials":6838,"activeCount":103},[],{"intervention":6840,"totalTrials":989,"cells":6841},"Ranibizumab",{"EARLY_PHASE1":6842,"PHASE1":6844,"PHASE2":6846,"PHASE3":6880,"PHASE4":6882,"NA":6884},{"trials":6843,"activeCount":103},[],{"trials":6845,"activeCount":103},[],{"trials":6847,"activeCount":103},[6848,6855,6865,6873],{"nctId":6849,"briefTitle":6850,"status":165,"phases":6851,"primaryCompletion":1914,"completion":1914,"start":4497,"enrollment":35,"conditions":6852,"interventions":6854},"NCT01201161","Ranibizumab for Diabetic Traction Retinal Detachment",[92],[4960,6853],"Retinal Detachment",[6840],{"nctId":6856,"briefTitle":6857,"status":165,"phases":6858,"primaryCompletion":2833,"completion":2833,"start":6859,"enrollment":414,"conditions":6860,"interventions":6864},"NCT01746563","Intravitreal Ranibizumab Combined With Panretinal Photocoagulation in Patients With Proliferative Diabetic Retinopathy",[91,92],"2011-05",[4960,6861,6862,6863,4408,4407],"Retinal Diseases","Eye Diseases","Diabetic Angiopathies",[6840],{"nctId":6866,"briefTitle":6867,"status":193,"phases":6868,"primaryCompletion":2943,"completion":2943,"start":1643,"enrollment":6869,"conditions":6870,"interventions":6871},"NCT01487629","Bevacizumab Versus Ranibizumab for the Treatment of Diabetic Macular Edema",[92],53,[4960,4959],[6872,6840],"Bevacizumab",{"nctId":6874,"briefTitle":6875,"status":165,"phases":6876,"primaryCompletion":3909,"completion":3909,"start":4970,"enrollment":17,"conditions":6877,"interventions":6879},"NCT01102946","Panretinal Photocoagulation (PRP) Plus Ranibizumab for Proliferative Diabetic Retinopathy",[92],[4960,6878],"Retinal Neovascularization",[6840],{"trials":6881,"activeCount":103},[],{"trials":6883,"activeCount":103},[],{"trials":6885,"activeCount":103},[],{"intervention":6887,"totalTrials":99,"cells":6888},"intravitreal injection of autologous bone marrow stem cells",{"EARLY_PHASE1":6889,"PHASE1":6891,"PHASE2":6900,"PHASE3":6907,"PHASE4":6909,"NA":6911},{"trials":6890,"activeCount":103},[],{"trials":6892,"activeCount":103},[6893],{"nctId":6894,"briefTitle":6895,"status":165,"phases":6896,"primaryCompletion":1914,"completion":2944,"start":1866,"enrollment":697,"conditions":6897,"interventions":6899},"NCT01068561","Autologous Bone Marrow-Derived Stem Cells Transplantation For Retinitis Pigmentosa",[91],[6898],"Retinitis Pigmentosa",[6887],{"trials":6901,"activeCount":103},[6902],{"nctId":6903,"briefTitle":6895,"status":165,"phases":6904,"primaryCompletion":4150,"completion":750,"start":3202,"enrollment":388,"conditions":6905,"interventions":6906},"NCT01560715",[92],[6898],[6887],{"trials":6908,"activeCount":103},[],{"trials":6910,"activeCount":103},[],{"trials":6912,"activeCount":103},[],{"intervention":6914,"totalTrials":99,"cells":6915},"Naltrexone",{"EARLY_PHASE1":6916,"PHASE1":6918,"PHASE2":6920,"PHASE3":6939,"PHASE4":6941,"NA":6943},{"trials":6917,"activeCount":103},[],{"trials":6919,"activeCount":103},[],{"trials":6921,"activeCount":103},[6922,6931],{"nctId":6923,"briefTitle":6924,"status":193,"phases":6925,"primaryCompletion":1493,"completion":6926,"start":6673,"enrollment":17,"conditions":6927,"interventions":6930},"NCT04738773","RCT for Gambling and Naltrexone, Using Use Eye-tracking Analysis to Predict Treatment Response",[92],"2023-12",[6928,6929,6914],"Eye Tracking","Gambling Disorder",[6914],{"nctId":6932,"briefTitle":6933,"status":193,"phases":6934,"primaryCompletion":6926,"completion":6926,"start":6935,"enrollment":17,"conditions":6936,"interventions":6938},"NCT04649892","Predicting Response to Naltrexone With Eye Tracking in Videogame Disorder",[92],"2021-01",[6937],"Gaming Disorder",[6914],{"trials":6940,"activeCount":103},[],{"trials":6942,"activeCount":103},[],{"trials":6944,"activeCount":103},[],{"intervention":6946,"totalTrials":175,"cells":6947},"Colchicine 0.5 MG twice day for one year",{"EARLY_PHASE1":6948,"PHASE1":6950,"PHASE2":6952,"PHASE3":6962,"PHASE4":6964,"NA":6966},{"trials":6949,"activeCount":103},[],{"trials":6951,"activeCount":103},[],{"trials":6953,"activeCount":103},[6954],{"nctId":6955,"briefTitle":6956,"status":193,"phases":6957,"primaryCompletion":4432,"completion":4759,"start":1526,"enrollment":235,"conditions":6958,"interventions":6961},"NCT03704181","Colchicine for Patients With Chagas´ Disease( B1 Stage)",[92],[6959,6960],"Chagas Disease","Colchicine Resistance",[6946],{"trials":6963,"activeCount":103},[],{"trials":6965,"activeCount":103},[],{"trials":6967,"activeCount":103},[],{"intervention":6969,"totalTrials":175,"cells":6970},"Intravitreal injection of ranibizumab",{"EARLY_PHASE1":6971,"PHASE1":6973,"PHASE2":6975,"PHASE3":6983,"PHASE4":6985,"NA":6987},{"trials":6972,"activeCount":103},[],{"trials":6974,"activeCount":103},[],{"trials":6976,"activeCount":103},[6977],{"nctId":6978,"briefTitle":6979,"status":193,"phases":6980,"primaryCompletion":1642,"completion":1642,"start":3438,"enrollment":1015,"conditions":6981,"interventions":6982},"NCT00993525","Intravitreal Ranibizumab For Persistent New Vessels In Diabetic Retinopathy(Inipe Study)",[91,92],[2277],[6969],{"trials":6984,"activeCount":103},[],{"trials":6986,"activeCount":103},[],{"trials":6988,"activeCount":103},[],{"intervention":6990,"totalTrials":175,"cells":6991},"convalescent plasma",{"EARLY_PHASE1":6992,"PHASE1":6994,"PHASE2":6996,"PHASE3":7007,"PHASE4":7009,"NA":7011},{"trials":6993,"activeCount":103},[],{"trials":6995,"activeCount":103},[],{"trials":6997,"activeCount":103},[6998],{"nctId":6999,"briefTitle":7000,"status":165,"phases":7001,"primaryCompletion":7002,"completion":7002,"start":7003,"enrollment":7004,"conditions":7005,"interventions":7006},"NCT04415086","Treatment of Patients With COVID-19 With Convalescent Plasma",[92],"2022-02-15","2020-06-01",129,[3576],[6990],{"trials":7008,"activeCount":103},[],{"trials":7010,"activeCount":103},[],{"trials":7012,"activeCount":103},[],{"intervention":7014,"totalTrials":175,"cells":7015},"Transdermal testosterone",{"EARLY_PHASE1":7016,"PHASE1":7018,"PHASE2":7020,"PHASE3":7035,"PHASE4":7037,"NA":7039},{"trials":7017,"activeCount":103},[],{"trials":7019,"activeCount":103},[],{"trials":7021,"activeCount":103},[7022],{"nctId":7023,"briefTitle":7024,"status":193,"phases":7025,"primaryCompletion":7026,"completion":7027,"start":4983,"enrollment":7028,"conditions":7029,"interventions":7033},"NCT06794346","Sexual Effects of Transdermal or Vaginal Testosterone",[92],"2024-10-01","2025-11-01",132,[7030,7031,866,7032],"Female Sexual Dysfunction","Postmenopausal Symptoms","Testosterone Adverse Reaction",[7014,7034],"Vaginal testosterone gel",{"trials":7036,"activeCount":103},[],{"trials":7038,"activeCount":103},[],{"trials":7040,"activeCount":103},[],{"intervention":7034,"totalTrials":175,"cells":7042},{"EARLY_PHASE1":7043,"PHASE1":7045,"PHASE2":7047,"PHASE3":7053,"PHASE4":7055,"NA":7057},{"trials":7044,"activeCount":103},[],{"trials":7046,"activeCount":103},[],{"trials":7048,"activeCount":103},[7049],{"nctId":7023,"briefTitle":7024,"status":193,"phases":7050,"primaryCompletion":7026,"completion":7027,"start":4983,"enrollment":7028,"conditions":7051,"interventions":7052},[92],[7030,7031,866,7032],[7014,7034],{"trials":7054,"activeCount":103},[],{"trials":7056,"activeCount":103},[],{"trials":7058,"activeCount":103},[],{"intervention":7060,"totalTrials":175,"cells":7061},"Endodontic treatment using Vitapex",{"EARLY_PHASE1":7062,"PHASE1":7064,"PHASE2":7066,"PHASE3":7076,"PHASE4":7078,"NA":7080},{"trials":7063,"activeCount":103},[],{"trials":7065,"activeCount":103},[],{"trials":7067,"activeCount":103},[7068],{"nctId":7069,"briefTitle":7070,"status":165,"phases":7071,"primaryCompletion":2443,"completion":2443,"start":1997,"enrollment":3416,"conditions":7072,"interventions":7074},"NCT02887456","Endodontic Treatment of Primary Teeth Using Mineral Trioxide Aggregate Paste",[92],[7073],"Teeth, Endodontically-Treated",[7060,7075],"Endodontic treatment using MTA paste",{"trials":7077,"activeCount":103},[],{"trials":7079,"activeCount":103},[],{"trials":7081,"activeCount":103},[],{"intervention":7075,"totalTrials":175,"cells":7083},{"EARLY_PHASE1":7084,"PHASE1":7086,"PHASE2":7088,"PHASE3":7094,"PHASE4":7096,"NA":7098},{"trials":7085,"activeCount":103},[],{"trials":7087,"activeCount":103},[],{"trials":7089,"activeCount":103},[7090],{"nctId":7069,"briefTitle":7070,"status":165,"phases":7091,"primaryCompletion":2443,"completion":2443,"start":1997,"enrollment":3416,"conditions":7092,"interventions":7093},[92],[7073],[7060,7075],{"trials":7095,"activeCount":103},[],{"trials":7097,"activeCount":103},[],{"trials":7099,"activeCount":103},[],{"intervention":7101,"totalTrials":175,"cells":7102},"Medical treatment",{"EARLY_PHASE1":7103,"PHASE1":7105,"PHASE2":7107,"PHASE3":7116,"PHASE4":7118,"NA":7120},{"trials":7104,"activeCount":103},[],{"trials":7106,"activeCount":103},[],{"trials":7108,"activeCount":103},[7109],{"nctId":7110,"briefTitle":7111,"status":165,"phases":7112,"primaryCompletion":3202,"completion":3202,"start":6629,"enrollment":17,"conditions":7113,"interventions":7115},"NCT01887223","Transconjunctival Needling Revision Versus Medical Treatment",[92],[7114],"Primary Open Angle Glaucoma",[7101],{"trials":7117,"activeCount":103},[],{"trials":7119,"activeCount":103},[],{"trials":7121,"activeCount":103},[],{"intervention":7123,"totalTrials":175,"cells":7124},"Nandrolone Decanoate",{"EARLY_PHASE1":7125,"PHASE1":7127,"PHASE2":7129,"PHASE3":7142,"PHASE4":7144,"NA":7146},{"trials":7126,"activeCount":103},[],{"trials":7128,"activeCount":103},[],{"trials":7130,"activeCount":103},[7131],{"nctId":7132,"briefTitle":7133,"status":165,"phases":7134,"primaryCompletion":834,"completion":834,"start":7135,"enrollment":32,"conditions":7136,"interventions":7141},"NCT02055456","Nandrolone Decanoate in the Treatment of Telomeropathies",[91,92],"2014-02-01",[7137,7138,7139,7140],"Aplastic Anemia","Bone Marrow Failure Syndromes","Idiopathic Pulmonary Fibrosis","Telomere Shortening",[7123],{"trials":7143,"activeCount":103},[],{"trials":7145,"activeCount":103},[],{"trials":7147,"activeCount":103},[],{"intervention":7149,"totalTrials":175,"cells":7150},"Chloroquine",{"EARLY_PHASE1":7151,"PHASE1":7153,"PHASE2":7155,"PHASE3":7165,"PHASE4":7167,"NA":7169},{"trials":7152,"activeCount":103},[],{"trials":7154,"activeCount":103},[],{"trials":7156,"activeCount":103},[7157],{"nctId":7158,"briefTitle":7159,"status":193,"phases":7160,"primaryCompletion":7161,"completion":1876,"start":4233,"enrollment":7028,"conditions":7162,"interventions":7164},"NCT00849602","The Effect of Chloroquine in the Treatment of Patients With Dengue",[91,92],"2008-05",[7163],"Dengue",[7149],{"trials":7166,"activeCount":103},[],{"trials":7168,"activeCount":103},[],{"trials":7170,"activeCount":103},[],{"intervention":7172,"totalTrials":175,"cells":7173},"Ascorbic Acid",{"EARLY_PHASE1":7174,"PHASE1":7176,"PHASE2":7178,"PHASE3":7188,"PHASE4":7190,"NA":7192},{"trials":7175,"activeCount":103},[],{"trials":7177,"activeCount":103},[],{"trials":7179,"activeCount":103},[7180],{"nctId":7181,"briefTitle":7182,"status":165,"phases":7183,"primaryCompletion":2070,"completion":2738,"start":7184,"enrollment":1633,"conditions":7185,"interventions":7187},"NCT01270152","Determining the Safe Dosage of Ascorbic Acid Used in the Treatment of Occluded Totally Implanted Central Venous Catheter",[92],"2008-10",[7186],"Occluded Totally Implanted Central Venous Catheter",[7172],{"trials":7189,"activeCount":103},[],{"trials":7191,"activeCount":103},[],{"trials":7193,"activeCount":103},[],{"intervention":7195,"totalTrials":175,"cells":7196},"Cochlear Implantation+dexamethasone",{"EARLY_PHASE1":7197,"PHASE1":7199,"PHASE2":7201,"PHASE3":7211,"PHASE4":7213,"NA":7215},{"trials":7198,"activeCount":103},[],{"trials":7200,"activeCount":103},[],{"trials":7202,"activeCount":103},[7203],{"nctId":7204,"briefTitle":7205,"status":165,"phases":7206,"primaryCompletion":4496,"completion":2081,"start":1822,"enrollment":3393,"conditions":7207,"interventions":7209},"NCT01588925","Hearing Preservation Using Dexamethasone and Hyaluronic Acid for Cochlear Implantation",[92],[7208],"Hearing Loss",[7195,7210],"Cochlear Implantation+dexamethasone+hyaluronic acid",{"trials":7212,"activeCount":103},[],{"trials":7214,"activeCount":103},[],{"trials":7216,"activeCount":103},[],{"intervention":7210,"totalTrials":175,"cells":7218},{"EARLY_PHASE1":7219,"PHASE1":7221,"PHASE2":7223,"PHASE3":7229,"PHASE4":7231,"NA":7233},{"trials":7220,"activeCount":103},[],{"trials":7222,"activeCount":103},[],{"trials":7224,"activeCount":103},[7225],{"nctId":7204,"briefTitle":7205,"status":165,"phases":7226,"primaryCompletion":4496,"completion":2081,"start":1822,"enrollment":3393,"conditions":7227,"interventions":7228},[92],[7208],[7195,7210],{"trials":7230,"activeCount":103},[],{"trials":7232,"activeCount":103},[],{"trials":7234,"activeCount":103},[],{"intervention":7236,"totalTrials":175,"cells":7237},"EPP-AF Gel 1%",{"EARLY_PHASE1":7238,"PHASE1":7240,"PHASE2":7242,"PHASE3":7255,"PHASE4":7257,"NA":7259},{"trials":7239,"activeCount":103},[],{"trials":7241,"activeCount":103},[],{"trials":7243,"activeCount":103},[7244],{"nctId":7245,"briefTitle":7246,"status":193,"phases":7247,"primaryCompletion":3106,"completion":7248,"start":7249,"enrollment":170,"conditions":7250,"interventions":7252},"NCT03024502","Patients With Vulvovaginal Candidiasis",[91,92],"2020-06","2018-01-30",[7251],"Vulvovaginal Candidiasis",[7236,7253,7254],"EPP-AF Gel 2%","Clotrimazole",{"trials":7256,"activeCount":103},[],{"trials":7258,"activeCount":103},[],{"trials":7260,"activeCount":103},[],{"intervention":7253,"totalTrials":175,"cells":7262},{"EARLY_PHASE1":7263,"PHASE1":7265,"PHASE2":7267,"PHASE3":7273,"PHASE4":7275,"NA":7277},{"trials":7264,"activeCount":103},[],{"trials":7266,"activeCount":103},[],{"trials":7268,"activeCount":103},[7269],{"nctId":7245,"briefTitle":7246,"status":193,"phases":7270,"primaryCompletion":3106,"completion":7248,"start":7249,"enrollment":170,"conditions":7271,"interventions":7272},[91,92],[7251],[7236,7253,7254],{"trials":7274,"activeCount":103},[],{"trials":7276,"activeCount":103},[],{"trials":7278,"activeCount":103},[],{"intervention":7254,"totalTrials":175,"cells":7280},{"EARLY_PHASE1":7281,"PHASE1":7283,"PHASE2":7285,"PHASE3":7291,"PHASE4":7293,"NA":7295},{"trials":7282,"activeCount":103},[],{"trials":7284,"activeCount":103},[],{"trials":7286,"activeCount":103},[7287],{"nctId":7245,"briefTitle":7246,"status":193,"phases":7288,"primaryCompletion":3106,"completion":7248,"start":7249,"enrollment":170,"conditions":7289,"interventions":7290},[91,92],[7251],[7236,7253,7254],{"trials":7292,"activeCount":103},[],{"trials":7294,"activeCount":103},[],{"trials":7296,"activeCount":103},[],{"intervention":1829,"totalTrials":175,"cells":7298},{"EARLY_PHASE1":7299,"PHASE1":7301,"PHASE2":7303,"PHASE3":7309,"PHASE4":7311,"NA":7313},{"trials":7300,"activeCount":103},[],{"trials":7302,"activeCount":103},[],{"trials":7304,"activeCount":103},[7305],{"nctId":1818,"briefTitle":1819,"status":165,"phases":7306,"primaryCompletion":1821,"completion":1822,"start":1823,"enrollment":1824,"conditions":7307,"interventions":7308},[92],[1826,1827,1828,1829],[1809,1829],{"trials":7310,"activeCount":103},[],{"trials":7312,"activeCount":103},[],{"trials":7314,"activeCount":103},[],{"intervention":7316,"totalTrials":175,"cells":7317},"Ibogaine Hydrochloride",{"EARLY_PHASE1":7318,"PHASE1":7320,"PHASE2":7322,"PHASE3":7332,"PHASE4":7334,"NA":7336},{"trials":7319,"activeCount":103},[],{"trials":7321,"activeCount":103},[],{"trials":7323,"activeCount":103},[7324],{"nctId":7325,"briefTitle":7326,"status":165,"phases":7327,"primaryCompletion":1012,"completion":1012,"start":1014,"enrollment":7328,"conditions":7329,"interventions":7331},"NCT03380728","Ibogaine in the Treatment of Alcoholism: an Open-label Escalating-dose Trial",[92],9,[7330],"Alcoholism",[7316],{"trials":7333,"activeCount":103},[],{"trials":7335,"activeCount":103},[],{"trials":7337,"activeCount":103},[],{"intervention":7339,"totalTrials":175,"cells":7340},"centrifuged fat graft",{"EARLY_PHASE1":7341,"PHASE1":7343,"PHASE2":7345,"PHASE3":7358,"PHASE4":7360,"NA":7362},{"trials":7342,"activeCount":103},[],{"trials":7344,"activeCount":103},[],{"trials":7346,"activeCount":103},[7347],{"nctId":7348,"briefTitle":7349,"status":165,"phases":7350,"primaryCompletion":3795,"completion":2033,"start":7351,"enrollment":32,"conditions":7352,"interventions":7356},"NCT01771913","Immunophenotyping of Fresh Stromal Vascular Fraction From Adipose Derived Stem Cells (ADSC) Enriched Fat Grafts",[92],"2012-03",[7353,7354,7355],"Breast Reconstruction","Contour Irregularities","Volume Insufficiency",[7339,7357],"ADSCs enriched fat graft",{"trials":7359,"activeCount":103},[],{"trials":7361,"activeCount":103},[],{"trials":7363,"activeCount":103},[],{"intervention":7357,"totalTrials":175,"cells":7365},{"EARLY_PHASE1":7366,"PHASE1":7368,"PHASE2":7370,"PHASE3":7376,"PHASE4":7378,"NA":7380},{"trials":7367,"activeCount":103},[],{"trials":7369,"activeCount":103},[],{"trials":7371,"activeCount":103},[7372],{"nctId":7348,"briefTitle":7349,"status":165,"phases":7373,"primaryCompletion":3795,"completion":2033,"start":7351,"enrollment":32,"conditions":7374,"interventions":7375},[92],[7353,7354,7355],[7339,7357],{"trials":7377,"activeCount":103},[],{"trials":7379,"activeCount":103},[],{"trials":7381,"activeCount":103},[],{"intervention":7383,"totalTrials":175,"cells":7384},"DC",{"EARLY_PHASE1":7385,"PHASE1":7387,"PHASE2":7389,"PHASE3":7400,"PHASE4":7402,"NA":7404},{"trials":7386,"activeCount":103},[],{"trials":7388,"activeCount":103},[],{"trials":7390,"activeCount":103},[7391],{"nctId":7392,"briefTitle":7393,"status":165,"phases":7394,"primaryCompletion":1761,"completion":1761,"start":2944,"enrollment":35,"conditions":7395,"interventions":7397},"NCT02766049","Study of Anti-HIV Cellular Therapy Based on Dendritic Cells Pulsed With Chemically Inactivated Virus",[91,92],[7396],"HIV Infection",[7383,7398,7399],"DC10e6+HIV-AT2","DC10e7+HIV-AT2",{"trials":7401,"activeCount":103},[],{"trials":7403,"activeCount":103},[],{"trials":7405,"activeCount":103},[],{"intervention":7398,"totalTrials":175,"cells":7407},{"EARLY_PHASE1":7408,"PHASE1":7410,"PHASE2":7412,"PHASE3":7418,"PHASE4":7420,"NA":7422},{"trials":7409,"activeCount":103},[],{"trials":7411,"activeCount":103},[],{"trials":7413,"activeCount":103},[7414],{"nctId":7392,"briefTitle":7393,"status":165,"phases":7415,"primaryCompletion":1761,"completion":1761,"start":2944,"enrollment":35,"conditions":7416,"interventions":7417},[91,92],[7396],[7383,7398,7399],{"trials":7419,"activeCount":103},[],{"trials":7421,"activeCount":103},[],{"trials":7423,"activeCount":103},[],{"intervention":7399,"totalTrials":175,"cells":7425},{"EARLY_PHASE1":7426,"PHASE1":7428,"PHASE2":7430,"PHASE3":7436,"PHASE4":7438,"NA":7440},{"trials":7427,"activeCount":103},[],{"trials":7429,"activeCount":103},[],{"trials":7431,"activeCount":103},[7432],{"nctId":7392,"briefTitle":7393,"status":165,"phases":7433,"primaryCompletion":1761,"completion":1761,"start":2944,"enrollment":35,"conditions":7434,"interventions":7435},[91,92],[7396],[7383,7398,7399],{"trials":7437,"activeCount":103},[],{"trials":7439,"activeCount":103},[],{"trials":7441,"activeCount":103},[],{"intervention":7443,"totalTrials":175,"cells":7444},"Propranolol",{"EARLY_PHASE1":7445,"PHASE1":7447,"PHASE2":7449,"PHASE3":7459,"PHASE4":7461,"NA":7463},{"trials":7446,"activeCount":103},[],{"trials":7448,"activeCount":103},[],{"trials":7450,"activeCount":103},[7451],{"nctId":7452,"briefTitle":7453,"status":165,"phases":7454,"primaryCompletion":6800,"completion":6800,"start":1914,"enrollment":388,"conditions":7455,"interventions":7457},"NCT01072045","Comparative Study of the Use of Beta Blocker and Oral Corticosteroid in the Treatment of Infantile Hemangioma",[92],[7456],"Hemangioma",[7443,7458],"Prednisone",{"trials":7460,"activeCount":103},[],{"trials":7462,"activeCount":103},[],{"trials":7464,"activeCount":103},[],{"intervention":7466,"totalTrials":175,"cells":7467},"BSSPlus solution",{"EARLY_PHASE1":7468,"PHASE1":7470,"PHASE2":7472,"PHASE3":7483,"PHASE4":7485,"NA":7487},{"trials":7469,"activeCount":103},[],{"trials":7471,"activeCount":103},[],{"trials":7473,"activeCount":103},[7474],{"nctId":7475,"briefTitle":7476,"status":165,"phases":7477,"primaryCompletion":7478,"completion":7184,"start":3731,"enrollment":1237,"conditions":7479,"interventions":7481},"NCT00801359","BSSPlus Versus Lactated Ringer's for Phacoemulsification",[92],"2008-08",[7480],"Cataract",[7466,7482],"Lactated Ringer's solution",{"trials":7484,"activeCount":103},[],{"trials":7486,"activeCount":103},[],{"trials":7488,"activeCount":103},[],{"intervention":7482,"totalTrials":175,"cells":7490},{"EARLY_PHASE1":7491,"PHASE1":7493,"PHASE2":7495,"PHASE3":7501,"PHASE4":7503,"NA":7505},{"trials":7492,"activeCount":103},[],{"trials":7494,"activeCount":103},[],{"trials":7496,"activeCount":103},[7497],{"nctId":7475,"briefTitle":7476,"status":165,"phases":7498,"primaryCompletion":7478,"completion":7184,"start":3731,"enrollment":1237,"conditions":7499,"interventions":7500},[92],[7480],[7466,7482],{"trials":7502,"activeCount":103},[],{"trials":7504,"activeCount":103},[],{"trials":7506,"activeCount":103},[],{"intervention":4965,"totalTrials":175,"cells":7508},{"EARLY_PHASE1":7509,"PHASE1":7511,"PHASE2":7513,"PHASE3":7519,"PHASE4":7521,"NA":7523},{"trials":7510,"activeCount":103},[],{"trials":7512,"activeCount":103},[],{"trials":7514,"activeCount":103},[7515],{"nctId":4955,"briefTitle":4956,"status":165,"phases":7516,"conditions":7517,"interventions":7518},[92],[4959,4960,4961],[4963,4964,4965],{"trials":7520,"activeCount":103},[],{"trials":7522,"activeCount":103},[],{"trials":7524,"activeCount":103},[],{"intervention":7526,"totalTrials":175,"cells":7527},"Synovial Tissue and Fat Pad Stromal Vascular Fraction",{"EARLY_PHASE1":7528,"PHASE1":7530,"PHASE2":7532,"PHASE3":7545,"PHASE4":7547,"NA":7549},{"trials":7529,"activeCount":103},[],{"trials":7531,"activeCount":103},[],{"trials":7533,"activeCount":103},[7534],{"nctId":7535,"briefTitle":7536,"status":193,"phases":7537,"primaryCompletion":7538,"completion":77,"start":7539,"enrollment":1003,"conditions":7540,"interventions":7544},"NCT05120700","Synovial Tissue and Fat Pad Stromal Vascular Fraction Bioengineering in Patients With Knee Articular Cartilage Injury",[91,92],"2025-04","2022-04",[7541,7542,7543],"Cell- and Tissue-Based Therapy","Cartilage Injury","Knee Injuries",[7526],{"trials":7546,"activeCount":103},[],{"trials":7548,"activeCount":103},[],{"trials":7550,"activeCount":103},[],{"intervention":7552,"totalTrials":175,"cells":7553},"acetylsalicylic acid",{"EARLY_PHASE1":7554,"PHASE1":7556,"PHASE2":7558,"PHASE3":7571,"PHASE4":7573,"NA":7575},{"trials":7555,"activeCount":103},[],{"trials":7557,"activeCount":103},[],{"trials":7559,"activeCount":103},[7560],{"nctId":7561,"briefTitle":7562,"status":193,"phases":7563,"primaryCompletion":7564,"completion":7565,"start":7566,"enrollment":7567,"conditions":7568,"interventions":7569},"NCT04466670","Hemostasis in COVID-19: an Adaptive Clinical Trial",[92],"2021-12-30","2022-05-30","2020-07-11",379,[3576],[7552,7570],"Unfractionated heparin nebulized",{"trials":7572,"activeCount":103},[],{"trials":7574,"activeCount":103},[],{"trials":7576,"activeCount":103},[],{"intervention":7570,"totalTrials":175,"cells":7578},{"EARLY_PHASE1":7579,"PHASE1":7581,"PHASE2":7583,"PHASE3":7589,"PHASE4":7591,"NA":7593},{"trials":7580,"activeCount":103},[],{"trials":7582,"activeCount":103},[],{"trials":7584,"activeCount":103},[7585],{"nctId":7561,"briefTitle":7562,"status":193,"phases":7586,"primaryCompletion":7564,"completion":7565,"start":7566,"enrollment":7567,"conditions":7587,"interventions":7588},[92],[3576],[7552,7570],{"trials":7590,"activeCount":103},[],{"trials":7592,"activeCount":103},[],{"trials":7594,"activeCount":103},[],{"intervention":7596,"totalTrials":175,"cells":7597},"Mesenchymal stem cell",{"EARLY_PHASE1":7598,"PHASE1":7600,"PHASE2":7602,"PHASE3":7615,"PHASE4":7617,"NA":7619},{"trials":7599,"activeCount":103},[],{"trials":7601,"activeCount":103},[],{"trials":7603,"activeCount":103},[7604],{"nctId":7605,"briefTitle":7606,"status":2670,"phases":7607,"primaryCompletion":7608,"completion":7608,"start":7609,"enrollment":2945,"conditions":7610,"interventions":7614},"NCT03362424","Mesenchymal Stem Cells in Rotator Cuff Repair",[92],"2023-12-01","2020-11-01",[7611,7612,7613],"Rotator Cuff Tear","Tendon Injuries","Mesenchymal Stem Cell",[7596],{"trials":7616,"activeCount":103},[],{"trials":7618,"activeCount":103},[],{"trials":7620,"activeCount":103},[],{"intervention":7622,"totalTrials":175,"cells":7623},"Silver Nitrate",{"EARLY_PHASE1":7624,"PHASE1":7626,"PHASE2":7628,"PHASE3":7638,"PHASE4":7640,"NA":7642},{"trials":7625,"activeCount":103},[],{"trials":7627,"activeCount":103},[],{"trials":7629,"activeCount":103},[7630],{"nctId":7631,"briefTitle":7632,"status":193,"phases":7633,"primaryCompletion":3172,"completion":3172,"start":7634,"enrollment":235,"conditions":7635,"interventions":7637},"NCT01125124","Safety and Effectiveness Study for Pleurodesis With Silver Nitrate in Malignant Pleural Effusion",[92],"2009-08",[7636],"Malignant Pleural Effusion",[7622],{"trials":7639,"activeCount":103},[],{"trials":7641,"activeCount":103},[],{"trials":7643,"activeCount":103},[],{"intervention":7645,"totalTrials":175,"cells":7646},"NaCl 7,5%",{"EARLY_PHASE1":7647,"PHASE1":7649,"PHASE2":7651,"PHASE3":7662,"PHASE4":7664,"NA":7666},{"trials":7648,"activeCount":103},[],{"trials":7650,"activeCount":103},[],{"trials":7652,"activeCount":103},[7653],{"nctId":7654,"briefTitle":7655,"status":165,"phases":7656,"primaryCompletion":2944,"completion":3172,"start":4233,"enrollment":1903,"conditions":7657,"interventions":7660},"NCT00555685","Hypertonic Saline Solution in Heart Failure",[92],[19,7658,7659],"Renal Failure","Hyponatremia",[7645,7661],"NaCl 0,9%",{"trials":7663,"activeCount":103},[],{"trials":7665,"activeCount":103},[],{"trials":7667,"activeCount":103},[],{"intervention":7661,"totalTrials":175,"cells":7669},{"EARLY_PHASE1":7670,"PHASE1":7672,"PHASE2":7674,"PHASE3":7680,"PHASE4":7682,"NA":7684},{"trials":7671,"activeCount":103},[],{"trials":7673,"activeCount":103},[],{"trials":7675,"activeCount":103},[7676],{"nctId":7654,"briefTitle":7655,"status":165,"phases":7677,"primaryCompletion":2944,"completion":3172,"start":4233,"enrollment":1903,"conditions":7678,"interventions":7679},[92],[19,7658,7659],[7645,7661],{"trials":7681,"activeCount":103},[],{"trials":7683,"activeCount":103},[],{"trials":7685,"activeCount":103},[],{"intervention":7687,"totalTrials":175,"cells":7688},"Intravenous bone marrow mesenchymal stem cells",{"EARLY_PHASE1":7689,"PHASE1":7691,"PHASE2":7693,"PHASE3":7701,"PHASE4":7703,"NA":7705},{"trials":7690,"activeCount":103},[],{"trials":7692,"activeCount":103},[],{"trials":7694,"activeCount":103},[7695],{"nctId":7696,"briefTitle":7697,"status":165,"phases":7698,"primaryCompletion":3622,"completion":3622,"start":3909,"enrollment":7328,"conditions":7699,"interventions":7700},"NCT01297972","Mesenchymal Stem Cells in the Treatment of Relapsed\u002FRefractory Severe Acquired Aplastic Anemia",[91,92],[7137],[7687],{"trials":7702,"activeCount":103},[],{"trials":7704,"activeCount":103},[],{"trials":7706,"activeCount":103},[],{"intervention":7708,"totalTrials":175,"cells":7709},"Intravenous Mesenchymal stem cell",{"EARLY_PHASE1":7710,"PHASE1":7712,"PHASE2":7714,"PHASE3":7723,"PHASE4":7725,"NA":7727},{"trials":7711,"activeCount":103},[],{"trials":7713,"activeCount":103},[],{"trials":7715,"activeCount":103},[7716],{"nctId":7717,"briefTitle":7718,"status":193,"phases":7719,"primaryCompletion":1760,"completion":1841,"start":3438,"enrollment":1003,"conditions":7720,"interventions":7722},"NCT01322789","Safety and Efficacy of Mesenchymal Stem Cells in Newly-diagnosed Type 1 Diabetic Patients",[91,92],[7721],"Diabetes Mellitus, Insulin-Dependent",[7708],{"trials":7724,"activeCount":103},[],{"trials":7726,"activeCount":103},[],{"trials":7728,"activeCount":103},[],{"intervention":1532,"totalTrials":175,"cells":7730},{"EARLY_PHASE1":7731,"PHASE1":7733,"PHASE2":7735,"PHASE3":7741,"PHASE4":7743,"NA":7745},{"trials":7732,"activeCount":103},[],{"trials":7734,"activeCount":103},[],{"trials":7736,"activeCount":103},[7737],{"nctId":1521,"briefTitle":1522,"status":193,"phases":7738,"primaryCompletion":1524,"completion":1525,"start":1526,"enrollment":1527,"conditions":7739,"interventions":7740},[92],[1529,1530],[1532,1512],{"trials":7742,"activeCount":103},[],{"trials":7744,"activeCount":103},[],{"trials":7746,"activeCount":103},[],{"intervention":7748,"totalTrials":175,"cells":7749},"Methotrexate Injectable Solution",{"EARLY_PHASE1":7750,"PHASE1":7752,"PHASE2":7754,"PHASE3":7766,"PHASE4":7768,"NA":7770},{"trials":7751,"activeCount":103},[],{"trials":7753,"activeCount":103},[],{"trials":7755,"activeCount":103},[7756],{"nctId":7757,"briefTitle":7758,"status":193,"phases":7759,"primaryCompletion":6926,"completion":7760,"start":7761,"enrollment":12,"conditions":7762,"interventions":7765},"NCT04622956","GVHD Prophylaxis With Methotrexate in Haploidentical HCT Using Posttransplant Cyclophosphamide",[91,92],"2025-12","2020-10-07",[7763,7764],"Graft Vs Host Disease","Hematopoietic Neoplasm",[7748],{"trials":7767,"activeCount":103},[],{"trials":7769,"activeCount":103},[],{"trials":7771,"activeCount":103},[],{"intervention":7773,"totalTrials":175,"cells":7774},"Ozone",{"EARLY_PHASE1":7775,"PHASE1":7777,"PHASE2":7779,"PHASE3":7789,"PHASE4":7791,"NA":7793},{"trials":7776,"activeCount":103},[],{"trials":7778,"activeCount":103},[],{"trials":7780,"activeCount":103},[7781],{"nctId":7782,"briefTitle":7783,"status":165,"phases":7784,"primaryCompletion":2009,"completion":1969,"start":1875,"enrollment":235,"conditions":7785,"interventions":7787},"NCT00946634","Ozone Therapy in Endodontic Practice, in Vivo Study",[92],[7786],"Primary Apical Periodontite",[7773,6033,7788],"Aqueous Ozone",{"trials":7790,"activeCount":103},[],{"trials":7792,"activeCount":103},[],{"trials":7794,"activeCount":103},[],{"intervention":7788,"totalTrials":175,"cells":7796},{"EARLY_PHASE1":7797,"PHASE1":7799,"PHASE2":7801,"PHASE3":7807,"PHASE4":7809,"NA":7811},{"trials":7798,"activeCount":103},[],{"trials":7800,"activeCount":103},[],{"trials":7802,"activeCount":103},[7803],{"nctId":7782,"briefTitle":7783,"status":165,"phases":7804,"primaryCompletion":2009,"completion":1969,"start":1875,"enrollment":235,"conditions":7805,"interventions":7806},[92],[7786],[7773,6033,7788],{"trials":7808,"activeCount":103},[],{"trials":7810,"activeCount":103},[],{"trials":7812,"activeCount":103},[],{"intervention":7814,"totalTrials":175,"cells":7815},"Pycnogenol Oral Product",{"EARLY_PHASE1":7816,"PHASE1":7818,"PHASE2":7820,"PHASE3":7831,"PHASE4":7833,"NA":7835},{"trials":7817,"activeCount":103},[],{"trials":7819,"activeCount":103},[],{"trials":7821,"activeCount":103},[7822],{"nctId":7823,"briefTitle":7824,"status":193,"phases":7825,"primaryCompletion":7826,"completion":168,"start":2396,"enrollment":7827,"conditions":7828,"interventions":7830},"NCT04203043","The Prevstain Trial",[92],"2020-03-28",338,[7829],"Varicose Veins",[7814],{"trials":7832,"activeCount":103},[],{"trials":7834,"activeCount":103},[],{"trials":7836,"activeCount":103},[],{"intervention":7838,"totalTrials":175,"cells":7839},"Bifidobacterium animalis subsp. lactis HN019",{"EARLY_PHASE1":7840,"PHASE1":7842,"PHASE2":7844,"PHASE3":7857,"PHASE4":7859,"NA":7861},{"trials":7841,"activeCount":103},[],{"trials":7843,"activeCount":103},[],{"trials":7845,"activeCount":103},[7846],{"nctId":7847,"briefTitle":7848,"status":165,"phases":7849,"primaryCompletion":7850,"completion":7851,"start":7852,"enrollment":1015,"conditions":7853,"interventions":7855},"NCT03386643","Effect of Bifidobacterium Animalis Subsp. Lactis HN019 on Oral Lichen Planus",[92],"2018-04-05","2019-12-06","2017-11-06",[7854],"Oral Lichen Planus",[7838,7856],"Clobetasol propionate 0.05%",{"trials":7858,"activeCount":103},[],{"trials":7860,"activeCount":103},[],{"trials":7862,"activeCount":103},[],{"intervention":7856,"totalTrials":175,"cells":7864},{"EARLY_PHASE1":7865,"PHASE1":7867,"PHASE2":7869,"PHASE3":7875,"PHASE4":7877,"NA":7879},{"trials":7866,"activeCount":103},[],{"trials":7868,"activeCount":103},[],{"trials":7870,"activeCount":103},[7871],{"nctId":7847,"briefTitle":7848,"status":165,"phases":7872,"primaryCompletion":7850,"completion":7851,"start":7852,"enrollment":1015,"conditions":7873,"interventions":7874},[92],[7854],[7838,7856],{"trials":7876,"activeCount":103},[],{"trials":7878,"activeCount":103},[],{"trials":7880,"activeCount":103},[],{"intervention":7882,"totalTrials":175,"cells":7883},"Topiramate",{"EARLY_PHASE1":7884,"PHASE1":7886,"PHASE2":7888,"PHASE3":7898,"PHASE4":7900,"NA":7902},{"trials":7885,"activeCount":103},[],{"trials":7887,"activeCount":103},[],{"trials":7889,"activeCount":103},[7890],{"nctId":7891,"briefTitle":7892,"status":165,"phases":7893,"primaryCompletion":1556,"completion":1556,"start":2048,"enrollment":7894,"conditions":7895,"interventions":7897},"NCT02138058","Topiramate Trial for Compulsive Buying",[92],42,[7896],"Compulsive Shopping",[7882],{"trials":7899,"activeCount":103},[],{"trials":7901,"activeCount":103},[],{"trials":7903,"activeCount":103},[],{"intervention":7905,"totalTrials":175,"cells":7906},"Midazolam",{"EARLY_PHASE1":7907,"PHASE1":7909,"PHASE2":7911,"PHASE3":7923,"PHASE4":7925,"NA":7927},{"trials":7908,"activeCount":103},[],{"trials":7910,"activeCount":103},[],{"trials":7912,"activeCount":103},[7913],{"nctId":7914,"briefTitle":7915,"status":3950,"phases":7916,"primaryCompletion":2833,"completion":2833,"start":6801,"enrollment":103,"conditions":7917,"interventions":7921},"NCT01402596","Evaluation of Pediatric Procedural Sedation With Rectal Chloral Hydrate or Intranasal Midazolam",[92],[7918,7919,7920],"Traumatic Brain Injury","Computed Tomography","Procedural Sedation",[7905,7922],"Chloral Hydrate",{"trials":7924,"activeCount":103},[],{"trials":7926,"activeCount":103},[],{"trials":7928,"activeCount":103},[],{"intervention":7922,"totalTrials":175,"cells":7930},{"EARLY_PHASE1":7931,"PHASE1":7933,"PHASE2":7935,"PHASE3":7941,"PHASE4":7943,"NA":7945},{"trials":7932,"activeCount":103},[],{"trials":7934,"activeCount":103},[],{"trials":7936,"activeCount":103},[7937],{"nctId":7914,"briefTitle":7915,"status":3950,"phases":7938,"primaryCompletion":2833,"completion":2833,"start":6801,"enrollment":103,"conditions":7939,"interventions":7940},[92],[7918,7919,7920],[7905,7922],{"trials":7942,"activeCount":103},[],{"trials":7944,"activeCount":103},[],{"trials":7946,"activeCount":103},[],{"intervention":7948,"totalTrials":175,"cells":7949},"Sodium nitroprusside",{"EARLY_PHASE1":7950,"PHASE1":7952,"PHASE2":7954,"PHASE3":7965,"PHASE4":7967,"NA":7969},{"trials":7951,"activeCount":103},[],{"trials":7953,"activeCount":103},[],{"trials":7955,"activeCount":103},[7956],{"nctId":7957,"briefTitle":7958,"status":165,"phases":7959,"primaryCompletion":1876,"completion":3172,"start":7960,"enrollment":32,"conditions":7961,"interventions":7963},"NCT01548612","Add-on Sodium Nitroprusside to Treatment as Usual in Schizophrenia",[92],"2006-02",[7962],"Schizophrenia",[7948,7964],"Glucose solution",{"trials":7966,"activeCount":103},[],{"trials":7968,"activeCount":103},[],{"trials":7970,"activeCount":103},[],{"intervention":7964,"totalTrials":175,"cells":7972},{"EARLY_PHASE1":7973,"PHASE1":7975,"PHASE2":7977,"PHASE3":7983,"PHASE4":7985,"NA":7987},{"trials":7974,"activeCount":103},[],{"trials":7976,"activeCount":103},[],{"trials":7978,"activeCount":103},[7979],{"nctId":7957,"briefTitle":7958,"status":165,"phases":7980,"primaryCompletion":1876,"completion":3172,"start":7960,"enrollment":32,"conditions":7981,"interventions":7982},[92],[7962],[7948,7964],{"trials":7984,"activeCount":103},[],{"trials":7986,"activeCount":103},[],{"trials":7988,"activeCount":103},[],{"intervention":7990,"totalTrials":175,"cells":7991},"Mirtazapine",{"EARLY_PHASE1":7992,"PHASE1":7994,"PHASE2":7996,"PHASE3":8009,"PHASE4":8011,"NA":8013},{"trials":7993,"activeCount":103},[],{"trials":7995,"activeCount":103},[],{"trials":7997,"activeCount":103},[7998],{"nctId":7999,"briefTitle":8000,"status":165,"phases":8001,"primaryCompletion":8002,"completion":8002,"start":8003,"enrollment":1604,"conditions":8004,"interventions":8007},"NCT03283488","Comparison Between Mirtazapine and Megestrol for the Control of Anorexia-cachexia in Cancer Patients in Palliative Care.",[92],"2022-02-02","2019-03-26",[8005,8006],"Cachexia; Cancer","Anorexia",[7990,8008],"Megestrol",{"trials":8010,"activeCount":103},[],{"trials":8012,"activeCount":103},[],{"trials":8014,"activeCount":103},[],{"intervention":8008,"totalTrials":175,"cells":8016},{"EARLY_PHASE1":8017,"PHASE1":8019,"PHASE2":8021,"PHASE3":8027,"PHASE4":8029,"NA":8031},{"trials":8018,"activeCount":103},[],{"trials":8020,"activeCount":103},[],{"trials":8022,"activeCount":103},[8023],{"nctId":7999,"briefTitle":8000,"status":165,"phases":8024,"primaryCompletion":8002,"completion":8002,"start":8003,"enrollment":1604,"conditions":8025,"interventions":8026},[92],[8005,8006],[7990,8008],{"trials":8028,"activeCount":103},[],{"trials":8030,"activeCount":103},[],{"trials":8032,"activeCount":103},[],{"intervention":8034,"totalTrials":175,"cells":8035},"Roflumilast",{"EARLY_PHASE1":8036,"PHASE1":8038,"PHASE2":8040,"PHASE3":8049,"PHASE4":8051,"NA":8053},{"trials":8037,"activeCount":103},[],{"trials":8039,"activeCount":103},[],{"trials":8041,"activeCount":103},[8042],{"nctId":8043,"briefTitle":8044,"status":193,"phases":8045,"primaryCompletion":3245,"completion":3245,"start":7851,"enrollment":414,"conditions":8046,"interventions":8048},"NCT03988816","Effect of Roflumilast on Quality of Life, Lung Function and Mucus Properties in Patients With Bronchiectasis",[92],[8047],"Bronchiectasis Adult",[8034],{"trials":8050,"activeCount":103},[],{"trials":8052,"activeCount":103},[],{"trials":8054,"activeCount":103},[],{"intervention":8056,"totalTrials":175,"cells":8057},"Clomiphene Citrate",{"EARLY_PHASE1":8058,"PHASE1":8060,"PHASE2":8062,"PHASE3":8073,"PHASE4":8075,"NA":8077},{"trials":8059,"activeCount":103},[],{"trials":8061,"activeCount":103},[],{"trials":8063,"activeCount":103},[8064],{"nctId":8065,"briefTitle":8066,"status":165,"phases":8067,"primaryCompletion":1839,"completion":1839,"start":8068,"enrollment":8069,"conditions":8070,"interventions":8072},"NCT02380755","Clomiphene Citrate for the Treatment of Obesity Related Male Hypogonadism",[92],"2015-04",78,[16,8071],"Hypoandrogenism",[8056],{"trials":8074,"activeCount":103},[],{"trials":8076,"activeCount":103},[],{"trials":8078,"activeCount":103},[],{"intervention":8080,"totalTrials":175,"cells":8081},"Methotrexate-LDE phase 1",{"EARLY_PHASE1":8082,"PHASE1":8084,"PHASE2":8086,"PHASE3":8099,"PHASE4":8101,"NA":8103},{"trials":8083,"activeCount":103},[],{"trials":8085,"activeCount":103},[],{"trials":8087,"activeCount":103},[8088],{"nctId":8089,"briefTitle":8090,"status":193,"phases":8091,"primaryCompletion":8092,"completion":8093,"start":8094,"enrollment":740,"conditions":8095,"interventions":8097},"NCT04610567","Treatment of Patients With Mild Coronavirus-19 (COVID-19) Disease With Methotrexate Associated to LDL Like Nanoparticles (Nano-COVID19)",[91,92],"2021-03-15","2021-07-15","2020-10-27",[8096,5547,5032],"Coronavirus",[8080,8098],"Methotrexate-LDE phase 2",{"trials":8100,"activeCount":103},[],{"trials":8102,"activeCount":103},[],{"trials":8104,"activeCount":103},[],{"intervention":8098,"totalTrials":175,"cells":8106},{"EARLY_PHASE1":8107,"PHASE1":8109,"PHASE2":8111,"PHASE3":8117,"PHASE4":8119,"NA":8121},{"trials":8108,"activeCount":103},[],{"trials":8110,"activeCount":103},[],{"trials":8112,"activeCount":103},[8113],{"nctId":8089,"briefTitle":8090,"status":193,"phases":8114,"primaryCompletion":8092,"completion":8093,"start":8094,"enrollment":740,"conditions":8115,"interventions":8116},[91,92],[8096,5547,5032],[8080,8098],{"trials":8118,"activeCount":103},[],{"trials":8120,"activeCount":103},[],{"trials":8122,"activeCount":103},[],{"intervention":4975,"totalTrials":175,"cells":8124},{"EARLY_PHASE1":8125,"PHASE1":8127,"PHASE2":8129,"PHASE3":8135,"PHASE4":8137,"NA":8139},{"trials":8126,"activeCount":103},[],{"trials":8128,"activeCount":103},[],{"trials":8130,"activeCount":103},[8131],{"nctId":4967,"briefTitle":4968,"status":165,"phases":8132,"primaryCompletion":4970,"completion":2009,"start":4971,"enrollment":1998,"conditions":8133,"interventions":8134},[92],[4973,4960],[4946,4975],{"trials":8136,"activeCount":103},[],{"trials":8138,"activeCount":103},[],{"trials":8140,"activeCount":103},[],{"intervention":8142,"totalTrials":175,"cells":8143},"Propolis",{"EARLY_PHASE1":8144,"PHASE1":8146,"PHASE2":8148,"PHASE3":8158,"PHASE4":8160,"NA":8162},{"trials":8145,"activeCount":103},[],{"trials":8147,"activeCount":103},[],{"trials":8149,"activeCount":103},[8150],{"nctId":8151,"briefTitle":8152,"status":165,"phases":8153,"primaryCompletion":8154,"completion":8155,"start":3599,"enrollment":1290,"conditions":8156,"interventions":8157},"NCT02766036","Propolis Effects in Patients With Chronic Kidney Disease",[92],"2018-02","2018-03",[548],[8142],{"trials":8159,"activeCount":103},[],{"trials":8161,"activeCount":103},[],{"trials":8163,"activeCount":103},[],{"intervention":8165,"totalTrials":175,"cells":8166},"PRP",{"EARLY_PHASE1":8167,"PHASE1":8169,"PHASE2":8171,"PHASE3":8183,"PHASE4":8185,"NA":8187},{"trials":8168,"activeCount":103},[],{"trials":8170,"activeCount":103},[],{"trials":8172,"activeCount":103},[8173],{"nctId":8174,"briefTitle":8175,"status":193,"phases":8176,"primaryCompletion":8177,"completion":8177,"start":8178,"enrollment":235,"conditions":8179,"interventions":8181},"NCT03138317","Evaluation of Platelet Rich Plasma (PRP) for Knee Osteoarthritis",[92],"2018-05-30","2017-01-02",[8180],"Osteoarthritis, Knee",[8165,8182],"Plasma",{"trials":8184,"activeCount":103},[],{"trials":8186,"activeCount":103},[],{"trials":8188,"activeCount":103},[],{"intervention":8182,"totalTrials":175,"cells":8190},{"EARLY_PHASE1":8191,"PHASE1":8193,"PHASE2":8195,"PHASE3":8201,"PHASE4":8203,"NA":8205},{"trials":8192,"activeCount":103},[],{"trials":8194,"activeCount":103},[],{"trials":8196,"activeCount":103},[8197],{"nctId":8174,"briefTitle":8175,"status":193,"phases":8198,"primaryCompletion":8177,"completion":8177,"start":8178,"enrollment":235,"conditions":8199,"interventions":8200},[92],[8180],[8165,8182],{"trials":8202,"activeCount":103},[],{"trials":8204,"activeCount":103},[],{"trials":8206,"activeCount":103},[],{"intervention":8208,"totalTrials":175,"cells":8209},"Caloric Management Protocol",{"EARLY_PHASE1":8210,"PHASE1":8212,"PHASE2":8214,"PHASE3":8223,"PHASE4":8225,"NA":8227},{"trials":8211,"activeCount":103},[],{"trials":8213,"activeCount":103},[],{"trials":8215,"activeCount":103},[8216],{"nctId":8217,"briefTitle":8218,"status":3950,"phases":8219,"primaryCompletion":1933,"completion":4060,"start":1702,"enrollment":103,"conditions":8220,"interventions":8222},"NCT02534181","Refeeding Syndrome in Cancer Patients",[92],[8221,6453,1530],"Refeeding Syndrome",[8208],{"trials":8224,"activeCount":103},[],{"trials":8226,"activeCount":103},[],{"trials":8228,"activeCount":103},[],{"intervention":8230,"totalTrials":175,"cells":8231},"Memantine",{"EARLY_PHASE1":8232,"PHASE1":8234,"PHASE2":8236,"PHASE3":8247,"PHASE4":8249,"NA":8251},{"trials":8233,"activeCount":103},[],{"trials":8235,"activeCount":103},[],{"trials":8237,"activeCount":103},[8238],{"nctId":8239,"briefTitle":8240,"status":193,"phases":8241,"primaryCompletion":8242,"completion":8243,"start":8244,"enrollment":2945,"conditions":8245,"interventions":8246},"NCT02630888","Efficacy of Memantine add-on in the Treatment of Bipolar Disorder (Type I) Nonresponders or Partial Responders Patients",[92],"2020-04","2020-09","2014-08",[1460],[8230],{"trials":8248,"activeCount":103},[],{"trials":8250,"activeCount":103},[],{"trials":8252,"activeCount":103},[],{"intervention":8254,"totalTrials":175,"cells":8255},"Topiramate flexible dosage",{"EARLY_PHASE1":8256,"PHASE1":8258,"PHASE2":8260,"PHASE3":8270,"PHASE4":8272,"NA":8274},{"trials":8257,"activeCount":103},[],{"trials":8259,"activeCount":103},[],{"trials":8261,"activeCount":103},[8262],{"nctId":8263,"briefTitle":8264,"status":165,"phases":8265,"primaryCompletion":8266,"start":1876,"enrollment":1373,"conditions":8267,"interventions":8269},"NCT01843699","Topiramate Trial for Pathological Gamblers",[92],"2010-11",[8268],"Pathological Gambling",[8254],{"trials":8271,"activeCount":103},[],{"trials":8273,"activeCount":103},[],{"trials":8275,"activeCount":103},[],{"intervention":8277,"totalTrials":175,"cells":8278},"Magnesium Sulfate 2 grams",{"EARLY_PHASE1":8279,"PHASE1":8281,"PHASE2":8283,"PHASE3":8294,"PHASE4":8296,"NA":8298},{"trials":8280,"activeCount":103},[],{"trials":8282,"activeCount":103},[],{"trials":8284,"activeCount":103},[8285],{"nctId":8286,"briefTitle":8287,"status":165,"phases":8288,"primaryCompletion":8289,"completion":8289,"start":8290,"enrollment":26,"conditions":8291,"interventions":8293},"NCT00500864","Magnesium Loading in Chronic Obstructive Pulmonary Disease",[91,92],"2007-11","2004-08",[8292],"Chronic Obstructive Pulmonary Disease (COPD)",[8277],{"trials":8295,"activeCount":103},[],{"trials":8297,"activeCount":103},[],{"trials":8299,"activeCount":103},[],{"intervention":8301,"totalTrials":175,"cells":8302},"Methylene Blue",{"EARLY_PHASE1":8303,"PHASE1":8305,"PHASE2":8307,"PHASE3":8323,"PHASE4":8325,"NA":8327},{"trials":8304,"activeCount":103},[],{"trials":8306,"activeCount":103},[],{"trials":8308,"activeCount":103},[8309],{"nctId":8310,"briefTitle":8311,"status":165,"phases":8312,"primaryCompletion":8313,"completion":8314,"start":8315,"enrollment":8316,"conditions":8317,"interventions":8322},"NCT07212842","Methylene Blue-Enhanced Ultrafiltration Improves Outcomes After Cardiopulmonary Bypass",[92],"2023-08-25","2024-03-16","2021-04-12",124,[8318,8319,8320,8321],"Cardiopulmonary Bypass Surgery","Aortic Valve Surgery","Mitral Valve Surgery","Myocardial Revascularization Surgery With Extracorporeal Circulation",[8301],{"trials":8324,"activeCount":103},[],{"trials":8326,"activeCount":103},[],{"trials":8328,"activeCount":103},[],{"intervention":8330,"totalTrials":175,"cells":8331},"Lithium Carbonate",{"EARLY_PHASE1":8332,"PHASE1":8334,"PHASE2":8336,"PHASE3":8347,"PHASE4":8349,"NA":8351},{"trials":8333,"activeCount":103},[],{"trials":8335,"activeCount":103},[],{"trials":8337,"activeCount":103},[8338],{"nctId":8339,"briefTitle":8340,"status":193,"phases":8341,"primaryCompletion":2009,"start":8342,"enrollment":208,"conditions":8343,"interventions":8346},"NCT01055392","Disease-modifying Properties of Lithium in the Neurobiology of Alzheimer's Disease",[92],"2007-03",[8344,8345],"Cognitive Impairment","Alzheimer Disease",[8330],{"trials":8348,"activeCount":103},[],{"trials":8350,"activeCount":103},[],{"trials":8352,"activeCount":103},[],{"intervention":8354,"totalTrials":175,"cells":8355},"Isoflurane",{"EARLY_PHASE1":8356,"PHASE1":8358,"PHASE2":8360,"PHASE3":8371,"PHASE4":8373,"NA":8375},{"trials":8357,"activeCount":103},[],{"trials":8359,"activeCount":103},[],{"trials":8361,"activeCount":103},[8362],{"nctId":8363,"briefTitle":8364,"status":193,"phases":8365,"primaryCompletion":8243,"completion":3245,"start":2553,"enrollment":414,"conditions":8366,"interventions":8369},"NCT04171193","Efficacy of Deep Anaesthesia With Isoflurane as a Fast-response Antidepressant Agent",[92],[2073,8367,8368],"Treatment Resistant Depression","Depressive Episode",[8354,8370],"Sertraline Pill",{"trials":8372,"activeCount":103},[],{"trials":8374,"activeCount":103},[],{"trials":8376,"activeCount":103},[],{"intervention":8370,"totalTrials":175,"cells":8378},{"EARLY_PHASE1":8379,"PHASE1":8381,"PHASE2":8383,"PHASE3":8389,"PHASE4":8391,"NA":8393},{"trials":8380,"activeCount":103},[],{"trials":8382,"activeCount":103},[],{"trials":8384,"activeCount":103},[8385],{"nctId":8363,"briefTitle":8364,"status":193,"phases":8386,"primaryCompletion":8243,"completion":3245,"start":2553,"enrollment":414,"conditions":8387,"interventions":8388},[92],[2073,8367,8368],[8354,8370],{"trials":8390,"activeCount":103},[],{"trials":8392,"activeCount":103},[],{"trials":8394,"activeCount":103},[],{"intervention":8396,"totalTrials":175,"cells":8397},"acellular dermal matrix graft",{"EARLY_PHASE1":8398,"PHASE1":8400,"PHASE2":8402,"PHASE3":8411,"PHASE4":8413,"NA":8415},{"trials":8399,"activeCount":103},[],{"trials":8401,"activeCount":103},[],{"trials":8403,"activeCount":103},[8404],{"nctId":8405,"briefTitle":8406,"status":165,"phases":8407,"primaryCompletion":1822,"completion":1728,"start":1876,"enrollment":35,"conditions":8408,"interventions":8409},"NCT02135471","Root Coverage in Smokers With Acellular Dermal Matrix Graft and Enamel Matrix Derivative",[92],[2138],[8396,8410],"enamel matrix derivative",{"trials":8412,"activeCount":103},[],{"trials":8414,"activeCount":103},[],{"trials":8416,"activeCount":103},[],{"intervention":8418,"totalTrials":175,"cells":8419},"Propolis Period",{"EARLY_PHASE1":8420,"PHASE1":8422,"PHASE2":8424,"PHASE3":8436,"PHASE4":8438,"NA":8440},{"trials":8421,"activeCount":103},[],{"trials":8423,"activeCount":103},[],{"trials":8425,"activeCount":103},[8426],{"nctId":8427,"briefTitle":8428,"status":165,"phases":8429,"primaryCompletion":8430,"completion":8431,"start":8432,"enrollment":17,"conditions":8433,"interventions":8435},"NCT04072341","Effects of Green Propolis Extract (EPP-AF) on Inflammation in Hemodialysis Patients.",[91,92],"2019-12-15","2020-01-30","2019-08-01",[8434],"Chronic Kidney Disease Requiring Chronic Dialysis",[8418],{"trials":8437,"activeCount":103},[],{"trials":8439,"activeCount":103},[],{"trials":8441,"activeCount":103},[],{"intervention":8443,"totalTrials":175,"cells":8444},"mouthwash with curcumin",{"EARLY_PHASE1":8445,"PHASE1":8447,"PHASE2":8456,"PHASE3":8458,"PHASE4":8460,"NA":8462},{"trials":8446,"activeCount":103},[],{"trials":8448,"activeCount":103},[8449],{"nctId":8450,"briefTitle":8451,"status":165,"phases":8452,"primaryCompletion":3622,"completion":3622,"start":5098,"enrollment":414,"conditions":8453,"interventions":8455},"NCT02152475","Photodynamic Therapy (PDT) for Oral Disinfection",[91],[8454],"Healthy",[8443],{"trials":8457,"activeCount":103},[],{"trials":8459,"activeCount":103},[],{"trials":8461,"activeCount":103},[],{"trials":8463,"activeCount":103},[],{"intervention":8465,"totalTrials":175,"cells":8466},"Prednisolone",{"EARLY_PHASE1":8467,"PHASE1":8469,"PHASE2":8481,"PHASE3":8483,"PHASE4":8485,"NA":8487},{"trials":8468,"activeCount":103},[],{"trials":8470,"activeCount":103},[8471],{"nctId":8472,"briefTitle":8473,"status":165,"phases":8474,"primaryCompletion":8475,"completion":8476,"start":8477,"enrollment":740,"conditions":8478,"interventions":8480},"NCT07380152","Corticosteroid Therapy in Pulmonary Sequelae of Covid-19",[91],"2022-06-09","2022-12-12","2021-08-10",[8479],"COVID-19 Pulmonary Complications",[8465],{"trials":8482,"activeCount":103},[],{"trials":8484,"activeCount":103},[],{"trials":8486,"activeCount":103},[],{"trials":8488,"activeCount":103},[],{"intervention":8490,"totalTrials":175,"cells":8491},"Estriol",{"EARLY_PHASE1":8492,"PHASE1":8494,"PHASE2":8508,"PHASE3":8510,"PHASE4":8512,"NA":8514},{"trials":8493,"activeCount":103},[],{"trials":8495,"activeCount":103},[8496],{"nctId":8497,"briefTitle":8498,"status":165,"phases":8499,"primaryCompletion":8500,"completion":8501,"start":4807,"enrollment":6423,"conditions":8502,"interventions":8505},"NCT03116022","Use of Estriol at Distal Third of Vagina Improving Coital Pain in Post-menopause Women",[91],"2018-12-31","2024-01-31",[8503,865,8504],"Dyspareunia","Sexual Dysfunction",[8490,8506,8507],"Distal estriol","Vaginal Gel",{"trials":8509,"activeCount":103},[],{"trials":8511,"activeCount":103},[],{"trials":8513,"activeCount":103},[],{"trials":8515,"activeCount":103},[],{"intervention":8506,"totalTrials":175,"cells":8517},{"EARLY_PHASE1":8518,"PHASE1":8520,"PHASE2":8526,"PHASE3":8528,"PHASE4":8530,"NA":8532},{"trials":8519,"activeCount":103},[],{"trials":8521,"activeCount":103},[8522],{"nctId":8497,"briefTitle":8498,"status":165,"phases":8523,"primaryCompletion":8500,"completion":8501,"start":4807,"enrollment":6423,"conditions":8524,"interventions":8525},[91],[8503,865,8504],[8490,8506,8507],{"trials":8527,"activeCount":103},[],{"trials":8529,"activeCount":103},[],{"trials":8531,"activeCount":103},[],{"trials":8533,"activeCount":103},[],{"intervention":8507,"totalTrials":175,"cells":8535},{"EARLY_PHASE1":8536,"PHASE1":8538,"PHASE2":8544,"PHASE3":8546,"PHASE4":8548,"NA":8550},{"trials":8537,"activeCount":103},[],{"trials":8539,"activeCount":103},[8540],{"nctId":8497,"briefTitle":8498,"status":165,"phases":8541,"primaryCompletion":8500,"completion":8501,"start":4807,"enrollment":6423,"conditions":8542,"interventions":8543},[91],[8503,865,8504],[8490,8506,8507],{"trials":8545,"activeCount":103},[],{"trials":8547,"activeCount":103},[],{"trials":8549,"activeCount":103},[],{"trials":8551,"activeCount":103},[],{"intervention":8553,"totalTrials":175,"cells":8554},"Olanzapine 5 Mg ORAL",{"EARLY_PHASE1":8555,"PHASE1":8557,"PHASE2":8567,"PHASE3":8569,"PHASE4":8571,"NA":8573},{"trials":8556,"activeCount":103},[],{"trials":8558,"activeCount":103},[8559],{"nctId":8560,"briefTitle":8561,"status":165,"phases":8562,"primaryCompletion":8563,"completion":739,"start":1310,"enrollment":388,"conditions":8564,"interventions":8566},"NCT07190482","Treatment of Tinnitus With Olanzapine",[91],"2024-12-20",[275,8565],"Tinnitus, Subjective",[8553],{"trials":8568,"activeCount":103},[],{"trials":8570,"activeCount":103},[],{"trials":8572,"activeCount":103},[],{"trials":8574,"activeCount":103},[],{"intervention":8576,"totalTrials":175,"cells":8577},"Curcumin",{"EARLY_PHASE1":8578,"PHASE1":8580,"PHASE2":8592,"PHASE3":8594,"PHASE4":8596,"NA":8598},{"trials":8579,"activeCount":103},[],{"trials":8581,"activeCount":103},[8582],{"nctId":8583,"briefTitle":8584,"status":165,"phases":8585,"primaryCompletion":3329,"completion":6800,"start":2081,"enrollment":26,"conditions":8586,"interventions":8588},"NCT02337192","Antimicrobial Photodynamic Therapy Applied in Orthodontic. Orthodontic Patients.",[91],[8587],"Dentist-Patient Relations",[8576,8589,8590,8591],"Surfactant","DMSO + water","Chlorhexidine gluconate",{"trials":8593,"activeCount":103},[],{"trials":8595,"activeCount":103},[],{"trials":8597,"activeCount":103},[],{"trials":8599,"activeCount":103},[],{"intervention":8589,"totalTrials":175,"cells":8601},{"EARLY_PHASE1":8602,"PHASE1":8604,"PHASE2":8610,"PHASE3":8612,"PHASE4":8614,"NA":8616},{"trials":8603,"activeCount":103},[],{"trials":8605,"activeCount":103},[8606],{"nctId":8583,"briefTitle":8584,"status":165,"phases":8607,"primaryCompletion":3329,"completion":6800,"start":2081,"enrollment":26,"conditions":8608,"interventions":8609},[91],[8587],[8576,8589,8590,8591],{"trials":8611,"activeCount":103},[],{"trials":8613,"activeCount":103},[],{"trials":8615,"activeCount":103},[],{"trials":8617,"activeCount":103},[],{"intervention":8590,"totalTrials":175,"cells":8619},{"EARLY_PHASE1":8620,"PHASE1":8622,"PHASE2":8628,"PHASE3":8630,"PHASE4":8632,"NA":8634},{"trials":8621,"activeCount":103},[],{"trials":8623,"activeCount":103},[8624],{"nctId":8583,"briefTitle":8584,"status":165,"phases":8625,"primaryCompletion":3329,"completion":6800,"start":2081,"enrollment":26,"conditions":8626,"interventions":8627},[91],[8587],[8576,8589,8590,8591],{"trials":8629,"activeCount":103},[],{"trials":8631,"activeCount":103},[],{"trials":8633,"activeCount":103},[],{"trials":8635,"activeCount":103},[],{"intervention":8591,"totalTrials":175,"cells":8637},{"EARLY_PHASE1":8638,"PHASE1":8640,"PHASE2":8646,"PHASE3":8648,"PHASE4":8650,"NA":8652},{"trials":8639,"activeCount":103},[],{"trials":8641,"activeCount":103},[8642],{"nctId":8583,"briefTitle":8584,"status":165,"phases":8643,"primaryCompletion":3329,"completion":6800,"start":2081,"enrollment":26,"conditions":8644,"interventions":8645},[91],[8587],[8576,8589,8590,8591],{"trials":8647,"activeCount":103},[],{"trials":8649,"activeCount":103},[],{"trials":8651,"activeCount":103},[],{"trials":8653,"activeCount":103},[],{"intervention":8655,"totalTrials":175,"cells":8656},"Oxytocin",{"EARLY_PHASE1":8657,"PHASE1":8659,"PHASE2":8671,"PHASE3":8673,"PHASE4":8675,"NA":8677},{"trials":8658,"activeCount":103},[],{"trials":8660,"activeCount":103},[8661],{"nctId":8662,"briefTitle":8663,"status":165,"phases":8664,"primaryCompletion":8665,"completion":8666,"start":8667,"enrollment":208,"conditions":8668,"interventions":8670},"NCT03183674","Oxytocin in Spectrum Autism Disorders",[91],"2017-07-20","2018-05-15","2016-07-15",[8669],"Autistic Disorder",[8655],{"trials":8672,"activeCount":103},[],{"trials":8674,"activeCount":103},[],{"trials":8676,"activeCount":103},[],{"trials":8678,"activeCount":103},[],{"intervention":8680,"totalTrials":175,"cells":8681},"Culture and isolation of autologous bone-marrow mesenchymal stem cells",{"EARLY_PHASE1":8682,"PHASE1":8684,"PHASE2":8694,"PHASE3":8696,"PHASE4":8698,"NA":8700},{"trials":8683,"activeCount":103},[],{"trials":8685,"activeCount":103},[8686],{"nctId":8687,"briefTitle":8688,"status":165,"phases":8689,"primaryCompletion":1997,"completion":1997,"start":2081,"enrollment":99,"conditions":8690,"interventions":8693},"NCT02330978","Intravitreal Mesenchymal Stem Cell Transplantation in Advanced Glaucoma.",[91],[8691,8692],"Retinal Degeneration","Primary Open-angle Glaucoma",[8680],{"trials":8695,"activeCount":103},[],{"trials":8697,"activeCount":103},[],{"trials":8699,"activeCount":103},[],{"trials":8701,"activeCount":103},[],{"intervention":8703,"totalTrials":175,"cells":8704},"human regular insulin",{"EARLY_PHASE1":8705,"PHASE1":8707,"PHASE2":8720,"PHASE3":8722,"PHASE4":8724,"NA":8726},{"trials":8706,"activeCount":103},[],{"trials":8708,"activeCount":103},[8709],{"nctId":8710,"briefTitle":8711,"status":165,"phases":8712,"completion":8713,"start":8714,"enrollment":8715,"conditions":8716,"interventions":8719},"NCT00370643","Glucose Control in Open Heart Surgery",[91],"2004-11","2002-10",98,[8717,8718,790],"Hyperglycaemia During Perioperative Period","Heart Valve Diseases",[8703],{"trials":8721,"activeCount":103},[],{"trials":8723,"activeCount":103},[],{"trials":8725,"activeCount":103},[],{"trials":8727,"activeCount":103},[],{"intervention":8729,"totalTrials":175,"cells":8730},"Alpha-type-1 Polarizing Dendritic Cells (aDC1) unpulsed with HIV peptides",{"EARLY_PHASE1":8731,"PHASE1":8733,"PHASE2":8743,"PHASE3":8745,"PHASE4":8747,"NA":8749},{"trials":8732,"activeCount":103},[],{"trials":8734,"activeCount":103},[8735],{"nctId":8736,"briefTitle":8737,"status":193,"phases":8738,"primaryCompletion":6926,"completion":6926,"start":3882,"enrollment":414,"conditions":8739,"interventions":8741},"NCT05786937","Therapeutic Vaccine Based on aDC1 Dendritic Cells for the Control of Viremia After ATI in HIV Infected Individuals",[91],[8740],"HIV Vaccine",[8729,8742],"Alpha-type-1 Polarizing Dendritic Cells (aDC1) pulsed with HIV peptides",{"trials":8744,"activeCount":103},[],{"trials":8746,"activeCount":103},[],{"trials":8748,"activeCount":103},[],{"trials":8750,"activeCount":103},[],{"intervention":8742,"totalTrials":175,"cells":8752},{"EARLY_PHASE1":8753,"PHASE1":8755,"PHASE2":8761,"PHASE3":8763,"PHASE4":8765,"NA":8767},{"trials":8754,"activeCount":103},[],{"trials":8756,"activeCount":103},[8757],{"nctId":8736,"briefTitle":8737,"status":193,"phases":8758,"primaryCompletion":6926,"completion":6926,"start":3882,"enrollment":414,"conditions":8759,"interventions":8760},[91],[8740],[8729,8742],{"trials":8762,"activeCount":103},[],{"trials":8764,"activeCount":103},[],{"trials":8766,"activeCount":103},[],{"trials":8768,"activeCount":103},[],{"intervention":8770,"totalTrials":175,"cells":8771},"Ibuprofen",{"EARLY_PHASE1":8772,"PHASE1":8781,"PHASE2":8783,"PHASE3":8785,"PHASE4":8787,"NA":8789},{"trials":8773,"activeCount":103},[8774],{"nctId":8775,"briefTitle":8776,"status":193,"phases":8777,"primaryCompletion":5330,"completion":1800,"start":6211,"enrollment":388,"conditions":8778,"interventions":8780},"NCT03953729","Effectiveness of Pre-emptive Analgesia in Children With Molar-incisor Hypomineralization (MIH)",[90],[28,8779],"Anxiety",[8770],{"trials":8782,"activeCount":103},[],{"trials":8784,"activeCount":103},[],{"trials":8786,"activeCount":103},[],{"trials":8788,"activeCount":103},[],{"trials":8790,"activeCount":103},[],{"intervention":8792,"totalTrials":175,"cells":8793},"Melatonin Replacement Therapy",{"EARLY_PHASE1":8794,"PHASE1":8806,"PHASE2":8808,"PHASE3":8810,"PHASE4":8812,"NA":8814},{"trials":8795,"activeCount":103},[8796],{"nctId":8797,"briefTitle":8798,"status":165,"phases":8799,"primaryCompletion":8800,"completion":8801,"start":8802,"enrollment":697,"conditions":8803,"interventions":8805},"NCT03885258","Melatonin Replacement Therapy in Pinealectomized Patients",[90],"2018-11-30","2019-02-28","2017-05-02",[8804],"Pineal Tumor",[8792],{"trials":8807,"activeCount":103},[],{"trials":8809,"activeCount":103},[],{"trials":8811,"activeCount":103},[],{"trials":8813,"activeCount":103},[],{"trials":8815,"activeCount":103},[],{"intervention":8817,"totalTrials":175,"cells":8818},"Amoxicilin and Metronidazole",{"EARLY_PHASE1":8819,"PHASE1":8831,"PHASE2":8833,"PHASE3":8835,"PHASE4":8837,"NA":8839},{"trials":8820,"activeCount":103},[8821],{"nctId":8822,"briefTitle":8823,"status":165,"phases":8824,"primaryCompletion":8825,"completion":8826,"start":8827,"enrollment":235,"conditions":8828,"interventions":8830},"NCT07592416","Clinical, Microbiological and Immunological Effects of the Adjuvant Use of Systemic Antibiotics and Probiotics in the Non-surgical Treatment of Periodontitis",[90],"2026-01-30","2026-02-11","2023-08-22",[8829,5748],"Healthy Adult Participants",[8817],{"trials":8832,"activeCount":103},[],{"trials":8834,"activeCount":103},[],{"trials":8836,"activeCount":103},[],{"trials":8838,"activeCount":103},[],{"trials":8840,"activeCount":103},[],{"intervention":6872,"totalTrials":8842,"cells":8843},7,{"EARLY_PHASE1":8844,"PHASE1":8846,"PHASE2":8848,"PHASE3":8880,"PHASE4":8882,"NA":8884},{"trials":8845,"activeCount":103},[],{"trials":8847,"activeCount":103},[],{"trials":8849,"activeCount":103},[8850,8854,8858,8865,8872],{"nctId":6866,"briefTitle":6867,"status":193,"phases":8851,"primaryCompletion":2943,"completion":2943,"start":1643,"enrollment":6869,"conditions":8852,"interventions":8853},[92],[4960,4959],[6872,6840],{"nctId":4955,"briefTitle":4956,"status":165,"phases":8855,"conditions":8856,"interventions":8857},[92],[4959,4960,4961],[4963,4964,4965],{"nctId":8859,"briefTitle":8860,"status":165,"phases":8861,"primaryCompletion":7161,"completion":7161,"start":8862,"enrollment":32,"conditions":8863,"interventions":8864},"NCT00690768","Pars Plana Vitrectomy (PPV) Versus Preoperative Intravitreal Bevacizumab Plus PPV to Treat Diabetic Tractional Retinal Detachment (IBETRA)",[92],"2008-03",[4960,6853],[6872],{"nctId":8866,"briefTitle":8867,"status":193,"phases":8868,"primaryCompletion":1729,"completion":1969,"start":1914,"enrollment":175,"conditions":8869,"interventions":8871},"NCT01091896","Adjuvant Intravitreal Bevacizumab in Pars Plana Vitrectomy for Vitreous Hemorrhage",[92],[8870],"Vitreous Hemorrhage Secondary to PDR",[6872,4963],{"nctId":8873,"briefTitle":8874,"status":165,"phases":8875,"primaryCompletion":3438,"completion":3438,"start":8289,"enrollment":8876,"conditions":8877,"interventions":8879},"NCT00596297","Preoperative Bevacizumab for Vitreous Hemorrhage",[91,92],16,[4960,8878],"Vitreous Hemorrhage",[4963],{"trials":8881,"activeCount":103},[],{"trials":8883,"activeCount":103},[],{"trials":8885,"activeCount":103},[8886,8894],{"nctId":8887,"briefTitle":8888,"status":165,"phases":8889,"primaryCompletion":8890,"completion":1996,"start":2943,"enrollment":7328,"conditions":8891,"interventions":8893},"NCT02015351","Intravitreal Bevacizumab for the Treatment of CNV in VKH Disease - A Prospective Study",[95],"2017-10",[8892],"Choroidal Neovascularization",[4963],{"nctId":8895,"briefTitle":8896,"status":165,"phases":8897,"primaryCompletion":2069,"completion":3201,"start":1875,"enrollment":2106,"conditions":8898,"interventions":8899},"NCT02310295","Prospective, Randomized Clinical Trial Comparing Macular Photocoagulation With or Without Intravitreal Bevacizumab or Triamcinolone for the Treatment of Diabetic Macular Edema",[95],[5058],[6872,8900],"Triamcinolone Acetonide",{"intervention":1776,"totalTrials":989,"cells":8902},{"EARLY_PHASE1":8903,"PHASE1":8905,"PHASE2":8907,"PHASE3":8909,"PHASE4":8915,"NA":8925},{"trials":8904,"activeCount":103},[],{"trials":8906,"activeCount":103},[],{"trials":8908,"activeCount":103},[],{"trials":8910,"activeCount":103},[8911],{"nctId":5741,"briefTitle":5742,"status":165,"phases":8912,"primaryCompletion":5744,"completion":5745,"start":5746,"enrollment":235,"conditions":8913,"interventions":8914},[93],[1774,5748,5749],[5730,5751,1776],{"trials":8916,"activeCount":103},[8917,8921],{"nctId":1768,"briefTitle":1769,"status":165,"phases":8918,"primaryCompletion":1771,"completion":1771,"start":1772,"enrollment":480,"conditions":8919,"interventions":8920},[94],[1774],[1776,1744],{"nctId":4754,"briefTitle":4755,"status":193,"phases":8922,"primaryCompletion":4757,"completion":4758,"start":4759,"enrollment":388,"conditions":8923,"interventions":8924},[94],[4761],[4741,1776],{"trials":8926,"activeCount":103},[8927],{"nctId":8928,"briefTitle":8929,"status":165,"phases":8930,"primaryCompletion":1590,"completion":3732,"start":8931,"enrollment":8932,"conditions":8933,"interventions":8937},"NCT00621491","Prevention of Venous Thrombosis After Permanent Transvenous Leads Implantation",[95],"2004-02",101,[8934,8935,8936],"Cardiac Pacing","Complications","Venous Thrombosis",[1776],{"intervention":6033,"totalTrials":989,"cells":8939},{"EARLY_PHASE1":8940,"PHASE1":8942,"PHASE2":8944,"PHASE3":8950,"PHASE4":8960,"NA":8962},{"trials":8941,"activeCount":103},[],{"trials":8943,"activeCount":103},[],{"trials":8945,"activeCount":103},[8946],{"nctId":7782,"briefTitle":7783,"status":165,"phases":8947,"primaryCompletion":2009,"completion":1969,"start":1875,"enrollment":235,"conditions":8948,"interventions":8949},[92],[7786],[7773,6033,7788],{"trials":8951,"activeCount":103},[8952,8956],{"nctId":6023,"briefTitle":6024,"status":165,"phases":8953,"primaryCompletion":6026,"completion":6027,"start":6028,"enrollment":6029,"conditions":8954,"interventions":8955},[92,93],[6031],[6012,6033],{"nctId":6751,"briefTitle":6752,"status":193,"phases":8957,"primaryCompletion":2070,"completion":2738,"start":1875,"enrollment":1176,"conditions":8958,"interventions":8959},[93],[2035],[6740,6033],{"trials":8961,"activeCount":103},[],{"trials":8963,"activeCount":103},[8964],{"nctId":8965,"briefTitle":8966,"status":193,"phases":8967,"primaryCompletion":4971,"completion":2070,"start":6028,"enrollment":5919,"conditions":8968,"interventions":8970},"NCT00994305","Protective Effect of N-acetylcysteine on Early Outcomes of Deceased Renal Transplant",[95],[8969],"Renal Transplantation",[8971,8972],"N-acetylcysteine","control",{"intervention":1692,"totalTrials":1466,"cells":8974},{"EARLY_PHASE1":8975,"PHASE1":8977,"PHASE2":8979,"PHASE3":8981,"PHASE4":8987,"NA":8993},{"trials":8976,"activeCount":103},[],{"trials":8978,"activeCount":103},[],{"trials":8980,"activeCount":103},[],{"trials":8982,"activeCount":103},[8983],{"nctId":1684,"briefTitle":1685,"status":165,"phases":8984,"primaryCompletion":1687,"completion":1687,"start":1688,"enrollment":170,"conditions":8985,"interventions":8986},[93],[1690],[1692,1693,1673],{"trials":8988,"activeCount":103},[8989],{"nctId":2207,"briefTitle":2208,"status":193,"phases":8990,"primaryCompletion":2210,"completion":2211,"start":2212,"enrollment":2213,"conditions":8991,"interventions":8992},[94],[2215,25,2216,28],[1692,2194],{"trials":8994,"activeCount":103},[8995],{"nctId":8996,"briefTitle":8997,"status":193,"phases":8998,"primaryCompletion":1902,"completion":2081,"start":3330,"enrollment":235,"conditions":8999,"interventions":9001},"NCT01900405","Intranasal Dexmedetomidine Sedation for Pediatric CT Imaging",[],[7918,9000],"Children",[1692],{"intervention":2470,"totalTrials":1466,"cells":9003},{"EARLY_PHASE1":9004,"PHASE1":9006,"PHASE2":9008,"PHASE3":9017,"PHASE4":9019,"NA":9025},{"trials":9005,"activeCount":103},[],{"trials":9007,"activeCount":103},[],{"trials":9009,"activeCount":103},[9010],{"nctId":9011,"briefTitle":9012,"status":165,"phases":9013,"primaryCompletion":7634,"completion":7634,"start":9014,"enrollment":726,"conditions":9015,"interventions":9016},"NCT01043965","Myocardial Perfusion in Type 2 Diabetes",[91,92],"2005-08",[2468],[2470],{"trials":9018,"activeCount":103},[],{"trials":9020,"activeCount":103},[9021],{"nctId":2464,"briefTitle":2465,"status":165,"phases":9022,"primaryCompletion":1913,"completion":1913,"start":1821,"enrollment":32,"conditions":9023,"interventions":9024},[94],[2468],[2470,2451],{"trials":9026,"activeCount":103},[9027],{"nctId":9028,"briefTitle":9029,"status":165,"phases":9030,"primaryCompletion":9031,"completion":9031,"start":9032,"enrollment":235,"conditions":9033,"interventions":9037},"NCT04892186","Effects of Myo-inositol in Women With Polycystic Ovary Syndrome",[95],"2023-10-20","2021-03-26",[9034,9035,9036],"Polycystic Ovary Syndrome","Resistance, Insulin","Glucose Intolerance",[9038,2470],"Myo-inositol",{"intervention":1706,"totalTrials":1466,"cells":9040},{"EARLY_PHASE1":9041,"PHASE1":9043,"PHASE2":9045,"PHASE3":9047,"PHASE4":9049,"NA":9062},{"trials":9042,"activeCount":103},[],{"trials":9044,"activeCount":103},[],{"trials":9046,"activeCount":103},[],{"trials":9048,"activeCount":103},[],{"trials":9050,"activeCount":103},[9051,9058],{"nctId":9052,"briefTitle":9053,"status":2489,"phases":9054,"primaryCompletion":5056,"completion":1642,"start":4233,"enrollment":414,"conditions":9055,"interventions":9056},"NCT00628355","Lidocaine Injection and Ischemic Compression on Chronic Pelvic Pain Treatment",[94],[3837],[9057],"lidocaine",{"nctId":1697,"briefTitle":1698,"status":165,"phases":9059,"primaryCompletion":1700,"completion":1701,"start":1702,"enrollment":1434,"conditions":9060,"interventions":9061},[94],[1704],[1673,1706,1707,1708],{"trials":9063,"activeCount":103},[9064],{"nctId":9065,"briefTitle":9066,"status":165,"phases":9067,"primaryCompletion":9068,"completion":9069,"start":9070,"enrollment":1003,"conditions":9071,"interventions":9074},"NCT03978845","Phrenic Nerve Block to Mitigate Self-inflicted Lung Injury",[95],"2019-12-31","2020-09-09","2019-05-15",[9072,9073],"Respiratory Failure","Mechanical Ventilation",[1706],{"intervention":7458,"totalTrials":1466,"cells":9076},{"EARLY_PHASE1":9077,"PHASE1":9079,"PHASE2":9081,"PHASE3":9087,"PHASE4":9089,"NA":9095},{"trials":9078,"activeCount":103},[],{"trials":9080,"activeCount":103},[],{"trials":9082,"activeCount":103},[9083],{"nctId":7452,"briefTitle":7453,"status":165,"phases":9084,"primaryCompletion":6800,"completion":6800,"start":1914,"enrollment":388,"conditions":9085,"interventions":9086},[92],[7456],[7443,7458],{"trials":9088,"activeCount":103},[],{"trials":9090,"activeCount":103},[9091],{"nctId":4316,"briefTitle":4317,"status":165,"phases":9092,"primaryCompletion":207,"completion":2832,"start":4319,"enrollment":4320,"conditions":9093,"interventions":9094},[94],[4322],[4303,4324,4325],{"trials":9096,"activeCount":103},[9097],{"nctId":9098,"briefTitle":9099,"status":2489,"phases":9100,"primaryCompletion":9101,"completion":9101,"start":9102,"enrollment":9103,"conditions":9104,"interventions":9105},"NCT03492255","CYCLONES - CYClophosphamide LOw Dose and No Extra Steroid",[95],"2021-07-02","2018-04-12",49,[447],[9106,9107,7458,9108],"Cyclophosphamide","Methylprednisolone","Mycophenolate Mofetil",{"intervention":8971,"totalTrials":1466,"cells":9110},{"EARLY_PHASE1":9111,"PHASE1":9113,"PHASE2":9115,"PHASE3":9124,"PHASE4":9126,"NA":9128},{"trials":9112,"activeCount":103},[],{"trials":9114,"activeCount":103},[],{"trials":9116,"activeCount":103},[9117],{"nctId":9118,"briefTitle":9119,"status":165,"phases":9120,"primaryCompletion":4734,"completion":4734,"start":7351,"enrollment":17,"conditions":9121,"interventions":9122},"NCT01555970","Efficacy Study of add-on Therapy With N-Acetylcysteine in Resistant Obsessive-compulsive Disorder",[92],[3601],[9123],"N-Acetylcysteine",{"trials":9125,"activeCount":103},[],{"trials":9127,"activeCount":103},[],{"trials":9129,"activeCount":103},[9130,9137],{"nctId":9131,"briefTitle":9132,"status":165,"phases":9133,"conditions":9134,"interventions":9136},"NCT00851708","Impact of N-Acetylcysteine on Oxidative Stress and Renal Function in Deceased Kidney Transplant Recipients",[95],[9135],"Deceased Kidney Transplantation",[8971],{"nctId":8965,"briefTitle":8966,"status":193,"phases":9138,"primaryCompletion":4971,"completion":2070,"start":6028,"enrollment":5919,"conditions":9139,"interventions":9140},[95],[8969],[8971,8972],{"intervention":9142,"totalTrials":99,"cells":9143},"Triamcinolone acetonide",{"EARLY_PHASE1":9144,"PHASE1":9146,"PHASE2":9148,"PHASE3":9156,"PHASE4":9158,"NA":9160},{"trials":9145,"activeCount":103},[],{"trials":9147,"activeCount":103},[],{"trials":9149,"activeCount":103},[9150],{"nctId":9151,"briefTitle":9152,"status":193,"phases":9153,"primaryCompletion":4497,"completion":4970,"start":1590,"enrollment":26,"conditions":9154,"interventions":9155},"NCT00801450","Intravitreal Injection Versus Sub-Tenon's Infusion of Triamcinolone Acetonide for Refractory Diabetic Macular Edema During Cataract Surgery",[91,92],[5058],[9142,9142],{"trials":9157,"activeCount":103},[],{"trials":9159,"activeCount":103},[],{"trials":9161,"activeCount":103},[9162],{"nctId":8895,"briefTitle":8896,"status":165,"phases":9163,"primaryCompletion":2069,"completion":3201,"start":1875,"enrollment":2106,"conditions":9164,"interventions":9165},[95],[5058],[6872,8900],{"intervention":1766,"totalTrials":99,"cells":9167},{"EARLY_PHASE1":9168,"PHASE1":9170,"PHASE2":9172,"PHASE3":9174,"PHASE4":9176,"NA":9182},{"trials":9169,"activeCount":103},[],{"trials":9171,"activeCount":103},[],{"trials":9173,"activeCount":103},[],{"trials":9175,"activeCount":103},[],{"trials":9177,"activeCount":103},[9178],{"nctId":1757,"briefTitle":1758,"status":165,"phases":9179,"primaryCompletion":1760,"completion":1760,"start":1761,"enrollment":1762,"conditions":9180,"interventions":9181},[94],[1764],[1744,1766],{"trials":9183,"activeCount":103},[9184],{"nctId":9185,"briefTitle":9186,"status":165,"phases":9187,"primaryCompletion":9188,"completion":9189,"start":9190,"enrollment":9191,"conditions":9192,"interventions":9198},"NCT02600260","Thromboprophylaxis in Pregnant Women in Hospital: A Prospective Clinical Trial",[95],"2019-07-31","2019-12-28","2014-12-01",7212,[9193,9194,8936,9195,9196,9197],"Thrombophilia Associated With Pregnancy","Perioperative\u002FPostoperative Complications","Pulmonary Embolism","Other Specified Risk Factors in Pregnancy","Deep Vein Thrombosis",[1766],{"intervention":9200,"totalTrials":99,"cells":9201},"Ibuprofen 600 mg",{"EARLY_PHASE1":9202,"PHASE1":9204,"PHASE2":9206,"PHASE3":9208,"PHASE4":9210,"NA":9221},{"trials":9203,"activeCount":103},[],{"trials":9205,"activeCount":103},[],{"trials":9207,"activeCount":103},[],{"trials":9209,"activeCount":103},[],{"trials":9211,"activeCount":103},[9212],{"nctId":9213,"briefTitle":9214,"status":193,"phases":9215,"primaryCompletion":9216,"completion":9217,"start":9218,"enrollment":480,"conditions":9219,"interventions":9220},"NCT03169127","Clinical Pharmacogenetic of Ibuprofen After Lower Third Molar Surgeries",[94],"2018-07-30","2020-07-01","2016-04-01",[28,2582,2583],[9200],{"trials":9222,"activeCount":103},[9223],{"nctId":9224,"briefTitle":9225,"status":165,"phases":9226,"primaryCompletion":9227,"completion":9227,"start":2033,"enrollment":247,"conditions":9228,"interventions":9230},"NCT02863614","Analgesia for Endometrial Scratching",[95],"2017-05",[9229,2035],"Subfertility",[9200,9231],"Lorazepam 1 mg",{"intervention":9233,"totalTrials":99,"cells":9234},"Ivabradine",{"EARLY_PHASE1":9235,"PHASE1":9237,"PHASE2":9239,"PHASE3":9249,"PHASE4":9251,"NA":9253},{"trials":9236,"activeCount":103},[],{"trials":9238,"activeCount":103},[],{"trials":9240,"activeCount":103},[9241],{"nctId":9242,"briefTitle":9243,"status":193,"phases":9244,"primaryCompletion":1839,"completion":4363,"start":5098,"enrollment":388,"conditions":9245,"interventions":9247},"NCT02236247","Control of Sinus Node Tachycardia as an Additional Therapy in Patients With Decompensated Heart Failure",[91,92],[9246],"Decompensated Heart Failure",[9248],"ivabradine",{"trials":9250,"activeCount":103},[],{"trials":9252,"activeCount":103},[],{"trials":9254,"activeCount":103},[9255],{"nctId":9256,"briefTitle":9257,"status":193,"phases":9258,"primaryCompletion":1688,"completion":6540,"start":9259,"enrollment":5569,"conditions":9260,"interventions":9262},"NCT03650205","Ivabradine to Prevent Anthracycline-induced Cardiotoxicity",[95],"2019-01-22",[1314,19,1313,1315,9261],"Oncology",[9233],{"intervention":9264,"totalTrials":99,"cells":9265},"Dexamethasone",{"EARLY_PHASE1":9266,"PHASE1":9268,"PHASE2":9270,"PHASE3":9272,"PHASE4":9274,"NA":9283},{"trials":9267,"activeCount":103},[],{"trials":9269,"activeCount":103},[],{"trials":9271,"activeCount":103},[],{"trials":9273,"activeCount":103},[],{"trials":9275,"activeCount":103},[9276],{"nctId":9277,"briefTitle":9278,"status":165,"phases":9279,"primaryCompletion":4496,"completion":3130,"start":1821,"enrollment":3247,"conditions":9280,"interventions":9282},"NCT01332812","Dexamethasone for the Prevention of Postoperative Cognitive Dysfunction",[94],[9281],"Postoperative Cognitive Dysfunction",[9264],{"trials":9284,"activeCount":103},[9285],{"nctId":9286,"briefTitle":9287,"status":193,"phases":9288,"primaryCompletion":9289,"completion":9290,"start":9291,"enrollment":2106,"conditions":9292,"interventions":9294},"NCT04148846","Sphenopalatine Blockade Versus Clinical Treatment",[95],"2020-09-25","2021-02-15","2019-09-20",[9293],"Headache, Post-Dural Puncture",[9295,9296,9297,9264,9298],"Dypirone","Ketoprofen","Gabapentin","Theophylline",{"intervention":5796,"totalTrials":99,"cells":9300},{"EARLY_PHASE1":9301,"PHASE1":9303,"PHASE2":9305,"PHASE3":9307,"PHASE4":9313,"NA":9315},{"trials":9302,"activeCount":103},[],{"trials":9304,"activeCount":103},[],{"trials":9306,"activeCount":103},[],{"trials":9308,"activeCount":103},[9309],{"nctId":5786,"briefTitle":5787,"status":2489,"phases":9310,"primaryCompletion":5789,"completion":5789,"start":5790,"enrollment":5791,"conditions":9311,"interventions":9312},[92,93],[5793,5794],[5796,5775],{"trials":9314,"activeCount":103},[],{"trials":9316,"activeCount":103},[9317],{"nctId":9318,"briefTitle":9319,"status":165,"phases":9320,"primaryCompletion":5818,"completion":6541,"start":2674,"enrollment":1003,"conditions":9321,"interventions":9323},"NCT03327116","Effect of Methotrexate on Inflammatory Response in Adult Atopic Dermatitis Patients",[95],[9322],"Atopic Dermatitis",[5796],{"intervention":9325,"totalTrials":99,"cells":9326},"Statin",{"EARLY_PHASE1":9327,"PHASE1":9329,"PHASE2":9331,"PHASE3":9333,"PHASE4":9335,"NA":9346},{"trials":9328,"activeCount":103},[],{"trials":9330,"activeCount":103},[],{"trials":9332,"activeCount":103},[],{"trials":9334,"activeCount":103},[],{"trials":9336,"activeCount":103},[9337],{"nctId":9338,"briefTitle":9339,"status":193,"phases":9340,"primaryCompletion":2833,"completion":4496,"start":9341,"enrollment":208,"conditions":9342,"interventions":9344},"NCT01346748","The Role of Statins in Preventing Cerebral Vasospasm Secondary to Subarachnoid Hemorrhage",[94],"2011-04",[9343],"Aneurysmal Subarachnoid Hemorrhage",[9345],"statin",{"trials":9347,"activeCount":103},[9348],{"nctId":9349,"briefTitle":9350,"status":165,"phases":9351,"primaryCompletion":9352,"completion":9352,"start":9291,"enrollment":9353,"conditions":9354,"interventions":9356},"NCT04986241","The Association of Statins on Cardiorespiratory Fitness and Exercise Adaptation",[],"2023-06-20",18557,[9355],"Statin Adverse Reaction",[9325],{"intervention":9358,"totalTrials":99,"cells":9359},"Sevoflurane",{"EARLY_PHASE1":9360,"PHASE1":9362,"PHASE2":9364,"PHASE3":9366,"PHASE4":9368,"NA":9370},{"trials":9361,"activeCount":103},[],{"trials":9363,"activeCount":103},[],{"trials":9365,"activeCount":103},[],{"trials":9367,"activeCount":103},[],{"trials":9369,"activeCount":103},[],{"trials":9371,"activeCount":103},[9372,9384],{"nctId":9373,"briefTitle":9374,"status":165,"phases":9375,"primaryCompletion":9376,"completion":9377,"start":9378,"enrollment":414,"conditions":9379,"interventions":9382},"NCT03379103","Bleeding in Knee Arthroplasty After Preconditioning With Sevoflurane",[95],"2018-12-19","2020-12-19","2018-02-02",[9380,9381],"Blood Loss, Surgical","Blood Transfusion",[9358,9383],"Propofol",{"nctId":9385,"briefTitle":9386,"status":165,"phases":9387,"primaryCompletion":9388,"completion":5331,"start":9389,"enrollment":9390,"conditions":9391,"interventions":9395},"NCT03787849","Epigenetics in PostOperative Pediatric Emergence Delirium",[95],"2021-12-07","2018-09-24",175,[9392,9393,9394],"Emergence Delirium","Postoperative Complications","DNA Methylation",[9358,9383],{"intervention":9383,"totalTrials":99,"cells":9397},{"EARLY_PHASE1":9398,"PHASE1":9400,"PHASE2":9402,"PHASE3":9404,"PHASE4":9406,"NA":9408},{"trials":9399,"activeCount":103},[],{"trials":9401,"activeCount":103},[],{"trials":9403,"activeCount":103},[],{"trials":9405,"activeCount":103},[],{"trials":9407,"activeCount":103},[],{"trials":9409,"activeCount":103},[9410,9414],{"nctId":9373,"briefTitle":9374,"status":165,"phases":9411,"primaryCompletion":9376,"completion":9377,"start":9378,"enrollment":414,"conditions":9412,"interventions":9413},[95],[9380,9381],[9358,9383],{"nctId":9385,"briefTitle":9386,"status":165,"phases":9415,"primaryCompletion":9388,"completion":5331,"start":9389,"enrollment":9390,"conditions":9416,"interventions":9417},[95],[9392,9393,9394],[9358,9383],{"intervention":8410,"totalTrials":99,"cells":9419},{"EARLY_PHASE1":9420,"PHASE1":9422,"PHASE2":9424,"PHASE3":9430,"PHASE4":9432,"NA":9434},{"trials":9421,"activeCount":103},[],{"trials":9423,"activeCount":103},[],{"trials":9425,"activeCount":103},[9426],{"nctId":8405,"briefTitle":8406,"status":165,"phases":9427,"primaryCompletion":1822,"completion":1728,"start":1876,"enrollment":35,"conditions":9428,"interventions":9429},[92],[2138],[8396,8410],{"trials":9431,"activeCount":103},[],{"trials":9433,"activeCount":103},[],{"trials":9435,"activeCount":103},[9436],{"nctId":9437,"briefTitle":9438,"status":165,"phases":9439,"primaryCompletion":9440,"completion":9441,"start":9442,"enrollment":1434,"conditions":9443,"interventions":9445},"NCT02195765","Randomized Clinical Trial of Enamel Matrix Derivative: Radiographic Analysis",[95],"2004-10","2005-10","2002-06",[9444],"Chronic Periodontitis",[8410],{"intervention":9447,"totalTrials":175,"cells":9448},"External Nasal Dilator Strip; 0.05% oxymetazoline chloride",{"EARLY_PHASE1":9449,"PHASE1":9451,"PHASE2":9453,"PHASE3":9455,"PHASE4":9457,"NA":9459},{"trials":9450,"activeCount":103},[],{"trials":9452,"activeCount":103},[],{"trials":9454,"activeCount":103},[],{"trials":9456,"activeCount":103},[],{"trials":9458,"activeCount":103},[],{"trials":9460,"activeCount":103},[9461],{"nctId":9462,"briefTitle":9463,"status":165,"phases":9464,"primaryCompletion":2738,"completion":3172,"start":2737,"enrollment":8876,"conditions":9465,"interventions":9467},"NCT01411969","Impact of External Nasal Dilator on the Rhinogram",[],[9466],"Nasal Obstruction",[9447],{"intervention":9469,"totalTrials":175,"cells":9470},"Lidocaine 10 MG\u002FML",{"EARLY_PHASE1":9471,"PHASE1":9473,"PHASE2":9475,"PHASE3":9477,"PHASE4":9479,"NA":9481},{"trials":9472,"activeCount":103},[],{"trials":9474,"activeCount":103},[],{"trials":9476,"activeCount":103},[],{"trials":9478,"activeCount":103},[],{"trials":9480,"activeCount":103},[],{"trials":9482,"activeCount":103},[9483],{"nctId":9484,"briefTitle":9485,"status":165,"phases":9486,"primaryCompletion":9487,"completion":9487,"start":9488,"enrollment":1290,"conditions":9489,"interventions":9490},"NCT05711641","Action of Intra-auricular Topical Lidocaine on Tinnitus",[95],"2023-06-01","2022-09-02",[8565],[9469,9491],"Distilled water",{"intervention":9491,"totalTrials":175,"cells":9493},{"EARLY_PHASE1":9494,"PHASE1":9496,"PHASE2":9498,"PHASE3":9500,"PHASE4":9502,"NA":9504},{"trials":9495,"activeCount":103},[],{"trials":9497,"activeCount":103},[],{"trials":9499,"activeCount":103},[],{"trials":9501,"activeCount":103},[],{"trials":9503,"activeCount":103},[],{"trials":9505,"activeCount":103},[9506],{"nctId":9484,"briefTitle":9485,"status":165,"phases":9507,"primaryCompletion":9487,"completion":9487,"start":9488,"enrollment":1290,"conditions":9508,"interventions":9509},[95],[8565],[9469,9491],{"intervention":9511,"totalTrials":175,"cells":9512},"Best medical treatment",{"EARLY_PHASE1":9513,"PHASE1":9515,"PHASE2":9517,"PHASE3":9519,"PHASE4":9521,"NA":9523},{"trials":9514,"activeCount":103},[],{"trials":9516,"activeCount":103},[],{"trials":9518,"activeCount":103},[],{"trials":9520,"activeCount":103},[],{"trials":9522,"activeCount":103},[],{"trials":9524,"activeCount":103},[9525],{"nctId":9526,"briefTitle":9527,"status":193,"phases":9528,"primaryCompletion":5286,"completion":1902,"start":2579,"enrollment":26,"conditions":9529,"interventions":9530},"NCT01771185","Metabolic Effects of Gastrointestinal Surgery in T2DM",[95],[2468],[9511],{"intervention":9532,"totalTrials":175,"cells":9533},"Sildenafil singly or in association with Bosentan",{"EARLY_PHASE1":9534,"PHASE1":9536,"PHASE2":9538,"PHASE3":9540,"PHASE4":9542,"NA":9544},{"trials":9535,"activeCount":103},[],{"trials":9537,"activeCount":103},[],{"trials":9539,"activeCount":103},[],{"trials":9541,"activeCount":103},[],{"trials":9543,"activeCount":103},[],{"trials":9545,"activeCount":103},[9546],{"nctId":9547,"briefTitle":9548,"status":165,"phases":9549,"primaryCompletion":2081,"completion":6585,"start":5676,"enrollment":388,"conditions":9550,"interventions":9553},"NCT01548950","Drug Therapy and Surgery in Congenital Heart Disease With Pulmonary Hypertension",[95],[9551,9552],"Congenital Heart Disease","Pulmonary Arterial Hypertension",[9532],{"intervention":9555,"totalTrials":175,"cells":9556},"Albuterol - Experimental",{"EARLY_PHASE1":9557,"PHASE1":9559,"PHASE2":9561,"PHASE3":9563,"PHASE4":9565,"NA":9567},{"trials":9558,"activeCount":103},[],{"trials":9560,"activeCount":103},[],{"trials":9562,"activeCount":103},[],{"trials":9564,"activeCount":103},[],{"trials":9566,"activeCount":103},[],{"trials":9568,"activeCount":103},[9569],{"nctId":9570,"briefTitle":9571,"status":165,"phases":9572,"primaryCompletion":1902,"completion":3129,"start":5676,"enrollment":9573,"conditions":9574,"interventions":9576},"NCT01323010","Efficacy and Safety of Increasing Doses of Inhaled Albuterol in Children With Acute Wheezing Episodes",[95],119,[9575,9000],"Asthma",[9555,9577],"Albuterol - Control",{"intervention":9577,"totalTrials":175,"cells":9579},{"EARLY_PHASE1":9580,"PHASE1":9582,"PHASE2":9584,"PHASE3":9586,"PHASE4":9588,"NA":9590},{"trials":9581,"activeCount":103},[],{"trials":9583,"activeCount":103},[],{"trials":9585,"activeCount":103},[],{"trials":9587,"activeCount":103},[],{"trials":9589,"activeCount":103},[],{"trials":9591,"activeCount":103},[9592],{"nctId":9570,"briefTitle":9571,"status":165,"phases":9593,"primaryCompletion":1902,"completion":3129,"start":5676,"enrollment":9573,"conditions":9594,"interventions":9595},[95],[9575,9000],[9555,9577],{"intervention":9597,"totalTrials":175,"cells":9598},"Flumazenil",{"EARLY_PHASE1":9599,"PHASE1":9601,"PHASE2":9603,"PHASE3":9605,"PHASE4":9607,"NA":9609},{"trials":9600,"activeCount":103},[],{"trials":9602,"activeCount":103},[],{"trials":9604,"activeCount":103},[],{"trials":9606,"activeCount":103},[],{"trials":9608,"activeCount":103},[],{"trials":9610,"activeCount":103},[9611],{"nctId":9612,"briefTitle":9613,"status":165,"phases":9614,"primaryCompletion":2943,"completion":2943,"start":1821,"enrollment":631,"conditions":9615,"interventions":9617},"NCT02157428","Effect of Flumazenil on Recovery From General Anesthesia With Isoflurane",[95],[9616],"Adverse Effect of Other General Anesthetics",[9597,9618],"saline",{"intervention":9618,"totalTrials":175,"cells":9620},{"EARLY_PHASE1":9621,"PHASE1":9623,"PHASE2":9625,"PHASE3":9627,"PHASE4":9629,"NA":9631},{"trials":9622,"activeCount":103},[],{"trials":9624,"activeCount":103},[],{"trials":9626,"activeCount":103},[],{"trials":9628,"activeCount":103},[],{"trials":9630,"activeCount":103},[],{"trials":9632,"activeCount":103},[9633],{"nctId":9612,"briefTitle":9613,"status":165,"phases":9634,"primaryCompletion":2943,"completion":2943,"start":1821,"enrollment":631,"conditions":9635,"interventions":9636},[95],[9616],[9597,9618],{"intervention":9638,"totalTrials":175,"cells":9639},"EDTA without re-filling",{"EARLY_PHASE1":9640,"PHASE1":9642,"PHASE2":9644,"PHASE3":9646,"PHASE4":9648,"NA":9650},{"trials":9641,"activeCount":103},[],{"trials":9643,"activeCount":103},[],{"trials":9645,"activeCount":103},[],{"trials":9647,"activeCount":103},[],{"trials":9649,"activeCount":103},[],{"trials":9651,"activeCount":103},[9652],{"nctId":9653,"briefTitle":9654,"status":193,"phases":9655,"primaryCompletion":1876,"completion":2070,"start":4497,"enrollment":9656,"conditions":9657,"interventions":9659},"NCT00757458","Evaluation of Bacterial and Fungal Contamination During Propofol Continuous Infusion",[95],652,[9658],"Drug Contamination",[9638],{"intervention":9661,"totalTrials":175,"cells":9662},"Epidural bupivacaine with vasoconstrictor 0.125%",{"EARLY_PHASE1":9663,"PHASE1":9665,"PHASE2":9667,"PHASE3":9669,"PHASE4":9671,"NA":9673},{"trials":9664,"activeCount":103},[],{"trials":9666,"activeCount":103},[],{"trials":9668,"activeCount":103},[],{"trials":9670,"activeCount":103},[],{"trials":9672,"activeCount":103},[],{"trials":9674,"activeCount":103},[9675],{"nctId":9676,"briefTitle":9677,"status":165,"phases":9678,"primaryCompletion":9679,"completion":9679,"start":9680,"enrollment":388,"conditions":9681,"interventions":9685},"NCT02666794","Plasmatic Catecholamines: Randomized Controlled Trial Comparing Epidural Versus Combined Spinal-epidural",[95],"2020-10-16","2017-07-12",[9682,9683,9684],"Fetal Bradycardia","Hypertonic Uterine","Catecholamines",[9661,9686,9687,9688,9689],"Epidural sufentanil","Intrathecal hyperbaric bupivacaine solution 0.5%","Intrathecal morphine","Intrathecal sufentanil",{"intervention":9686,"totalTrials":175,"cells":9691},{"EARLY_PHASE1":9692,"PHASE1":9694,"PHASE2":9696,"PHASE3":9698,"PHASE4":9700,"NA":9702},{"trials":9693,"activeCount":103},[],{"trials":9695,"activeCount":103},[],{"trials":9697,"activeCount":103},[],{"trials":9699,"activeCount":103},[],{"trials":9701,"activeCount":103},[],{"trials":9703,"activeCount":103},[9704],{"nctId":9676,"briefTitle":9677,"status":165,"phases":9705,"primaryCompletion":9679,"completion":9679,"start":9680,"enrollment":388,"conditions":9706,"interventions":9707},[95],[9682,9683,9684],[9661,9686,9687,9688,9689],{"intervention":9687,"totalTrials":175,"cells":9709},{"EARLY_PHASE1":9710,"PHASE1":9712,"PHASE2":9714,"PHASE3":9716,"PHASE4":9718,"NA":9720},{"trials":9711,"activeCount":103},[],{"trials":9713,"activeCount":103},[],{"trials":9715,"activeCount":103},[],{"trials":9717,"activeCount":103},[],{"trials":9719,"activeCount":103},[],{"trials":9721,"activeCount":103},[9722],{"nctId":9676,"briefTitle":9677,"status":165,"phases":9723,"primaryCompletion":9679,"completion":9679,"start":9680,"enrollment":388,"conditions":9724,"interventions":9725},[95],[9682,9683,9684],[9661,9686,9687,9688,9689],{"intervention":9688,"totalTrials":175,"cells":9727},{"EARLY_PHASE1":9728,"PHASE1":9730,"PHASE2":9732,"PHASE3":9734,"PHASE4":9736,"NA":9738},{"trials":9729,"activeCount":103},[],{"trials":9731,"activeCount":103},[],{"trials":9733,"activeCount":103},[],{"trials":9735,"activeCount":103},[],{"trials":9737,"activeCount":103},[],{"trials":9739,"activeCount":103},[9740],{"nctId":9676,"briefTitle":9677,"status":165,"phases":9741,"primaryCompletion":9679,"completion":9679,"start":9680,"enrollment":388,"conditions":9742,"interventions":9743},[95],[9682,9683,9684],[9661,9686,9687,9688,9689],{"intervention":9689,"totalTrials":175,"cells":9745},{"EARLY_PHASE1":9746,"PHASE1":9748,"PHASE2":9750,"PHASE3":9752,"PHASE4":9754,"NA":9756},{"trials":9747,"activeCount":103},[],{"trials":9749,"activeCount":103},[],{"trials":9751,"activeCount":103},[],{"trials":9753,"activeCount":103},[],{"trials":9755,"activeCount":103},[],{"trials":9757,"activeCount":103},[9758],{"nctId":9676,"briefTitle":9677,"status":165,"phases":9759,"primaryCompletion":9679,"completion":9679,"start":9680,"enrollment":388,"conditions":9760,"interventions":9761},[95],[9682,9683,9684],[9661,9686,9687,9688,9689],{"intervention":9763,"totalTrials":175,"cells":9764},"creatine supplementation",{"EARLY_PHASE1":9765,"PHASE1":9767,"PHASE2":9769,"PHASE3":9771,"PHASE4":9773,"NA":9775},{"trials":9766,"activeCount":103},[],{"trials":9768,"activeCount":103},[],{"trials":9770,"activeCount":103},[],{"trials":9772,"activeCount":103},[],{"trials":9774,"activeCount":103},[],{"trials":9776,"activeCount":103},[9777],{"nctId":9778,"briefTitle":9779,"status":165,"phases":9780,"completion":9781,"start":9782,"enrollment":3393,"conditions":9783,"interventions":9785},"NCT00465140","Effects of Creatine Supplementation on Renal Function",[95],"2007-01","2004-01",[9784],"Renal Insufficiency",[9763],{"intervention":9787,"totalTrials":175,"cells":9788},"Antimicrobial",{"EARLY_PHASE1":9789,"PHASE1":9791,"PHASE2":9793,"PHASE3":9795,"PHASE4":9797,"NA":9799},{"trials":9790,"activeCount":103},[],{"trials":9792,"activeCount":103},[],{"trials":9794,"activeCount":103},[],{"trials":9796,"activeCount":103},[],{"trials":9798,"activeCount":103},[],{"trials":9800,"activeCount":103},[9801],{"nctId":9802,"briefTitle":9803,"status":165,"phases":9804,"primaryCompletion":2624,"completion":9068,"start":9805,"enrollment":9806,"conditions":9807,"interventions":9809},"NCT03559530","Acinetobacter Baumannii-related Osteomyelitis: Clinical and Epidemiological Characterization",[],"2017-05-01",262,[9808],"Osteomyelitis",[9787],{"intervention":9231,"totalTrials":175,"cells":9811},{"EARLY_PHASE1":9812,"PHASE1":9814,"PHASE2":9816,"PHASE3":9818,"PHASE4":9820,"NA":9822},{"trials":9813,"activeCount":103},[],{"trials":9815,"activeCount":103},[],{"trials":9817,"activeCount":103},[],{"trials":9819,"activeCount":103},[],{"trials":9821,"activeCount":103},[],{"trials":9823,"activeCount":103},[9824],{"nctId":9224,"briefTitle":9225,"status":165,"phases":9825,"primaryCompletion":9227,"completion":9227,"start":2033,"enrollment":247,"conditions":9826,"interventions":9827},[95],[9229,2035],[9200,9231],{"intervention":9829,"totalTrials":175,"cells":9830},"Uréia",{"EARLY_PHASE1":9831,"PHASE1":9833,"PHASE2":9835,"PHASE3":9837,"PHASE4":9839,"NA":9841},{"trials":9832,"activeCount":103},[],{"trials":9834,"activeCount":103},[],{"trials":9836,"activeCount":103},[],{"trials":9838,"activeCount":103},[],{"trials":9840,"activeCount":103},[],{"trials":9842,"activeCount":103},[9843],{"nctId":9844,"briefTitle":9845,"status":165,"phases":9846,"primaryCompletion":7351,"completion":6120,"start":1914,"enrollment":1373,"conditions":9847,"interventions":9849},"NCT01754740","The Role of Xerostomia in Burning Mouth Syndrome: Case - Control Study",[95],[9848],"Burning Mouth Syndrome",[9829],{"intervention":9851,"totalTrials":175,"cells":9852},"Progesterone 400 Mg Vaginal Suppository on PCOS",{"EARLY_PHASE1":9853,"PHASE1":9855,"PHASE2":9857,"PHASE3":9859,"PHASE4":9861,"NA":9863},{"trials":9854,"activeCount":103},[],{"trials":9856,"activeCount":103},[],{"trials":9858,"activeCount":103},[],{"trials":9860,"activeCount":103},[],{"trials":9862,"activeCount":103},[],{"trials":9864,"activeCount":103},[9865],{"nctId":9866,"briefTitle":9867,"status":165,"phases":9868,"primaryCompletion":9869,"completion":9870,"start":9871,"enrollment":631,"conditions":9872,"interventions":9875},"NCT05062135","Progesterone Action on Endometrium of PCOS",[95],"2014-09-10","2019-04-21","2014-02-10",[9873,9874],"Polycystic Ovary","Progesterone Resistance",[9851],{"intervention":9877,"totalTrials":175,"cells":9878},"Experimental: melatonin treatment group",{"EARLY_PHASE1":9879,"PHASE1":9881,"PHASE2":9883,"PHASE3":9885,"PHASE4":9887,"NA":9889},{"trials":9880,"activeCount":103},[],{"trials":9882,"activeCount":103},[],{"trials":9884,"activeCount":103},[],{"trials":9886,"activeCount":103},[],{"trials":9888,"activeCount":103},[],{"trials":9890,"activeCount":103},[9891],{"nctId":9892,"briefTitle":9893,"status":165,"phases":9894,"primaryCompletion":9895,"completion":9896,"start":9897,"enrollment":9898,"conditions":9899,"interventions":9904},"NCT06868745","Effects of Melatonin Supplementation on Sleep Quality in Patients With Advanced Glaucoma",[95],"2023-07-20","2024-06-26","2022-05-04",64,[3734,9900,9901,9902,9903],"Sleep Disturbance","Circadian Rhythm","Melatonin","Actigraphy",[9877],{"intervention":9906,"totalTrials":175,"cells":9907},"oral epithelial cells obtained by rinsing with 3% sucrose",{"EARLY_PHASE1":9908,"PHASE1":9910,"PHASE2":9912,"PHASE3":9914,"PHASE4":9916,"NA":9918},{"trials":9909,"activeCount":103},[],{"trials":9911,"activeCount":103},[],{"trials":9913,"activeCount":103},[],{"trials":9915,"activeCount":103},[],{"trials":9917,"activeCount":103},[],{"trials":9919,"activeCount":103},[9920],{"nctId":9921,"briefTitle":9922,"status":165,"phases":9923,"primaryCompletion":9924,"completion":9925,"start":9926,"enrollment":235,"conditions":9927,"interventions":9929},"NCT03371446","DNA Methylation Profile of the SOCS-1 Gene Promoter in Smokers Patients With Chronic Periodontitis.",[],"2017-10-16","2017-11-18","2016-06-06",[3465,9928],"Epigenetics",[9906],{"intervention":9931,"totalTrials":175,"cells":9932},"methylene blue dye",{"EARLY_PHASE1":9933,"PHASE1":9935,"PHASE2":9937,"PHASE3":9939,"PHASE4":9941,"NA":9943},{"trials":9934,"activeCount":103},[],{"trials":9936,"activeCount":103},[],{"trials":9938,"activeCount":103},[],{"trials":9940,"activeCount":103},[],{"trials":9942,"activeCount":103},[],{"trials":9944,"activeCount":103},[9945],{"nctId":9946,"briefTitle":9947,"status":165,"phases":9948,"primaryCompletion":5285,"completion":5285,"start":5286,"enrollment":20,"conditions":9949,"interventions":9950},"NCT02938988","Antimicrobial Photodynamic Therapy as an Adjunct Treatment for Periodontal Disease in Down's Syndrome Patients",[95],[3465],[9931],{"intervention":9952,"totalTrials":175,"cells":9953},"Bronchodilator",{"EARLY_PHASE1":9954,"PHASE1":9956,"PHASE2":9958,"PHASE3":9960,"PHASE4":9962,"NA":9964},{"trials":9955,"activeCount":103},[],{"trials":9957,"activeCount":103},[],{"trials":9959,"activeCount":103},[],{"trials":9961,"activeCount":103},[],{"trials":9963,"activeCount":103},[],{"trials":9965,"activeCount":103},[9966],{"nctId":9967,"briefTitle":9968,"status":193,"phases":9969,"primaryCompletion":9970,"completion":9971,"start":9972,"enrollment":17,"conditions":9973,"interventions":9974},"NCT05183841","Bronchodilators on the Exercise Capacity of Bronchiectasis Patients",[95],"2024-11","2025-11","2022-04-14",[8047],[9952],{"intervention":9976,"totalTrials":175,"cells":9977},"N-acetylcysteine syrup",{"EARLY_PHASE1":9978,"PHASE1":9980,"PHASE2":9982,"PHASE3":9984,"PHASE4":9986,"NA":9988},{"trials":9979,"activeCount":103},[],{"trials":9981,"activeCount":103},[],{"trials":9983,"activeCount":103},[],{"trials":9985,"activeCount":103},[],{"trials":9987,"activeCount":103},[],{"trials":9989,"activeCount":103},[9990],{"nctId":9991,"briefTitle":9992,"status":165,"phases":9993,"primaryCompletion":9994,"completion":9995,"start":9996,"enrollment":235,"conditions":9997,"interventions":10000},"NCT04793646","N-acetylcysteine for Primary Sjögren's Syndrome",[95],"2024-12-31","2025-01-21","2021-04-30",[9998,9999],"Sjögren Syndrome","Sicca Syndrome",[9976],{"intervention":9295,"totalTrials":175,"cells":10002},{"EARLY_PHASE1":10003,"PHASE1":10005,"PHASE2":10007,"PHASE3":10009,"PHASE4":10011,"NA":10013},{"trials":10004,"activeCount":103},[],{"trials":10006,"activeCount":103},[],{"trials":10008,"activeCount":103},[],{"trials":10010,"activeCount":103},[],{"trials":10012,"activeCount":103},[],{"trials":10014,"activeCount":103},[10015],{"nctId":9286,"briefTitle":9287,"status":193,"phases":10016,"primaryCompletion":9289,"completion":9290,"start":9291,"enrollment":2106,"conditions":10017,"interventions":10018},[95],[9293],[9295,9296,9297,9264,9298],{"intervention":9296,"totalTrials":175,"cells":10020},{"EARLY_PHASE1":10021,"PHASE1":10023,"PHASE2":10025,"PHASE3":10027,"PHASE4":10029,"NA":10031},{"trials":10022,"activeCount":103},[],{"trials":10024,"activeCount":103},[],{"trials":10026,"activeCount":103},[],{"trials":10028,"activeCount":103},[],{"trials":10030,"activeCount":103},[],{"trials":10032,"activeCount":103},[10033],{"nctId":9286,"briefTitle":9287,"status":193,"phases":10034,"primaryCompletion":9289,"completion":9290,"start":9291,"enrollment":2106,"conditions":10035,"interventions":10036},[95],[9293],[9295,9296,9297,9264,9298],{"intervention":9297,"totalTrials":175,"cells":10038},{"EARLY_PHASE1":10039,"PHASE1":10041,"PHASE2":10043,"PHASE3":10045,"PHASE4":10047,"NA":10049},{"trials":10040,"activeCount":103},[],{"trials":10042,"activeCount":103},[],{"trials":10044,"activeCount":103},[],{"trials":10046,"activeCount":103},[],{"trials":10048,"activeCount":103},[],{"trials":10050,"activeCount":103},[10051],{"nctId":9286,"briefTitle":9287,"status":193,"phases":10052,"primaryCompletion":9289,"completion":9290,"start":9291,"enrollment":2106,"conditions":10053,"interventions":10054},[95],[9293],[9295,9296,9297,9264,9298],{"intervention":9298,"totalTrials":175,"cells":10056},{"EARLY_PHASE1":10057,"PHASE1":10059,"PHASE2":10061,"PHASE3":10063,"PHASE4":10065,"NA":10067},{"trials":10058,"activeCount":103},[],{"trials":10060,"activeCount":103},[],{"trials":10062,"activeCount":103},[],{"trials":10064,"activeCount":103},[],{"trials":10066,"activeCount":103},[],{"trials":10068,"activeCount":103},[10069],{"nctId":9286,"briefTitle":9287,"status":193,"phases":10070,"primaryCompletion":9289,"completion":9290,"start":9291,"enrollment":2106,"conditions":10071,"interventions":10072},[95],[9293],[9295,9296,9297,9264,9298],{"intervention":10074,"totalTrials":175,"cells":10075},"Hypertonic Saline",{"EARLY_PHASE1":10076,"PHASE1":10078,"PHASE2":10080,"PHASE3":10082,"PHASE4":10084,"NA":10086},{"trials":10077,"activeCount":103},[],{"trials":10079,"activeCount":103},[],{"trials":10081,"activeCount":103},[],{"trials":10083,"activeCount":103},[],{"trials":10085,"activeCount":103},[],{"trials":10087,"activeCount":103},[10088],{"nctId":10089,"briefTitle":10090,"status":2489,"phases":10091,"primaryCompletion":6800,"completion":6800,"start":1945,"enrollment":1290,"conditions":10092,"interventions":10094},"NCT02045238","Inhaled Hypertonic Saline Use in the Emergency Department to Treat Acute Viral Bronchiolitis",[95],[10093],"Bronchiolitis",[10074],{"intervention":10096,"totalTrials":175,"cells":10097},"Atosiban",{"EARLY_PHASE1":10098,"PHASE1":10100,"PHASE2":10102,"PHASE3":10104,"PHASE4":10106,"NA":10108},{"trials":10099,"activeCount":103},[],{"trials":10101,"activeCount":103},[],{"trials":10103,"activeCount":103},[],{"trials":10105,"activeCount":103},[],{"trials":10107,"activeCount":103},[],{"trials":10109,"activeCount":103},[10110],{"nctId":10111,"briefTitle":10112,"status":165,"phases":10113,"primaryCompletion":10114,"completion":5224,"start":4083,"enrollment":1176,"conditions":10115,"interventions":10119},"NCT04468568","In Utero Repair of Myelomeningocele: Atosiban Versus Terbutaline",[],"2020-01-31",[10116,10117,10118],"Myelomeningocele","Terbutaline Adverse Reaction","Pregnancy; Malformation Central Nervous System",[10096,10120],"Terbutaline",{"intervention":10120,"totalTrials":175,"cells":10122},{"EARLY_PHASE1":10123,"PHASE1":10125,"PHASE2":10127,"PHASE3":10129,"PHASE4":10131,"NA":10133},{"trials":10124,"activeCount":103},[],{"trials":10126,"activeCount":103},[],{"trials":10128,"activeCount":103},[],{"trials":10130,"activeCount":103},[],{"trials":10132,"activeCount":103},[],{"trials":10134,"activeCount":103},[10135],{"nctId":10111,"briefTitle":10112,"status":165,"phases":10136,"primaryCompletion":10114,"completion":5224,"start":4083,"enrollment":1176,"conditions":10137,"interventions":10138},[],[10116,10117,10118],[10096,10120],{"intervention":10140,"totalTrials":175,"cells":10141},"Renal transplant recipients were allocated to TCL\u002FMMF or to CyA\u002FMMF groups",{"EARLY_PHASE1":10142,"PHASE1":10144,"PHASE2":10146,"PHASE3":10148,"PHASE4":10150,"NA":10152},{"trials":10143,"activeCount":103},[],{"trials":10145,"activeCount":103},[],{"trials":10147,"activeCount":103},[],{"trials":10149,"activeCount":103},[],{"trials":10151,"activeCount":103},[],{"trials":10153,"activeCount":103},[10154],{"nctId":10155,"briefTitle":10156,"status":165,"phases":10157,"primaryCompletion":10158,"completion":10159,"start":10160,"enrollment":1604,"conditions":10161,"interventions":10163},"NCT01892761","MPA Pharmacokinetics in Renal Transplantation",[],"2003-03","2005-06","2002-09",[10162],"Kidney Transplantation Recipients",[10140],{"intervention":10165,"totalTrials":175,"cells":10166},"oral contraceptive",{"EARLY_PHASE1":10167,"PHASE1":10169,"PHASE2":10171,"PHASE3":10173,"PHASE4":10175,"NA":10177},{"trials":10168,"activeCount":103},[],{"trials":10170,"activeCount":103},[],{"trials":10172,"activeCount":103},[],{"trials":10174,"activeCount":103},[],{"trials":10176,"activeCount":103},[],{"trials":10178,"activeCount":103},[10179],{"nctId":10180,"briefTitle":10181,"status":165,"phases":10182,"primaryCompletion":1875,"completion":1875,"start":7960,"enrollment":691,"conditions":10183,"interventions":10184},"NCT00842140","Safety of Hormonal Contraceptives Therapies in Polycystic Ovary Syndrome (PCOS) Women",[95],[9034],[10165,10185,10186],"Oral contraceptive plus spironolactone","Oral contraceptive plus metformin",{"intervention":10185,"totalTrials":175,"cells":10188},{"EARLY_PHASE1":10189,"PHASE1":10191,"PHASE2":10193,"PHASE3":10195,"PHASE4":10197,"NA":10199},{"trials":10190,"activeCount":103},[],{"trials":10192,"activeCount":103},[],{"trials":10194,"activeCount":103},[],{"trials":10196,"activeCount":103},[],{"trials":10198,"activeCount":103},[],{"trials":10200,"activeCount":103},[10201],{"nctId":10180,"briefTitle":10181,"status":165,"phases":10202,"primaryCompletion":1875,"completion":1875,"start":7960,"enrollment":691,"conditions":10203,"interventions":10204},[95],[9034],[10165,10185,10186],{"intervention":10186,"totalTrials":175,"cells":10206},{"EARLY_PHASE1":10207,"PHASE1":10209,"PHASE2":10211,"PHASE3":10213,"PHASE4":10215,"NA":10217},{"trials":10208,"activeCount":103},[],{"trials":10210,"activeCount":103},[],{"trials":10212,"activeCount":103},[],{"trials":10214,"activeCount":103},[],{"trials":10216,"activeCount":103},[],{"trials":10218,"activeCount":103},[10219],{"nctId":10180,"briefTitle":10181,"status":165,"phases":10220,"primaryCompletion":1875,"completion":1875,"start":7960,"enrollment":691,"conditions":10221,"interventions":10222},[95],[9034],[10165,10185,10186],{"intervention":10224,"totalTrials":175,"cells":10225},"Ovulation induction with choriogonadotropin alfa",{"EARLY_PHASE1":10226,"PHASE1":10228,"PHASE2":10230,"PHASE3":10232,"PHASE4":10234,"NA":10236},{"trials":10227,"activeCount":103},[],{"trials":10229,"activeCount":103},[],{"trials":10231,"activeCount":103},[],{"trials":10233,"activeCount":103},[],{"trials":10235,"activeCount":103},[],{"trials":10237,"activeCount":103},[10238],{"nctId":10239,"briefTitle":10240,"status":193,"phases":10241,"primaryCompletion":6800,"completion":6800,"start":1913,"enrollment":414,"conditions":10242,"interventions":10243},"NCT01668056","Synchronization of Ovarian Stimulation for in Vitro Fertilization With Follicular Wave Emergence",[95],[2035],[10224],{"intervention":10245,"totalTrials":175,"cells":10246},"Lavage with physiologic saline solution",{"EARLY_PHASE1":10247,"PHASE1":10249,"PHASE2":10251,"PHASE3":10253,"PHASE4":10255,"NA":10257},{"trials":10248,"activeCount":103},[],{"trials":10250,"activeCount":103},[],{"trials":10252,"activeCount":103},[],{"trials":10254,"activeCount":103},[],{"trials":10256,"activeCount":103},[],{"trials":10258,"activeCount":103},[10259],{"nctId":10260,"briefTitle":10261,"status":193,"phases":10262,"primaryCompletion":10263,"completion":10264,"start":10265,"enrollment":17,"conditions":10266,"interventions":10269},"NCT03089723","Saline Lavage X Saline Lavage and Osteonil® Mini in Rizarthritis",[95],"2018-03-30","2019-08-30","2017-03-30",[10267,10268],"Rhizarthrosis","Metabolic Disease",[10245,10270],"Lavage with physiologic saline solution and Osteonil® Mini",{"intervention":10270,"totalTrials":175,"cells":10272},{"EARLY_PHASE1":10273,"PHASE1":10275,"PHASE2":10277,"PHASE3":10279,"PHASE4":10281,"NA":10283},{"trials":10274,"activeCount":103},[],{"trials":10276,"activeCount":103},[],{"trials":10278,"activeCount":103},[],{"trials":10280,"activeCount":103},[],{"trials":10282,"activeCount":103},[],{"trials":10284,"activeCount":103},[10285],{"nctId":10260,"briefTitle":10261,"status":193,"phases":10286,"primaryCompletion":10263,"completion":10264,"start":10265,"enrollment":17,"conditions":10287,"interventions":10288},[95],[10267,10268],[10245,10270],{"intervention":10290,"totalTrials":175,"cells":10291},"Molecular analysis.",{"EARLY_PHASE1":10292,"PHASE1":10294,"PHASE2":10296,"PHASE3":10298,"PHASE4":10300,"NA":10302},{"trials":10293,"activeCount":103},[],{"trials":10295,"activeCount":103},[],{"trials":10297,"activeCount":103},[],{"trials":10299,"activeCount":103},[],{"trials":10301,"activeCount":103},[],{"trials":10303,"activeCount":103},[10304],{"nctId":10305,"briefTitle":10306,"status":193,"phases":10307,"primaryCompletion":1997,"completion":1933,"start":2047,"enrollment":10308,"conditions":10309,"interventions":10311},"NCT02656134","Small Bowel Endoscopic Evaluation in Familial Adenomatous Polyposis (FAP)",[],55,[10310],"Familial Adenomatous Polyposis",[10290],{"intervention":10313,"totalTrials":175,"cells":10314},"Yellow Fever vaccine",{"EARLY_PHASE1":10315,"PHASE1":10317,"PHASE2":10319,"PHASE3":10321,"PHASE4":10323,"NA":10325},{"trials":10316,"activeCount":103},[],{"trials":10318,"activeCount":103},[],{"trials":10320,"activeCount":103},[],{"trials":10322,"activeCount":103},[],{"trials":10324,"activeCount":103},[],{"trials":10326,"activeCount":103},[10327],{"nctId":10328,"briefTitle":10329,"status":165,"phases":10330,"primaryCompletion":10331,"completion":10332,"start":10333,"enrollment":6630,"conditions":10334,"interventions":10338},"NCT03430388","Yellow Fever Vaccine in Patients With Rheumatic Diseases",[95],"2018-03-24","2019-02-24","2018-01-31",[3710,574,576,10335,579,10336,456,453,578,582,10337],"Inflammatory Myopathy","Mixed Connective Tissue Disease","Juvenile Dermatomyositis",[10313],{"intervention":10340,"totalTrials":175,"cells":10341},"Ursodeoxycholic Acid 300mg",{"EARLY_PHASE1":10342,"PHASE1":10344,"PHASE2":10346,"PHASE3":10348,"PHASE4":10350,"NA":10352},{"trials":10343,"activeCount":103},[],{"trials":10345,"activeCount":103},[],{"trials":10347,"activeCount":103},[],{"trials":10349,"activeCount":103},[],{"trials":10351,"activeCount":103},[],{"trials":10353,"activeCount":103},[10354],{"nctId":10355,"briefTitle":10356,"status":165,"phases":10357,"primaryCompletion":2491,"completion":5568,"start":1933,"enrollment":414,"conditions":10358,"interventions":10361},"NCT03489889","Development of Ursodeoxycholic Acid 300 mg at Hospital Das Clinicas of the University of São Paulo School of Medicine",[95],[10359,10360],"Ursodeoxycholic Acid","Primary Biliary Cirrhosis",[10340,10340],{"intervention":10363,"totalTrials":175,"cells":10364},"etonogestrel implant",{"EARLY_PHASE1":10365,"PHASE1":10367,"PHASE2":10369,"PHASE3":10371,"PHASE4":10373,"NA":10375},{"trials":10366,"activeCount":103},[],{"trials":10368,"activeCount":103},[],{"trials":10370,"activeCount":103},[],{"trials":10372,"activeCount":103},[],{"trials":10374,"activeCount":103},[],{"trials":10376,"activeCount":103},[10377],{"nctId":10378,"briefTitle":10379,"status":165,"phases":10380,"primaryCompletion":4233,"completion":4233,"start":6027,"enrollment":17,"conditions":10381,"interventions":10383},"NCT00828542","Safety of the Etonogestrel-releasing Implant During the Puerperium of Healthy Women",[95],[10382,2677],"Breastfeeding",[10363,10384],"depot medroxyprogesterone acetate",{"intervention":10384,"totalTrials":175,"cells":10386},{"EARLY_PHASE1":10387,"PHASE1":10389,"PHASE2":10391,"PHASE3":10393,"PHASE4":10395,"NA":10397},{"trials":10388,"activeCount":103},[],{"trials":10390,"activeCount":103},[],{"trials":10392,"activeCount":103},[],{"trials":10394,"activeCount":103},[],{"trials":10396,"activeCount":103},[],{"trials":10398,"activeCount":103},[10399],{"nctId":10378,"briefTitle":10379,"status":165,"phases":10400,"primaryCompletion":4233,"completion":4233,"start":6027,"enrollment":17,"conditions":10401,"interventions":10402},[95],[10382,2677],[10363,10384],{"intervention":10404,"totalTrials":175,"cells":10405},"5mg melatonin supplementation",{"EARLY_PHASE1":10406,"PHASE1":10408,"PHASE2":10410,"PHASE3":10412,"PHASE4":10414,"NA":10416},{"trials":10407,"activeCount":103},[],{"trials":10409,"activeCount":103},[],{"trials":10411,"activeCount":103},[],{"trials":10413,"activeCount":103},[],{"trials":10415,"activeCount":103},[],{"trials":10417,"activeCount":103},[10418],{"nctId":10419,"briefTitle":10420,"status":165,"phases":10421,"primaryCompletion":7608,"completion":7608,"start":10422,"enrollment":208,"conditions":10423,"interventions":10426},"NCT07343947","Melatonin Supplementation in Ovarian Response",[95],"2022-01-31",[2035,10424,10425],"Infertility (IVF Patients)","Infertile Women Undergoing IVF or ICSI",[10404],{"intervention":10428,"totalTrials":175,"cells":10429},"Intravitreal Bone Marrow Stem Cells",{"EARLY_PHASE1":10430,"PHASE1":10432,"PHASE2":10434,"PHASE3":10436,"PHASE4":10438,"NA":10440},{"trials":10431,"activeCount":103},[],{"trials":10433,"activeCount":103},[],{"trials":10435,"activeCount":103},[],{"trials":10437,"activeCount":103},[],{"trials":10439,"activeCount":103},[],{"trials":10441,"activeCount":103},[10442],{"nctId":10443,"briefTitle":10444,"status":193,"phases":10445,"primaryCompletion":1996,"completion":3106,"start":5676,"enrollment":414,"conditions":10446,"interventions":10447},"NCT01518842","Effect of Intravitreal Bone Marrow Stem Cells on Ischemic Retinopathy",[95],[4410],[10428],{"intervention":10449,"totalTrials":175,"cells":10450},"Intracervical anesthesia with lidocaine 2%",{"EARLY_PHASE1":10451,"PHASE1":10453,"PHASE2":10455,"PHASE3":10457,"PHASE4":10459,"NA":10461},{"trials":10452,"activeCount":103},[],{"trials":10454,"activeCount":103},[],{"trials":10456,"activeCount":103},[],{"trials":10458,"activeCount":103},[],{"trials":10460,"activeCount":103},[],{"trials":10462,"activeCount":103},[10463],{"nctId":10464,"briefTitle":10465,"status":165,"phases":10466,"primaryCompletion":1945,"completion":1945,"start":2274,"enrollment":740,"conditions":10467,"interventions":10468},"NCT02155166","Effect of Intracervical on the Pain Associated With the Insertion of the LNG-IUS",[95],[28],[10449,10469],"ibuprofen 400 mg",{"intervention":10469,"totalTrials":175,"cells":10471},{"EARLY_PHASE1":10472,"PHASE1":10474,"PHASE2":10476,"PHASE3":10478,"PHASE4":10480,"NA":10482},{"trials":10473,"activeCount":103},[],{"trials":10475,"activeCount":103},[],{"trials":10477,"activeCount":103},[],{"trials":10479,"activeCount":103},[],{"trials":10481,"activeCount":103},[],{"trials":10483,"activeCount":103},[10484],{"nctId":10464,"briefTitle":10465,"status":165,"phases":10485,"primaryCompletion":1945,"completion":1945,"start":2274,"enrollment":740,"conditions":10486,"interventions":10487},[95],[28],[10449,10469],{"intervention":10489,"totalTrials":175,"cells":10490},"Ephedrine",{"EARLY_PHASE1":10491,"PHASE1":10493,"PHASE2":10495,"PHASE3":10497,"PHASE4":10499,"NA":10501},{"trials":10492,"activeCount":103},[],{"trials":10494,"activeCount":103},[],{"trials":10496,"activeCount":103},[],{"trials":10498,"activeCount":103},[],{"trials":10500,"activeCount":103},[],{"trials":10502,"activeCount":103},[10503],{"nctId":10504,"briefTitle":10505,"status":193,"phases":10506,"primaryCompletion":195,"start":195,"enrollment":235,"conditions":10507,"interventions":10509},"NCT02245191","Ephedrine, Phenylephrine and Metaraminol Effects on Maternal Cardiac Output, Uterine Blood Flow and Fetal Circulation",[95],[10508],"Preeclampsia",[10489,10510,10511],"Phenylephrine","Metaraminol",{"intervention":10510,"totalTrials":175,"cells":10513},{"EARLY_PHASE1":10514,"PHASE1":10516,"PHASE2":10518,"PHASE3":10520,"PHASE4":10522,"NA":10524},{"trials":10515,"activeCount":103},[],{"trials":10517,"activeCount":103},[],{"trials":10519,"activeCount":103},[],{"trials":10521,"activeCount":103},[],{"trials":10523,"activeCount":103},[],{"trials":10525,"activeCount":103},[10526],{"nctId":10504,"briefTitle":10505,"status":193,"phases":10527,"primaryCompletion":195,"start":195,"enrollment":235,"conditions":10528,"interventions":10529},[95],[10508],[10489,10510,10511],{"intervention":10511,"totalTrials":175,"cells":10531},{"EARLY_PHASE1":10532,"PHASE1":10534,"PHASE2":10536,"PHASE3":10538,"PHASE4":10540,"NA":10542},{"trials":10533,"activeCount":103},[],{"trials":10535,"activeCount":103},[],{"trials":10537,"activeCount":103},[],{"trials":10539,"activeCount":103},[],{"trials":10541,"activeCount":103},[],{"trials":10543,"activeCount":103},[10544],{"nctId":10504,"briefTitle":10505,"status":193,"phases":10545,"primaryCompletion":195,"start":195,"enrollment":235,"conditions":10546,"interventions":10547},[95],[10508],[10489,10510,10511],{"intervention":10549,"totalTrials":175,"cells":10550},"Salbutamol",{"EARLY_PHASE1":10551,"PHASE1":10553,"PHASE2":10555,"PHASE3":10557,"PHASE4":10559,"NA":10561},{"trials":10552,"activeCount":103},[],{"trials":10554,"activeCount":103},[],{"trials":10556,"activeCount":103},[],{"trials":10558,"activeCount":103},[],{"trials":10560,"activeCount":103},[],{"trials":10562,"activeCount":103},[10563],{"nctId":10564,"briefTitle":10565,"status":165,"phases":10566,"primaryCompletion":4807,"completion":10567,"start":10568,"enrollment":23,"conditions":10569,"interventions":10572},"NCT02523833","Small Airway Involvement in Patients With Chronic Hypersensitivity Pneumonitis",[95],"2017-11-20","2015-09-01",[10570,10571],"Hypersensitivity Pneumonitis","Airway Disease Small",[10549],{"intervention":10574,"totalTrials":175,"cells":10575},"adjuvant chemotherapy with 5-FU isolated",{"EARLY_PHASE1":10576,"PHASE1":10578,"PHASE2":10580,"PHASE3":10582,"PHASE4":10584,"NA":10586},{"trials":10577,"activeCount":103},[],{"trials":10579,"activeCount":103},[],{"trials":10581,"activeCount":103},[],{"trials":10583,"activeCount":103},[],{"trials":10585,"activeCount":103},[],{"trials":10587,"activeCount":103},[10588],{"nctId":10589,"briefTitle":10590,"status":165,"phases":10591,"primaryCompletion":2444,"completion":10592,"start":1702,"enrollment":414,"conditions":10593,"interventions":10596},"NCT03213444","Impact of Adjuvant Chemotherapy in Patients With Colon Cancer",[95],"2019-02",[10594,10595],"Colon Cancer","Adjuvant Chemotherapy",[10574,10597],"adjuvant chemotherapy with 5-FU associated with oxaliplatin",{"intervention":10597,"totalTrials":175,"cells":10599},{"EARLY_PHASE1":10600,"PHASE1":10602,"PHASE2":10604,"PHASE3":10606,"PHASE4":10608,"NA":10610},{"trials":10601,"activeCount":103},[],{"trials":10603,"activeCount":103},[],{"trials":10605,"activeCount":103},[],{"trials":10607,"activeCount":103},[],{"trials":10609,"activeCount":103},[],{"trials":10611,"activeCount":103},[10612],{"nctId":10589,"briefTitle":10590,"status":165,"phases":10613,"primaryCompletion":2444,"completion":10592,"start":1702,"enrollment":414,"conditions":10614,"interventions":10615},[95],[10594,10595],[10574,10597],{"intervention":10617,"totalTrials":175,"cells":10618},"Colchicine 0.5 MG",{"EARLY_PHASE1":10619,"PHASE1":10621,"PHASE2":10623,"PHASE3":10625,"PHASE4":10627,"NA":10629},{"trials":10620,"activeCount":103},[],{"trials":10622,"activeCount":103},[],{"trials":10624,"activeCount":103},[],{"trials":10626,"activeCount":103},[],{"trials":10628,"activeCount":103},[],{"trials":10630,"activeCount":103},[10631],{"nctId":10632,"briefTitle":10633,"status":165,"phases":10634,"primaryCompletion":10635,"completion":10635,"start":10636,"enrollment":208,"conditions":10637,"interventions":10639},"NCT05956145","Effect of Low Dose of Colchicine on Platelet Reactivity",[95],"2024-04-03","2021-06-17",[10638,25],"Platelet Aggregation, Spontaneous",[10617],{"intervention":10641,"totalTrials":175,"cells":10642},"Standard group",{"EARLY_PHASE1":10643,"PHASE1":10645,"PHASE2":10647,"PHASE3":10649,"PHASE4":10651,"NA":10653},{"trials":10644,"activeCount":103},[],{"trials":10646,"activeCount":103},[],{"trials":10648,"activeCount":103},[],{"trials":10650,"activeCount":103},[],{"trials":10652,"activeCount":103},[],{"trials":10654,"activeCount":103},[10655],{"nctId":10656,"briefTitle":10657,"status":165,"phases":10658,"primaryCompletion":10659,"completion":10660,"start":10661,"enrollment":273,"conditions":10662,"interventions":10664},"NCT04005534","US-Guided Preemptive Brachial Plexus Blockade May Reduce Post-operative Pain: a Randomized Study",[95],"2024-03-01","2024-03-10","2022-12-14",[4736,10663],"Rotator Cuff Injuries",[10641,10665],"Preemptive group",{"intervention":10665,"totalTrials":175,"cells":10667},{"EARLY_PHASE1":10668,"PHASE1":10670,"PHASE2":10672,"PHASE3":10674,"PHASE4":10676,"NA":10678},{"trials":10669,"activeCount":103},[],{"trials":10671,"activeCount":103},[],{"trials":10673,"activeCount":103},[],{"trials":10675,"activeCount":103},[],{"trials":10677,"activeCount":103},[],{"trials":10679,"activeCount":103},[10680],{"nctId":10656,"briefTitle":10657,"status":165,"phases":10681,"primaryCompletion":10659,"completion":10660,"start":10661,"enrollment":273,"conditions":10682,"interventions":10683},[95],[4736,10663],[10641,10665],{"intervention":10685,"totalTrials":175,"cells":10686},"Estradiol valerate",{"EARLY_PHASE1":10687,"PHASE1":10689,"PHASE2":10691,"PHASE3":10693,"PHASE4":10695,"NA":10697},{"trials":10688,"activeCount":103},[],{"trials":10690,"activeCount":103},[],{"trials":10692,"activeCount":103},[],{"trials":10694,"activeCount":103},[],{"trials":10696,"activeCount":103},[],{"trials":10698,"activeCount":103},[10699],{"nctId":10700,"briefTitle":10701,"status":165,"phases":10702,"primaryCompletion":4970,"completion":4970,"start":3623,"enrollment":157,"conditions":10703,"interventions":10705},"NCT01120665","Isolated and Associated Effects of Physical Exercise and Estrogen Therapy on Climactercs Women",[95],[10704],"Women's Health",[10685],{"intervention":10707,"totalTrials":175,"cells":10708},"Statins and Ezetimibe",{"EARLY_PHASE1":10709,"PHASE1":10711,"PHASE2":10713,"PHASE3":10715,"PHASE4":10717,"NA":10719},{"trials":10710,"activeCount":103},[],{"trials":10712,"activeCount":103},[],{"trials":10714,"activeCount":103},[],{"trials":10716,"activeCount":103},[],{"trials":10718,"activeCount":103},[],{"trials":10720,"activeCount":103},[10721],{"nctId":10722,"briefTitle":10723,"status":193,"phases":10724,"start":10725,"conditions":10726,"interventions":10728},"NCT00475826","Evaluation of Chylomicrons Metabolism in Sub-Clinical Atherosclerosis in Patients Whit Heterozigous Familial Hypercholesterolemia (FH) Treated With Statin Plus Ezetimibe",[95],"2007-04",[10727],"Heterozigous Familial Hypercholesterolemia",[10707],{"intervention":10730,"totalTrials":175,"cells":10731},"Hydrochlorothiazide",{"EARLY_PHASE1":10732,"PHASE1":10734,"PHASE2":10736,"PHASE3":10738,"PHASE4":10740,"NA":10742},{"trials":10733,"activeCount":103},[],{"trials":10735,"activeCount":103},[],{"trials":10737,"activeCount":103},[],{"trials":10739,"activeCount":103},[],{"trials":10741,"activeCount":103},[],{"trials":10743,"activeCount":103},[10744],{"nctId":10745,"briefTitle":10746,"status":193,"phases":10747,"primaryCompletion":5568,"completion":5568,"start":10748,"enrollment":1604,"conditions":10749,"interventions":10751},"NCT03082742","The Effect of Diuretics on Mineral and Bone Disorder in Chronic Kidney Disease Patients",[95],"2015-08-01",[10750,1906],"Secondary Hyperparathyroidism",[10730,10752],"Furosemide",{"intervention":10752,"totalTrials":175,"cells":10754},{"EARLY_PHASE1":10755,"PHASE1":10757,"PHASE2":10759,"PHASE3":10761,"PHASE4":10763,"NA":10765},{"trials":10756,"activeCount":103},[],{"trials":10758,"activeCount":103},[],{"trials":10760,"activeCount":103},[],{"trials":10762,"activeCount":103},[],{"trials":10764,"activeCount":103},[],{"trials":10766,"activeCount":103},[10767],{"nctId":10745,"briefTitle":10746,"status":193,"phases":10768,"primaryCompletion":5568,"completion":5568,"start":10748,"enrollment":1604,"conditions":10769,"interventions":10770},[95],[10750,1906],[10730,10752],{"intervention":10772,"totalTrials":175,"cells":10773},"Ketamine plus general anesthesia",{"EARLY_PHASE1":10774,"PHASE1":10776,"PHASE2":10778,"PHASE3":10780,"PHASE4":10782,"NA":10784},{"trials":10775,"activeCount":103},[],{"trials":10777,"activeCount":103},[],{"trials":10779,"activeCount":103},[],{"trials":10781,"activeCount":103},[],{"trials":10783,"activeCount":103},[],{"trials":10785,"activeCount":103},[10786],{"nctId":10787,"briefTitle":10788,"status":193,"phases":10789,"primaryCompletion":7760,"completion":7760,"start":10790,"enrollment":837,"conditions":10791,"interventions":10793},"NCT04360473","Ketamine Versus Magnesium Sulfate in the Time and Awakening Quality of General Anesthesia.",[95],"2022-03-14",[10792],"Awakening, Post-Anesthesia Delayed",[10772,10794,10795],"Magnesium sulfate plus general anesthesia","ketamine plus magnesium sulfate plus general anesthesia",{"intervention":10794,"totalTrials":175,"cells":10797},{"EARLY_PHASE1":10798,"PHASE1":10800,"PHASE2":10802,"PHASE3":10804,"PHASE4":10806,"NA":10808},{"trials":10799,"activeCount":103},[],{"trials":10801,"activeCount":103},[],{"trials":10803,"activeCount":103},[],{"trials":10805,"activeCount":103},[],{"trials":10807,"activeCount":103},[],{"trials":10809,"activeCount":103},[10810],{"nctId":10787,"briefTitle":10788,"status":193,"phases":10811,"primaryCompletion":7760,"completion":7760,"start":10790,"enrollment":837,"conditions":10812,"interventions":10813},[95],[10792],[10772,10794,10795],{"intervention":10795,"totalTrials":175,"cells":10815},{"EARLY_PHASE1":10816,"PHASE1":10818,"PHASE2":10820,"PHASE3":10822,"PHASE4":10824,"NA":10826},{"trials":10817,"activeCount":103},[],{"trials":10819,"activeCount":103},[],{"trials":10821,"activeCount":103},[],{"trials":10823,"activeCount":103},[],{"trials":10825,"activeCount":103},[],{"trials":10827,"activeCount":103},[10828],{"nctId":10787,"briefTitle":10788,"status":193,"phases":10829,"primaryCompletion":7760,"completion":7760,"start":10790,"enrollment":837,"conditions":10830,"interventions":10831},[95],[10792],[10772,10794,10795],{"intervention":10833,"totalTrials":175,"cells":10834},"Drug prescription pattern",{"EARLY_PHASE1":10835,"PHASE1":10837,"PHASE2":10839,"PHASE3":10841,"PHASE4":10843,"NA":10845},{"trials":10836,"activeCount":103},[],{"trials":10838,"activeCount":103},[],{"trials":10840,"activeCount":103},[],{"trials":10842,"activeCount":103},[],{"trials":10844,"activeCount":103},[],{"trials":10846,"activeCount":103},[10847],{"nctId":10848,"briefTitle":10849,"status":165,"phases":10850,"primaryCompletion":2943,"completion":2943,"start":2943,"enrollment":10851,"conditions":10852,"interventions":10855},"NCT01696656","Prescription Pattern of Adjuvant Drugs and Vitamins in Patients Undergoing Long-term Home Nutritional Support for Intestinal Insufficiency",[],37,[10853,10854],"Intestinal Insufficiency","Short Bowel Syndrome",[10833],{"intervention":10857,"totalTrials":175,"cells":10858},"Lipid-lowering agents",{"EARLY_PHASE1":10859,"PHASE1":10861,"PHASE2":10863,"PHASE3":10865,"PHASE4":10867,"NA":10869},{"trials":10860,"activeCount":103},[],{"trials":10862,"activeCount":103},[],{"trials":10864,"activeCount":103},[],{"trials":10866,"activeCount":103},[],{"trials":10868,"activeCount":103},[],{"trials":10870,"activeCount":103},[10871],{"nctId":10872,"briefTitle":10873,"status":2489,"phases":10874,"primaryCompletion":10875,"completion":10875,"start":1839,"enrollment":26,"conditions":10876,"interventions":10878},"NCT03092154","Lipid-lowering Agents in Patients With Dermatomyositis and Polymyositis",[95],"2022-05-31",[10877],"Treatment Side Effects",[10857],{"intervention":9038,"totalTrials":175,"cells":10880},{"EARLY_PHASE1":10881,"PHASE1":10883,"PHASE2":10885,"PHASE3":10887,"PHASE4":10889,"NA":10891},{"trials":10882,"activeCount":103},[],{"trials":10884,"activeCount":103},[],{"trials":10886,"activeCount":103},[],{"trials":10888,"activeCount":103},[],{"trials":10890,"activeCount":103},[],{"trials":10892,"activeCount":103},[10893],{"nctId":9028,"briefTitle":9029,"status":165,"phases":10894,"primaryCompletion":9031,"completion":9031,"start":9032,"enrollment":235,"conditions":10895,"interventions":10896},[95],[9034,9035,9036],[9038,2470],{"intervention":10898,"totalTrials":175,"cells":10899},"use of lipid-lowering drugs.",{"EARLY_PHASE1":10900,"PHASE1":10902,"PHASE2":10904,"PHASE3":10906,"PHASE4":10908,"NA":10910},{"trials":10901,"activeCount":103},[],{"trials":10903,"activeCount":103},[],{"trials":10905,"activeCount":103},[],{"trials":10907,"activeCount":103},[],{"trials":10909,"activeCount":103},[],{"trials":10911,"activeCount":103},[10912],{"nctId":10913,"briefTitle":10914,"status":165,"phases":10915,"primaryCompletion":3329,"completion":2273,"start":3130,"enrollment":2106,"conditions":10916,"interventions":10919},"NCT02530827","Energy Expenditure of People Living With HIV\u002FAIDS",[],[10917,10918],"HIV\u002FAIDS","HIV Lipodystrophy Syndrome",[10898],{"intervention":10921,"totalTrials":175,"cells":10922},"unfractionated Heparin",{"EARLY_PHASE1":10923,"PHASE1":10925,"PHASE2":10927,"PHASE3":10929,"PHASE4":10931,"NA":10933},{"trials":10924,"activeCount":103},[],{"trials":10926,"activeCount":103},[],{"trials":10928,"activeCount":103},[],{"trials":10930,"activeCount":103},[],{"trials":10932,"activeCount":103},[],{"trials":10934,"activeCount":103},[10935],{"nctId":10936,"briefTitle":10937,"status":165,"phases":10938,"primaryCompletion":5029,"completion":3542,"start":10939,"enrollment":10940,"conditions":10941,"interventions":10942},"NCT04487990","CoV-Hep Study: Regional Anticoagulation Modalities in Continuous Venous Venous Hemodialysis in Patients With COVID-19",[95],"2020-06-29",118,[1487,5032],[10921],{"intervention":10944,"totalTrials":175,"cells":10945},"potassium diclofenac",{"EARLY_PHASE1":10946,"PHASE1":10948,"PHASE2":10950,"PHASE3":10952,"PHASE4":10954,"NA":10956},{"trials":10947,"activeCount":103},[],{"trials":10949,"activeCount":103},[],{"trials":10951,"activeCount":103},[],{"trials":10953,"activeCount":103},[],{"trials":10955,"activeCount":103},[],{"trials":10957,"activeCount":103},[10958],{"nctId":10959,"briefTitle":10960,"status":165,"phases":10961,"primaryCompletion":2009,"completion":2009,"start":8862,"enrollment":414,"conditions":10962,"interventions":10963},"NCT01009021","Oral Diclofenac for Retinal Photocoagulation in Diabetic Retinopathy",[95],[28],[10944],{"intervention":10965,"totalTrials":175,"cells":10966},"Allopurinol",{"EARLY_PHASE1":10967,"PHASE1":10969,"PHASE2":10971,"PHASE3":10973,"PHASE4":10975,"NA":10977},{"trials":10968,"activeCount":103},[],{"trials":10970,"activeCount":103},[],{"trials":10972,"activeCount":103},[],{"trials":10974,"activeCount":103},[],{"trials":10976,"activeCount":103},[],{"trials":10978,"activeCount":103},[10979],{"nctId":10980,"briefTitle":10981,"status":165,"phases":10982,"primaryCompletion":10983,"completion":10983,"start":10984,"enrollment":388,"conditions":10985,"interventions":10988},"NCT05601271","Effect of Allopurinol on Markers of Mineral and Bone Metabolism",[95],"2025-03-01","2021-03-01",[548,10986,10987],"Osteodystrophy","Uric Acid Concentration, Serum, Quantitative Trait Locus 7",[10965],{"intervention":10990,"totalTrials":175,"cells":10991},"Magnesium sulfate through real weight group",{"EARLY_PHASE1":10992,"PHASE1":10994,"PHASE2":10996,"PHASE3":10998,"PHASE4":11000,"NA":11002},{"trials":10993,"activeCount":103},[],{"trials":10995,"activeCount":103},[],{"trials":10997,"activeCount":103},[],{"trials":10999,"activeCount":103},[],{"trials":11001,"activeCount":103},[],{"trials":11003,"activeCount":103},[11004],{"nctId":11005,"briefTitle":11006,"status":165,"phases":11007,"primaryCompletion":11008,"completion":11008,"start":11009,"enrollment":5919,"conditions":11010,"interventions":11011},"NCT04003688","Magnesium Sulfate Dose in Obese Patients.",[95],"2020-11-12","2019-08-26",[1673,4736,16],[10990,11012],"Magnesium sulfate through ideal corrected weight group",{"intervention":11012,"totalTrials":175,"cells":11014},{"EARLY_PHASE1":11015,"PHASE1":11017,"PHASE2":11019,"PHASE3":11021,"PHASE4":11023,"NA":11025},{"trials":11016,"activeCount":103},[],{"trials":11018,"activeCount":103},[],{"trials":11020,"activeCount":103},[],{"trials":11022,"activeCount":103},[],{"trials":11024,"activeCount":103},[],{"trials":11026,"activeCount":103},[11027],{"nctId":11005,"briefTitle":11006,"status":165,"phases":11028,"primaryCompletion":11008,"completion":11008,"start":11009,"enrollment":5919,"conditions":11029,"interventions":11030},[95],[1673,4736,16],[10990,11012],{"intervention":11032,"totalTrials":175,"cells":11033},"haloperidol+promethazine",{"EARLY_PHASE1":11034,"PHASE1":11036,"PHASE2":11038,"PHASE3":11040,"PHASE4":11042,"NA":11044},{"trials":11035,"activeCount":103},[],{"trials":11037,"activeCount":103},[],{"trials":11039,"activeCount":103},[],{"trials":11041,"activeCount":103},[],{"trials":11043,"activeCount":103},[],{"trials":11045,"activeCount":103},[11046],{"nctId":11047,"briefTitle":11048,"status":165,"phases":11049,"primaryCompletion":1969,"completion":1969,"start":4970,"enrollment":2071,"conditions":11050,"interventions":11052},"NCT01485692","Four Interventions in the Management of Psychomotor Agitation, Safety and Efficacy Evaluation",[95],[11051],"Psychomotor Agitation",[11032,11053,11054,11055],"haloperidol + midazolam","olanzapine","Ziprasidone",{"intervention":11053,"totalTrials":175,"cells":11057},{"EARLY_PHASE1":11058,"PHASE1":11060,"PHASE2":11062,"PHASE3":11064,"PHASE4":11066,"NA":11068},{"trials":11059,"activeCount":103},[],{"trials":11061,"activeCount":103},[],{"trials":11063,"activeCount":103},[],{"trials":11065,"activeCount":103},[],{"trials":11067,"activeCount":103},[],{"trials":11069,"activeCount":103},[11070],{"nctId":11047,"briefTitle":11048,"status":165,"phases":11071,"primaryCompletion":1969,"completion":1969,"start":4970,"enrollment":2071,"conditions":11072,"interventions":11073},[95],[11051],[11032,11053,11054,11055],{"intervention":11054,"totalTrials":175,"cells":11075},{"EARLY_PHASE1":11076,"PHASE1":11078,"PHASE2":11080,"PHASE3":11082,"PHASE4":11084,"NA":11086},{"trials":11077,"activeCount":103},[],{"trials":11079,"activeCount":103},[],{"trials":11081,"activeCount":103},[],{"trials":11083,"activeCount":103},[],{"trials":11085,"activeCount":103},[],{"trials":11087,"activeCount":103},[11088],{"nctId":11047,"briefTitle":11048,"status":165,"phases":11089,"primaryCompletion":1969,"completion":1969,"start":4970,"enrollment":2071,"conditions":11090,"interventions":11091},[95],[11051],[11032,11053,11054,11055],{"intervention":11055,"totalTrials":175,"cells":11093},{"EARLY_PHASE1":11094,"PHASE1":11096,"PHASE2":11098,"PHASE3":11100,"PHASE4":11102,"NA":11104},{"trials":11095,"activeCount":103},[],{"trials":11097,"activeCount":103},[],{"trials":11099,"activeCount":103},[],{"trials":11101,"activeCount":103},[],{"trials":11103,"activeCount":103},[],{"trials":11105,"activeCount":103},[11106],{"nctId":11047,"briefTitle":11048,"status":165,"phases":11107,"primaryCompletion":1969,"completion":1969,"start":4970,"enrollment":2071,"conditions":11108,"interventions":11109},[95],[11051],[11032,11053,11054,11055],{"intervention":11111,"totalTrials":175,"cells":11112},"Methyl Aminolevulinate",{"EARLY_PHASE1":11113,"PHASE1":11115,"PHASE2":11117,"PHASE3":11119,"PHASE4":11121,"NA":11123},{"trials":11114,"activeCount":103},[],{"trials":11116,"activeCount":103},[],{"trials":11118,"activeCount":103},[],{"trials":11120,"activeCount":103},[],{"trials":11122,"activeCount":103},[],{"trials":11124,"activeCount":103},[11125],{"nctId":11126,"briefTitle":11127,"status":193,"phases":11128,"primaryCompletion":11129,"completion":2444,"start":1997,"enrollment":32,"conditions":11130,"interventions":11132},"NCT03013647","Daylight Photodynamic Therapy for Actinic Keratosis and Skin Field Cancerization",[95],"2017-04",[11131],"Actinic Keratosis",[11111],{"intervention":11134,"totalTrials":175,"cells":11135},"mepivacaine chloridrato epinephrine",{"EARLY_PHASE1":11136,"PHASE1":11138,"PHASE2":11140,"PHASE3":11142,"PHASE4":11144,"NA":11146},{"trials":11137,"activeCount":103},[],{"trials":11139,"activeCount":103},[],{"trials":11141,"activeCount":103},[],{"trials":11143,"activeCount":103},[],{"trials":11145,"activeCount":103},[],{"trials":11147,"activeCount":103},[11148],{"nctId":11149,"briefTitle":11150,"status":193,"phases":11151,"primaryCompletion":207,"completion":2832,"start":8244,"enrollment":414,"conditions":11152,"interventions":11155},"NCT02603198","2%-Mepivacaine With Two Different Vasoconstrictors Solutions in Third Molar Surgery a Comparative Study",[95],[28,11153,11154],"Trismus","Edema",[11134,11156],"mepivacaine chloridrato levonordefrin",{"intervention":11156,"totalTrials":175,"cells":11158},{"EARLY_PHASE1":11159,"PHASE1":11161,"PHASE2":11163,"PHASE3":11165,"PHASE4":11167,"NA":11169},{"trials":11160,"activeCount":103},[],{"trials":11162,"activeCount":103},[],{"trials":11164,"activeCount":103},[],{"trials":11166,"activeCount":103},[],{"trials":11168,"activeCount":103},[],{"trials":11170,"activeCount":103},[11171],{"nctId":11149,"briefTitle":11150,"status":193,"phases":11172,"primaryCompletion":207,"completion":2832,"start":8244,"enrollment":414,"conditions":11173,"interventions":11174},[95],[28,11153,11154],[11134,11156],{"intervention":11176,"totalTrials":175,"cells":11177},"calcitriol",{"EARLY_PHASE1":11178,"PHASE1":11180,"PHASE2":11182,"PHASE3":11184,"PHASE4":11186,"NA":11188},{"trials":11179,"activeCount":103},[],{"trials":11181,"activeCount":103},[],{"trials":11183,"activeCount":103},[],{"trials":11185,"activeCount":103},[],{"trials":11187,"activeCount":103},[],{"trials":11189,"activeCount":103},[11190],{"nctId":11191,"briefTitle":11192,"status":193,"phases":11193,"primaryCompletion":750,"completion":1902,"start":6027,"enrollment":235,"conditions":11194,"interventions":11197},"NCT00926315","Gene Expression Profile of Breast Cancer Samples After Vitamin D Supplementation",[95],[11195,11196],"Breast Neoplasms","Postmenopausal Disorder",[11176,11198],"Calcitriol",{"intervention":11200,"totalTrials":175,"cells":11201},"Corticosteroid monotherapy",{"EARLY_PHASE1":11202,"PHASE1":11204,"PHASE2":11206,"PHASE3":11208,"PHASE4":11210,"NA":11212},{"trials":11203,"activeCount":103},[],{"trials":11205,"activeCount":103},[],{"trials":11207,"activeCount":103},[],{"trials":11209,"activeCount":103},[],{"trials":11211,"activeCount":103},[],{"trials":11213,"activeCount":103},[11214],{"nctId":11215,"briefTitle":11216,"status":165,"phases":11217,"primaryCompletion":11218,"completion":11218,"start":11219,"enrollment":1324,"conditions":11220,"interventions":11224},"NCT03811366","Multimodal Analysis and Electroretinogram in VKH From Acute Onset - Part I",[95],"2017-01-31","2011-06-01",[11221,5547,11222,11223],"Uveomeningoencephalitic Syndrome","Choroid Disease","Visual Impairment",[11200],{"intervention":11226,"totalTrials":175,"cells":11227},"Lidocaine with epinephrine",{"EARLY_PHASE1":11228,"PHASE1":11230,"PHASE2":11232,"PHASE3":11234,"PHASE4":11236,"NA":11238},{"trials":11229,"activeCount":103},[],{"trials":11231,"activeCount":103},[],{"trials":11233,"activeCount":103},[],{"trials":11235,"activeCount":103},[],{"trials":11237,"activeCount":103},[],{"trials":11239,"activeCount":103},[11240],{"nctId":11241,"briefTitle":11242,"status":193,"phases":11243,"primaryCompletion":1997,"completion":11244,"start":3795,"enrollment":273,"conditions":11245,"interventions":11246},"NCT02228083","Dental Anesthesia in Heart Failure Patients",[95],"2017-09",[19],[11226],{"intervention":9106,"totalTrials":175,"cells":11248},{"EARLY_PHASE1":11249,"PHASE1":11251,"PHASE2":11253,"PHASE3":11255,"PHASE4":11257,"NA":11259},{"trials":11250,"activeCount":103},[],{"trials":11252,"activeCount":103},[],{"trials":11254,"activeCount":103},[],{"trials":11256,"activeCount":103},[],{"trials":11258,"activeCount":103},[],{"trials":11260,"activeCount":103},[11261],{"nctId":9098,"briefTitle":9099,"status":2489,"phases":11262,"primaryCompletion":9101,"completion":9101,"start":9102,"enrollment":9103,"conditions":11263,"interventions":11264},[95],[447],[9106,9107,7458,9108],{"intervention":9107,"totalTrials":175,"cells":11266},{"EARLY_PHASE1":11267,"PHASE1":11269,"PHASE2":11271,"PHASE3":11273,"PHASE4":11275,"NA":11277},{"trials":11268,"activeCount":103},[],{"trials":11270,"activeCount":103},[],{"trials":11272,"activeCount":103},[],{"trials":11274,"activeCount":103},[],{"trials":11276,"activeCount":103},[],{"trials":11278,"activeCount":103},[11279],{"nctId":9098,"briefTitle":9099,"status":2489,"phases":11280,"primaryCompletion":9101,"completion":9101,"start":9102,"enrollment":9103,"conditions":11281,"interventions":11282},[95],[447],[9106,9107,7458,9108],{"intervention":9108,"totalTrials":175,"cells":11284},{"EARLY_PHASE1":11285,"PHASE1":11287,"PHASE2":11289,"PHASE3":11291,"PHASE4":11293,"NA":11295},{"trials":11286,"activeCount":103},[],{"trials":11288,"activeCount":103},[],{"trials":11290,"activeCount":103},[],{"trials":11292,"activeCount":103},[],{"trials":11294,"activeCount":103},[],{"trials":11296,"activeCount":103},[11297],{"nctId":9098,"briefTitle":9099,"status":2489,"phases":11298,"primaryCompletion":9101,"completion":9101,"start":9102,"enrollment":9103,"conditions":11299,"interventions":11300},[95],[447],[9106,9107,7458,9108],{"intervention":11302,"totalTrials":175,"cells":11303},"Intrathecal Clonidine",{"EARLY_PHASE1":11304,"PHASE1":11306,"PHASE2":11308,"PHASE3":11310,"PHASE4":11312,"NA":11314},{"trials":11305,"activeCount":103},[],{"trials":11307,"activeCount":103},[],{"trials":11309,"activeCount":103},[],{"trials":11311,"activeCount":103},[],{"trials":11313,"activeCount":103},[],{"trials":11315,"activeCount":103},[11316],{"nctId":11317,"briefTitle":11318,"status":165,"phases":11319,"primaryCompletion":2033,"completion":1556,"start":8068,"enrollment":9898,"conditions":11320,"interventions":11322},"NCT02550444","Intrathecal Clonidine in Cesarean Section May Lead to Worse Blood Gas Results in the Newborns",[95],[11321],"Pregnancy",[11302,11323],"Intravenous Clonidine",{"intervention":11323,"totalTrials":175,"cells":11325},{"EARLY_PHASE1":11326,"PHASE1":11328,"PHASE2":11330,"PHASE3":11332,"PHASE4":11334,"NA":11336},{"trials":11327,"activeCount":103},[],{"trials":11329,"activeCount":103},[],{"trials":11331,"activeCount":103},[],{"trials":11333,"activeCount":103},[],{"trials":11335,"activeCount":103},[],{"trials":11337,"activeCount":103},[11338],{"nctId":11317,"briefTitle":11318,"status":165,"phases":11339,"primaryCompletion":2033,"completion":1556,"start":8068,"enrollment":9898,"conditions":11340,"interventions":11341},[95],[11321],[11302,11323],{"intervention":11343,"totalTrials":175,"cells":11344},"Antidepressant",{"EARLY_PHASE1":11345,"PHASE1":11347,"PHASE2":11349,"PHASE3":11351,"PHASE4":11353,"NA":11355},{"trials":11346,"activeCount":103},[],{"trials":11348,"activeCount":103},[],{"trials":11350,"activeCount":103},[],{"trials":11352,"activeCount":103},[],{"trials":11354,"activeCount":103},[],{"trials":11356,"activeCount":103},[11357],{"nctId":11358,"briefTitle":11359,"status":193,"phases":11360,"primaryCompletion":8155,"completion":11361,"start":8068,"enrollment":2071,"conditions":11362,"interventions":11364},"NCT02441387","Predictors of the Outcome of Late Life Depression",[],"2019-07",[11363],"Major Depression",[11343],{"intervention":11366,"totalTrials":175,"cells":11367},"Dipeptidyl Peptidase IV inhibitors",{"EARLY_PHASE1":11368,"PHASE1":11370,"PHASE2":11372,"PHASE3":11374,"PHASE4":11376,"NA":11378},{"trials":11369,"activeCount":103},[],{"trials":11371,"activeCount":103},[],{"trials":11373,"activeCount":103},[],{"trials":11375,"activeCount":103},[],{"trials":11377,"activeCount":103},[],{"trials":11379,"activeCount":103},[11380],{"nctId":11381,"briefTitle":11382,"status":165,"phases":11383,"primaryCompletion":2737,"completion":751,"start":1876,"enrollment":2106,"conditions":11384,"interventions":11386},"NCT00881543","\"Effect of Dipeptidyl Peptidase IV After Diets in näive Type 2 Diabetic Patients\"",[95],[11385],"Diabetes Type 2",[11366],{"intervention":11388,"totalTrials":175,"cells":11389},"Simvastatin 80 mg\u002Fday for 6 weeks",{"EARLY_PHASE1":11390,"PHASE1":11392,"PHASE2":11394,"PHASE3":11396,"PHASE4":11398,"NA":11400},{"trials":11391,"activeCount":103},[],{"trials":11393,"activeCount":103},[],{"trials":11395,"activeCount":103},[],{"trials":11397,"activeCount":103},[],{"trials":11399,"activeCount":103},[],{"trials":11401,"activeCount":103},[11402],{"nctId":11403,"briefTitle":11404,"status":165,"phases":11405,"primaryCompletion":1875,"completion":7634,"start":1632,"enrollment":8069,"conditions":11406,"interventions":11408},"NCT00474123","Antiplatelet and Anti-inflammatory Effects of Statins and Ezetimibe",[95],[11407],"Stable Angina",[11388,11409],"Ezetimibe 10 mg \u002F Simvastatin 20 mg",{"intervention":11409,"totalTrials":175,"cells":11411},{"EARLY_PHASE1":11412,"PHASE1":11414,"PHASE2":11416,"PHASE3":11418,"PHASE4":11420,"NA":11422},{"trials":11413,"activeCount":103},[],{"trials":11415,"activeCount":103},[],{"trials":11417,"activeCount":103},[],{"trials":11419,"activeCount":103},[],{"trials":11421,"activeCount":103},[],{"trials":11423,"activeCount":103},[11424],{"nctId":11403,"briefTitle":11404,"status":165,"phases":11425,"primaryCompletion":1875,"completion":7634,"start":1632,"enrollment":8069,"conditions":11426,"interventions":11427},[95],[11407],[11388,11409],{"intervention":11429,"totalTrials":175,"cells":11430},"Toluidine Blue O",{"EARLY_PHASE1":11431,"PHASE1":11433,"PHASE2":11435,"PHASE3":11437,"PHASE4":11439,"NA":11441},{"trials":11432,"activeCount":103},[],{"trials":11434,"activeCount":103},[],{"trials":11436,"activeCount":103},[],{"trials":11438,"activeCount":103},[],{"trials":11440,"activeCount":103},[],{"trials":11442,"activeCount":103},[11443],{"nctId":11444,"briefTitle":11445,"status":165,"phases":11446,"primaryCompletion":11447,"completion":11447,"start":11448,"enrollment":1176,"conditions":11449,"interventions":11452},"NCT03264118","Effects of Antimicrobial Photodynamic Therapy on Regeneration of Class II Furcation Lesions",[95],"2018-12-22","2017-04-02",[11450,3465,11451],"Periodontitis, Chronic","Periodontal Bone Loss",[11429],{"intervention":11454,"totalTrials":175,"cells":11455},"Remifentanil group",{"EARLY_PHASE1":11456,"PHASE1":11458,"PHASE2":11460,"PHASE3":11462,"PHASE4":11464,"NA":11466},{"trials":11457,"activeCount":103},[],{"trials":11459,"activeCount":103},[],{"trials":11461,"activeCount":103},[],{"trials":11463,"activeCount":103},[],{"trials":11465,"activeCount":103},[],{"trials":11467,"activeCount":103},[11468],{"nctId":11469,"briefTitle":11470,"status":165,"phases":11471,"primaryCompletion":11472,"completion":11472,"start":11473,"enrollment":17,"conditions":11474,"interventions":11476},"NCT04005599","Opioid Sparing General Venous Anesthesia With Magnesium Sulfate",[95],"2022-01-06","2019-06-03",[1673,4736,11475],"Opioid Use",[11454,11477],"Magnesium sulfate group",{"intervention":11477,"totalTrials":175,"cells":11479},{"EARLY_PHASE1":11480,"PHASE1":11482,"PHASE2":11484,"PHASE3":11486,"PHASE4":11488,"NA":11490},{"trials":11481,"activeCount":103},[],{"trials":11483,"activeCount":103},[],{"trials":11485,"activeCount":103},[],{"trials":11487,"activeCount":103},[],{"trials":11489,"activeCount":103},[],{"trials":11491,"activeCount":103},[11492],{"nctId":11469,"briefTitle":11470,"status":165,"phases":11493,"primaryCompletion":11472,"completion":11472,"start":11473,"enrollment":17,"conditions":11494,"interventions":11495},[95],[1673,4736,11475],[11454,11477],{"intervention":11497,"totalTrials":175,"cells":11498},"Etoricoxib",{"EARLY_PHASE1":11499,"PHASE1":11501,"PHASE2":11503,"PHASE3":11505,"PHASE4":11507,"NA":11509},{"trials":11500,"activeCount":103},[],{"trials":11502,"activeCount":103},[],{"trials":11504,"activeCount":103},[],{"trials":11506,"activeCount":103},[],{"trials":11508,"activeCount":103},[],{"trials":11510,"activeCount":103},[11511],{"nctId":11512,"briefTitle":11513,"status":165,"phases":11514,"completion":11515,"start":6186,"enrollment":2945,"conditions":11516,"interventions":11517},"NCT00529594","Analgesic Effect of Etoricoxib (ARCOXIA®) 120MG During Retinal Laser Photocoagulation",[95],"2006-11",[2277],[11497],{"intervention":11519,"totalTrials":175,"cells":11520},"Levothyroxine",{"EARLY_PHASE1":11521,"PHASE1":11523,"PHASE2":11525,"PHASE3":11527,"PHASE4":11529,"NA":11531},{"trials":11522,"activeCount":103},[],{"trials":11524,"activeCount":103},[],{"trials":11526,"activeCount":103},[],{"trials":11528,"activeCount":103},[],{"trials":11530,"activeCount":103},[],{"trials":11532,"activeCount":103},[11533],{"nctId":11534,"briefTitle":11535,"status":165,"phases":11536,"primaryCompletion":2738,"completion":2738,"start":1590,"enrollment":414,"conditions":11537,"interventions":11539},"NCT01189344","Levothyroxine (L-T4) Absorption After Bariatric Surgery",[95],[11538],"Morbid Obesity",[11519],{"intervention":11541,"totalTrials":175,"cells":11542},"Bone Grafting",{"EARLY_PHASE1":11543,"PHASE1":11545,"PHASE2":11547,"PHASE3":11549,"PHASE4":11551,"NA":11553},{"trials":11544,"activeCount":103},[],{"trials":11546,"activeCount":103},[],{"trials":11548,"activeCount":103},[],{"trials":11550,"activeCount":103},[],{"trials":11552,"activeCount":103},[],{"trials":11554,"activeCount":103},[11555],{"nctId":11556,"briefTitle":11557,"status":165,"phases":11558,"primaryCompletion":11559,"completion":11559,"start":11560,"enrollment":32,"conditions":11561,"interventions":11563},"NCT03941977","Treatment of Bone Marrow Edema Lesions of the Knee With Percutaneous Grafting",[95],"2018-12-30","2014-11-05",[11562],"Bone Marrow Edema",[11541],{"intervention":11565,"totalTrials":175,"cells":11566},"ingenol mebutate",{"EARLY_PHASE1":11567,"PHASE1":11569,"PHASE2":11571,"PHASE3":11573,"PHASE4":11575,"NA":11577},{"trials":11568,"activeCount":103},[],{"trials":11570,"activeCount":103},[],{"trials":11572,"activeCount":103},[],{"trials":11574,"activeCount":103},[],{"trials":11576,"activeCount":103},[],{"trials":11578,"activeCount":103},[11579],{"nctId":11580,"briefTitle":11581,"status":165,"phases":11582,"primaryCompletion":195,"completion":8244,"start":1761,"enrollment":740,"conditions":11583,"interventions":11584},"NCT02242747","Safety and Tolerability Study of Ingenol Mebutate Compared to 5-FU to Treat Facial Actinic Keratosis",[95],[11131],[11565,11585],"5% 5-FU",{"intervention":11585,"totalTrials":175,"cells":11587},{"EARLY_PHASE1":11588,"PHASE1":11590,"PHASE2":11592,"PHASE3":11594,"PHASE4":11596,"NA":11598},{"trials":11589,"activeCount":103},[],{"trials":11591,"activeCount":103},[],{"trials":11593,"activeCount":103},[],{"trials":11595,"activeCount":103},[],{"trials":11597,"activeCount":103},[],{"trials":11599,"activeCount":103},[11600],{"nctId":11580,"briefTitle":11581,"status":165,"phases":11601,"primaryCompletion":195,"completion":8244,"start":1761,"enrollment":740,"conditions":11602,"interventions":11603},[95],[11131],[11565,11585],{"intervention":11605,"totalTrials":175,"cells":11606},"timolol maleate 0,5%",{"EARLY_PHASE1":11607,"PHASE1":11609,"PHASE2":11611,"PHASE3":11613,"PHASE4":11615,"NA":11617},{"trials":11608,"activeCount":103},[],{"trials":11610,"activeCount":103},[],{"trials":11612,"activeCount":103},[],{"trials":11614,"activeCount":103},[],{"trials":11616,"activeCount":103},[],{"trials":11618,"activeCount":103},[11619],{"nctId":11620,"briefTitle":11621,"status":165,"phases":11622,"completion":11623,"start":11624,"enrollment":1645,"conditions":11625,"interventions":11626},"NCT00435058","Visual Function Changes After Intraocular Pressure Reduction",[95],"2006-04","2005-09",[3734],[11605,11627,11628],"brimonidine tartrate 0,2%","travoprost 0,004%",{"intervention":11627,"totalTrials":175,"cells":11630},{"EARLY_PHASE1":11631,"PHASE1":11633,"PHASE2":11635,"PHASE3":11637,"PHASE4":11639,"NA":11641},{"trials":11632,"activeCount":103},[],{"trials":11634,"activeCount":103},[],{"trials":11636,"activeCount":103},[],{"trials":11638,"activeCount":103},[],{"trials":11640,"activeCount":103},[],{"trials":11642,"activeCount":103},[11643],{"nctId":11620,"briefTitle":11621,"status":165,"phases":11644,"completion":11623,"start":11624,"enrollment":1645,"conditions":11645,"interventions":11646},[95],[3734],[11605,11627,11628],{"intervention":11628,"totalTrials":175,"cells":11648},{"EARLY_PHASE1":11649,"PHASE1":11651,"PHASE2":11653,"PHASE3":11655,"PHASE4":11657,"NA":11659},{"trials":11650,"activeCount":103},[],{"trials":11652,"activeCount":103},[],{"trials":11654,"activeCount":103},[],{"trials":11656,"activeCount":103},[],{"trials":11658,"activeCount":103},[],{"trials":11660,"activeCount":103},[11661],{"nctId":11620,"briefTitle":11621,"status":165,"phases":11662,"completion":11623,"start":11624,"enrollment":1645,"conditions":11663,"interventions":11664},[95],[3734],[11605,11627,11628],{"intervention":11666,"totalTrials":175,"cells":11667},"Anthracycline & Cyclophosphamide treatment scheme",{"EARLY_PHASE1":11668,"PHASE1":11670,"PHASE2":11672,"PHASE3":11674,"PHASE4":11676,"NA":11678},{"trials":11669,"activeCount":103},[],{"trials":11671,"activeCount":103},[],{"trials":11673,"activeCount":103},[],{"trials":11675,"activeCount":103},[],{"trials":11677,"activeCount":103},[],{"trials":11679,"activeCount":103},[11680],{"nctId":11681,"briefTitle":11682,"status":165,"phases":11683,"primaryCompletion":11684,"completion":11685,"start":11686,"enrollment":1350,"conditions":11687,"interventions":11691},"NCT04568161","Effect of Anthracyclines and Cyclophosphamide on Cardiovascular Responses",[95],"2022-09-03","2025-03-03","2020-08-03",[1313,11688,11689,11690,6518],"Cardiovascular Disease","Neurovascular Disorder","Endothelial Disfunction",[11666],{"intervention":11693,"totalTrials":175,"cells":11694},"Testosterone Cypionate 100 MG\u002FML",{"EARLY_PHASE1":11695,"PHASE1":11697,"PHASE2":11699,"PHASE3":11701,"PHASE4":11703,"NA":11705},{"trials":11696,"activeCount":103},[],{"trials":11698,"activeCount":103},[],{"trials":11700,"activeCount":103},[],{"trials":11702,"activeCount":103},[],{"trials":11704,"activeCount":103},[],{"trials":11706,"activeCount":103},[11707],{"nctId":11708,"briefTitle":11709,"status":165,"phases":11710,"primaryCompletion":11711,"completion":11712,"start":11713,"enrollment":11714,"conditions":11715,"interventions":11718},"NCT05487794","Effect of Dose Fractionation of Testosterone Cypionate on Transgender Men with Erythrocytosis",[95],"2024-11-18","2024-12-17","2022-09-01",46,[1110,11716,11717],"Transsexualism","Hematologic Diseases",[11693],{"intervention":11720,"totalTrials":175,"cells":11721},"TAU",{"EARLY_PHASE1":11722,"PHASE1":11724,"PHASE2":11726,"PHASE3":11728,"PHASE4":11730,"NA":11732},{"trials":11723,"activeCount":103},[],{"trials":11725,"activeCount":103},[],{"trials":11727,"activeCount":103},[],{"trials":11729,"activeCount":103},[],{"trials":11731,"activeCount":103},[],{"trials":11733,"activeCount":103},[11734],{"nctId":11735,"briefTitle":11736,"status":165,"phases":11737,"primaryCompletion":8068,"completion":1702,"start":3909,"enrollment":11738,"conditions":11739,"interventions":11741},"NCT02300051","Intervention Study for Individuals With Compulsive Sexual Behavior",[95],135,[11740],"Compulsive Sexual Behavior",[11720]]